Efficient synthesis of biologically active small molecules by Tunbridge, Gemma Ann
 Efficient Synthesis of Biologically Active 
Small Molecules 
 
Gemma Ann Tunbridge 
 
A thesis submitted for the degree of Doctor of Philosophy 
University of Bath 
Department of Pharmacy and Pharmacology 
October 2012 
 
This research has been carried out under the supervision of  
Dr Lorenzo Caggiano 
 
COPYRIGHT 
Attention is drawn to the fact that copyright of this thesis rests with the author. A copy of this 
thesis has been supplied on condition that anyone who consults it is understood to recognise 
that its copyright rests with the author and that they must not copy it or use material from it 
except as permitted by law or with the consent of the author. 
 
This thesis may be made available for consultation within the University library and may be 
photocopied or lent to other libraries for the purposes of consultation 
 
Signed...................................................... 
 
Date......................................................... 
  
 
 
 
 
 
 
 
 
 
For Mum and Dad. 
 
 
 
  
 
 
 
 
 
 
 
 
 
“Ordinary riches can be stolen; real riches cannot. In your soul are infinitely precious things 
that cannot be taken from you.” 
Oscar Wilde 
 
 
- I - 
Contents 
CONTENTS ...........................................................................................................................................................I 
ACKNOWLEDGMENTS ................................................................................................................................. IV 
ABSTRACT ........................................................................................................................................................ VI 
LIST OF FIGURES ......................................................................................................................................... VII 
LIST OF TABLES .......................................................................................................................................... VIII 
LIST OF SCHEMES .......................................................................................................................................... IX 
LIST OF ABBREVIATIONS ......................................................................................................................... XIII 
 
1. CHAPTER ONE - INTRODUCTION OF TETRAHYDROISOQUINOLINES AND 
DIHYDROISOQUINOLINONES ................................................................................................................. - 1 - 
1.1. 1,2,3,4-TETRAHYDROISOQUINOLINES ..................................................................................................... - 1 - 
1.1.1. Biological Activity of 1,2,3,4-Tetrahydroisoquinolines ................................................................. - 1 - 
1.1.2. Current Syntheses of 1,2,3,4-Tetrahydroisoquinolines .................................................................. - 2 - 
1.1.3. Proposed Synthetic Route via Alkylation ....................................................................................... - 5 - 
1.2. DIHYDROISOQUINOLINONES .................................................................................................................... - 7 - 
1.2.1. Amaryllidaceae Family of Plants .................................................................................................. - 7 - 
1.2.2. Galanthamine ................................................................................................................................ - 7 - 
1.2.3. Pancratistatin and Narciclasine .................................................................................................... - 8 - 
1.3. PROJECT AIMS AND OBJECTIVES ........................................................................................................... - 21 - 
2. CHAPTER TWO - 1,2,3,4-TETRAHYDROISOQUINOLINES .......................................................... - 22 - 
2.1. PROPOSED SYNTHESIS VIA FRIEDEL-CRAFTS ALKYLATION ................................................................... - 22 - 
2.1.1. Synthesis of Model Substrates ...................................................................................................... - 22 - 
2.1.2. Attempted Cyclisations ................................................................................................................ - 24 - 
2.1.3. Formation of Carbonates from Carbon Dioxide ......................................................................... - 27 - 
2.1.4. Applications ................................................................................................................................. - 35 - 
2.2. PROPOSED SYNTHESIS VIA FRIEDEL-CRAFTS ACYLATION ..................................................................... - 36 - 
2.2.1. Proposed disconnection approach ............................................................................................... - 36 - 
2.2.2. Transformation ............................................................................................................................ - 37 - 
2.2.3. Synthesis of Intermediates ........................................................................................................... - 38 - 
2.2.4. Cyclisation of Intermediates ........................................................................................................ - 40 - 
2.3. CONCLUSIONS ....................................................................................................................................... - 47 - 
3. CHAPTER THREE - A/B ANALOGUES OF DIHYDROISOQUINOLINONES ............................. - 48 - 
3.1. PROPOSED SYNTHETIC ROUTE............................................................................................................... - 48 - 
3.1.1. Step One - Indanones ................................................................................................................... - 49 - 
3.1.2. Step Two - Schmidt Reaction ....................................................................................................... - 50 - 
3.1.3. Step Two - Beckmann Rearrangement ......................................................................................... - 51 - 
3.2. RESULTS AND DISCUSSION .................................................................................................................... - 53 - 
3.2.1. Step One - Intramolecular Indanone Synthesis ............................................................................ - 53 - 
3.2.2. Step Two - Schmidt Reaction ....................................................................................................... - 56 - 
3.3. TETRAZOLES ......................................................................................................................................... - 60 - 
3.3.1. Optimisation ................................................................................................................................ - 60 - 
3.3.2. Synthesis and Mechanism ............................................................................................................ - 62 - 
3.3.3. Biological Activity of Tetrazoles .................................................................................................. - 63 - 
3.4. OXIDATION REACTIONS ........................................................................................................................ - 64 - 
3.4.1. Dehydrogenation using DDQ ...................................................................................................... - 65 - 
3.4.2. Dehydrogenation using Pd/C ....................................................................................................... - 66 - 
- II - 
3.5. BIOLOGICAL ACTIVITY .......................................................................................................................... - 67 - 
3.6. CONCLUSIONS ....................................................................................................................................... - 70 - 
4. CHAPTER FOUR - A/B/C ANALOGUES OF DIHYDROISOQUINOLINONES ............................ - 71 - 
4.1. PROPOSED SYNTHETIC ROUTE............................................................................................................... - 71 - 
4.1.1. Route 1 - Intermolecular Indanone Synthesis - Mechanistic Pathways ....................................... - 72 - 
4.1.2. Route 1 - Nazarov Cyclisation ..................................................................................................... - 73 - 
4.1.3. Route 1 - Introducing Functionalisation ...................................................................................... - 73 - 
4.1.4. Route 2 - Intermolecular Indanone Synthesis .............................................................................. - 74 - 
4.1.5. Route 2 - Introducing Functionalisation ...................................................................................... - 74 - 
4.2. RESULTS AND DISCUSSION .................................................................................................................... - 75 - 
4.2.1. Route 1 - Intermolecular Indanone Synthesis .............................................................................. - 75 - 
4.2.2. Route 1 - Introducing Functionality ............................................................................................ - 82 - 
4.2.3. Route 2 - Intermolecular Indanone Synthesis .............................................................................. - 85 - 
4.2.4. Route 2 - Introducing Functionalisation ...................................................................................... - 87 - 
4.2.5. Schmidt Reaction and Beckmann Rearrangement ....................................................................... - 90 - 
4.2.6. Overview ...................................................................................................................................... - 92 - 
4.3. ALTERNATIVE PROPOSED SYNTHETIC ROUTE ....................................................................................... - 93 - 
4.3.1. Step 1 - Heck Cross-Coupling Reaction ...................................................................................... - 93 - 
4.3.2. Step 2 - Modified Curtius Rearrangement ................................................................................... - 95 - 
4.4. RESULTS AND DISCUSSION - STEP 1 - HECK REACTION ......................................................................... - 96 - 
4.4.1. Optimisation of Heck Reaction .................................................................................................... - 96 - 
4.4.2. Functionalisation on A-ring....................................................................................................... - 101 - 
4.4.3. Functionalisation on C-ring ...................................................................................................... - 102 - 
4.5. RESULTS AND DISCUSSION - STEP 2 - MODIFIED CURTIUS REARRANGEMENT ..................................... - 106 - 
4.6. BIOLOGICAL ACTIVITY ........................................................................................................................ - 109 - 
4.7. CONCLUSIONS ..................................................................................................................................... - 111 - 
5. INDANOCINE......................................................................................................................................... - 112 - 
5.1. INTRODUCTION .................................................................................................................................... - 112 - 
5.2. AIM ..................................................................................................................................................... - 113 - 
5.3. SYNTHETIC ROUTE AND PROPOSED ANALOGUES ................................................................................ - 114 - 
5.4. SYNTHESIS OF ANALOGUES ................................................................................................................. - 115 - 
5.5. BIOLOGICAL ACTIVITY ........................................................................................................................ - 119 - 
5.6. NCI 60-CELL LINE SCREEN ................................................................................................................. - 121 - 
5.6.1. One-Dose Data .......................................................................................................................... - 121 - 
5.6.2. Five-Dose Data .......................................................................................................................... - 123 - 
5.6.3. Repeat of Five-Dose Data.......................................................................................................... - 126 - 
5.6.4. COMPARE Analysis .................................................................................................................. - 127 - 
5.7. CONCLUSIONS ..................................................................................................................................... - 130 - 
6. CONCLUSIONS ..................................................................................................................................... - 131 - 
7. EXPERIMENTAL .................................................................................................................................. - 133 - 
7.1. GENERAL EXPERIMENTAL ................................................................................................................... - 133 - 
7.2. MTS CELL PROLIFERATION ASSAY PROTOCOL .................................................................................... - 135 - 
7.3. CHAPTER TWO - 1,2,3,4-TETRAHYDROISOQUINOLINES ....................................................................... - 136 - 
7.3.1. Alkylation ................................................................................................................................... - 136 - 
7.3.2. Acylation - Schotten-Baumann Reactions .................................................................................. - 152 - 
7.4. CHAPTER THREE - A/B ANALOGUES OF DIHYDROISOQUINOLINONES ................................................. - 162 - 
7.4.1. Indanone Synthesis .................................................................................................................... - 162 - 
7.4.2. Schmidt Reactions ...................................................................................................................... - 169 - 
7.4.3. Tetrazoles................................................................................................................................... - 173 - 
7.4.4. Oxidation Reactions ................................................................................................................... - 178 - 
7.5. CHAPTER FOUR - A/B/C ANALOGUES OF DIHYDROISOQUINOLINONES................................................ - 180 - 
7.5.1. Intermolecular Indanone Synthesis............................................................................................ - 180 - 
- III - 
7.5.2. Schmidt Reaction and Beckmann Rearrangement ..................................................................... - 198 - 
7.5.3. Heck Reaction ............................................................................................................................ - 202 - 
7.5.4. Modified Curtius Rearrangement .............................................................................................. - 210 - 
7.6. INDANOCINE CHAPTER ......................................................................................................................... - 214 - 
8. APPENDICES ......................................................................................................................................... - 236 - 
8.1. CHAPTER TWO..................................................................................................................................... - 236 - 
8.1.1. CO2 Labelling experiments ........................................................................................................ - 236 - 
8.1.2. Crystal Structure Data - Compound 69 ..................................................................................... - 240 - 
8.2. CHAPTER THREE.................................................................................................................................. - 246 - 
8.2.1. HMBC of Tetrazole 120 ............................................................................................................. - 246 - 
8.2.2. IC50 Values of A/B Lactams and Tetrazoles in HT29 and MDA231 Cancer Cell Lines ............ - 249 - 
8.3. CHAPTER FOUR ................................................................................................................................... - 254 - 
8.3.1. Crystal Structure Data - Indanone 136 ..................................................................................... - 254 - 
8.3.2.
 1
H NMR and HRMS of Indanone 141 ........................................................................................ - 257 - 
8.3.3. NOESY spectrum of Indanone 145 ............................................................................................ - 258 - 
8.3.4. NOESY spectrum of Lactam 148 ............................................................................................... - 260 - 
8.3.5. IC50 Values of A/B/C Indanones and Lactams in the HT29 Cancer Cell Line ........................... - 263 - 
8.4. CHAPTER FIVE ..................................................................................................................................... - 265 - 
8.4.1. IC50 Values of Indanocine Analogues in HT29 and MDA231 Cancer Cell Lines ...................... - 265 - 
8.4.2. NCI 60 Cell Line Screen - One-Dose Data ................................................................................ - 275 - 
8.4.3. NCI 60 Cell Line Screen - Five-Dose Data ............................................................................... - 284 - 
8.4.4. Repeat of Five-Dose Data.......................................................................................................... - 289 - 
8.4.5. COMPARE Data of Compound 177 .......................................................................................... - 292 - 
9. REFERENCES ........................................................................................................................................ - 294 - 
 
- IV - 
Acknowledgments 
I would like to start by thanking Dr Lorenzo Caggiano for his help and supervision 
throughout my PhD. His enthusiasm for chemistry is infectious and he always helped to keep 
me motivated in the lab. I am extremely grateful he offered me a position within his group. I 
must also express my gratitude to The University of Bath for funding my PhD project.  
 
I would also like to say a huge thank you to Dr Pauline Wood for her help teaching and 
supporting me with the biological aspects of my project. Thank you to Dr Tim Woodman for 
his help with NMR, Dr Anneke Lubben for mass spectrometry and Dr Mary Mahon for 
running my lovely crystal structures.  
 
I would like to say a particular thank you to my group Natalie Griffiths, Alex Ciupa and Dr 
Katie Judd. They all made my time special in the lab and were always willing to help when 
called upon. I must express particular thanks to Alex for his support keeping my cells alive! 
Natalie really supported me in my final year and has been a great friend. Thank you for all 
your gin in your garden whilst we spent time knitting, it was great fun!  
 
I would really like to thank all members of laboratories 3.11 and 3.5 past and present for 
making my three years so enjoyable. Everyone has been so kind and supportive and I will 
really miss working with you all. I especially enjoyed as part of my PhD the conferences we 
all attended, especially Birmingham. My time drinking with Alex and Amit on the train was 
brilliant fun, thanks guys! Also thanks to Helen Paine for the wonderful BBQs, I will miss 
you all loads.    
 
I would like to say a special thank you to Benjamin Young for inspiring me each and every 
day, his enthusiasm and laugh is contagious. Natalie, Ben and I were true fume hood buddies 
and I already miss our random chats! I would also like to thank Dr Joanna Swarbrick for 
helping me throughout my PhD work when I asked her questions and she has become a close 
friend.  
 
- V - 
I also have to say a huge thanks to Dr Amit Nathubhai, he has been there for me throughout 
the whole of my PhD. I consider him a great friend and I am truly grateful for all of his 
support. Thanks matey!  
 
I must say a special thank you to Kate Meredith. Kate has been the best friend I could have 
asked for throughout my PhD at Bath. She has supported me and I really could not have got 
through my three years at Bath without her. I already miss our wine nights and tea breaks. 
She has become a true friend for life. Thanks Kate, you are a star! 
 
I would like to make a special mention to my sister Dr Victoria Tunbridge. It was a pleasure 
to share our time together in Bath throughout our PhDs and meeting for coffee and dinner 
was always a joy. She has always been supportive and looked after me. If I ever need anyone 
I can always call my big sister!  
 
I cannot express in words the thanks I have for my Mum and Dad. Not only have they 
supported me throughout my time at university, they have always been there for me, cared 
for me and are always so proud of me. I am truly grateful for what they have done and I love 
them both so much.  
 
Last but not least I would like to thank Carlo Di Iulio. He has supported me fully throughout 
my time at university, especially during my PhD. He has been my rock and I could not have 
completed my PhD without his support, love and kindness. I know he will always be there at 
my side and I love him with all of my heart. Thank you so much, you truly are my soulmate.  
 
- VI - 
Abstract 
Pancratistatin and narciclasine are natural products isolated from Pancratium litorale
1
 and 
Narcissus poeticus
2
 respectively. Pancratistatin and Narciclasine have been shown to possess 
potent antitumour activity
3
 however they have never been widely exploited due to their 
limited availability from natural sources.
4
 Pancratistatin and narciclasine both contain a 
dihydroisoquinolinone framework. The work described in this thesis explores synthetic 
routes relating to this dihydroisoquinolinone framework, as well as comparable 
tetrahydroisoquinolines. An initial proposed synthetic route involved the synthesis of the 
dihydroisoquinolinone framework via the corresponding indanone. Indanones have also been 
shown to possess potential antitumour activity.
5
  
 
A range of lactam and indanone analogues were synthesised and a selection were tested for 
biological activity against cancer cell lines. The most biologically active lactam analogue 
synthesised was lactam 170. Lactam 170 was synthesised via two steps from commercially 
available starting materials in an overall 51 % yield and was tested in the HT29 colon cancer 
cell line to give an IC50 value of 9 μM. Indanone 177 is an analogue of natural product 
indanocine and was synthesised via two steps in an overall 49 % yield. Analogue 177 was 
tested in the 60 cell line screen by the National Cancer Institute (NCI) to give a mean GI50 
value of 1.29 μM and is currently under consideration for further testing. This thesis 
describes the synthesis and biological testing of the aforementioned compounds as well as an 
array of analogues.  
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1. Chapter One - Introduction of Tetrahydroisoquinolines 
and Dihydroisoquinolinones 
 
The aim of this project was to investigate the synthesis of both tetrahydroisoquinolines and 
dihydroisoquinolinones using established and new synthetic methods, as these are privileged 
motifs found in a variety of biologically active compounds (Figure 1).
6,7
 
 
Figure 1: Structure of tetrahydroisoquinolines and dihydroisoquinolinones 
 
1.1. 1,2,3,4-Tetrahydroisoquinolines 
 
1.1.1. Biological Activity of 1,2,3,4-Tetrahydroisoquinolines 
Many analogues of 1,2,3,4-tetrahydroisoquinolines have been found to possess antitumour 
activity,
8,9
 have the potential to treat Alzheimer’s disease10 and are widely studied cytotoxic 
agents. Berberrubine, a protoberberine alkaloid exhibits antitumour activity in animal models 
(Figure 2).
11
 It has also been previously reported that noscapine, a plant alkaloid, binds to 
tubulin and induces apoptosis selectively in tumour cells to display anticancer activity in 
ovarian and T-cell lymphoma cancers.
12
 These examples demonstrate the utility of the 
1,2,3,4-tetrahydroisoquinoline core and why these types of compounds are of great interest.   
 
Figure 2: Berberrubine and noscapine are natural alkaloids that contain the 1,2,3,4-tetrahydroisoquinoline 
framework 
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1.1.2. Current Syntheses of 1,2,3,4-Tetrahydroisoquinolines 
The existing syntheses of this framework include a Pictet-Spengler,
13-15
 a Friedel-Crafts
16
 or 
a Pomeranz-Fritsch
17
 reaction.  
 
The most popular synthetic approach to 1,2,3,4-tetrahydroisoquinolines has been the Pictet-
Spengler reaction, which is shown by the disconnection at position a (Scheme 1).
15
   
 
Scheme 1: Possible disconnection approaches to the synthesis of 1,2,3,4-tetrahydroisoquinolines 
 
Although this reaction has been employed in many syntheses, it is limited by non-trivial 
synthesis of the arylethylamine starting material and lack of stereocontrol in the newly 
formed stereogenic centre at the C1 position. Following disconnection at position b affords 
more accessible starting materials from benzylation of a simple ethanolamine derivative. This 
disconnection involves either an intramolecular Friedel-Crafts cyclisation
16
 or Pomeranz-
Fritsch reaction but unfortunately these are typified by low yields and harsh reaction 
conditions. 
 
1.1.2.1 Pictet-Spengler reaction 
The Pictet-Spengler reaction proceeds via the condensation of an arylethylamine with an 
aldehyde to give the desired 1,2,3,4-tetrahydroisoquinoline framework (Scheme 2).   
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Scheme 2: Mechanism of the Pictet-Spengler reaction 
 
There is a lack of effective enantioselective synthetic routes to obtain an enantiomerically 
pure tetrahydroisoquinoline ring system. An effective method has previously been reported 
using a chiral auxiliary mediated Pictet-Spengler reaction (Scheme 3).
14
 The first step in this 
synthesis involves the use of a chiral auxiliary which is removed using mild acid. Desired 
product 1 was synthesised in high yield (75 % over 2 steps) and with excellent 
stereoselectivity. 
 
Scheme 3: Enantioselective Pictet-Spengler reaction using a chiral auxiliary 
 
1.1.2.2 Pomeranz-Fritsch Reaction 
1,2,3,4-Tetrahydroisoquinolines have been formed via a Pomeranz-Fritsch reaction following 
disconnection at position b (Scheme 1).  
 
Bobbitt et al. reported the reaction of benzaldehyde derivative 2 and aminoacetaldehyde 
diethyl acetal in the presence of an acid to form imine 3, which was subsequently 
catalytically reduced to the amine 4 (Scheme 4).
17
 Amine 4 was then treated with 6M HCl(aq.) 
to form compound 5. Hydrogenation of compound 5 afforded 1,2,3,4-tetrahydroisoquinoline 
6 in good yield (80-90 %).   
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Scheme 4: Previously reported Pomeranz-Fritsch reaction to afford compound 6 in 80-90 % yield
17
 
 
1.1.2.3 Intramolecular Friedel-Crafts Alkylation 
1,2,3,4-Tetrahydroisoquinolines have also been formed via a Friedel-Crafts alkylation 
reaction by disconnection at position b (Scheme 1), which requires an aromatic ring and an 
alkyl halide in the presence of a strong Lewis acid catalyst. Two mechanistic routes are 
possible for the cyclisation reaction, which are outlined in Scheme 5.  
 
Scheme 5: Two possible mechanistic pathways to synthesise the tetrahydroisoquinoline core 
 
The tetrahydroisoquinoline can be obtained directly from the amino alcohol via an aziridine 7 
(Route A) or an amino-halide intermediate 8 (Route B).   
 
 - 5 -  
This pathway has been previously investigated using ammonium chloride with aluminium 
chloride at 185 
o
C and deuterium was used to label the ethanolamine 9 (Scheme 6).
18
 If the 
aziridine were involved then both products 9A and 9B would be expected in approximately a 
1:1 ratio. Only 9A was isolated in 100 % yield indicating that the reaction proceeds 
exclusively via Route B and not by the aziridine intermediate.   
 
Scheme 6: Deuterium labelled tetrahydroisoquinolines
18
 
 
1.1.3. Proposed Synthetic Route via Alkylation 
The proposed synthetic route to access the 1,2,3,4-tetrahydroisoquinoline core 10 exploits the 
disconnection approach at position b followed by position c (Scheme 1 and Scheme 7). 
Chirality can easily be introduced following this route (R
2) as the β-amino alcohol 11 can be 
synthesised in a one step reduction of a variety of naturally occurring, enantiomerically pure 
α-amino acids.   
 
Scheme 7: Proposed disconnection approach to synthesise the 1,2,3,4-tetrahydroisoquinoline core via alkylation 
 
β-amino alcohols 12 can be transformed into their α-substituted amino alcohols 13 selectively 
(Scheme 8).
19
 Initial addition of trifluoroacetic anhydride (TFAA) activates the alcohol, 
followed by neighbouring group participation from the nucleophilic nitrogen to afford an 
aziridinium cation intermediate. Base hydrolysis then affords the rearranged amino alcohol in 
a regio-, stereo- and enantioselective method.   
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Scheme 8: The selective transformation of β-amino alcohols to their corresponding α-substituted amino 
alcohols via an aziridinium cation intermediate
19
 
 
The proposed synthesis potentially involves a similar aziridinium ion intermediate 14 by 
neighbouring group participation (Scheme 9). It is hoped that the electron-rich aromatic ring 
will then cyclise by intramolecular attack to relieve the ring strain of aziridinium cation 14 to 
form the desired 1,2,3,4-tetrahydroisoquinoline core 15.     
 
Scheme 9: Possible mechanisms of the proposed synthesis 
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Direct attack would also be feasible in this disconnection approach (Route B, Scheme 5). 
Mendelson et al. used the same disconnection approach on a very similar substrate and 
discovered their reaction did not proceed via the aziridine intermediate (Scheme 6).
18
 
 
1.2. Dihydroisoquinolinones 
 
1.2.1. Amaryllidaceae Family of Plants 
The Amaryllidaceae family of plants is found across the tropical and warm regions of the 
world and has proven to be a plentiful source for therapeutic agents. To date, up to 500 
compounds have been isolated from this family of plants and several of these have been 
shown to possess a wide range of biological activities.
20
 As a result, much attention has been 
paid to the isolation, identification and research into these natural products. From 2009-2011, 
nineteen new alkaloids have been isolated from the Amaryllidaceae family of plants.
21
 
 
These plants are primarily used for their ornamental properties. However, when a cut daffodil 
is placed in a vase with other flowers, it can have a detrimental effect on the other plants and 
can shorten their vase life. Extracts from the bulb of the daffodil (Narcissus) were first 
exploited by the physician Hippokrates of Kos in Ancient Greece (B.C. 460-370), who 
recommended the use of a pessary prepared from narcissus oil to treat uterine tumours.
7
 
 
1.2.2. Galanthamine 
Galanthamine (Figure 3) is an alkaloid previously isolated from both the daffodil and 
snowdrop bulbs. This is the first example of a natural product isolated from the 
Amaryllidaceae family of plants which has been commercially approved (marketed in the 
UK as Reminyl by Shire Pharmaceuticals) and is used for the treatment of Alzheimer’s 
disease.
22
 Alzheimer’s disease is a common form of dementia and previous research has 
revealed that the brains of sufferers show a diminished level of acetylcholine (ACh). 
Acetylcholine (ACh) is a neurotransmitter of the central nervous system, which increases 
awareness and learning.
23
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Figure 3: Galanthamine 
 
Acetylcholinesterase is an enzyme responsible for the removal of ACh in vivo, therefore a 
common treatment for Alzheimer’s disease is by the use of acetylcholinesterase inhibitors. 
Galanthamine is an example of an acetylcholinesterase inhibitor, which has been shown to 
slow the progression of the disease. This example highlights why there is great interest in this 
group of plants and the collection of compounds isolated from them.  
 
1.2.3. Pancratistatin and Narciclasine 
 
1.2.3.1 Isolation 
Pancratistatin 16 and narciclasine 17 are two more examples of natural products isolated 
from the bulbs of the daffodil (Figure 4). Pancratistatin 16 and was first isolated from 
Pancratium litorale in 1984 by Pettit et al.
1
 and narciclasine 17 from Narcissus poeticus in 
1967,
2
 which was fully characterised in 1968 by Piozzi et al.
24
 Both contain the same basic 
dihydroisoquinolinone core structure. 
 
Figure 4: Pancratistatin 16 and narciclasine 17 
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1.2.3.2 Biological Activity 
These natural products are of great interest as they both possess potent antitumour activity 
that has previously been explored.
7
 Pancratistatin 16 and narciclasine 17 have been tested 
against the National Cancer Institute (NCI) 60 cell line screen with mean GI50 values of 
0.091 μM and 0.016 μM respectively.7 In preliminary investigations they displayed antiviral 
activity in mice with the Japanese encephalitis virus but only at near toxic concentrations and 
with low selectivity.
25
  
 
Little is known about the precise mode of action of these compounds. There is increasing 
interest in the biological research of pancratistatin 16 and narciclasine 17 in order to establish 
their exact anticancer mode of action and some preliminary studies on the natural products 
have previously been reported and are now described. 
 
In 1975, Carrasco and co-workers reported that narciclasine 17 inhibits eukaryotic protein 
synthesis by interfering with peptidyl transferase by specifically targeting the 60S ribosome 
subunit of the A site (Figure 5).
26
  
 
Figure 5: Illustration representing translation during peptide synthesis
adapted from27
 
 
eEF1A is a protein which delivers aa-tRNA to the empty A site of the ribosome during 
peptide synthesis. It has recently been reported that narciclasine 17 binds to the eEF1A, 
therefore preventing the delivery of the aa-tRNA to the A site and subsequently inhibiting 
peptide synthesis.
28
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Melanoma is an extremely aggressive form of skin cancer and is resistant to many forms of 
anticancer therapies.
29
 One third of early-stage melanoma patients will suffer from 
metastases and patients with metastatic melanomas unfortunately have a survival period of 
up to 6 - 8 months.
28
 Narciclasine has been shown to display IC50 values between 30-100 nM 
in melanoma cell lines, irrespective of their levels of resistance. 
 
Cell apoptosis can be triggered through two different pathways; the first is the death receptor 
pathway, also known as the extrinsic pathway, which is initiated through the stimulation of 
transmembrane death receptors on the cell membrane. The second is via the mitochondrial 
pathway, also known as the intrinsic pathway and is directly initiated at the mitochondria 
within the cell.
30
  
 
In 2007, Dumont et al. reported that narciclasine 17 induces apoptosis selectively in a range 
of cancerous cells compared to normal human lung fibroblasts.
31
  
 
Figure 6: Summary of the induced apoptosis pathways by narciclasine 17
adapted from 31
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In this same report, when PC-3 prostate and MCF-7 breast cancer cell lines were treated with 
narciclasine; both death receptors FAS and DR4 were stimulated, leading to the activation of 
the death-inducing signalling complex (DISC) (Figure 6).  
 
PC-3 prostate cancer cells behave like type 1 cells on treatment with narciclasine 17, where 
the required concentration of caspase-8 is sufficient and triggers the caspase cascade, 
resulting in cell death. MCF-7 breast cancer cells behave like type 2 cells where these cells 
lack the required concentration of caspase-8 and amplify the apoptotic signal by triggering 
the mitochondrial pathway, resulting in the release of cytochrome c, consequently causing 
cell death. 
 
Current cancer treatments cause DNA damage in both healthy and cancerous cells. For future 
treatments to be selective, the differences between normal and cancerous cells need to be 
exploited. Previous studies have shown a difference between the mitochondria of cancerous 
cells and those of non-cancerous cells, therefore making the mitochondria an attractive target 
for potentially selective anticancer treatment.
32
  
 
In 2005, McLachlan et al. reported that pancratistatin 16 selectively induces apoptosis at 
1 μM concentrations within 24 hours in cancerous cells but does not appear to have an effect 
on healthy cells at the same concentration, even after 96 hours of treatment.
33
 This same 
study also revealed that the mitochondria appear to be the sites of action of pancratistatin 16. 
The amount of reactive oxygen species (ROS), which are linked to mitochondrial 
disfunction, have been shown to increase when cancer cells are treated with pancratistatin 16, 
while normal cells do not show this increase.  
 
The role of the mitochondria is to produce energy for cells in the form of ATP. If there is a 
decrease in ATP, then this also indicates mitochondrial disfunction. McLachlan et al. 
revealed that the cellular concentrations of ATP in cancerous cells decrease during treatment 
with pancratistatin 16.
33
 Normal cells do not show any change in the concentration of ATP 
on treatment with pancratistatin 16.  
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The tumour-suppressor protein p53 activates the pro-apoptotic proteins in the cytoplasm, 
BAX and BID, in the intrinisic apoptotic pathway. Current cancer treatments require p53 to 
work effectively; however, cancers mutate and become resistant to these treatments. More 
recently, Griffin et al. reported that pancratistatin 16 induces apoptosis in both p53-negative 
(HT-29) and p53-wild type (HCT116) colon cancer cell lines, without showing toxicity to 
normal colon cells (CCD-18Co).
34
  
 
1.2.3.3 Structure-Activity Relationship of Pancratistatin 
Previous research on pancratistatin 16 has identified several structural features that are 
required for its anticancer activity (Figure 7).
7
 The A-ring must contain at least three oxygen 
substituents and the removal of the free phenol at the C7 position (7-deoxypancratistatin) on 
the A-ring has been shown to decreases the activity of pancratistatin 10-fold.
35
 The fused B/C 
ring junction must be trans in order to retain the activity, which was demonstrated in 2002 by 
Hudlicky et al. where the cis epimer of 7-deoxypancratistatin was inactive against six cancer 
cell lines.
36
 The C-ring must contain at least three hydroxy groups in order to retain cytotoxic 
activity,
37,38
 although the required relative and absolute configuration of these hydroxy 
groups is not yet known.  
 
Figure 7: Structural elements required for the anticancer activity of pancratistatin 16 
 
To date, no alterations to the lactam present in the B-ring have been shown to improve 
activity compared to the natural product. The corresponding lactone of 7-deoxypancratistatin 
tested in L1210, a mouse lymphocytic leukaemia cell line, showed no significant biological 
activity.
39
 
 
 - 13 -  
1.2.3.4 Current Syntheses of Pancratistatin 
The first total synthesis of (+/−)-pancratistatin was reported in 1989 by Danishefsky et al.40 
The synthesis took a total of 26 steps to complete and gave an overall 0.13 % yield.  
 
Heathcock et al. in 1992 published work on the successful synthesis of two analogues of 
pancratistatin, 18 and 19, containing the dihydroisoquinolinone lactam core (Figure 8).
41
 
Their aim was to develop an efficient synthesis of these analogues and achieve sufficient 
quantities to enable the subsequent application of these compounds in clinical trials. 
 
Figure 8: Pancratistatin skeleton models 18 and 19
41
 
 
The synthesis of model compound 18 was achieved in only 4 steps and the synthesis of 
analogue 19 was synthesised in only 9 steps, both through a similar synthetic strategy. 
 
Piperonylic acid 20 was transformed into the acid chloride, which was then treated with 
diethylamine in diethylether to give the corresponding amide 21 in 71 % yield (Scheme 10). 
Metalation at the ortho position,
42
 followed by the addition of trimethyl borate, afforded the 
corresponding boronate, which was oxidised with 30 % aqueous H2O2 and acetic acid. The 
resulting crude phenol was protected as the tert-butyldimethylsilyl ether 22 in 80 % yield. 
 
The tertiary amide directs ortho lithiation for a second time on intermediate 22 followed by 
the addition of 1-nitrocyclohexene in THF to afford a mixture of cis and trans 1,4-addition 
product 23 in 70 % yield. This underwent epimerisation on treatment with Et3N in ethanol to 
yield pure trans isomer 24. The nitro group was then reduced to the amine which, without 
purification, underwent cyclisation to obtain the desired model compound 19 in 47 % yield. 
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Scheme 10: Synthesis of tricyclic skeleton 19
41
 
 
In 1995, Tian et al. published the first enantioselective synthesis of (+)-pancratistatin via a 
14-step synthesis with an overall 2 % yield.
43
 Later that same year, another asymmetric 
synthesis of (+)-pancratistatin was published by Trost and Pulley, which took 15 steps and 
gave a greater overall yield of 11 %.
44
  
 
Over the following years, many groups published enantioselective syntheses of (+)-
pancratistatin, which entail a large number of steps and low overall yields (Table 1). 
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Research group Year Number of steps Overall yield (%) 
Hudlicky
43
 1995 14 2.0 
Trost
44
 1995 15 11.0 
Doyle
45
 1997 24 1.0 
Magnus
46
 1998 19 1.2 
Rigby
47
 2000 22 0.4 
Pettit
48
 2001 10 steps from narciclasine 3.6 
Kim
49
 2002 16 4.0 
Ko
50
 2004 17 5.8 
Li
51
 2006 12 9.0 
Table 1: Previously reported total syntheses of (+)-pancratistatin 
 
The main transformation in the 22 step total synthesis reported by Rigby et al. in 2000 
involves a hydrogen bond-controlled aryl enamide photocyclisation to afford the desired 
trans B/C ring junction intermediate 25 (Scheme 11).
47
 
 
Scheme 11: Photocyclisation step in the reported total synthesis of pancratistatin by Rigby et al.
47
 
 
The synthetic conversion of (+)-pancratistatin from (+)-narciclasine by Pettit et al., published 
in 2001,
48
 provided the opportunity to study the structure activity relationship of 
pancratistatin further. Narciclasine is more easily isolated and so is available in more 
practical quantities than is pancratistatin and, therefore, was an attractive precursor to study. 
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In 2006, Li et al. reported the synthesis of (+)-pancratistatin via 12 steps from pinitol 26 
(Scheme 12).
51
 Their synthesis employs the use of two coupling fragments, bromide 
intermediate 27 and compound 28, which was synthesised from pinitol 26. 
 
Scheme 12: Retro-synthetic approach of (+)-pancratistatin using pinitol 26 as starting material
51
 
 
In 2004, Hudlicky et al. speculated that a factor which may explain the activity of 
pancratistatin 16 could be the hydrogen-bonding donor-accepting pairing of the β-ketoamide 
framework.
52
 They consequently explored the replacement of this core with an indole moiety 
to synthesise analogues which would hopefully mimic the anticancer activity of pancratistatin 
16 (Figure 9). Molecular models of pancratistatin 16 and analogue 29 showed similar spatial 
similarities and a variety of indole analogues were synthesised and tested against 4 cancer 
cell lines.  
 
These cancer cell lines include P388 (lymphocytic leukaemia), BXPC-3 (pancreatic 
adenocarcinoma), MCF-7 (breast adenocarcinoma) and KM20L2 (colon adenocarcinoma). 
Pancratistatin 16 displayed promising anticancer activity in the cell lines with IC50 values 
ranging from 0.062 μM - 0.138 μM. In comparison, compound 29 unfortunately displayed 
only slight activity in P388 lymphocytic leukaemia cell and no activity in the other three cell 
lines.
52
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Figure 9: Synthesis of indole analogue 29 which shows similar spatial similarities to pancratistatin
52
 
 
More recently, de la Sovera et al. envisioned that utilising a triazole 30 to replace the 
aromatic ring in pancratistatin 16 could be an interesting replacement (Figure 10).
53
 The 
group synthesised four compounds containing the triazole core and are currently looking into 
the biological results of these new analogues.   
 
Figure 10: Analogue of pancratistatin which contains a triazole core 30
53
 
 
Vshyvenko et al. have synthesised two C-1 analogues of pancratistatin in 17 steps from 
bromobenzene (Figure 11).
54
 Initial biological results show promising anticancer activities in 
four cancer cell lines, with analogues 31 and 32 showing IC50 values of 0.06 μM and 0.09 
μM, respectively, in prostate cancer cell line HTB-81. Ma et al. also discovered that analogue 
31 selectively induces apoptosis in pancreatic carcinoma cells.
55
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Figure 11: Novel C-1 analogues of pancratistatin, 31 and 32
54
 
 
1.2.3.5 Current Syntheses of Narciclasine 
The first synthesis of (+)-narciclasine was reported in 1997 by Rigby and Matteo, which was 
accomplished in 23 steps with an overall 0.2 % yield.
56
 
 
Two following enantioselective syntheses of (+)-narciclasine were reported in 1999. 
Gonzalez et al. achieved a 0.6 % overall yield in a total of 12 steps
57
 and Keck et al. 
exploited the use of vinyl radicals and oxime ethers in their 14-step synthesis, with an overall 
yield of 11 %.
58
 
 
A more recent example by Yan et al. reported a 9-step synthesis with an impressive total 
yield of 17 %.
59
 This short synthesis involved the use of stereocontrolled epoxidation 
followed by a SnCl4 intramolecular arylation to yield the cis intermediate 33 (Scheme 13).  
 
Scheme 13: SnCl4-catalysed intramolecular cyclisation to afford compound 33
59
 
 
Most recently, Matveenko et al. reported a convergent synthesis of (−)-narciclasine in an 
overall yield of 7 %.
60
 Intermediate 34 was synthesised in 10 steps and intermediate 35 in 9 
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steps (Scheme 14). It is not known whether the Suzuki-Miyaura cross-coupling reaction 
occurs before or after the amide bond forming reaction but, when the two intermediates were 
subjected to a Suzuki-Miyaura cross-coupling reaction under microwave conditions, 
followed by deprotection, the desired (−)-narciclasine was isolated.  
 
Scheme 14: Synthesis of (−)-narciclasine using intermediates 34 and 3560 
 
 
1.2.3.6 Drug Development of Pancratistatin and Narciclasine 
Although the biological activity of pancratistatin and narciclasine is known, they have never 
been widely exploited due to their limited availability from natural sources; isolation can also 
be very costly. Petitt et al. isolated 6.5 g of pancratistatin from 45 kg of daffodil bulbs
3
 and, 
since the first isolation of narciclasine in 1967,
2
 32 species of bulb have been studied for 
narciclasine content, which only typically yields 100-120 mg/kg.
61
  
 
In addition the clinical development of pancratistatin has been hampered due to its poor 
aqueous solubility (<53 μg mL-1),62 therefore an effort has been made to develop prodrugs. In 
2000, Pettit et al. synthesised a large range of phosphate prodrugs and tested both their 
solubility and activity in a range of cancer cell lines (Figure 12).
62
  
 
The use of the phosphate prodrugs considerably improved their aqueous solubility and these 
were found to hold similar activities against the murine P388 lymphocytic leukaemia cell line 
(IC50 values ranging from 0.033 μM to 0.086 μM) when compared to the IC50 value of 0.065 
μM for the parent compound. 
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Figure 12: Range of phosphate prodrugs tested for solubility and biological activity
62
 
 
Pettit et al. then went on to synthesise a second generation of phosphate prodrugs using the 
other hydroxy groups of pancratistatin (Figure 13).
63
 Many of the phosphate prodrugs exhibit 
good activity against the murine P388 lymphocytic leukaemia cell line, with IC50 values 
ranging from 0.039 - 0.422 μM. 
 
Figure 13: A second generation of phosphate prodrugs tested for solubility and their biological activity against 
the murine P388 lymphocytic leukaemia cell line
63
 
 
Due to the promising biological activities of pancratistatin and narciclasine and their limited 
availability from natural sources, there is a great interest in finding a short and efficient 
synthesis of these compounds. The natural products themselves are not good medicinal 
candidates due to their poor aqueous solubility. Previous strategies have involved attempting 
the total synthesis of either pancratistatin 16 or narciclasine 17 and subsequently working 
around disadvantages of the natural products by developing prodrugs for example.  
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1.3. Project Aims and Objectives 
The primary aim of this project was to develop new syntheses for a range of 
tetrahydroisoquinoline and dihydroisoquinolinone analogues and to explore their biological 
activities.  
 
The dihydroisoquinolinone framework is present in many natural products, including 
pancratistatin 16 and narciclasine 17. The aim was to access simple dihydroisoquinolinone 
analogues via straightforward chemistry, using a short and efficient synthesis from 
commercially available starting materials. The strategy was to first synthesise a simple A/B 
framework of the natural products pancratistatin 16 and narciclasine 17. Once the A/B 
framework synthesis was established the intention was to develop this further and apply this 
synthetic strategy to access the A/B/C framework of pancratistatin 16 and narciclasine 17. 
 
Once the A/B/C framework method has been established alternative starting materials can be 
explored to access a range of novel non-natural analogues. This approach, if successful, gives 
access to a potentially large library of biologically active compounds. The aim was then to 
test these compounds for biological activity and any promising candidates could potentially 
be synthesised on a large enough scale for clinical application. 
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2. Chapter Two - 1,2,3,4-Tetrahydroisoquinolines 
 
2.1. Proposed Synthesis via Friedel-Crafts Alkylation 
1,2,3,4-Tetrahydroisoquinolines were initially investigated. The proposed synthetic route via 
alkylation has been attempted with the initial synthesis of model substrate intermediates 36 
(Scheme 15). 
 
Scheme 15: Proposed synthesis of 1,2,3,4-tetrahydroisoquinolines via alkylation 
 
2.1.1. Synthesis of Model Substrates 
Model substrates were synthesised to attempt the intramolecular cyclisation by a tethered 
aromatic ring system. Bis-alkylation of commercially available ethanolamine 37 with 3-
methoxybenzyl chloride, potassium carbonate and nBu4NI at reflux in MeCN for 3.5 hours 
afforded amino alcohol 38 in 80 % yield (Scheme 16). It is possible that the other 20 % has 
also alkylated at the alcohol position or alkylated at the nitrogen to afford the ammonium 
salt; however, no other products were isolated.   
 
Scheme 16: Bis-alkylation of ethanolamine 37 to yield desired amino alcohol 38 
 
nBu4NI is used to catalyse the reaction. Iodide is a good nucleophile so easily displaces the 
chloride of the 3-methoxybenzyl chloride resulting in 3-methoxybenzyl iodide. This more 
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potent alkylating agent reacts to form the desired amino alcohol 38. 3-Methoxybenzyl 
chloride was used as it is electron-rich, which may also promote the cyclisation reaction. The 
proposed novel synthesis also utilises an iodide as an intermediate to encourage the 
cyclisation reaction. 
 
To form iodide intermediate 39, amino alcohol 38, I2, PPh3 and imidazole were stirred 
vigorously at room temperature for 3.5 hours to afford desired iodide 39 in 67 % yield 
(Scheme 17).  
 
Scheme 17: Formation of iodide intermediate 39 from amino alcohol 38 
 
Non-substituted benzyl alcohol was also synthesised as an intermediate to explore whether an 
electron-rich substituent is required for cyclisation. Amino alcohol 40 was synthesised in 
99 % yield (Scheme 18).  
 
Scheme 18: Synthesis of amino alcohol 40 from ethanol amine 37 
 
Iodide intermediate 41 was then synthesised from amino alcohol 40 with I2, PPh3 and 
imidazole at room temperature for 5 hours in 69 % yield (Scheme 19).  
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Scheme 19: Formation of iodide intermediate 41 from amino alcohol 40 
 
2.1.2. Attempted Cyclisations  
Iodide has been used as the leaving group rather than trifluoroacetic anhydride (TFAA) as 
reported by Metro et al. (Scheme 8).
19
 The pKa of HI is -10 compared to ~0 for CF3CO2H 
indicating that iodide is a much better leaving group. Neighbouring group participation by 
the nitrogen under the reaction conditions could displace the iodide generating an aziridinium 
ion intermediate. The tethered ring system could then potentially undergo nucleophilic attack 
on the highly strained 3-membered ring to afford 1,2,3,4-tetrahydroisoquinoline 42 (Scheme 
20).    
 
Scheme 20: Cyclisation via aziridinium intermediate to afford 1,2,3,4-tetrahydroisoquinoline 42 
 
This ring-closure is described as a 5-endo-tet cyclisation which, according to Baldwin’s 
Guidelines, are kinetically disfavoured. Baldwin’s guidelines are a set of empirically derived 
Guidelines as to which cyclisations are favoured and which are not. The mechanistic 
rationale for these guidelines is based on the 3-D geometry of the orbitals which have to 
interact. 5-Endo-tet cyclisations are not favoured by Baldwin’s Guidelines, although there are 
exceptions, including a well-known 5-endo-trig anomaly of the formation of a cyclic acetal 
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from a carbonyl compound and ethylene glycol (Scheme 21). This example is 
electrophilically led, which is similar to the proposed reaction shown in Scheme 20. 
 
Scheme 21: 5-Endo-trig anomaly 
 
Attempts to generate tetrahydroisoquinoline 42 from iodide 39 were made using heat and 
radicals (Scheme 22). Gentle heating did not encourage the formation of the desired product 
42 and then forcing the reaction by heating at 100 
o
C for 72 hours caused the substrate to 
decompose without formation of the desired cyclised product 42. The use of dicumyl 
peroxide (DCP), a ‘tin-free’ radical, was also attempted.64 DCP decomposes to form a methyl 
radical which is an extremely reactive species. This should then react with the carbon-iodide 
bond to subsequently promote cyclisation of the aromatic system. Unfortunately, the desired 
cyclic product 42 was not observed in any of these reactions. 
 
As previously mentioned, iodide is a powerful nucleophile and therefore there is competition 
between the iodide and the tethered aromatic ring to attack the aziridinium ion. When the 
iodide attacks the aziridinium ion the starting material is reformed. Silver oxide was added to 
sequester the iodide in an attempt to prevent it from attacking the aziridinium ion. This forces 
the equilibrium to form the aziridinium ion and the subsequent attack from the tethered 
aromatic nucleophile to form the desired product. 
 
To test this hypothesis, the reaction of alkyl iodide intermediate 39 and Ag2O in CH2Cl2 at 
room temperature, open to the air was attempted. The cyclic compound 42 was not obtained; 
instead the unexpected symmetrical carbonate product 43 was isolated in 90 % yield along 
with the corresponding alcohol 38 in 7 % yield (Scheme 22). 
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Scheme 22: Isolation of unexpected carbonate 43 in 90 % yield 
 
The presence of the carbonyl group was determined by IR (1744 cm
-1
) and 
13
C NMR (δ 
155.09 ppm), although initially it was unclear how this carbonyl group had been trapped 
within the molecule. Unfortunately, this reaction was not reproducible and only starting 
iodide 39, along with its corresponding alcohol 38, were isolated.  
 
Silver oxide is a sorbent for CO2 which is used to purify air within space suits worn by 
astronauts.
65
 Carbon dioxide is absorbed by silver oxide to produce silver carbonate:  
Ag2O (s) + CO2 (g)   Ag2CO3 (s) 
 
The same reaction was then repeated but this time under an atmosphere of CO2 and the 
symmetrical carbonate 43 was isolated in a reproducible 94 % yield (Scheme 23). 
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Scheme 23: Reaction under CO2 to afford symmetrical carbonate 43 
 
2.1.3. Formation of Carbonates from Carbon Dioxide 
The reaction mechanism is difficult to understand due to the symmetry of the product 43 
obtained therefore two reactions were attempted using a similar alkyl iodide but with the 
addition of methanol as an external nucleophile. One reaction was performed under a N2 
atmosphere and the other under a CO2 atmosphere.  
 
The reaction in the presence of CO2 for 16 hours yielded carbonate 44 in 99 % yield (Scheme 
24).  
 
Scheme 24: Synthesis of carbonate 44 under a CO2 atmosphere 
 
The same reaction under a N2 atmosphere yielded ether 45 in 98 % yield, which is simply the 
product from an SN2 reaction (Scheme 25). These reactions demonstrate that atmospheric 
CO2 is the likely source of the carbonyl group present in the product. 
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Scheme 25: Synthesis of ether 45 under a N2 atmosphere 
 
These same reaction conditions were attempted on unsubstituted iodide intermediate 41 and 
the corresponding carbonate 46 (Scheme 26) and ether 47 (Scheme 27) were also isolated in 
high yields after only 35 minutes.  
 
Scheme 26: Synthesis of carbonate 46 under a CO2 atmosphere 
 
 
Scheme 27: Synthesis of ether 47 under N2 atmosphere 
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This three-component coupling reaction occurs successfully combining a solid, liquid and a 
gas. Kim et al. previously reported a similar three-component coupling reaction in the 
presence of Cs2CO3 and CO2 (Scheme 28).
66
 
 
Scheme 28: Synthesis of carbonate using Cs2CO3
66
 
 
In 2002, Shi and Shen reported a three-component coupling reaction of alcohols, CO2 and 
alkyl halides in the presence of K2CO3 and nBu4NI (Scheme 29).
67
 
 
Scheme 29: Three-component coupling reaction to synthesise carbonate
67
 
 
In 1994, Teranishi reported the preparation of carbonates using Ag2CO3 (Scheme 30).
68
 
 
Scheme 30: Successful preparation for carbonates using silver carbonate
68
 
 
Since the formation of Ag2CO3 is possible in situ (Ag2O (s) + CO2 (g)   Ag2CO3 (s)), we 
examined the effects of using pre-formed Ag2CO3 in the presence and absence of CO2 to help 
further understand the mechanism of this reaction. Following conditions reported by 
Teranishi, Ag2CO3 and 5 equivalents of MeOH were added to a stirred solution of iodide 
intermediate 41 in CHCl3 and the reaction was stirred at room temperature open to the 
atmosphere for 2.5 hours.
68
 The unsymmetrical methyl carbonate 46 was not observed; 
instead the symmetrical carbonate 48 was obtained in 57 % yield (Scheme 31). This product 
is presumably formed by the displacement of the iodide twice and the carbonyl is 
incorporated from the silver carbonate. 
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Scheme 31: Synthesis of symmetrical carbonate 48 from Ag2CO3
68
 
 
The same reaction conditions were performed under a CO2 atmosphere to afford the 
unsymmetrical carbonate 46 in 60 % yield, which suggests the carbonyl from this reaction is 
incorporated from the gaseous CO2 present in the reaction flask (Scheme 32) 
 
Scheme 32: Synthesis of unsymmetrical carbonate 46 in the presence of Ag2CO3 
 
The amount of MeOH and Ag2O was investigated in the reaction, in addition to other silver 
salts (Scheme 33). These results are shown in (Scheme 34, Table 2 and Table 3). 
 
A large excess of 25 equivalents of MeOH (1.00 % v/v) in the reaction gave 100 % 
conversion to the desired unsymmetrical carbonate 46 (Entry 3, Table 2). Lowering the 
equivalents of MeOH promoted the formation of both the symmetrical carbonate 48 and the 
alcohol 40 (Entries 1 and 2, Table 2). No alternative silver salts in this reaction gave any 
desired product (Scheme 34). 1.1 equivalents of Ag2O gave the greatest yield of desired 
unsymmetrical carbonate 46 (Entry 1, Table 3). 
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Scheme 33: Optimisation of reaction conditions to synthesise carbonate 46 
 
Entry Eq. of 
MeOH 
MeOH 
concentration 
(v/v %) 
Ratio of 
unsymmetrical 
carbonate 46
*
 
Ratio of 
alcohol 40
*
 
Ratio of 
symmetrical 
carbonate 48
*
 
1 1.1 0.04 0.65 0.13 0.22 
2 5.0 0.20 0.69 0.22 0.09 
3 25 1.00 1 0 0 
*ratio obtained by 
1
H NMR of crude reaction mixture 
Table 2: Different equivalents of MeOH attempted in reaction conditions 
 
 
Scheme 34: Attempted synthesis of carbonates using different silver salts with 25 eq. MeOH in CHCl3 under an 
atmosphere of CO2  
 
Entry Eq. Ag2O % yield of 46 
1 1.1 95 
2 0.7 80 
3 0.5 67 
Table 3: Different equivalents of Ag2O to synthesise carbonate 46 
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The optimised conditions to afford desired carbonate 46 are shown in Scheme 26, as any 
variations from these reaction conditions diminished the yields of the reaction. 
 
To date, reactions have been performed on functionalised iodides with possible neighbouring 
group participation from the nitrogen. To explore whether these optimised reaction 
conditions occur on unfunctionalised iodides, 1-iodooctane 50 was submitted to the 
optimised reaction conditions (Scheme 35).  
 
The reaction occurred at a much slower rate and mixtures of compounds were observed by 
1
H NMR of the crude reaction mixture. The major product in this reaction was the 
unsymmetrical carbonate in 37 %.  
 
Scheme 35: Mixture of compounds observed by 
1
H NMR of crude reaction mixture 
 
The same reaction conditions were attempted in neat MeOH as the solvent, which improved 
the ratio of unsymmetrical carbonate observed by 
1
H NMR in the crude reaction mixture to 
69 % (Scheme 36). 
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Scheme 36: Mixture of compounds observed by 
1
H NMR of crude reaction mixture (MeOH as solvent) 
 
These results indicate that the carbonyl group originates from the gaseous CO2 present in the 
reaction vessel. To demonstrate the ability of the Ag2O-mediated reaction to capture gaseous 
CO2 and transform it into functionalised carbonates, the reaction with 
13
C-enriched CO2 was 
performed (Scheme 37). 
 
Scheme 37: 
13
C-labelled CO2 experiments to afford hexyl methyl carbonate 51 
 
Either 100 % 
12
CO2 or 100 % 
13
CO2 were generated by adding 3M HCl(aq) to either  5 
equivalents of NaH
12
CO3 or NaH
13
CO3 and bubbling the CO2 evolved directly through the 
reaction mixture and into an empty balloon. After 4 hours, the reaction mixture was filtered 
to remove the silver salts and evaporated under reduced pressure to afford the hexyl methyl 
carbonate 51 without the need for further purification. 
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Yield of 51 
(%) 
Measured ratio Observed ratio 
13
C NMR 
Observed ratio 
HRMS 
 
12
C 
13
C 
12
C 
13
C 
12
C 
        13
C 
68 100 0 100 0 100 0 
60 0 100 2.1 97.9 2.9 97.1 
Table 4: Results of 
13
C labelled CO2 experiments 
 
The yields of the methyl carbonate 51 vary between 60 % and 68 % which is a reflection of 
the heterogeneity of this reaction (Table 4). The reactants are in three different phases; gas 
(CO2), liquid (solution of Hex-I in MeOH) and solid (insoluble Ag2O).  
 
The product was analysed by both 
13
C NMR and High Resolution Mass Spectrometry. The 
integration of the carbonyl peak in the 
13
C NMR spectrum provides information on the 
incorporation of 
13
C using a simultaneous equation calculation (shown in appendices section 
8.1.1.). Due to different relaxation times, the integral of the carbonyl peak differs to the 
integrals of the remaining peaks in the NMR spectra. From the background 
13
C NMR spectra, 
we can determine the difference in the integrals, which is incorporated in the simultaneous 
equation calculation as the “integration factor”. Also, the carbonyl signal for the 13C 
compound (x) will be 100 % abundant, so in order to make a direct comparison with the 
carbonyl signal for the 
12
C compound (y), we must use a conversion factor which accounts 
for the natural abundance of 
13
C (1.11 %). For all other C signals, x + y will simply equal the 
integral of that peak. 
 
A ratio between the 
12
C and 
13
C products could also be determined from integration of the 
corresponding peaks obtained by High Resolution Mass Spectrometry (See calculations in 
appendices 8.1.1.). The m/z of 100 % 
12
C compound shows the MNa
+
 ion at 183.1035 
(39,090, 91.26 %) and 184.1067 (3,746, 8.74 %), due to the natural abundance of 
13
C present 
in carbonate 51. Using this background reading, the ratios of the mixtures were calculated. 
The proportion of the peak at 184.1 due to the natural abundance of 
13
C is (3 746/39 090) of 
the peak at 183.09. 
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The results shown in Table 4 illustrate that the carbonyl is generated from the CO2 in the 
reaction mixture and that it is possible to generate 
13
C-labelled carbonates specifically 
labelled at the carbonyl group from 
13
CO2 under mild reaction conditions.  
To investigate this reaction further, amines were used as an alternative nucleophile. Both 
aniline and benzylamine were combined with 2-iodopropane to afford secondary amine 52 in 
46 % yield, formed from a simple displacement reaction (Scheme 38). The desired carbamate 
was not obtained, possibly due to the lack of nucleophilicity of the amine.  
 
Scheme 38: Formation of secondary amine 52 
 
Carbamate 53 was synthesised from benzylamine in a 14 % yield (Scheme 39). No other 
products were isolated; however, the low yields could possibly be caused by a competing 
displacement reaction.  
 
Scheme 39: Synthesis of carbamate 53 under a CO2 atmosphere 
 
2.1.4. Applications 
CO2 absorption from the atmosphere could be a crucial factor in helping to reduce the effect 
of global warming. CO2 is an attractive sustainable renewable carbon resource in organic 
synthesis as it is abundant and non toxic. The chemical fixation of CO2 into organic 
molecules has generated a lot of interest over the past two decades due to its potential 
environmental benefits.
69
 
 
Organic carbonates have been used for many years in a wide range of applications.
70
 These 
include polymer science,
71
 medical applications
72
 and as protecting groups in synthetic 
chemistry. Carbonates are most commonly synthesised by the use of phosgene,
73
 its 
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derivatives, or carbon monoxide.
74
 Phosgene provides a simple high-yielding route towards 
the formation of carbonates; however, phosgene is a highly toxic reagent and therefore is not 
ideal. Dimethyl carbonate can be synthesised by carbonylation of methanol; however, this 
also involves the use of a toxic gas, carbon monoxide.
75
 This therefore provides a demand for 
developing novel and safe procedures. 
 
Many cancer treatments are not selective and target DNA in both healthy and cancerous cells, 
causing damage to proliferating healthy cells within the body. One strategy to provide an 
increase in the efficacy of these drugs is the development of prodrugs which are non-toxic.
76
 
Prodrugs are transformed into their corresponding biologically active compounds after 
administration, either by metabolism or chemical breakdown.  
 
The three-component coupling reaction in the presence of Ag2O to synthesise carbonates 
could potentially be applied to the synthesis of 
13
C-labelled carbonate prodrugs. The use of 
NaH
13
CO3 would trap the labelled CO2 in a known position and one of the most effective 
ways to follow drug metabolism is to use site-specific labelling.  
 
The proposed synthetic route (disconnection shown in Scheme 7) to synthesise 1,2,3,4-
tetrahydroisoquinolines via alkylation was unsuccessful. An alternative more favourable 
reaction which may access this framework could be an intramolecular Friedel-Crafts 
acylation reaction, which is now discussed. (see section 2.2.).  
 
2.2. Proposed Synthesis via Friedel-Crafts Acylation 
 
2.2.1. Proposed disconnection approach 
Lactam 54 could be synthesised via a Friedel-Crafts acylation reaction following 
disconnection at position a to afford intermediate 55 (Scheme 40). Intermediate 55 can be 
accessed via a Schotten-Baumann reaction following disconnection at position b, to furnish 
two readily accessible starting materials, an acid chloride and an amino acid.   
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Scheme 40: Disconnection approach to synthesise compound 54 
 
Chen et al. synthesised isoquinoline-1,3,4-trione which was found to inhibit caspase-3, a 
protein which plays a crucial role in cell apoptosis (Figure 14).
77
  
 
Figure 14: Caspase-3 inhibitor isoquinoline-1,3,4-trione
77
 
  
Lactam 54 could subsequently be reduced to potentially access a large range of analogues, 
using a variety of amino acid starting materials, which could possess biological activity. 
 
2.2.2. Transformation 
The Schotten-Baumann reaction is a biphasic reaction in which an amide is formed from an 
amine and acid chloride (Scheme 41). Two equivalents of base are required to prevent the 
acid produced in the reaction forming a salt with the remaining unreacted amine, resulting in 
a diminished yield. To optimise the reaction conditions, the second equivalent of aqueous 
base is added slowly during the reaction.  
 
Scheme 41: Schotten-Baumann reaction 
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2.2.3. Synthesis of Intermediates 
Following a procedure reported by Albrecht et al.,
78
 benzoyl chloride and glycine gave 
desired intermediate 56 in a respectable 46 % yield (Scheme 42).  
 
Scheme 42: Synthesis of intermediate 56 
To introduce functionality on the benzene ring, acid chloride 57 was synthesised using 
piperonylic acid and thionyl chloride at 80 
o
C for 4 hours (Scheme 43). Alternative reagents 
are oxalyl chloride and DMF in CH2Cl2, which also carried out this transformation. Thionyl 
chloride is much less easy to remove than oxalyl chloride, owing to its higher boiling point. 
However, it was the preferred method, as DMF was much more difficult to remove during 
work up.  
 
Scheme 43: Synthesis of acid chloride 57 
 
Acid chloride 57 was then submitted to the same Schotten-Baumann conditions with glycine 
to afford intermediate 58 in a diminished 27 % yield (Scheme 44).  
 
Scheme 44: Synthesis of intermediate 58 
 
The reaction is performed in biphasic conditions, yet the acid chloride 57 still gives the 
desired products. By-products from this reaction could arise from hydrolysis of the acid 
choride which could be the reason for the discrepancy in yields of these two Schotten-
Baumann reactions (Scheme 42 and Scheme 44).  
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Presumably increasing the rate of stirring could promote hydrolysis of the acid chloride 
which may be a reason for diminished yields. To explore this hypothesis, the synthesis of 
intermediate 58 was carried out but with alterations in the experimental procedure.  
 
An initial reaction with extremely vigorous stirring was performed, followed by another more 
dilute reaction with additional Et2O. An alternative solvent of CH2Cl2 was also investigated. 
All three gave the desired product 58 but in diminished yields. This suggests these reactions 
are extremely capricious due to the heterogeneity of the reaction mixture. 
 
3,4,5-Trimethoxybenzoyl chloride 59 with glycine in Et2O and aqueous NaOH at room 
temperature for 1 hour was unsuccessful. Only the starting material, 3,4,5-trimethoxy 
carboxylic acid 60, was isolated from the reaction mixture, which is formed from hydrolysis 
of acid chloride 59. The reason this reaction failed is due to the insolubility of 3,4,5-
trimethoxybenzoyl chloride 59 in Et2O. Identical reactions with either CH2Cl2 or acetone as 
the solvent, 3,4,5-trimethoxybenzoyl chloride 59 was again insoluble and only starting 3,4,5-
trimethoxy carboxylic acid 60 was isolated from the reaction mixtures. 
 
However, the use of 1,4-dioxane as a solvent, previously reported by Reeve and Pane, 
intermediate 61 was isolated in 63 % yield (Scheme 45).
79
   
 
Scheme 45: Synthesis of intermediate 61 in 63 % yield
79
 
 
Using 3,4,5-trimethoxybenzoyl chloride 59, alternative amino acids were then investigated 
(Scheme 46). Previously the product precipitated upon the addition of HCl(aq.), however no 
precipitate was observed in these reactions and traditional extraction techniques were used. 
Different ratios of intermediates 62, 63, 64, 65 and also trimethoxybenzoic acid 60 were 
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extracted from the reacton mixtures (Scheme 46). No modification in the equivalents of 
amino acid improved the yields or ratios of these reactions.  
 
Scheme 46: Schotten-Baumann reactions - *yields calculated by 
1
H NMR spectroscopy of crude reaction 
mixture 
 
2.2.4. Cyclisation of Intermediates 
The Friedel-Crafts acylation reaction to cyclise the Schotten-Baumann intermediates will 
now be discussed (Scheme 47). 
 
Scheme 47: Cyclisation of Schotten-Baumann intermediates 
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Intermediate 58 (Scheme 44) was subjected to thionyl chloride at room temperature to make 
the corresponding acid chloride, to investigate the Friedel-Crafts cyclisation. Unfortunately 
no desired cyclised product was seen by 
1
H NMR spectroscopy and the reactants 
decomposed to give a mixture of unidentified compounds. The reaction was resubmitted to 
50 
o
C heating in chlorobenzene for 16 hours to explore the possibility that the reaction was 
not yet complete. However, no identifiable products or cyclised material were present.  
 
Cyclisation of intermediate 56 (Scheme 42) was attempted using a similar strategy to make 
the corresponding acid chloride, instead using oxalyl chloride and DMF in CH2Cl2 at room 
temperature for 1 hour. No desired cyclised product was observed and the starting material 
had decomposed.  
 
The benzene ring with no substitution may not be nuceophilic enough to cyclise and 
therefore trimethoxy intermediate 61 (Scheme 45) was investigated. However, submitting 61 
to oxalyl chloride and DMF in CH2Cl2 at room temperature for 1.5 hours gave a mixture of 
products and after column chromatography the desired cyclised product was not isolated.  
 
Nicolaou et al. reported a Friedel-Crafts acylation through the activation of a carboxylic acid 
with neat BF3·OEt2 (Scheme 48).
80
 
 
Scheme 48: BF3.Et2O complex
80 
 
Following the procedure reported by Nicolaou et al.
80
 the treatment of trimethoxy 
intermediate 61 with neat BF3·Et2O at 120 
o
C for 1 hour afforded no desired product. Friedel-
Crafts cyclisation procedures have been reported by Ramana and Potnis
81
 and Jia et al.
82
 
using H2SO4 at 90 
o
C and room temperature. Intermediate 61 was subjected to these reaction 
conditions but no desired product was observed.  
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Activating the carboxylic acid intermediate 61 using TFAA and/or TFA was also explored;  
again no desired product was observed, although Barlow and Walsh reported a similar 
transformation in PPA with gentle heating over a water bath for 30 minutes.
83
 Following this 
procedure on trimethoxy intermediate 61, only starting material was also isolated. 
 
An explanation for the overall unsuccessful Friedel-Crafts cyclisation of these acids could be 
due to the incorrect orientation. The amide prefers to sit in the trans conformer 67 rather than 
the cis conformer 66. The trans conformer 67 forces the acid away from the nucleophilic 
aromatic ring, thus preventing the intramolecular cyclisation from occurring (Scheme 49). 
 
Scheme 49: Amide conformations 
 
An approach to overcome this is to synthesise di-acid intermediate 68, which lacks this 
problem as the second carboxylic acid group is always available to react with the aromatic 
ring promoting the Friedel-Crafts acylation reaction (Scheme 50). Under the conditions 
reported by Reeve et al.
79
 using 1,4-dioxane as solvent, di-acid 68 was synthesised in 75 % 
yield (Scheme 50).  
 
Scheme 50: Synthesis of intermediate 68 in 75 % yield 
 
To explore the cyclisation of intermediate 68, the di-acid was submitted to thionyl chloride 
with DMF at 80 
o
C for 4 hours and two products were isolated. After purification by column 
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chromatography, methyl 3,4,5-trimethoxybenzoate 70 was isolated in 51 % yield (Scheme 
51).  
 
Furthermore a second unknown compound was isolated and after thorough examination of 
the analytical data, the structure was still unclear. To clarify the structure of this mysterious 
product, a crystal structure was collected (Figure 15, See appendices 8.1.2.), which 
successfully resolved the structure and matched the analytical data when assigned to 
compound 69 (Figure 15 and Scheme 51).  
 
Scheme 51: Unexpected compounds 69 and 70 from SOCl2 cyclisation reaction 
 
 
 
Figure 15: Crystal structure of compound 69 
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The formation of cyclic product 69 was unexpected. The solid state structure of compound 69 
shows the incorporation of a sulfur and chlorine atom from the thionyl chloride as well as the 
presence of a methyl ester. The methyl esters present in products 69 and 70 are formed by the 
addition of MeOH used to quench the reaction mixture. This reaction in thionyl chloride to 
synthesise compound 69 was, unfortunately, not reproducible and, when these reaction 
conditions were repeated, only higher yields of the methyl ester 70 were isolated in all cases.  
 
Wright previously synthesised a similar molecular scaffold in a one-pot procedure through 
the use of ortho lithiation (Scheme 52).
84
 Benzamide 71 was treated with n-BuLi in THF at 0 
o
C for 1 hour, followed by the addition of sulfur powder. The reaction was heated at 50 
o
C 
until the starting material was consumed and the reaction was quenched into dilute acetic 
acid. The mixture was cooled thoroughly in ice and phosgene dissolved in toluene was 
added. After 24 hours products 72 were isolated in good yields (56 - 74 %). 
.  
Scheme 52: Compound 72 was previously synthesised using a one pot procedure
84
 
 
The mechanism of this unexpected transformation (Scheme 51) was then explored. O’Hagen 
et al. reported the transformation of acetic acid to chloroacetyl chloride 73 in the presence of 
thionyl chloride and N-chlorosuccinimide (Scheme 53).
85
  
 
Scheme 53: Synthesis of chloroacetyl chloride 73
85
 
 
Due to the irreproducibility of this reaction, the procedure reported by O’Hagan et al. was 
attempted with acid 68.
85
 Acid 68 in thionyl chloride and NCS at 85 
o
C for 90 minutes gave 
no desired product 69 by crude 
1
H NMR, only a mixture of unidentifiable compounds. The 
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mechanism also must consider the sulfur from thionyl chloride which has been incorporated 
into the structure. The mechanism of this reaction could possibly incorporate a Pummerer-
type rearrangement.  
 
Due to the irreproducible nature of these reactions the role of other factors such as the 
presence of air were investigated. The previous reaction conditions were repeated with air 
bubbled through the mixture at the start of the reaction. The reaction mixture was then heated 
at 80 
o
C for 4 hours and the desired product 69 was isolated in a diminished 13 % yield 
(Scheme 54), the major product of the reaction was trimethoxybenzoic acid 60, which was 
isolated in 56 % yield.  
 
Scheme 54: Synthesis of compound 69 from acid 68 in thionyl chloride and DMF at 80 
o
C for 4 hours, open to 
the atmosphere 
 
Combining the possibility of chlorinating at the α position (Scheme 53), the improvement in 
yield upon the addition of air (Scheme 54) and a Pummerer-type rearrangement, the proposed 
mechanism is shown (Scheme 55). 
 
The proposed mechanism incorporates the double chlorination on both carboxylic acid 
groups, followed by nucleophilic attack of the electron-rich aromatic ring on SOCl2 to afford 
intermediate 74. Cyclisation followed by intramolecular attack of the sulfoxide on the acid 
chloride forms the cyclic intermediate 75, followed by the loss of CO2. Structure 75 does 
seem unlikely, although the same effect could also be achieved if this step occured via 
intermolecular attack from the sulfoxide of another molecule, again followed by the loss of 
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CO2 to result in the same compound 76. Attack of -OH and loss of the chloride affords 1,3-
thiazinanedione intermediate which is quenched with MeOH to form the observed product 
69. Further investigation is still required to determine the precise mechanism of this 
transformation and to subsequently optimise the reaction conditions.   
 
Scheme 55: Proposed mechanism for the formation of compound 69 
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2.3. Conclusions 
The aim of the work described within this chapter was to synthesise the 
tetrahydroisoquinoline framework present in a wide range of natural products. The synthesis 
of this framework was initially attempted using a Friedel-Crafts alkylation reaction. Although 
the appropriate precursors were synthesised in good yields the Friedel-Crafts alkylation 
approach proved unsuccessful.  
 
An unexpected but interesting carbonate side product was observed during the attempted 
Friedel-Crafts cyclisation reactions. This serendipitous result was due to the incorporation of 
CO2 from the atmosphere in the presence of Ag2O. A side project was pursued to explore this 
further as a potential synthesis for carbonate compounds. Mechanistic studies of the 
carbonate synthesis were conducted using 
13
C-labelled CO2. These studies proved that CO2 
present in the reaction vessel was indeed the source of the carbonyl moiety. A range of 
carbonates were subsequently synthesised using this novel approach in high yields. 
 
Alternative, more favourable, Friedel-Crafts acylation reaction conditions were then explored 
to access the tetrahydroisoquinoline framework. This approach was also unsuccessful 
however, the use of SOCl2 led to an interesting side product. Both a sulfur and chlorine atom, 
from the SOCl2, were incorporated into the precursor to form a novel cyclic product, which 
was crystographically characterised. Preliminary mechanistic studies were performed and a 
mechanism was proposed.  
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3. Chapter Three - A/B Analogues of 
Dihydroisoquinolinones 
  
Dihydroisoquinolinones were subsequently investigated as these analogues are also found in 
many naturally occuring compounds (Figure 16). 
 
Figure 16: Structure of tetrahydroisoquinolines and dihydroisoquinolinones 
 
3.1. Proposed Synthetic Route 
The initial focus was to synthesise the A/B lactam core to make the simplified 
dihydroisoquinolinone framework of pancratistatin 16 and narciclasine 17 (Figure 17) 
 
Figure 17: Pancratistatin 16 and narciclasine 17 
 
The proposed synthetic route to access the simplified A/B lactam core of pancratistatin 16 
and narciclasine 17 involves two main transformations (Scheme 56). The lactam framework 
78 will be accessed via an indanone intermediate 77 using a Schmidt reaction or Beckmann 
rearrangement (Step Two). The indanone intermediate 77 will be synthesised following 
disconnection at position a via a Friedel-Crafts acylation reaction on a substituted propanoic 
acid (Step One). 
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Scheme 56: Proposed disconnection approach to access the simplified A/B lactam core of pancratistatin 16 and 
narciclasine 17 
 
3.1.1. Step One - Indanones 
The indanone is not only an important intermediate to gain access to the lactam core; it may 
also be of great interest itself as indanones have been shown to possess potential biological 
activity. Natural products containing the indanone framework have previously been isolated 
from the bark of Taiwania cryptomerioides and other related plants (Figure 18).
5
 Both natural 
products Taiwaniaquinol B and D have been tested for their cytotoxicity against the KB 
epidermoid carcinoma cancer cell line.
86
 Taiwaniaquinol B gave an IC50 value of >10 μM 
and Taiwaniaquinol D gave an improved IC50 value of 3.5 μM. 
 
Figure 18: Taiwaniaquinol B and Taiwaniaquinol D
5 
 
Another compound which contains the indanone moiety and which has been shown to 
possess biological activity is indanocine 79 (Figure 19).
87
 Indanocine has an IC50 value of 
0.001 μM against the Jurkat cell line87 and more recently has been shown to bind to 
microtubules selectively, inducing apoptosis in multi-drug resistant cancer cells.
88
 Indanones 
are very attractive structures in their own right and the intermediates synthesised in this route 
may be of interest to pursue further. 
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Figure 19: Indanocine 79
87
 
 
3.1.2. Step Two - Schmidt Reaction 
The second transformation in the proposed synthetic route is the formation of the lactam core 
from is corresponding indanone which could be achieved by a Schmidt reaction or Beckmann 
rearrangement.  
 
The Schmidt reaction was first discovered in 1924 by Karl Friedrich Schmidt who reported 
the transformation of benzophenone 80 and hydrazoic acid to benzanilide 81 (Scheme 57).
89
 
 
Scheme 57: The first reported Schmidt reaction on benzophenone 80 to afford benzanilide 81
89
 
 
When the indanone intermediate 77 is treated with sodium azide under acidic conditions, it 
should undergo a Schmidt reaction to yield the desired lactam 78 (Scheme 58). 
 
Scheme 58: Schmidt reaction to yield desired lactam 78 from indanone 77 
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The mechanism for the Schmidt reaction on a ketone (indanone 77) starts with the activation 
of the carbonyl by protonation, followed by nucleophilic addition by the azide to form 
intermediate 82 (Scheme 59). Intermediate 82 then loses water in an elimination reaction to 
form imine 83, which undergoes alkyl migration driven by the loss of nitrogen. The 
subsequent attack of water and loss of a proton affords 84, which is the tautomer of the final 
amide (lactam 78).  
 
Scheme 59: Schmidt reaction mechanism 
 
Imine 83 could also undergo aryl migration to afford the undesired lactam regioisomer 86. 
Although the cation intermediate formed on elimination of the nitrogen via alkyl migration is 
more stabilised by the benzylic position, as shown in Scheme 61. 
 
3.1.3. Step Two - Beckmann Rearrangement 
The same transformation could also be carried out using a Beckmann rearrangement on an 
oxime intermediate under acidic conditions (Scheme 60). The use of the Beckmann 
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rearrangement allows an alternative method to access the desired lactam framework 78 and is 
worth investigating. 
 
Scheme 60: Beckmann rearrangement 
 
The mechanism of this reaction is outlined in Scheme 61. Oxime 85 is initially formed, 
which under acidic conditions becomes protonated and migration of the group trans to the 
OH in the oxime occurs.  
 
Scheme 61: Beckmann rearrangement mechanism 
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3.2. Results and Discussion 
 
3.2.1. Step One - Intramolecular Indanone Synthesis 
A/B analogues were initially used as a simplified framework and intramolecular indanone 
syntheses were attempted from substituted propanoic acids as starting materials. 
 
Dallemagne et al. reported in 1991 a procedure for intramolecular cyclisation reactions, to 
generate indanones from their corresponding dihydrocinnamic acids, using trifluoroacetic 
acid (TFA) and trifluoroacetic anhydride (TFAA) (Scheme 62).
90
 
 
Scheme 62: Intramolecular cyclisation using TFA/TFAA to afford indanones
90
 
 
Following these reaction conditions, 3-(3,4-methylenedioxyphenyl)propanoic acid 87 was 
treated with TFA and TFAA at 50 
o
C for 3 hours. After aqueous work-up, the desired 
indanone 88 was isolated in 20 % yield. Without an aqueous work-up, column 
chromatography of the reaction mixture gave the desired indanone 88 in 81 % yield (Scheme 
63). Unfortunately the results were not consistent so the reaction was explored further.  
 
Scheme 63: Intramolecular A/B indanone synthesis of compound 88 
 
3-(3,4-Methylenedioxyphenyl)propanoic acid 87 was treated with TFA:TFAA (1:1) in a 
sealed pressure tube and heated to 100 
o
C for 1 hour. The isolation of indanone 88 gave a 
comparable 84 % yield, although it was difficult to isolate the products from the crude 
mixture by column chromatography due to by-products eluting closely.  
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A similar transformation by Kolokythas et al. in 2006 was reported using TFA and TFAA in 
a (2:1) ratio.
91
 This was attempted on acid 87 in TFA: TFAA (2:1) at 100 
o
C in a sealed 
pressure tube for 2 hours to yield 72 % of indanone 88.  
 
It was then investigated whether the addition of either TFAA or TFA alone would afford the 
indanone product. The reaction of acid 87 in 2 eq. of TFA at 100 
o
C for 2 hours gave only 
starting material. However, the reaction in 1 eq. of TFAA at 100 
o
C for 2 hours afforded 80 
% yield of indanone 88 with the most effective purification (Scheme 64).  
 
Scheme 64: Optimised conditions for intramolcular indanone synthesis 
 
Other substituted 3-arylpropanoic acids were then subjected to these optimised conditions, as 
shown in Scheme 65. 
 
Scheme 65: Synthesis of intramolecular indanones 90 and 92 
 
3-(3,4-dimethoxyphenyl)propanoic acid 89 gave the corresponding indanone 90 in 74 % 
yield and 3-(3,4,5-trimethoxyphenyl)propanoic acid 91 afforded indanone 92 in 88 % yield. 
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The reaction with hydrocinnamic acid 93 gave a complicated mixture of compounds and no 
desired product 94 was isolated, suggesting the aromatic ring carrying no activating methoxy 
groups may not be nucleophilic enough for this cyclisation to occur.  
 
The scope of this reaction was explored further by subjecting 4-(indol-3-yl)butanoic acid 95 
to the optimised reaction conditions, affording the desired cyclic ketone 96 in 72 % yield 
(Scheme 66). This transformation had previously been reported with PPA in toluene at 110 
o
C for 4 hours in 85 % yield.
92
  
 
Scheme 66: Intramolecular Friedel-Crafts cyclisation reaction to synthesise cyclic ketone 96 
 
The reaction of TFAA with 4-(indol-3-yl)propanoic acid 97 proved unsuccessful, instead, a 
procedure reported by Maertens et al. in 2004 was used. Following this procedure, PPA was 
treated with 4-(indol-3-yl)propanoic acid 97 in toluene at 110 
o
C for 4 hours to yield the 
cyclic ketone 98 in 81 % yield (Scheme 67).
92
  
 
Scheme 67: Intramolecular Friedel-Crafts cyclisation reaction to synthesise cyclic ketone 98 
 
3-(Furan-2-yl)propanoic acid 99 in TFAA at 100 
o
C in a pressure tube for 2 hours did not 
yield the desired corresponding cyclic ketone. Instead, the furanyl ring performed an 
intermolecular attack on TFAA to afford product 100 in 14 % yield and a mixture of other 
unidentified compounds (Scheme 68). The methyl ester was obtained possibly due to the 
presence of an anhydride intermediate in the reaction mixture, which upon treatment with 
MeOH to transfer the reaction mixture from the pressure tube afforded the methyl ester 
product 100.  
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Scheme 68: The formation of side product 100 from 3-(furan-2-yl) propanoic acid 
 
3.2.2. Step Two - Schmidt Reaction 
The first transformation has been carried out under mild conditions and high yields to afford 
a range of A/B indanone derivatives. The Schmidt reaction or Beckmann rearrangement 
should now provide access to the A/B lactam core. 
 
Schmidt reactions attempted on A/B indanone 88 using previously reported H2SO4 or PPA 
were unsuccessful. Since the indanone structures have previously been synthesised using 
TFA, the same conditions were attempted using TFA as the acid in the Schmidt reaction. 
When this reaction was performed, the desired lactam 101 was obtained in 32 % yield.  
 
To optimise the conditions and improve this yield, the experiment was repeated with 2 eq. 
NaN3 at 100 
o
C in TFA and left to stir for 22 hours in a sealed pressure tube, which gave 
lactam 101 in an improved 63 % yield (Scheme 69). This reaction yields N2 gas as a side 
product and so safety measures were taken to prevent the danger of increasing pressure. 
 
Scheme 69: Schmidt reaction on A/B indanone 88 to afford lactam 101 in 63 % yield 
 
This same lactam 101 has previously been synthesised following a different route within the 
group. An identical analytical 
1
H NMR spectrum confirmed that 101 is the observed 
regioisomer.
93
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In 1965, Lansbury and Mancuso reported that the Schmidt reaction of lactam 102 in PPA 
mainly gave the product of alkyl migration (Scheme 70).
94
 However, using indanone 94 with 
no substitution, the major product was from aryl migration. 
 
Scheme 70: Non-regiospecificity in the Schmidt reaction
94
 
  
More recently, Torrisi et al. in 2010 reported a Schmidt reaction on indanone 103 and NaN3 
again in H2SO4 to afford also the product from aryl migration, lactam 105 in 61 % yield 
(Scheme 71).
95
 
 
Scheme 71: Schmidt reaction on indanone 103 to afford lactams 104 and 105
95
 
 
In 2006, Jesudason et al. reported a Schmidt reaction on a similar A/B indanone 106 with a 
methoxy group ortho to the carbonyl group.
96
 Using H2SO4, the major product was from 
migration of the alkyl group to afford the desired regioisomer, lactam 107 in 79 % yield 
(Scheme 72).  
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Scheme 72: Schmidt reaction on indanone 106 to synthesise lactam 107 in 79 % yield
96
 
 
In 2009, Ortega et al. reported a Schmidt reaction on unsubstituted A/B indanones 108 
(Scheme 73).
97
 Schmidt reactions using PPA or H2SO4 have previously afforded lactams 
from aryl migration as the major product (Scheme 70 and 71). However, Ortega et al. found 
that, by changing the reaction medium to concentrated aqueous HCl, lactams from alkyl 
migration 109 are afforded as the major product in 75-85 % yields (Scheme 73).  
 
Scheme 73: An example of a Schmidt reaction using conc. aq. HCl as the acid catalyst
97
 
 
A previous report with a similar substrate containing the A/B/C lactam ring system 110 
showed high regioselectivity in a Schmidt reaction to give lactam 111 in 55 % yield (Scheme 
74).
98
 Alkyl migration rather than aryl migration leads to the more stable cation, as the 
positive charge is stabilised at the benzylic position, which could be the reason for the 
formation of the desired regioisomer. 
 
Scheme 74: Schmidt reaction to yield desired regioisomer 111 in 55 % yield
98
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As previously discussed, Schmidt reactions attempted on A/B indanone 88 utilising 
previously reported conditions were unsuccessful. Instead of using PPA or H2SO4, reaction 
conditions of 2 eq. NaN3 at 100 
o
C in TFA for 22 hours in a sealed pressure tube gave the 
best results (Scheme 69).  
 
In 2006, a Beckmann rearrangment on a similar A/B/C indanone 112 was reported and the 
regioisomer 113 was isolated (Scheme 75).
99
 No yield for this reaction was reported.    
 
Scheme 75: Beckmann rearrangement using PPA to afford lactam 113 
99
 
 
The optimised conditions using TFAA and 2 eq. NaN3 at 100 
o
C in TFA for 22 hours in a 
sealed pressure tube developed to isolate lactam 101 (Scheme 69) have been applied to the 
other synthesised A/B indanones to give the desired corresponding lactams 114 and 115 from 
alkyl migration (Scheme 76). The other possible regioisomers were not observed in these 
reactions.  
 
Scheme 76: Optimised Schmidt reactions to afford A/B lactams 114 and 115 
 
The desired regioisomer, lactam 116, was also formed from a Schmidt reaction on cyclic 
ketone 96 in 24 % yield (Scheme 77). 
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Scheme 77: Schmidt reaction on cyclic ketone 96 to afford lactam 116 
 
3.3. Tetrazoles 
 
3.3.1. Optimisation 
Yadav et al. recently reported a Schmidt reaction on a variety of substrates in the presence of 
FeCl3, an example of which is shown in Scheme 78.
100
 The identical procedure was repeated 
using cyclohexanone 117 but, unfortunately, no desired lactam 118 was formed and only 
starting material was recovered.  
 
Scheme 78: Schmidt reaction in the presence of FeCl3 to afford lactam 118 in 70 % yield
100
 
 
Conducting the reaction at 40 
o
C for 3.5 hours led to partial reaction, shown in scheme 79. 
Crude 
1
H NMR showed a mixture of starting material 117, lactam 118 and also the 
unexpected tetrazole 119.  
 
Scheme 79: Mixture of products from a Schmidt reaction on ketone 117 
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Previously, this transformation of a cyclic ketone to its corresponding tetrazole had been 
reported using NaN3 and AlCl3.
101
 
 
To prevent the formation of tetrazole 119, the reaction was repeated using only 1 equivalent 
of NaN3. This indeed did prevent the sythesis of the tetrazole and only lactam 118 was 
observed by 
1
H NMR.   
 
To investigate the formation of tetrazole 119, the reaction was performed using 4 equivalents 
of NaN3. The reaction was again carried out at 40 
o
C with FeCl3 and CH2Cl2 as the solvent 
and the desired tetrazole 119 was isolated in 80 % yield (Scheme 80).  
 
Scheme 80: Synthesis of tetrazole 117 
 
These optimised reaction conditions were then applied to the dimethoxy indanone 90 but the 
reaction did not give the desired product and only starting material was isolated. 
Dichloroethane was used as the solvent in order to cater for an increase in temperature to 84 
o
C. After 24 hours, only starting material was observed by TLC and after heating in a 
pressure tube at 120 
o
C for 6 hours, again only starting material was recovered.  
 
Indanone 90 when subjected to FeCl3, 4 equivalents of NaN3 in dichloroethane at 100 
o
C in a 
pressure tube for 16 hours afforded tetrazole 120 in 44 % yield (Scheme 81). The 
regioisomer of the tetrazole was determined by HMBC NMR (see appendices 8.2.1.).  
 
Scheme 81: Formation of tetrazole 120 
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However, this reaction was extremely capricious and, when the exact conditions were 
repeated on the identical substrate 90, only starting material was recovered.  
 
3.3.2. Synthesis and Mechanism 
In the previous optimised Schmidt reactions (Scheme 76 and 77) only 2 equivalents of NaN3 
were used. The addition of 4 equivalents gave rise to not only the same desired lactams, 
though in diminished yields, but also their corresponding tetrazoles (Scheme 82). These 
reactions are low yielding, but are reproducible.  
 
Scheme 82: Synthesis of tetrazoles 120, 121 and 122 
 
The mechanism of this transformation was then investigated. As both the lactam and 
tetrazole are formed in the same reaction vessel, lactam 101 was placed back into the same 
reaction conditions, to determine whether any tetrazole is again formed, which would 
indicate the lactam is an intermediate towards the tetrazole. No tetrazole 121 was observed 
after 18 hours under the reaction conditions, only lactam remained, which suggests the 
lactam is not an intermediate towards the tetrazole (Scheme 83). 
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Scheme 83: Lactam 101 placed back into the same reaction conditions and no tetrazole 121 was observed 
 
The proposed mechanism is outlined below (Scheme 84). The lactam is formed by capturing 
the benzylic cation by the addition of H2O as the nucleophile. However, in the presence of an 
excess of NaN3, the N3
-
 nucleophile captures the cation instead which then cyclises to afford 
the tetrazole in the observed isomer.  
 
Scheme 84: Proposed tetrazole mechanism 
  
3.3.3. Biological Activity of Tetrazoles 
Compounds containing the tetrazole moiety have been shown to possess a range of biological 
activities (Figure 20). Losartan is commonly used for the treatment of hypertension, TAK-
456 is an antifungal agent and PTZ is used to treat anxiety.
102,103
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Figure 20: Drugs which contain the tetrazole moiety 
 
Kumar et al. have reported the biological evaluation on tetrazole-containing compounds as 
potential anticancer agents.
103
 In this report, a series of novel tetrazole containing analogues 
were synthesised and tested against a range of five cancer cell lines, showing promising 
anticancer activites. The three analogues below displayed good activity in the liver carcinoma 
cell line (HepG2) and also prostate cancer cell line (DU145) (Figure 21).  
 
Figure 21: Three analogues containing the tetrazole moiety which show promising anticancer activity
103
 
 
3.4. Oxidation Reactions  
The 10b position on narciclasine 17 is sp
2
 hybridised (Figure 22). To mimic this, oxidation of 
the A/B lactams has been investigated to determine whether this alters the biological 
activities of these simplified lactam analogues.  
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Figure 22: The sp
2
 hybridisation at position 10b in narciclasine 17 enhances potency 
 
3.4.1. Dehydrogenation using DDQ 
Tsai et al. reported the dehydrogenation of a lactam to afford its corresponding oxidised 
product in 70 % yield using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (Scheme 
85).
104
 
 
Scheme 85: Dehydrogenation using DDQ in 1,4-dioxane under reflux
104
 
 
Lingam et al. later also reported dehydrogenation using DDQ as a step in the first reported 
total synthesis of Bauerine C (Scheme 86).
105
 
 
Scheme 86: Dehydrogenation in the synthesis of Bauerine C
105
 
 
The reaction of DDQ (8 eq.) in 1,4-dioxane at 110 
o
C for 18 hours was performed on 
trimethoxy lactam 115. Starting material and product were shown to be present by 
1
H NMR 
spectroscopy of the crude reaction mixture. However, the DDQ and its products proved 
extremely difficult to remove from the desired material.  
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Previous work within the group involved similar transformations using DDQ as a reagent, 
these reactions also obtained low yields as the products were difficult to isolate and therefore 
an alternative procedure was investigated.  
 
3.4.2. Dehydrogenation using Pd/C 
Hutchinson et al. reported the successful dehydrogenation of a cyclic lactam to afford its 
oxidised product, using Pd/C in EtOH (Scheme 87).
106
  
 
Scheme 87: The oxidation of a lactam using Pd/C
106
 
 
Later, Dufour and Kirsch also reported oxidation by use of Pd/C in xylene (Scheme 88).
107
 
 
Scheme 88: Oxidation of a lactam using Pd/C in xylene
107
 
 
Following this procedure reported by Dufour and Kirsch, trimethoxy lactam 113 and Pd/C in 
xylene were heated at reflux for 24 hours. However, only starting material was recovered.  
 
Awvah and Capretta reported this transformation using solvent-free conditions on dimethoxy 
lactam 114 to isolate desired product 123 in 98 % yield (Scheme 89).
108
  
 
Scheme 89: Oxidation of lactam 114 in solvent-free conditions using Pd/C at 150 
o
C for 30 minutes 
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These conditions were repeated on the identical substrate 114, unfortunately only starting 
material was recovered. After discussions with the authors, they suggested using previously 
reported solvent-free conditions at 200 - 210 
o
C.
109
 These conditions were repeated under an 
argon atmosphere as described and the desired products 123 and 124 were isolated (Scheme 
90).  
 
Scheme 90: Oxidations of A/B lactams 114 and 115 to afford compounds 123 and 124 
 
The large difference in yields of these two substrates demonstrates that these are very 
capricious reactions. An alternative method which was explored is the use of a microwave. 
Lactam 114 and Pd/C in xylene at 200 
o
C in a microwave for 60 minutes afforded lactam 123 
in 98 % yield (Scheme 91). This reaction is reproducible and these appear to be the most 
efficient conditions for this transformation.  
 
Scheme 91: Successful oxidation of lactam 114 in the microwave to afford compound 123 in 98 % yield 
 
3.5. Biological Activity 
The A/B lactam and tetrazoles have been tested in an MTS cell proliferation assay using 
colon cancer cell line HT29 and breast cancer cell line MDA-MB-231.  
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Previously synthesised via a different route and tested on the HT29 cell line within the group 
were the A/B lactams and A/B oxidised lactams (Figure 23).
110
 
 
Figure 23: Compounds previously synthesised and tested within the group
110
 
 
The weak activities of these A/B lactam analogues are expected. This is because they all lack 
the C-ring which, as explained previously in the structure-activity relationship of 
pancratistatin, is required to retain the activity (1.2.3.3.). As previously discussed, the 
presence of the free phenol in pancratistain has been shown to increase the activity by 10-
fold. Lactam 126 would therefore be expected to display increased activity compared to 
lactam 114, although the observed difference is not significant.   
 
Oxidised products (125, 123 and 127) show improved activity, which mimics the difference 
between pancratistatin and narciclasine. Pancratistatin 16 and narciclasine 17, when tested in 
the National Cancer Institute 60 cell line screen, displayed GI50 values of 0.091 μM and 
0.016 μM, respectively. Narciclasine 17 contains the sp2-hybridised 10b position and its 
activity is slightly greater than pancratistatin 16. The oxidised A/B lactams also demonstrate 
this improved activity compared to their corresponding hydrogenated lactam analogues 
(Figure 23). 
 
Trimethoxy lactam 115 was tested in both HT29 and MDA231 cancer cell lines (Figure 24, 
see appendices 8.2.2.). The IC50 value of lactam 115 was above the highest measured 
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concentration of 500 μM. Methylenedioxy lactam 101 and dimethoxy lactam 114 also gave 
an IC50 value >500 μM. 
 
Figure 24: IC50 values of trimethoxy lactam 115 in HT29 and MDA231 cancer cell lines 
 
Due to the potential activity of the tetrazole side products, the analogues synthesised were 
also tested in both HT29 and MDA231 cancer cell lines (Figure 25, see appendices 8.2.2.). 
These compounds were not active in either of the colon or breast cancer cell lines, so were 
not pursued any further. Oxidation of these compounds was considered but the stability of 
these tetrazoles at such high temperatures is unclear, so oxidations were not performed.  
 
Figure 25: IC50 values of tetrazoles 120, 121 and 122 in HT29 and MDA231 cancer cell lines 
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3.6. Conclusions 
The aim of the work described within this chapter was to synthesise a range of A/B 
indanones that could subsequently be transformed into their corresponding lactams. Indanone 
formation was conducted using a range of commercially available substituted propanoic 
acids. The formation of indanones was acheived via an intramolecular Friedel-Crafts 
acylation reaction using TFAA as an activator and a library of indanones were synthesised in 
high yield. 
 
A Schmidt reaction or Beckmann rearrangement was proposed to access the A/B lactam 
framework from the indanone intermediate. Schmidt reactions were first attempted for a 
range of indanones and proved successful; due to the success of these transformations 
Beckmann rearrangements were not attempted. The Schmidt reaction conditions were then 
optimised and were used to synthesise a library of A/B lactams from their corresponding 
indanones in good yield. During the optimisation of the Schmidt reaction conditions the 
synthesis of tetrazoles was observed when a large excess of NaN3 was used. This 
phenomenon was explored further and a range of tetrazoles were synthesised in low yield.  
 
The lactams and tetrazoles were submitted for biological testing for growth inhibition against 
HT29 and MDA231 cancer cell lines. IC50 values were not observed for any of the tetrazoles, 
with concentrations tested up to 500 µM. A range of lactams were also tested and showed 
low activity, with IC50 values ranging from 71 µM to >500 µM. No significant activity was 
anticipated for these lactams as they lack a C-ring and associated functionality. 
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4. Chapter Four - A/B/C Analogues of 
Dihydroisoquinolinones 
 
4.1. Proposed Synthetic Route 
The proposed synthetic route can also be applied to the A/B/C ring system through two main 
transformations. The A/B/C lactam framework will also be accessed via an indanone 
intermediate using a Schmidt reaction or Beckmann rearrangement. The indanone 
intermediate could potentially be synthesised through two different routes, depending on the 
disconnection approach used (Scheme 92).  
 
Scheme 92: Proposed disconnection approach to synthesise A/B/C ring system through two main 
transformations 
 
Disconnections at positions a and b results in commercially available starting materials α,β-
unsaturated cyclohexene carboxylic acid and a functionalised benzene ring (Route 1). The 
second approach uses alternative disconnections at positions a and c. The two commercially 
available starting materials comprise of a functionalised cyclohexene ring and a substituted 
benzoic acid (Route 2).   
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Once optimised this synthetic strategy of utilising two different routes towards the indanone 
intermediate enables flexibility in the variety of commercially available starting materials 
which could potentially be used. This facilitates the ability to produce a wider range of novel 
non-natural analogues of the pancratistatin and narciclasine core.  
 
As previously discussed the second transformation to form the lactam scaffold from its 
corresponding indanone can be performed using NaN3 under acidic conditions to undergo a 
Schmidt reaction. Alternative conditions to afford the lactam core utilises a Beckmann 
rearrangement which is performed with NH2OH under acidic conditions. 
 
4.1.1. Route 1 - Intermolecular Indanone Synthesis - Mechanistic Pathways 
Indanone synthesis following Route 1 with disconnections a and b (Scheme 92) provides an 
α,β-unsaturated cyclohexene carboxylic acid and a functionalised benzene ring as starting 
materials. This reaction mechanistically can proceed through two different pathways 
(Scheme 93).  
 
Scheme 93: Indanone synthesis via Route 1 which can follow two different mechanistic pathways 
 
If the α,β-unsaturated carboxylic acid and benzene ring starting materials initially undergo a 
Friedel-Crafts acylation reaction to form the aryl vinyl ketone 128. This intermediate can 
then undergo either a Nazarov cyclisation or an intramolecular Friedel-Crafts alkylation to 
afford the desired indanone (Pathway A).   
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Alternatively, the α,β-unsaturated carboxylic acid and benzene ring in the initial step could 
react through a 1,4 conjugate addition to afford acid intermediate 129, followed by an 
intramolecular Friedel-Crafts acylation reaction (Pathway B) to yield the same indanone. 
 
4.1.2. Route 1 - Nazarov Cyclisation 
Divinyl ketone 128 intermediate formed in Pathway A can undergo a Nazarov cyclisation, a 
ring-closing 4π electrocyclisation reaction, to afford the desired indanone.111 For this 
transformation to occur, acidic reaction conditions are required to protonate the ketone, 
which forms a favourable conjugated π system, five p-orbitals with 4π electrons, to 
encourage the electrocyclisation to proceed (Scheme 94).  
 
Scheme 94: Nazarov cyclisation mechanism 
 
In 2006, Liang et al. reported the synthesis of similar structures Taiwaniaquinoids (Figure 
18) using a Nazarov triflation procedure.
112
  
 
4.1.3. Route 1 - Introducing Functionalisation 
Route 1 must be capable of incorporating substitution both on the A-ring and the C-ring in 
order to achieve the functionalisation required to retain activity.   
 
There are a range of commercially available substituted benzene rings, including anisole, 1,3-
benzodioxole and 1,2,3-trimethoxybenzene (Figure 26). An example of a more functionalised 
α,β-unsaturated carboxylic acid is commercially available shikimic acid (Figure 26). This 
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may require a protection-deprotection strategy in order to obtain the highly oxygenated C-
ring of pancratistatin and narciclasine analogues.  
 
Figure 26: Commercially available starting materials to incorporate substitution via Route 1 
 
4.1.4. Route 2 - Intermolecular Indanone Synthesis 
Complementary Route 2 follows two different disconnections at positions a and c (Scheme 
92). The commercially available starting materials include a cyclohexene ring and a 
substituted benzoic acid.  
 
An example of this transformation was previously reported by Rand and Dolinsky between 
benzoic acid and cyclohexene in polyphosphoric acid (PPA) to afford indanone 130 in 52 % 
yield (Scheme 95).
113
  
 
Scheme 95: Synthesis of Indanone 130 in the presence of PPA
113
 
 
4.1.5. Route 2 - Introducing Functionalisation 
Incorporation of substitution on the A-ring and C-ring is also important in Route 2. A variety 
of commercially available substituted olefins could be used to gain interesting substitution 
around the C-ring. Also various substituted benzoic acids are commercially available to 
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achieve functionalisation on the A-ring (Figure 27). The regioselectivity in the indanone 
formation of the functionalised cyclohexene C-rings will depend on the type of olefin used. 
 
Figure 27: Commercially available starting materials to incorporate functionalisation via Route 2 
 
4.2. Results and Discussion 
 
4.2.1. Route 1 - Intermolecular Indanone Synthesis  
Ramana et al. synthesised thermodynamically more stable cis
114
 indanone 131 in 59 % yield 
from anisole and an α,β-unsaturated ester in concentrated H2SO4 at 90 
o
C (Scheme 96).
81
 The 
methoxy group present in anisole is electron-donating and therefore directs ortho or para. 
The indanone 131 obtained shows that this mechanism proceeded initially with a 1,4-addition 
followed by a Friedel-Crafts acylation reaction following Pathway B (Scheme 93).  
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Scheme 96: Synthesis of cis indanone 131 
 
This experimental procedure using the same reagents, anisole and α,β-unsaturated methyl 
ester, was performed to check the reproducibility of this literature example. However, mostly 
starting materials were present by crude 
1
H NMR. Only when the crude sample was 
submitted to mass spectrometry was a peak corresponding to the product identified. 
 
Tang et al. developed an efficient Friedel-Crafts acylation followed by a Friedel-Crafts 
alkylation to afford the skeleton of the taiwaniaquinoids
5
 following Pathway A. In this report 
reactions were attempted on reagents anisole and geranic acid (Scheme 97). Various acidic 
media were tried including H2SO4 with AcOH, PPA, BF3·Et2O and methanesulfonic acid 
with phosphorus pentoxide. The most successful reaction reported was methanesulfonic acid 
with phosphorus pentoxide which yielded 75 % of the desired indanone 132.  
 
Scheme 97: Synthesis of indanone 132 in 75 % yield
5
 
 
The identical reaction was performed as reported; however the TLC and 
1
H NMR spectrum 
of the crude reaction mixture showed complicated mixtures of inseparable compounds. The 
reaction was repeated under a N2 atmosphere and also at room temperature though these 
reactions were again unsuccessful. The same reaction conditions were attempted using 
anisole with cyclohexene-1-carboxylic acid, from which only a trace of impure indanone was 
obtained after column chromatograhy. 
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Successful indanone syntheses using substituted benzene rings with α,β-unsaturated methyl 
esters in the presence of AcOH and H2SO4 (1: 9) at 5 
o
C have been reported (Scheme 98).
115
 
The report states their mechanism proceeds through a conjugate addition followed by a 
cyclo-acylation reaction (Pathway B). When the reaction was carried out, no desired product 
was obtained; instead the starting material was isolated in 75 % yield.  
 
Scheme 98: Reported indanone synthesis using AcOH-H2SO4
115
 
 
The syntheses of a series of indanones were reported using α,β-unsaturated acyl chlorides and 
AlCl3 in dry dichlorobenzene under microwave conditions.
116
 The reported mechanism 
proceeds via a tandem Friedel-Crafts acylation followed by a Nazarov cyclisation (Pathway 
A).  
 
Acid chloride 133 was synthesised from its carboxylic acid using either thionyl chloride
117
 or 
oxalyl chloride
118
. Similar conditions using AlCl3, under N2 at 80 
o
C were attempted using 
cyclohexene-1-carbonyl chloride 133 and anisole (Scheme 99). Unfortunately the starting 
materials decomposed and no desired indanone or starting material was isolated.  
 
Scheme 99: Unsuccessful indanone formation from acid chloride 133 and AlCl3 
 
The same reaction conditions were then repeated at room temperature and a mixture of 
products were obtained. After column chromatography, uncyclised alkene 134 was isolated 
in 44 % yield and chloride 135 was isolated in 4.5 % yield (Scheme 100).  
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Scheme 100: Synthesis of compounds 134 and 135 at room temperature in the presence of AlCl3  
 
Under these reaction conditions, the methoxy group present in anisole demethylated and 
reacted to afford a mixture of other products which were identified by HRMS but not isolated 
(Figure 28).  
 
Figure 28: By-products from reaction shown in Scheme 100 
 
The isolation of alkene 134 reinforces the reported mechanism by Yin et al. of an initial 
Friedel-Crafts acylation reaction followed by the Nazarov cyclisation or Friedel-Crafts 
alkylation using AlCl3 (Pathway A).
116
 
 
A similar reaction of cyclohexenoyl chloride 133 and AlCl3 in dry benzene, under reflux for 
five hours has been reported to obtain the corresponding indanone in 65 % yield.
119
 When 
these exact reaction conditions on identical substrates were repeated, only starting material 
was recovered. 
 
Nicolaou et al. reported the use of BF3·Et2O to perform a Friedel-Crafts acylation reaction.
80
 
A variety of conditions and substrates were attempted at temperatures ranging from room 
temperature to 120 
o
C and no indanones were recovered. 
 
Due to the previous success of TFAA on the A/B intramolecular indanone analogues, this 
was also applied to the intermolecular indanone synthesis. Reactions with anisole or at lower 
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temperatures of 50 
o
C gave no desired indanone. Therefore, optimisation was carried out on 
1,3-benzodioxole and  cyclohexene-1-carboxylic acid (Scheme 101). 
 
Scheme 101: Optimisation of indanone 136 via Route 1 
 
Different ratios of TFA: TFAA were used, the work-up was modified, the equivalents of 
benzodioxole were varied and the time of reaction was also adjusted (Table 5). Optimum 
conditions (Method 1I) of cyclohexene-1-carboxylic acid and 2 eq. of 1,2-benzodioxole in 
TFAA at 100 
o
C for 4 hours afforded desired indanone 136 in 84 % yield. The addition of 
other acids were also investigated; however, the yields did not improve.
120
 The same reaction 
was also attempted using methyl cyclohexene-1-carboxylate but only starting material was 
recovered, indicating the starting material must be as the free acid for this reaction to 
proceed. 
Method TFAA:TFA 
ratio 
Aq. 
wash 
Addition 
of acid? 
Eq. of 
Benzodioxole 
Time (h) Yield of 
136 
1A 1:2 No No 1.0 1 66% 
1B 1:2 No No 1.0 3.5 82% 
1C 1:2 No No 1.0 6 72% 
1D 1:2 No No 1.1 17 56% 
1E 1:2 Yes No 2.0 4 59% 
1F 1:0 Yes No 2.0 4 75% 
1G 1:0 Yes H3PO4 2.0 4 57% 
1H 1:0 Yes H2SO4 2.0 4 31% 
1I 1:0 No No 2.0 4 84% 
Table 5: Optimisation of the reaction conditions to afford indanone 136 using 1 eq. of cyclohexene-1-
carboxylic acid at 100 
0
C 
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As previously discussed (1.2.3.3.) the indanone must have a trans fused B/C ring junction to 
retain biological activity of these analogues. The dihedral angle of the two hydrogen atoms 
was modelled using Chem 3D Pro 11 and MM2 minimisation. The angles were calculated at 
~36
o
 for the cis geometry and ~167
o
 for the trans geometry. Using the Karplus equation
121
 
the J coupling between the two hydrogen atoms was predicted to be ~7.5 Hz for the cis and 
~12 Hz for the trans isomer. The J coupling between the two hydrogen atoms was observed 
as 7.0 Hz by 
1
H NMR spectroscopy, indicating the product is the cis isomer. The relative 
configuration was confirmed by an X-ray crystal structure (Figure 29). The cystal structure 
shows that the H(5) and H(10) hydrogen atoms reside as the cis isomer relative to each other, 
with a H(5)-C(5)-C(10) angle of 110.7(1) 
o
 and a C(5)-C(10)-H(10) angle of 106.3(1) 
o
. Also, 
the C(11)-O(3) bond length is 1.2236(15) Å, which is consistent with a C=O double bond.  
 
 
Figure 29: Crystal structure of indanone 136 
 
House and Carlson have shown that, for this type of compound, the cis isomer is more 
stable.
114
 The cis geometry is not ideal in the synthesis of pancratistatin analogues but, once 
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substitution is introduced to the model compounds, the most stable isomer may be the desired 
trans geometry. 
 
Some natural lycorine alkaloids, which are also isolated from the Amaryllidaceae species of 
plants, contain a cis B/C ring junction and also possess a wide range of biological activities 
(Figure 30).
122
 
 
Figure 30: Lycorine-type alkaloids with cis B/C fused rings 
 
Optimised conditions (Method 1I) were repeated using the same substrates to ensure its 
reproducibility. The yields of indanone 136 in the reactions were fairly consistent, which 
implies that the reaction is reliable. However, on one occasion, another unexpected product 
was isolated after column chromatography, indanone 137 (Scheme 102). This was not a 
stable compound and decomposed over time. This is an unlikely compound to survive after 
column chromatography and, after many other attempts, this alternative product was not 
isolated or observed again.  
 
Scheme 102: Unexpected observed indanone 137 
 
The use of 1,3-benzodioxole as a starting material does not provide any information on the 
mechanism of this reaction, owing to its symmetry. Therefore, the use of 1,2,3-
trimethoxybenzene as the nucleophile was attempted and indanone 138 was obtained in 28 % 
yield. A repeat of this same reaction with aqueous work-up gave an improved 57 % yield of 
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indanone 138 (Scheme 103). The regioselectivity was determined by NOESY NMR, where 
irradiation of Ha gave NOE to one methoxy and three aliphatic protons (Figure 31). 
Regioisomer 138a was not observed in either reaction which indicates that the mechanism 
most likely goes via an initial Friedel-Crafts acylation, followed by a Nazarov cyclisation 
(Pathway A). However, the failure to observe the formation of 138a is not conclusive 
evidence of the order of the two steps. The conjugate addition could have taken place first at 
the 5-position of the trimethoxybenzene, followed by ring-closing Friedel-Crafts reaction 
(Pathway B). This reaction was very capricious and it was not always possible to access the 
desired indanone in as good yield.  
 
Scheme 103: Formation of trimethoxyindanone 138 in 57 % yield 
 
 
Figure 31: NOESY connectivities of protons on indanone 138 
 
4.2.2. Route 1 - Introducing Functionality 
Optimised conditions using 1,3-benzodioxole and cyclohexene-1-carboxylic acid to afford 
indanone 136  in 84 % yield were applied to other α,β-unsaturated carboxylic acids to yield 
the desired corresponding indanones (Scheme 104).  
 - 83 -  
 
Scheme 104: Optimised conditions via Route 1 
 
Commercially available shikimic acid 139 was protected as the free acid in a one step 
reaction, forming the triacetate 140 in quantitative yield, following literature precedent 
(Scheme 105).
123
 
 
Scheme 105: Protection of shikimic acid with acetate esters 140
123
 
 
A variety of reactions were attempted at room temperature, 50 
o
C and 100 
o
C but 
unfortunately these were all ineffective at yielding the desired indanone 141. The reaction 
was then carried out at 150 
o
C for 18 hours. After attempts at purification, trace amounts of 
products corresponding to 141 and 142 were observed in both 
1
H NMR and HRMS (Scheme 
106, see appendices 8.3.2. for 
1
H NMR and HRMS of desired compound 141). The 
observation of a signal corresponding to 142 in the 
1
H NMR spectrum of the crude reaction 
mixture reinforces the proposal that this mechanism procedes via an initial Friedel-Crafts 
acylation reaction, followed by a Nazarov cyclisation. 
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Scheme 106: Synthesis of indanone 141 using protected shikimic acid 
 
Due to the protection, deprotection strategy required for shikimic acid, alternative C-rings 
were also investigated. Following the procedure reported by Ravikumar et al., 3-furoic acid 
and N-phenylmaleimide were heated at reflux in MeCN to yield the Diels-Alder product 143 
in 65 % yield.
124
 N-Ethylmaleimide and 3-furoic acid in MeCN at reflux afforded the Diels-
Alder product 144 also in 65 % yield (Scheme 107). Only the exo products were observed in 
both these reactions and no endo products were isolated, which was established by utilising 
the Karplus equation. 
 
Scheme 107: Observed exo products from Diels-Alder reaction 
  
The dihedral angle H
A
-C-C-H
B
 for the endo product is 35.4
o
 and 82.2
o
 for the exo (Figure 
32). Using the Karplus equation, 
121
 the vicinal 
3
J coupling constants will vary depending on 
whether the product is endo or exo. The endo product with a dihedral angle of 35.4
o
 will have 
a 
3
J coupling of ~10 Hz and the exo product with a dihedral angle of 82.2
o
 will have an 
extremely low 
3
J coupling, if any is seen. No coupling is observed by 
1
H NMR between these 
two protons in products 143 and 144, which is consistent with the exo product. 
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Figure 32: Endo and exo products 
 
The α,β-unsaturated carboxylic acids 143 and 144 were subjected to the optimised 
intermolecular indanone synthesis reaction conditions. Any variation on temperature or time 
yielded no desired indanones, only starting materials, and often resulted in decomposition to 
afford a mixture of unidentifiable compounds.  
 
4.2.3. Route 2 - Intermolecular Indanone Synthesis  
The use of TFAA and TFA were again exploited when Route 2 was investigated due to its 
success in previous reactions. Optimisation was carried out on piperonylic acid and 
cyclohexene, in order to access the same indanone 136 for direct comparison (Scheme 108). 
 
Scheme 108: Optimisation of the synthesis of indanone 136 via Route 2 
 
Different equivalents of TFAA and TFA were used, the equivalents of cyclohexene were 
varied and the time was also altered (Table 6). Optimum conditions (Method 2C) of 
piperonylic acid and 1.1 eq. of cyclohexene in TFAA at 100 
o
C for 16 hours afforded desired 
indanone 136 in 51 % yield. 
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Method Eq. TFAA TFA (eq.) Eq. cyclohexene Time (h) Yield % 
2A 3.5 0 1.0 4 35 
2B 3.5 0 1.1 6 14 
2C 3.5 0 1.1 16 51 
2D 3.5 0 2.0 17 47 
2E 2.0 6.5 1.1 17 10 
2F 1.0 6.5 1.1 17 18 
Table 6: Optimisation of the synthesis of indanone 136 via Route 2 at 100 
o
C 
 
2,3,4-Trimethoxybenzoic acid was then subjected to these optimised reaction conditions from 
Table 6 (Method 2C). However, this reaction only yielded 13 % of indanone 138 and 
therefore the reaction with this substrate also had to also be optimised (Table 7). Optimum 
conditions (Method 2E) with 1.1 eq of TFAA and addition of 0.5 mL of TFA at 100 
o
C for 16 
hours afforded desired indanone 138 in 38 % yield (Scheme 109).  
 
Scheme 109: Synthesis of indanone 138 
 
Method Eq. TFAA TFA (eq.) Eq. cyclohexene Time (h) Yield % 
2A 3.5 0 1.1 16 13 
2B 3.5 0 1.1 18 16 
2C 3.5 0 1.1 6 9 
2D 3.5 0 1.0 24 7 
2E 1.1 6.5 2.0 16 38 
Table 7: Optimisation of the synthesis of indanone 138 via Route 2 at 100 
o
C 
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These optimised conditions (Table 7) were applied to 3,4,5-trimethoxybenzoic acid. However 
indanone 138a was isolated in a reduced 9 % yield (Scheme 110).   
 
Scheme 110: Synthesis of indanone 138a in 9 % yield 
 
4.2.4. Route 2 - Introducing Functionalisation 
The optimised conditions that used piperonylic acid and cyclohexene to afford indanone 136 
in 51 % yield, shown in Scheme 111, were applied to other substituted cyclohexenes to 
attempt to synthesise the corresponding functionalised indanones.   
 
Scheme 111: Optimised conditions for the synthesis of indanone 136 via Route 2 
 
These optimised conditions were attempted on a variety of substrates to synthesise indanones 
with substituted C-rings. First cyclopentene was attempted to yield the cis indanone 145 in 41 
% yield. (Scheme 112, see appendices 8.3.3. for NOESY NMR).  
 
Scheme 112: Synthesis of indanone 145 
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The incorporation of other C-rings was then attempted, first with minimal functionalisation. 
1,3-Cyclohexadiene, 1,4-cyclohexadiene and norbornylene were treated with piperonylic acid 
but the synthesis of their corresponding indanones was unsuccessful, despite varying the time 
and temperature of the reaction conditions (Figure 33). 
 
Figure 33: The unsuccessful incorporation of several functionalised C-rings 
 
Baran et al. reported the successful Diels-Alder cyclisation reaction between furan and 
vinylene carbonate in a 4:1 ratio of endo to exo (Scheme 113).
125
  This reaction was repeated, 
also with microwave irradiation at 200 
o
C and only starting material was isolated. 
 
Scheme 113: Diels-Alder reaction between furan and vinylene carbonate
125
 
 
Diels-Alder reactions require an electron-rich diene and electron-poor dienophile in order to 
proceed. Alternatively an electron-rich dienophile and electron-poor diene will react. Furan is 
an electron-rich diene and therefore an electron-poor dienophile is required. However, the 
electron density of vinylene carbonate is unclear and both arguments have previously been 
reported. Burnell et al. stated that vinylene carbonate is electron-rich
126
 and Bouredeland et 
al. argued that it is electron-poor.
127
  
 
N-Phenylmaleimide is an electron-poor dienophile and, by treating this with furan, the exo 
Diels-Alder product 146 was synthesised in 72 % yield (Scheme 114).
124
 The structure of the 
exo product was confirmed using the Karplus equation.
121
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Scheme 114: Synthesis of Diels-Alder product 146 from N-phenylmaleimide and furan 
 
The dihedral angle H
A
-C-C-H
B
 for the endo product is 37
o
 which will have a 
3
J coupling of 
~8 Hz and 81
o
 for the exo product, which will have an extremely low 
3
J coupling of ~0-2 Hz 
(Figure 34). The coupling between these two protons observed in the 
1
H NMR for product 
146 is between 0-1 Hz, which is consistent with the exo product. 
 
Figure 34: Endo and exo coupling 
 
The Diels-Alder product 146 was then submitted to the conditions used previously for 
syntheses of the indanones but, unfortunately, the reagents decomposed during the reaction to 
afford a mixture of unidentifiable products.  
 
In conclusion, the indanone synthesis is extremely limited via Routes 1 and 2. Any variation 
on either the A-ring or the C-ring resulted in diminished yields or unsuccessful reactions. To 
explore the second main transformation the Schmidt reaction was attempted on both isolated 
indanones 136 and 145 (Figure 35).  
 
Figure 35: Indanones 136 and 145 to be used as reagents in the Schmidt reaction 
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4.2.5. Schmidt Reaction and Beckmann Rearrangement 
Following a procedure reported by Elderfield and Losin
128
 indanone 136 and NaN3 in H2SO4 
and toluene at 100 
o
C afforded no desired product. However, the unexpected deprotected diol 
147 was isolated in 53 % yield (Scheme 115).   
 
Scheme 115: Synthesis of diol 147 in 53 % yield 
 
Following the conditions reported by Irie et al.
98
, reaction of indanone 136 and NaN3 in 
trichloroacetic acid for two days afforded lactam 148 in 19 % yield (Scheme 116). No lactam 
148a was observed or isolated from the reaction mixture. The cis configuration of the B/C 
ring junction and the regiochemistry of the lactam were confirmed by NOESY NMR (See 
appendices 8.3.4.). Irie et al. also reported that even small modifications in the structure of 
the starting indanone can alter the success of the Schmidt reaction, which could explain the 
low yield of 19 %.
129
  
 
Scheme 116: Two successful Schmidt reactions on indanone 136 
 
Following the procedure reported by Jesudason et al.
96
, reaction of indanone 136 and NaN3 
in H2SO4 and toluene for 4 days yielded lactam 148 in 21 % yield (Scheme 116). 
Regioisomer 148a was not observed. 
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After the success of the Schmidt reactions on A/B indanone analogues using 2 equivalents of 
NaN3 in TFA at 100 
o
C for 18 hours (Scheme 69 and 76), the same conditions were 
investigated on A/B/C indanone 136. However, only starting material was recovered. The 
alternative conditions using 4 equivalents of NaN3 in TFA at 100 
o
C for 18 hours were then 
attempted, furnishing the desired regiolactam 148 in an improved 40 % yield (Scheme 117).  
 
Scheme 117: Schmidt reaction to yield lactam 148 in 40 % yield 
 
The identical procedure was attempted on indanone 145 but only starting material was 
recovered and no desired lactam 149 was observed (Scheme 118). 
 
Scheme 118: Unsuccessful Schmidt reaction on indanone 145 
 
A Beckmann Rearrangement was also attempted on A/B/C indanone 136. Initially the 
corresponding oxime 150 was synthesised using hydroxylamine in MeOH and pyridine at 90 
o
C for 18 hours in 88 % yield (Scheme 119). 
 
Scheme 119: Synthesis of oxime 150 
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Oxime 150 in PPA at 120 
o
C for 2 hours gave a mixture of unidentifiable products.
130
 Due to 
some success using TFA in the Schmidt reactions, oxime 150 was heated at 100 
o
C in TFA in 
a pressure tube for 2 hours. By TLC and NMR spectroscopy, only starting oxime or indanone 
were shown to remain.  
 
4.2.6. Overview 
The Schmidt reaction is low yielding, although the desired dihydroisoquinolinone core has 
been synthesised in just two steps. Scheme 120 outlines the optimised two step sequence to 
access the lactam core.  
 
Indanone intermediate 136 can be prepared via two different routes. Lactam 148 can then be 
accessed using a Schmidt reaction in 40 % yield. Although this synthetic route is successful it 
is extremely limited. Any alterations or inclusion of functionality on the A-ring or C-ring 
cause diminished yields, or unsuccessful reactions. Therefore a new synthetic route will now 
be explored. 
 
Scheme 120: Optimised two step synthesis of the dihydroisoquinolinone core 
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4.3. Alternative Proposed Synthetic Route  
The alternative proposed synthetic route again involves two main transformations. The 
disconnection approach is outlined in Scheme 121.  
 
This approach involves an initial Heck cross-coupling reaction between a substituted 
bromobenzene and a substituted α,β-unsubstituted carboxylic acid to afford acid intermediate 
152. The intermediate 152 can then undergo a modified Curtius rearrangement previously 
developed within our group
93
 to potentially afford the desired A/B/C dihydroisoquinolinone 
ring system 153 (Scheme 121). 
 
Scheme 121: Second alternative disconnection approach to access the lactam framework 
 
4.3.1. Step 1 - Heck Cross-Coupling Reaction 
The Nobel Prize in Chemistry 2010 was awarded jointly to Richard F. Heck, Ei-ichi Negishi 
and Akira Suzuki "for palladium-catalyzed cross couplings in organic synthesis”.131 
Palladium chemistry has become an indispensable tool for many organic chemists. The Heck-
Mizoroki reaction (most commonly known as the Heck reaction) was independently 
discovered by both Mizoroki and Heck in the 1970s and today is a widely used palladium-
catalysed cross-coupling reaction.
132
  
 
In the Heck reaction aryl, alkenyl and benzyl halides are coupled with activated alkenes in 
the presence of palladium catalysts to give their corresponding trans substituted alkenes 
(Scheme 122) and is an important transformation in the synthesis of pharmaceuticals and 
agrochemicals.
131
 
 - 94 -  
 
Scheme 122: Heck reaction
131
 
 
The reaction mechanism of the Heck reaction is shown in Scheme 123. The reaction starts 
with oxidative addition of the aryl-X compound (X can be Br, Cl, OTf, etc.) to Pd
0 
to form 
the Pd
II
 species. Coordination and insertion of the olefin generates an alkylpalladium 
complex. After rotation of the C-C bond, β-H elimination occurs and the substituted alkene is 
released. The active Pd
0 
species is reformed via reductive elimination by the addition of a 
base. 
 
Scheme 123: Mechanism for the Heck reaction
131
 
 
The initial Heck reaction between a substituted bromobenzene and a substituted α,β-
unsaturated cyclohexene carboxylic acid will potentially yield desired acid intermediate 151 
(Scheme 124). The double bond in this ring will migrate, as shown in Scheme 121, due to the 
constrained olefin ring system. The alkylpalladium complex formed in the mechanism is 
constrained in a ring and has restricted rotation; therefore for β-H elimination to occur it must 
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take a hydride from the neighbouring carbon, resulting in the migration of the alkene 
(Scheme 124). 
 
Scheme 124: First main transformation is the Heck cross-coupling reaction 
 
4.3.2. Step 2 - Modified Curtius Rearrangement 
A successful reaction previously developed within the group is a modified Curtius 
rearrangement (Scheme 125).
93,110
 This transformation yields the desired lactam 126 from 3-
(3,4,5-trimethoxyphenyl)propanoic acid.  
 
Scheme 125: Modified Curtius rearrangement 
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3-(3,4,5-Trimethoxyphenyl)propanoic acid is initially activated by DPPA which is then 
displaced by the azide to form the acyl azide. Rearrangement yields isocyanate 154 which is 
captured by the aromatic ring. Demethylation of the methoxy group occurs due to the BF3 
which initially complexes to the carbonyl oxygen (Scheme 126). This then directs the Lewis 
acid to form a bidentate complex with the oxygen of the 8-methoxy group. With the Lewis 
acid attached to to this methoxy group, a nucleophile can then attack the methyl carbon. The 
BF2 complex is then hydrolysed to afford the free phenol.  
 
Scheme 126: Formation of BF2 complex and subsequent demethylation of 8-methoxy group 
 
4.4. Results and Discussion - Step 1 - Heck Reaction 
 
4.4.1. Optimisation of Heck Reaction 
Martin et al., in 2001, reported a Heck coupling reaction followed by a hydrogenation 
between acrylic acid and 4-tert-butoxy-bromobenzene to yield the desired product 155 in 92 
% yield (Scheme 127).
133
 The Heck coupling reaction is performed in H2O at 100 
o
C with the 
addition of 1.6 M aqueous Na2CO3 and PdCl2. The reduction of the trans double bond form 
in situ is then carried out in Pd on carbon under a H2 atmosphere to yield product 155. 
 
Scheme 127: Reductive Heck cross-coupling reaction
133
 
 
Unfortunately after many attempts of this reaction using 5-bromo-1,2,3-trimethoxybenzene 
156 and α,β-unsaturated cyclohexene carboxylic acid as starting materials, the Heck coupling 
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reaction was unsuccessful (Scheme 128). A small trace of product 157 was observed in the 
reaction mixture; mostly, starting material was recovered. 
 
Scheme 128: Reductive Heck cross-coupling reaction to afford a trace of compound 157 
 
A variety of Heck reaction conditions were then attempted on 5-bromo-1,2,3-
trimethoxybenzene 156 and α,β-unsaturated cyclohexene carboxylic acid as reagents, to 
potentially yield desired product 157.  
 
Table 8 displays a summary of the Heck reactions attempted to synthesise acid intermediate 
157. Unforunately all of these were unsuccessful. Only starting materials were seen by TLC 
and 
1
H NMR spectroscopy. In each reaction, Pd(OAc)2 was used as the palladium source. A 
possibility for the failure of these reactions could be due to catalyst inactivation.  
Met-
hod 
156 
(eq.) 
Acid 
(eq.) 
Pd source / 
ligand 
Base Solvent Temp 
(
o
C) 
Time 
(h) 
Result 
A
134
 2 1 Pd(OAc)2 
(10mol%) 
PPh3 
(20mol%) 
Na2CO3 
(2 eq.) 
DMF  
degassed 
100 16 Starting 
materials 
B
135
 2 1 Pd(OAc)2 
(10mol%) 
Et3N  
(2 eq.) 
MeCN 
degassed 
100 16 Starting 
materials 
C
136
 1.5 1 Pd(OAc)2 
(20mol%) 
PPh3 
(40mol%) 
Ag2CO3 
(7 eq.) 
DMF 
degassed 
70 16 Starting 
materials 
D
137
 2 1 Pd(OAc)2  
(0.3 eq.) 
PPh3 (0.6 eq.) 
Na2CO3 
(5 eq.) 
tBu4NCl.H2O 
& DMF 
degassed 
90 16 Starting 
materials 
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E
137
 1 2 Pd(OAc)2  
(5mol%) 
NaHCO3 
(4 eq.) 
tBu4NCl.H2O 
& DMF 
degassed 
90 16 Starting 
materials 
D
138
 1 2 Pd(OAc)2  
(5mol%) 
PPh3 
(20mol%) 
Et3N 
(1.1 eq.) 
Toluene 
degassed 
100 16 Starting 
materials 
E 1 1 Pd(OAc)2  
(1mol%) 
PPh3 
(4mol%) 
Et3N 
(2.1 eq.) 
Xylene  
degassed 
100 16 Starting 
materials 
F
139
 1 1.5 Pd(OAc)2  
(5mol%) 
DIPEA 
(1.5 eq.) 
tBu4NCl 
DMA/H2O 
degassed 
120 16 Starting 
materials 
G
140
 2 1 (PPh3)2PdCl2 
(10mol%) 
Na2CO3 
(2 eq.) 
DMF 
Pressure tube 
120 16 Starting 
materials 
Table 8: Attempts of a Heck cross-coupling reaction to yield intermediate 157 
 
Due to the unsuccessful attempts of the Heck cross-coupling reactions, it was decided to 
return to the initial conditions using H2O at 100 
o
C with the addition of Na2CO3 and PdCl2 as 
a trace of product was seen in this reaction (Scheme 128).
133
 Initially acrylic acid was 
explored as the starting material which was used in the reported synthesis. Only the Heck 
cross-coupling reaction has been explored here, without the reported reduction reaction. 
Scheme 129 displays the trans product 158 expected from this Heck reaction. 
 
Scheme 129: Optimisation of Heck reaction to yield compound 158 
 
Initial reactions were carried out using three different palladium catalysts all under the same 
reaction conditions (Table 9).  
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Method Pd Source Na2CO3 Solvent Temp 
(
o
C) 
Time 
(h) 
Yield of 158 
(%) 
Method 1 PdCl2  
(10mol %) 
3 eq. H2O 100 24 13 % 
 
Method 2 (PPh3)2PdCl2 
(10mol %) 
3 eq. H2O 100 24 71 % 
 
Method 3 Pd(OAc)2 
(10mol %) 
3 eq. H2O 100 24 4 % 
 
Table 9: Heck cross-coupling reaction using three different Pd catalysts *yields calculated by 
1
H NMR 
spectroscopy of crude reaction mixture 
 
Both product 158 and acrylic acid were present in all three reaction mixtures. The yields 
were calculated by 
1
H NMR spectroscopy of the crude reaction mixture. As shown in Table 
9, Method 2 using (PPh3)2PdCl2 as the palladium source gave the greatest yield of product 
158 (71 % yield).  
 
A reaction with an excess of bromobenzene 156, α,β-unsaturated cyclohexene carboxylic 
acid and (PPh3)2PdCl2 as the Pd source was attempted. An excess of bromobenzene 156 was 
used to drive the reaction to completion with any unreacted bromobenzene being removed 
during work-up. However, both product 157 (49 % yield) and starting material were present 
in the 
1
H NMR spectrum.  
 
Scheme 130: Successful Heck cross-coupling reaction 
 
Identical reaction conditions were then performed but for 48 hours rather than 24 hours, 
although this did not improve the yield of this reaction. The loading of the catalyst was 
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increased to 20mol % but again this did not improve the yield. The addition of an alternative 
base was then explored. The addition of Cs2CO3 decreased the yield of compound 157 to 20 
%. However, the addition of K2CO3 as a base increased the yield of compound 157 by crude 
1
H NMR to 55 %. 
 
The optimised Heck reaction on trimethoxybromobenzene 156 using (PPh3)2PdCl2 and 
K2CO3 as a base at 100 
o
C for 24 hours yielded the desired acid 157 after an aqueous work up 
and column chromatography in 43 % yield (Scheme 131). 
 
Scheme 131: Heck cross-coupling reaction to afford compound 157  
 
These conditions were carried out on a 2 mmol scale. The yield decreased to 33 % when the 
reaction was performed on a larger 4 mmol scale. Also, if the concentration was increased to 
4 mL H2O for 1 mmol of acid rather than 8 mL H2O for 1 mmol of acid, the yield did not 
have a significant change at 41 %. 
 
The optimised Heck conditions shown in Scheme 131 were then applied to 4-bromo-1,2-
dimethoxybenzene 159 to yield desired acid intermediate 160 but in only 8 % yield (Scheme 
132).  
 
Scheme 132: Low-yielding Heck cross-coupling reaction 
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These optimised conditions using a combined basic and acidic work-up so far have been low 
yielding due to the difficulty of extracting out the acid. An alternative work-up was therefore 
attempted on the Heck reaction between bromobenzene 156 and α,β-unsaturated carboxylic 
acid. After 24 hours the reaction mixture was acidified, the water was removed under 
reduced pressure and, after column chromatography, the desired product 157 was isolated in 
78 % yield (Scheme 133). 
 
Scheme 133: Optimised Heck cross-coupling reaction to yield intermediate 157 
 
4.4.2. Functionalisation on A-ring 
Combining the optimised Heck reaction conditions and work-up performed on 5-bromo-
1,2,3-trimethoxybenzene 156 to yield intermediate 157 (Scheme 133), the conditions were 
then performed on 4-bromo-1,2-dimethoxybenzene 159 and 5-bromo-1,3-benzodioxole 161 
(Scheme 134).The desired acid intermediates 160 and 162 were isolated in 63 % and 40 % 
yields respectively. The alkene has migrated in each reaction due to the mechanism of the 
Heck reaction.  
 
 Scheme 134: Optimised Heck reaction on substituted A-rings  
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The modified Curtius rearrangement previously developed within the group can now be 
applied to these acid intermediates potentially to yield the desired lactam framework. 
 
4.4.3. Functionalisation on C-ring 
 
4.4.3.1 Shikimic Acid 
5-Bromo-1,2,3-trimethoxybenzene 156 gave the highest yield in the Heck reaction (Scheme 
133) so was therefore used as the bromobenzene when substitution on the A-ring was 
explored. As previously mentioned (4.1.3.) shikimic acid 139 is a commercially available 
α,β-unsaturated cyclohexene carboxylic acid which can easily be used to incorporate 
functionality on the C-ring (Scheme 135). 
 
Scheme 135: The use of shikimic acid to incorporate functionality on the C-ring 
 
The Heck reaction was initially attempted without protection of the hydroxy groups (Scheme 
136). Unfortunately, no desired product was seen by NMR, only a mixture of unidentifiable 
compounds.  
 
Scheme 136: Unsuccessful Heck reaction without protecting the shikimic acid 
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In this proposed synthetic route, the alcohol groups present on shikimic acid require 
protection. Protection of shikimic acid 139 with acetate groups was previously successful 
(Scheme 137), although these protecting groups will not be suitable for the conditions for the 
modified Curtius rearrangement. 
 
Scheme 137: Protection of shikimic acid with acetate groups 
 
For this reason, alternative benzyl protecting groups were explored. Initial reactions to 
protect the hydroxy groups with a benzyl group were performed using K2CO3 in DMF at 80 
o
C for 24 hours
141
 and another using KOH in dioxane at reflux
142
 although both were 
unsuccessful. Mixtures of unidentifiable compounds were seen by TLC and crude 
1
H NMR. 
 
A reaction was then performed using NaH as a base.
143
 The desired product 163 was isolated 
in a low yield of 15 % (Scheme 138).  
 
Scheme 138: Low-yielding benzyl protection of shikimic acid.
143
 
 
This was then subjected to saponification in 1M NaOH(aq.) in EtOH at room temperature for 
17 hours to yield the free acid 164 in 95 % yield (Scheme 139).
144
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Scheme 139: Hydrolysis to yield free acid 164
144
 
 
Protected shikimic acid was then subjected to the optimised Heck conditions to hopefully 
yield desired intermediate 165 (Scheme 140). Unfortunately, this was unsuccessful and 
1
H 
NMR spectroscopy of the crude reaction mixture appeared to show that the benzyl protecting 
groups were lost under the reaction conditions. 
 
Scheme 140: Unsuccessful Heck reaction on protected shikimic acid 
 
4.4.3.2 Mono-Oxygenated C-Ring 
Due to the high number of hydroxy groups present on shikimic acid, a simpler mono-
oxygenated C-ring was considered. This would allow optimisation of the reaction conditions 
in the presence of only one alcohol group, which will potentially be simpler to optimise. 
 
The Horner-Wadsworth-Emmons reaction, followed by an aldol reaction in situ, was 
performed on glutaraldehyde using triethyl phosphonoacetate.
145
 The reaction yielded the 
desired cyclised product 166 in 39 % yield and the di-ester product from the Horner-
Wadsworth-Emmons reaction 167 was also isolated in 5 % yield (Scheme 141). Repeating 
this reaction on a larger scale of 20 mmol, the yield of product 166 diminished to 14 %.  
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Scheme 141: Horner-Wadsworth-Emmons reaction on glutaraldehyde, followed by an aldol reaction in situ  
 
Cyclised product 166 was then saponified to yield desired free acid 168 in 58 % yield 
(Scheme 142).
146
  
 
Scheme 142: Saponification of ester 166 
 
When acid 168 was submitted to the Heck conditions, mostly starting material was recovered 
(Scheme 143). This reaction may have been unsuccessful due to the alcohol possibly forming 
the ketone by keto-enol tautomerisation. 
 
Scheme 143: Unsuccessful Heck cross-coupling reaction on 5-Bromo-1,2,3-trimethoxybenzene 156 and acid or 
ester 168/166 
 
Ester 166 was also subjected to the Heck reaction; however, this again was unsuccessful. 
Mixtures of starting material and unidentifiable compounds were isolated (Scheme 143). 
 
Attempts to protect the mono-oxygenated ring 166 were then made, although this proved 
very difficult to achieve. Initial reaction conditions include 2 equivalents of benzyl bromide 
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with the addition of NaOH in a mixture of H2O and EtOH at 80 
o
C for 22 hours.
147
 
Unfortunately, the benzyl bromide and EtOH reacted to form ethoxybenzene.The reaction of 
ester 163 with NaH and benzyl bromide in THF at room temperature for 22 hours was then 
attempted and only starting material was isolated from this reaction. 
 
Alternative reaction conditions using Ag2O and benzyl bromide in DMF at room temperature 
for 16 hours was explored; however, only starting material and a mixture of unidentifiable 
compounds were isolated.
148
 Experiments using ester 163 Ag2O and benzyl bromide at room 
temperature for 16 hours in Et2O or CHCl3 were performed.
149
 Both reactions gave starting 
material and no desired product.  
 
An alternative reaction using NaH in DMF with the addition of TBAI was attempted
150
 
followed by saponification. Acid 169 was synthesised in less than 65 % over two steps. The 
saponification was a very low yielding raction so only small amounts of the desired benzyl 
protected free acid 169 was present by 
1
H NMR (Scheme 144).  
 
Scheme 144: Protection of ester 166 followed by saponification to yield acid 169 
 
Alternative protecting groups must be explored. Once the mono-oxygenated C-ring and 
shikimic acid have both been protected with the appropriate protecting group this proposed 
strategy to access the desired lactam core should be achievable.   
 
4.5. Results and Discussion - Step 2 - Modified Curtius 
Rearrangement  
The second main transformation in this alternative proposed synthetic route involves a 
modified Curtius rearrangement previously developed within our group. An initial reaction 
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using 3-(3,4,5-trimethoxyphenyl)propanoic acid afforded lactam 126 in 76 % yield (Scheme 
145).
93
 The mechanism of this reaction is summarised in Scheme 125 and Scheme 126.   
 
Scheme 145: Successful modified Curtius rearrangement to yield lactam 126 in 76 % yield 
 
These reaction conditions were then attempted on Heck product 157. The desired lactam 170 
was isolated in 21 % yield and the BF2 complex 171 was isolated in 39 % yield, with the 
double bond present in the C-ring moving back into conjugation (Scheme 146). 
 
Scheme 146: Modified Curtius rearrangement to yield lactam 170 in 21 % yield 
 
This was a promising result as the BF2 complex can be hydrolysed further to then isolated 
desired lactam 170 in a greater yield. The reaction was repeated and the third hydrolysis step 
was heated to 60 
o
C for 4 hours to yield the desired lactam 170 in an improved 65 % yield 
(Scheme 147). 
 - 108 -  
 
Scheme 147: Modified Curtius rearrangement to yield lactam 170 in 65 % yield 
 
The effect of these conditions was then investigated on both Heck products 160 and 162. 
Unfortunately, these reactions did not yield the desired lactams 172 and 173 (Scheme 148). 
 
As previously mentioned, the presence of the free phenol on the A-ring increases the activity 
of these compounds. The failure of the modified Curtius rearrangement on intermediates 160 
and 162, which do not contain the free phenol, is only a minor setback to the overall synthetic 
route as these are not expected to be as active as lactam 170. Once the mono-oxygenated C-
ring is protected, the Heck reaction can be performed using 5-bromo-1,2,3-
trimethoxybenzene 156 which is the most reactive A-ring reagent in the modified Curtius 
rearrangement. 
 
Scheme 148: Unsuccessful modified Curtius rearrangements in compounds 160 and 162 
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4.6. Biological Activity 
The A/B/C indanones and lactams have have also been tested in an MTS cell proliferation 
assay using colon cancer cell line HT29. 
 
A/B/C indanones 136 and 138 were both tested for their biological activity against the HT29 
cell line. Indanone 138 had a greater activity with an IC50 value of 221 μM, although this is 
not highly active (Figure 36). 
 
Figure 36: Low activity of A/B/C indanones against HT29 cell line 
 
The two synthesised A/B/C lactams 148 and 170 were also tested against the HT29 colon 
cancer cell line. The corresponding A/B lactam 101 of A/B/C lactam 148 has an IC50 value of 
>500 μM in the HT29 cell line (Figure 23). Lactam 148 contains the C-ring but also has an 
IC50 value of >500 μM. Both lactams 101 and 148 lack the free phenol so the low biological 
activities are as expected (Figure 37). 
 
Figure 37: IC50 values of A/B/C lactams 148 and 170 in HT29 colon cancer cell line 
 
Lactam 170 contains both the C-ring and the free phenol. It also contains the double bond 
which has previously been shown to increase the activity. Its corresponding A/B lactam 127 
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has an IC50 value of 71 μM in HT29 cells (Figure 23). Lactam 170 has an IC50 value of 9 μM 
in the HT29 cell line. This is the most biologically active analogue synthesised to date. 
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4.7. Conclusions 
The aim of the work described within this chapter was to synthesise a range of A/B/C 
indanones and subsequently transform them into their corresponding A/B/C lactams. A range 
of reaction conditions were used to attempt this synthesis and largely proved unsuccessful. 
The synthesis of A/B/C indanones was achieved using similar reaction conditions to those for 
A/B indanones described in Chapter 3; however the synthesis was sensitive to temperature 
and reaction time. Any alterations of functionality on the A-ring or C-ring diminished the 
yield or rendered the reactions unsuccessful. Therefore, each A/B/C indanone required 
tailored reaction conditions, in terms of reaction time and temperature, to produce any 
product in reasonable yield. A single A/B/C lactam was reliably synthesised via a Schmidt 
reaction. 
 
The previous conditions were limited in their ability to synthesise a library of A/B/C lactams 
and so a new synthetic route was explored. The new proposed synthetic route was two steps; 
the first step was a Heck reaction using a Pd catalyst and commercially available starting 
materials and the second step was a modified Curtius rearrangement. This route was used to 
synthesis an A/B/C lactam, 170, containing phenol functionality on the A-ring and an 
unfunctionalised C-ring. This is a novel and interesting synthetic route to 
dihydroisoquinolinones and could be further explored to incorporate functionality on the C-
ring. 
 
Several of the compounds described in this chapter were tested for biological activity against 
the HT29 colon cancer cell line. Lactam 170, a dihydroisoquinolinone, showed promising 
results with an IC50 value of 9 µM. Lactam 170 lacks functionality on the C-ring; if 
functionality is incorporated then biological activity should further improve. 
 
 - 112 -  
5. Indanocine 
 
5.1. Introduction 
As previously mentioned in section 3.1.1. many natural products which contain the indanone 
framework have been shown to possess biological activity.
5
 Indanocine 76 is an example of a 
biologically active compound which contains the indanone moiety within its structure (Figure 
38).
87
  
 
Figure 38: Indanocine 76 
 
Indanocine has an IC50 value of 0.001 μM against the Jurkat cell line.
87
 It has been shown to 
bind to microtubules at the colchicine site that blocks tubulin polymerisation
152
 and it 
selectively induces apoptosis in multi-drug resistant cancer cells.
88
  
 
A screen of indanocine 76 was performed by the NCI in 49 cancer cell lines. The average 
GI50 value was less than 20 nM and the antiproliferative concentrations were lower in the 
multidrug-resistant cells than in the corresponding parent cells (three examples are shown in 
Table 10). 
Cell Line Wild type (GI50) Multidrug resistant (GI50) 
MCF-7 (human breast) 20 ± 5 nM 4 ± 1 nM 
MES-SA (human uterine) 85 ± 6 nM 12 ± 3 nM 
HL-60 (human leukaemia) 40 ± 3 nM 2 ± 0.2 nM 
Table 10: Growth-inhibitory concentrations of indanocine 76
88
 
 
Indanocine had poor activity in several animal models possibly due to its poor aqueous 
solubility.
151
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5.2. Aim 
As previously mentioned in section 1.2.3.4. Rinner et al. explored the replacement of the core 
with an indole moiety to synthesise analogues with spatial similarities which would hopefully 
mimic the anticancer activity of pancratistatin (Figure 39).
52
 Pancratistatin 16 displayed 
promising anticancer activity in the cell lines with IC50 values ranging from 0.062 μM - 0.138 
μM. In comparison, compound 29 unfortunately displayed only slight activity in P388 
lymphocytic leukaemia cell and no activity in the other three cell lines.
52
 
 
Figure 39: Replacement of the lactam core with an indole moiety
52
 
 
The aim of this project is to apply these same principles to indanocine 76. Using the same 
rationale as Rinner, a range of potential novel analogues are proposed (Figure 40). It is hoped 
that by substituting a primary amine for a secondary amine will create a better bioisostere 
than substituting an alcohol with a secondary amine as Rinner did.  
 
Figure 40: Indole analogue of indanocine 76 
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5.3. Synthetic Route and Proposed Analogues 
The proposed synthetic route involves two synthetic steps (Scheme 149). The first is an 
intramolecular Friedel-Crafts acylation reaction to afford the desired indanone intermediate, 
as previously synthesised and described in Chapter 3. The second transformation involves a 
Claisen-Schmidt condensation reaction using a variety of aldehydes to afford a range of 
desired analogues. Theoretically the E and Z geometric isomers can equally be formed in this 
aldol condensation reaction however the Z configuration is highly unfavourable due to the 
stong steric interactions between the aryl and the carbonyl group.
152
 
 
Scheme 149: Proposed synthetic route towards the synthesis of indanocine analogues 
 
For potential optimum activity, positions 3’ and 5’ should be substituted with hydrophobic 
groups. Aldehydes which contain the hydroxy group at position 4’ and hydrophobic regions 
at positions 3’ and 5’ were explored, including 4-hydroxy-3,5-dimethylbenzaldehyde and 4-
hydroxy-3,5-dimethoxybenzaldehyde (Figure 41).  
 
Figure 41: Proposed 5-membered ring analogues of indanocine 
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It was also decided to investigate the effect of the hydroxy group at position 4’. The hydroxyl 
group was removed with the use of aldehydes 3,5-dimethylbenzaldehyde and 3,5-
dimethoxybenzaldehyde. It was also decided to examine the effect of the protection of the 
indole nitrogen with a methyl group compared to the free nitrogen. 
 
Hallgas et al. investigated the antiproliferative activity profiling of 2-
benzylidenecycloalkanones (Figure 42).
152
 They discovered that the preferred most active 
core structure is the cyclohexanone. 
 
Figure 42: 2-Benzylidenecycloalkanones 
 
Therefore 6-membered analogues were also synthesised to determine if these are more active 
(Figure 43). 
 
Figure 43: Proposed 6-membered ring analogues of indanocine 
 
5.4. Synthesis of Analogues 
Using cyclic ketones previously synthesised as part of the narciclasine and pancratistatin 
project described in Chapter 3, compounds 96 and 98 were used to synthesise novel 
indanocine analogues. Methylation reactions were performed on indanones 96 and 98 
following the procedure reported by Judd et al.
93
 to afford desired methylated intermediates 
174 and 175 in a 95 % and 92 % yield respectively (Scheme 150).  
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Scheme 150: Methylation of indoles 98 and 96
93
 
 
Reactions were then performed using a range of aldehydes shown in Table 11 with 
compound 98 and methylated compound 174 to afford a wide range of 5-membered ring 
analogues. 
 
A large range of conditions were studied to synthesise these analogues, including NaOMe in 
MeOH at room temperature,
153
 NaOEt in THF at room temperature,
154
 Na2CO3 in H2O at 70 
o
C,
155
 LiOH.H2O in EtOH at room temperature,
156
 3 % ethanolic NaOH at room 
temperature
157
 and in solvent free conditions by grinding in the presence of NaOH.
158
   
 
Following conditions using 4 % ethanolic KOH at room temperature for 16 hours, desired 
analogues were synthesised in good yields (shown in Table 11).
159
  
 
The alternative reaction using 2-methoxyethanol as the solvent with >99 % aqueous KOH 
solution at 120 
o
C for 20 hours afforded the desired analogues in good yields. The use of 2-
methoxyethanol as a solvent was previously demonstrated in an aldol condensation reaction 
within the group, which is the reason reactions using this unusual solvent were attempted. 
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98 
 
176 
4 % (w/v) ethanolic 
KOH, room temp. 
16 hours 
71 % 
177 
> 99 % aq. KOH 
solution in  2-
methoxyethanol, 
120 
o
C, 20 hours 
61 % 
178 
4 % (w/v) ethanolic 
KOH, room temp. 
16 hours 
72 % 
179 
> 99 % aq. KOH 
solution in  2-
methoxyethanol, 
120 
o
C, 20 hours 
54 % 
174 
 
180 
4 % (w/v) ethanolic 
KOH, room temp. 
16 hours 
45 % 
181 
> 99 % aq. KOH 
solution in  2-
methoxyethanol, 
120 
o
C, 20 hours 
3 % 
182 
4 % (w/v) ethanolic 
KOH, room temp. 
17 hours 
12 % 
183 
> 99 % aq. KOH 
solution in  2-
methoxyethanol, 
120 
o
C, 20 hours 
49 % 
Table 11: Conditions for condensation reactions 
 
Compound 182 was synthesised in a low 12 % yield using 4 % ethanolic KOH at room 
temperature for 17 hours,
159
 which were the most successful reaction conditions for this 
analogue. Analogue 181 was synthesised in the lowest yield of 3 % using 2-methoxyethanol 
and saturated KOH at 120 
o
C for 20 hours, which were the only reaction conditions to 
provide this analogue. 
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The formation of analogue 177 was attempted using LiOH.H2O in EtOH at 30 
o
C for 26 
hours
156
 but no desired product was observed. Only the reduced alcohol 184 was isolated in 
17 % yield, which is caused by a Cannizzaro reaction (Scheme 151). 
 
Scheme 151: Reduction of aldehyde by cannizzaro reaction to yield alcohol 184 
 
Compound 185 was also synthesised in 62 % yield using 4 % ethanolic KOH at room 
temperature for 17 hours. This analogue was also explored due to the availability of the 
aldehyde and the methoxy group at the 4’ position rather than a hydroxy group (Scheme 
152).  
 
Scheme 152: Synthesis of analogue 185 
 
Reactions were then performed using a range of aldehydes shown in Table 12 with ketone 96 
and methylated compound 175 to afford a wide range of 6-membered ring analogues. 
 
The use of 6-membered cyclic ketones 96 and 175 gave lower yields when aldol 
condensation reactions were performed with the same range of aldehydes. Previous 
conditions using KOH were unsuccessful on these analogues; therefore, other conditions 
were investigated (Table 12). Following a procedure reported by Bhagat et al.,
156
 LiOH.H2O 
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in EtOH was used to synthesise many analogues. BF3.OEt2 was also utilised to yield desired 
analogues under acidic conditions.
160
 
 
 
  
  
96 
 
186 
LiOH.H2O in 
EtOH, 30 
o
C 
21 hours 
32 % 
187 
BF3.OEt2 
dioxane , 60 
o
C 
6 hours 
21 % 
188 
LiOH.H2O in EtOH, 
30 
o
C 
6 hours 
52 % 
189 
BF3.OEt2 
dioxane , 70 
o
C 
21 hours 
33 % 
175 
 
190 
LiOH.H2O in 
EtOH, 30 
o
C 
20 hours 
55 % 
191 
BF3.OEt2 
dioxane , 60 
o
C 
14 hours 
11 % 
192 
4 % (w/v) ethanolic 
KOH, room temp. 
16 hours 
28 % 
193 
Not isolated 
Table 12: Conditions for condensation reactions 
 
5.5. Biological Activity 
The library of analogues were then tested in an MTS cell proliferation assay using colon 
cancer cell line HT29 and breast cancer cell line MDA231.  
  
The results are displayed in Table 13. The most active analogues in the HT29 colon cancer 
cell line are the 6-membered cyclic ketones 186, 187 and 191, where all three analogues have 
an IC50 value of 6 μM. Analogues 186 and 187 contain the free indole nitrogen and analogues 
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187 and 191 contain the free phenol. However, all the 5-membered cyclic ketones tested had 
low activity in the HT29 colon cancer cell line. 
 
  
  
98 
 
176 
HT29  
IC50 = >500 μM 
177 
Not tested 
178 
HT29  
IC50 = >500 μM 
179 
HT29  
IC50 = >500 μM 
174 
 
180 
HT29  
IC50 = >500 μM 
MDA231 
IC50 = >500 μM 
181 
Not tested 
182 
Not tested 
183 
HT29  
IC50 = >500 μM 
 
96 
 
186 
HT29  
IC50 = 6 μM 
MDA231 
IC50 = 5 μM 
187 
HT29  
IC50 = 6 μM 
MDA231 
IC50 = 33 μM (+/- 
3 SEM)  
188 
 
 
MDA231 
IC50 = >500 μM 
189 
Not tested 
175 
 
190 
HT29  
IC50 = 20 μM 
MDA231 
IC50 = >500 μM 
191 
HT29  
IC50 = 6 μM 
192 
HT29  
IC50 = >500 μM 
MDA231 
IC50 = >500 μM 
193 
Not isolated 
Table 13: IC50 values of indanocine analogues in HT29 and MDA231 cancer cell lines 
 
The most active analogue in the breast cancer cell line MDA231 is compound 186 with an 
IC50 value of 5 μM. The second most active analogue 187 has an IC50 value of 33 μM. It is 
interesting that the two most active compounds tested are compounds 186 and 187, which are 
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structurally similar. The only difference between the two compounds is the presence of the free 
phenol in 187. Other analogues which were tested all possessed low activity.  
 
5.6. NCI 60-Cell Line Screen 
 
5.6.1. One-Dose Data 
The National Cancer Institute has a service which tests the activity of compounds for 
potential anticancer activity by testing them in 60 different human tumour cell lines. The NCI 
screens up to 3000 compounds per year and the testing is performed in two parts. Firstly, a 
single concentration of 15μg mL-1 is tested in all 60 cell lines and if the results from this 
initial screen meet the selection criteria, then a second five-dose test is performed in all 60 
cell lines, which measures the GI50 value, the TGI (total growth inhibition) and the LC50.  
 
 
 
Figure 44: Compounds selected for one-dose testing  
 
 
 - 122 -  
Nine diverse compounds were selected from the library of compounds synthesised. 
Compounds 177, 179, 186, 187, 188, 189, 190, 191 and 192 were chosen and the NCI 
accepted to test all nine compounds (Figure 44). These compounds were chosen as they 
incorporate all of the structural differences explored within the analogues.  
 
The results from one-dose data are presented as a mean graph of the percentage growth of the 
cancer cells. The growth is measured relative to the control which is not treated with the drug 
and relative to the number of cells at time zero. The mean graph displays growth inhibition 
(values between 0 and 100) and lethality (values less than 0). A value of 100 means no 
growth inhibition and a value of 60 would mean 40% growth inhibition. A value of 0 means 
no net growth over the assay and a value of -100 would mean all cells are dead.  
 
Good growth inhibition is important; however, selectivity is also of interest when analysing 
the data. Table 14 displays the mean growth inhibition of 9 tested analogues (see appendices 
8.4.2. for mean graphs).  
Compound Mean Growth  
Inhibition Value 
Growth 
Inhibition (%) 
Range Selected for five-
dose testing? 
177  32.85 67.15 % 123.79 Selected 
179 95.04 4.96 % 68.41 Not selected 
186  26.76 73.24 % 112.94 Selected 
187  22.14 77.86 % 124.36 Selected 
188 56.97 43.03 % 102.08 Selected 
189 88.06 11.94 % 79.21 Not selected 
190 79.22 20.78 % 75.74 Not selected 
191 34.20 65.80 % 103.60 Selected 
192 90.22 9.78 % 40.08 Not selected 
Table 14: Mean growth inhibition of one-dose data  
 
Compound 187 has the best mean growth inhibition of 77.86 % with the greatest range of 
124.36. This compound contains the free indole, a phenol and the six membered cyclic 
ketone and has been selected for the five-dose screen. Compounds 177 and 186 both have 
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promising mean growth inhibitions of 67.15 % and 73.24 % respectively. These both also 
have a high range which indicates the possibility of better selectivity and were selected for 
five-dose testing.  
 
Analogue 188 does not contain the phenol and has the lowest growth inhibition (43.03 %) of 
the compounds selected. It does have a good range of 102.08 so is therefore also of interest.  
 
5.6.2. Five-Dose Data 
Parameters which are collected in the five-dose screen include the GI50 value, the TGI and 
the LC50. The GI50 value measures 50 % inhibition of cell growth and indicates the 
concentration needed to reduce the growth of treated cells to half that of untreated cells. The 
TGI (100 %, total growth inhibition) is the concentration required to inhibit cell growth 
completely. Finally, the LC50 is the lethal concentration which is the concentration required 
that kills treated cells by 50 %. Table 15 displays the results from the 5 analogues selected 
for five-dose data (see appendices 8.4.3. for mean graphs). 
Compound Growth 
Inhibition 
from one-dose 
data (%) 
Mean 
GI50 
(μM) 
Range Mean 
TGI 
(μM) 
Mean 
LC50 
(μM) 
Selected for 
repeat of five-
dose testing? 
177 67.15 % 1.29 162 39.8 87.1 Selected 
186 73.24 % 1.41 93 40.7 89.1 Not selected 
187  77.86 % 0.62 178 11.5 44.7 Selected 
188 43.03 % 6.79 13.8 58.9 97.7 Not selected 
191 65.80 % 0.91 151 16.6 72.4 Selected 
Table 15: GI50 value, mean TGI and mean LC50 from five-dose data of five tested analogues 
 
Compound 188 is the least active of the five analogues tested with a GI50 value of 6.79 μM 
and a low range value of only 13.8. It also requires the highest concentration of 58.9 μM in 
order to inhibit growth by 100 %. Analogue 188 also had the lowest growth inhibiton of 
43.03 % from the one-dose data and was not selected for a repeat of the five-dose screen. 
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Compound 187 displayed the most potential in the one-dose data and is again the most active 
of the five analogues tested in the five-dose screen with a GI50 vaue of 0.62 μM. This 
compound also has the lowest concentration required to inhibit cell growth completely with a 
TGI value of 11.5 μM and was selected for a repeat of the five-dose screen.  
 
Analogues 177 and 191 both display good growth inhibition with GI50 values of 1.29 μM and 
0.91 μM respectively and also have high range values of 162 and 151. Analogue 177 is a 5-
membered cyclic ketone and 191 is a 6-membered cyclic ketone, but both compounds 
contain the free phenol and methyl groups as the hydrophobic region.  
 
Surprisingly, analogue 186 which showed strong initial growth inhibition in the one-dose 
data (73.24 %) has not been selected for a repeat of five-dose data. This analogue has 
relatively poor activity compared to the other analogues with a GI50 value of 1.41 μM.  
 
Most of these analogues also display a subtle trend. The GI50 values are greater than the mean 
GI50 value across most of the melanoma cell lines tested. Figure 45 displays this trend for 
compound 187. 
      Cell line              log10GI50        GI50 
 
 
Figure 45: GI50 values in melanoma cell lines for analogue 187 
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Compounds 177 (Figure 46) and 191 (Figure 47) were the other two analogues selected for 
repeat five-dose testing and these also exhibit the same trend. The GI50 values are greater 
than the mean GI50 value across most of the melanoma cell lines. 
      Cell line             log10GI50       GI50 
 
 
Figure 46: GI50 values in melanoma cell lines for analogue 177 
 
      Cell line             log10GI50       GI50 
 
 
Figure 47: GI50 values in melanoma cell lines for analogue 191 
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5.6.3. Repeat of Five-Dose Data 
Interestingly all three lead compounds which were selected for a repeat of five-dose testing 
contain the same 4-hydroxy-3,5-dimethylphenyl moiety in their structure (Figure 48). They 
do differ slightly in the other regions of their structure with one indole protected with a 
methyl group and another containing a 5-membered cyclic ketone.  
 
Figure 48: Three lead compounds identified from five-dose data 
 
Table 16 outlines the results from the repeat of the five-dose screen for the three lead 
compounds 177, 187 and 191.  
Compound Growth 
Inhibition 
from one-
dose data 
(%) 
Mean GI50 
from initial 
five-dose 
data 
(μM) 
Mean GI50 
(μM)  
Range Mean 
TGI 
(μM) 
Mean 
LC50 
(μM) 
177 67.15 % 1.29 1.35 200 34.7 95.5 
187 77.86 % 0.62 0.57 91 8.71 43.7 
191 65.80 % 0.91 0.97 186 19.5 79.4 
Table 16: Results from the repeat of five-dose data 
 
Analogue 177 is the least active out of the three compounds tested with a mean GI50 value of 
1.35 μM and the range for this compound is a maximum value of 200.  
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Compound 187 is again the most active of the three analogues tested with a mean GI50 value 
of 0.57 μM. However, in this second screen, the range for this compound is much lower than 
the previous results with a value of 91. Compound 187 also has the lowest concentration 
required to inhibit cell growth by 100 % with a TGI value of 8.71 μM.  
 
Compounds 187 and 191 were not selected by the NCI for further testing. Compound 177 
however has been selected for Biological Evaluation Committee (BEC) review (Figure 49). 
Members of this committee review data for compounds and decide whether to select them for 
additional studies. The review is based on criteria, including drugability, how novel the 
structure is, its mechanism of action and its potency. If the analogue is selected then more 
compound will be submitted to the NCI for further testing. Analogue 177 was therefore the 
compound selected for COMPARE analysis.  
 
Figure 49: Lead compound 177 identified from five-dose data 
 
5.6.4. COMPARE Analysis 
The National Cancer Institute COMPARE programme utilises the activity profile created in 
the mean graph data from the five-dose data and evaluates this to find other compounds 
within the NCI database with similar activity patterns. If the activity pattern of the ‘seed’ 
compound is similar to a known active compound, then it is likely that the two compounds 
will have similar targets and mechanisms of action. This programme can potentially assign a 
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suggested mechanism of action for novel compounds simply by comparison of activity 
profiles across 60 cancer cell lines. 
 
Compound 177 was selected for COMPARE analysis and an average from both sets of 5 
dose data was used in the Public Standard Agents database to give more reliable reports using 
GI50, TGI and LC50.  
 
Table 17 displays the results from the COMPARE analysis using GI50 data (see appendices 
8.4.5 for full table). The activity profile of analogue 177 was analysed against the ‘standard 
agents public database’ and a range of microtubule binders were amongst the top ranked 
compounds. The percentage correlations of the chosen tubulin binders displayed in Table 17 
range from 29 % up to 38 %. The correlation values are relatively low, so no firm 
conclusions can be made, however a wide range of tubulin binders were associated with 
analogue 177. The association with a number of tubulin binders may indicate analogue 177 
has the same mode of action. 
Rank Database Seed 
compound 
Target 
compound 
Correlation 
(%) 
Mecanism of action? 
1 Standard 
Agents 
177 Maytansine 38 Tubulin binder - inhibits 
microtubule assembly 
4 Standard 
Agents 
177 Rhizoxin 34 Tubulin binder - inhibits 
microtubule assembly 
5 Standard 
Agents 
177 Vinblastine 
sulphate 
34 Tubulin binder - inhibits 
microtubule assembly 
11 Standard 
Agents 
177 Cisplatin 30 Crosslinks DNA interfering 
with cell division by mitosis 
17 Standard 
Agents 
177 Paclitaxel 29 Tubulin binder - inhibits 
microtubule assembly 
Table 17: COMPARE analysis in the standard agents database of compound 177 using GI50 values 
 
The same tubulin-binding compounds were also amongst the top-ranked compounds which 
match the TGI and LC50 activity profiles of compound 177 (Table 18 and Table 19). 
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Rank Database Seed 
compound 
Target 
compound 
Correlation 
(%) 
Mecanism of action? 
5 PUBLIC 
TGI 
177 Paclitaxel 33 Tubulin binder - interferes 
with the breakdown of 
microtubules 
9 PUBLIC 
TGI 
177 Maytansine 29 Tubulin binder - inhibits 
microtubule assembly 
11 PUBLIC 
TGI 
177 Vinblastine 
sulphate 
27 Tubulin binder - inhibits 
microtubule assembly 
Table 18: COMPARE analysis in the standard agents database of compound 177 using TGI values 
 
Rank Database Seed 
compound 
Target 
compound 
Correlation 
(%) 
Mecanism of action? 
2 PUBLIC 
LC50 
177 Maytansine 43 Tubulin binder - inhibits 
microtubule assembly 
4 PUBLIC 
LC50 
177 Paclitaxel 27 Tubulin binder - interferes 
with the breakdown of 
microtubules 
Table 19: COMPARE analysis in the standard agents database of compound 177 using LC50 values 
 
In this chapter is reported a range of novel indanocine analogues along with their anticancer 
activitities. One lead compound 177 has been identified as a promising anticancer agent and 
is under BEC review by the NCI. COMPARE data indicate that compound 177 possibly 
targets the microtubules and inhibits microtubule assembly. This mode of action is consistent 
with indanocine 76, which is the original analogue that these libraries were based on. Further 
tests to verify this could be performed to strengthen this hypothesis. 
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5.7. Conclusions 
The work in this chapter describes the attempted synthesis of a range of indanocine 
analogues. Indanocine is an example of a biologically active compound which contains the 
indanone moiety within its structure. The aim of this work was to synthesise indole 
containing analogues with spatial similarities to indanocine and to test them for biological 
activity. 
 
The proposed synthetic route contained two steps, the first step was a Friedel-Craft acylation 
reaction and the second step was a Claisen-Schmidt condensation reaction. This synthetic 
route was used to produce fifteen analogues in mid to low yield under varying conditions. 
Pure compounds were isolated and tested for preliminary biological activity against two 
cancer cell lines; HT29 and MDA231. A wide variety of biological activities were observed 
with three analogues giving promising results; 186, 187 and 188. These three compounds 
individually resulted in IC50 values <7 µM against the HT29 cancer cell line and analogue 
186 gave an IC50 value of 5.4 µM against the MDA231 cancer cell line. 
 
Nine of the fifteen isolated compounds, with a variety of structural motifs, were accepted for 
testing by the NCI. The analogues were initially tested using a single dose in the NCI 60 cell 
line screen. Five analogues were selected for further testing in a five-dose screen based on 
their high growth inhibition results in one-dose testing. Analogues 187, 191 and 177 showed 
promising results with mean GI50 vaues of 0.62, 0.91 and 1.29 µM respectively. These were 
selected for repeat five-dose testing, after which compound 177 was selected for review by 
the NCI Biological Evaluation Committee. 
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6. Conclusions 
The primary aim of this thesis was to develop new syntheses for a range of analogues that 
contain the tetrahydroisoquinoline or dihydroisoquinolinone framework, and to explore their 
biological activities.  
 
Synthesis of the tetrahydroisoquinoline framework was initially investigated using a Friedel-
Crafts alkylation reaction. Although the appropriate precursors were synthesised in good 
yields, the Friedel-Crafts alkylation approach proved unsuccessful. During attempted 
cyclisation reactions an unexpected, but interesting, carbonate side product was observed. 
The carbonate side product was formed by incorporation of CO2 from the atmosphere in the 
presence of Ag2O. This was further explored as a potential synthetic route to carbonate 
compounds and a range of carbonates were subsequently synthesised in high yields. 
Alternative, more favourable, Friedel-Crafts acylation reaction conditions were then 
explored. This approach was also unsuccessful however, the use of SOCl2 led to an 
interesting side product with both a sulfur and chlorine atom being incorporated into the 
novel compound 69. 
 
The synthesis of the dihydroisoquinolinone framework was investigated. An initial proposed 
synthetic route involved the synthesis of the dihydroisoquinolinone framework via the 
corresponding indanone. The formation of A/B indanones was acheived via an 
intramolecular Friedel-Crafts acylation reaction using TFAA as an activator, and a library of 
indanones were synthesised in high yield. A Schmidt reaction was used to synthesise a 
library of A/B lactams from their corresponding indanones in good yield. The synthesis of 
A/B/C indanones was achieved using similar reaction conditions to those for A/B indanones, 
however the synthesis was sensitive to temperature and reaction time. A single A/B/C lactam 
148 was reliably synthesised via a Schmidt reaction.  
 
Due to the capricious nature of the intial synthetic route, an alternative synthesis was 
explored to access the A/B/C dihydroisoquinolinone framework. The first step was a Heck 
cross-coupling reaction and the second step was a modified Curtius rearrangement. This 
route was used to synthesis A/B/C lactam 170 in an overall 51 % yield, which gave an IC50 
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value of 9 μM when tested against the HT29 colon cancer cell line. Lactam 170 lacks 
functionality on the C-ring; if functionality is incorporated then the biological activity should 
further improve. 
 
Indanocine is an example of a biologically active compound which contains an indanone 
moiety within its structure. The synthesis of novel analogues of indanocine was explored. 
The proposed synthetic route involved two steps, the first step was a Friedel-Craft acylation 
reaction and the second step was a Claisen-Schmidt condensation reaction. This synthetic 
route was used to produce fifteen analogues in mid to low yield under varying conditions. 
Compounds 186 and 187 when tested against cancer cell line HT29 resulted in IC50 values <7 
µM and analogue 186 gave an IC50 value of 5.4 µM against the MDA231 cancer cell line. 
 
Nine of the fifteen isolated compounds, with a variety of structural motifs, were accepted for 
testing by the NCI. The analogues were initially tested using a single dose in the NCI 60 cell 
line screen. Five analogues were selected for further testing in a five-dose screen based on 
their high growth inhibition results in one-dose testing. Analogues 187, 191 and 177 showed 
promising results with mean GI50 values, across 60 cell lines, of 0.62, 0.91 and 1.29 µM 
respectively. These were selected for repeat five-dose testing, after which compound 177 was 
selected for review by the NCI Biological Evaluation Committee. Compound 177 is currently 
under consideration by the NCI as a candidate for further testing.  
 
The work undertaken in this thesis has pioneered new synthetic routes that can be used to 
produce biologically active compounds. The synthetic chemistry within this thesis was 
conducted using a framework approach. The biologically active compounds synthesised 
represent only a portion of the compounds that could be accessed via the routes that were 
developed, and further work could potentially unlock many interesting medicinal candidates. 
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7. Experimental 
 
7.1. General Experimental 
Chemicals, solvents and reagents used are commercially available and were used without 
further purification.   
 
All TLC’s were carried out on Merck Aluminium-backed TLC plates Silicagel 60 F254. 
They were viewed using UV light of wavelength 254 nm and then stained with either 
potassium permanganate or 2,4-dinitrophenylhydrazine (DNP), which were then heated 
gently with a heatgun. Column chromatography was used to purify compounds with Merck 
Silica gel (0.040-0.063 mm). Compounds were loaded as a CHCl3 solution or dry loaded by 
adsorption onto silica.   
 
1
H NMR spectra were obtained on JEOL Eclipse (270 MHz), Varian Mercury VX (400 
MHz) or Bruker Avance III (400 MHz) spectrometers. 
13
C NMR spectra were obtained on 
JEOL Eclipse (67.9 MHz), Varian Mercury VX (100 MHz) or Bruker Avance III (100 MHz) 
spectrometers. The chemical shifts are recorded in parts per million (ppm) with reference to 
residual solvent peaks. The coupling constants J are in Hertz (Hz), recorded to the nearest 0.5 
Hz and are not rationalised. The multiplicities are assigned as a singlet (s), doublet (d), triplet 
(t), quartet (q), quintet (quint), septet (sept), doublet of doublets (dd), doublet of triplets (dt), 
triplet of doublets (td), doublet of doublet of doublets (ddd), broad singlet (brs) and multiplet 
(m). The +ve or -ve symbols after the carbon NMR peaks represent the number of protons 
attached where +ve indicates CH and CH3 and –ve indicates C and CH2. 
19
F NMR spectra 
were obtained on a Bruker Avance III (100 MHz) spectrometer. 
 
Mass Spectrometry (MS) and High Resolution Mass Spectrometry (HRMS) were carried out 
on a micrOTOF
TM
 from Bruker Daltonics (Bremen, Germany), which uses electrospray 
source (ESI-TOF). It has a mass accuracy of 5 ppm externally calibrated using sodium 
formate solution, which is applicable to both positive and negative ionisation modes. All 
theoretical and calculated values are reported to 4 decimal places. In the event of an observed 
ion having an error of greater than 5 ppm from the theoretical value it is still reported with 
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the margin of error stated. The data was processed using external calibration with the Bruker 
Daltonics software, DataAnalysis
TM
 as part of the overall hardware control software, 
Compass 1.1
TM
 and the samples were analysed under positive electrospray ionisation mode. 
Ions are usually present as both protonated molecules and as the sodium complex. The mass 
spectrometer collects information on both accurate mass of the molecules and isotope 
patterns enabling determination of the molecular formula. The samples are added by syringe 
pump or flow injection using an autosampler in an Agilent 1100 LC system.  
 
Infrared spectra (IR) were recorded on either Perkin-Elmer, Spectrum RX I FT-IR system 
and all values are recorded in cm
-1
.  
 
Melting points were obtained using a Reichert-Jung heated-stage microscope. 
 
X-ray Crystallography was performed by Dr Mary Mahon. Single crystals were analysed at 
150(2) K using graphite monochromated Mo(K) radiation and a Nonius Kappa CCD 
diffractometer. The structures were solved using SHELXS-97 and refined using SHELXL-
97. 
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7.2. MTS Cell proliferation assay protocol 
This assay uses a 96-well plate format to determine cell viability and is based on the Promega 
Cell Titer 96 Aqueous One Solution Cell Proliferation Assay. Seed densities of 500 cells per 
well were used and final drug concentrations of 500 µM, 200 µM, 100 µM, 50 µM, 20 µM, 
10 µM, 5 µM, 2 µM, 1 µM and 500 nM in 1% DMSO. Drugs were incubated with the HT29 
cell line for 72 hours prior to reading and IC50 curves were generated using SigmaPlot 8 
software.  
 
General Procedure: 
1. 96-Well tissue culture plates: 100 μL per well final volume. 
2. Cell suspension added in 50 μL culture medium. 
Test compound added in 50 μL culture medium (plus other solvent if necessary). 
3. Cell suspension added to wells several hours before adding test compound. 
This can be from 2-3 hours, depending on the experiment. 
Cells plus test compound incubated at 37 
o
C, 5 % CO2 in humidified air for 3 days. 
4. MTS reagent added, 20 μL per well. 
5. Plate returned to incubator for 3 hours. 
6. OD490nm recorded after 3 hours. 
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7.3. Chapter Two - 1,2,3,4-Tetrahydroisoquinolines 
 
7.3.1. Alkylation 
 
General Procedure 1, Synthesis of bis-alkylation of primary amines 
nBu4NI (0.3 eq.) was added to a rapidly stirred suspension of the required amine (1 eq.), the 
required benzyl chloride (2.2 eq.) and K2CO3 (3 eq.) in MeCN (6 mL/ 1 mmol) open to the 
air. After 3.5 hours at 82 
o
C, the mixture was concentrated under reduced pressure. The 
residue was suspended in H2O (30 mL) and the product extracted with EtOAc (4 x 30 mL). 
The combined organic layers were washed with brine (30 mL), dried on MgSO4, filtered and 
concentrated under reduced pressure. After column chromatography [silica, light petroleum 
(b.p. 40-60 
o
C) EtOAc gradient column], the desired product was isolated. 
 
General Procedure 2, Iodination reaction open to the air 
The required alkylated amino alcohol (1 eq.), I2 (1.1 eq.), PPh3 (1.1 eq.) and imidazole (1.1 
eq.) were suspended in CH2Cl2 (4 mL/ 1 mmol) open to the air. After 3.5 hours of stirring at 
room temperature, the mixture was concentrated under reduced pressure. EtOAc (30 mL) and 
sat. aq. NaHCO3 solution (40 mL) were added, the layers separated and the aqueous layer 
extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine (30 
mL), dried on MgSO4, filtered and concentrated under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], the 
desired product was isolated.  
 
General Procedure 3, Iodination reaction under N2 
The required alkylated amino alcohol (1 eq.), I2 (1.1 eq.), PPh3 (1.1 eq.) and imidazole (1.1 
eq.) were suspended in CH2Cl2 (4 mL/ 1 mmol) under a N2 atmosphere. After 5 hours of 
stirring at room temperature, the mixture was concentrated under reduced pressure. EtOAc 
(30 mL) and sat. aq. NaHCO3 solution (40 mL) were added, the layers separated and the 
aqueous layer extracted with EtOAc (2 x 30 mL). The combined organic layers were washed 
with brine (30 mL), dried on MgSO4, filtered and concentrated under reduced pressure. After 
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column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 
the desired product was isolated.  
 
Synthesis of 2-(bis(3-methoxybenzyl)amino)ethanol 38 
 
According to General Procedure 1, using ethanolamine 37 (302 μL, 5 mmol, 1 eq.), nBu4NI 
(554 mg, 1.5 mmol, 0.3 eq.), 3-methoxybenzyl chloride (1.6 mL, 11 mmol, 2.2 eq.) and 
K2CO3 (2.07 g, 15 mmol, 3 eq.) in MeCN (30 mL), alcohol 38 (1.2 g, 80 % yield) was 
isolated as a colourless oil. 
1
H NMR (400 MHz; CDCl3): δH 7.24 (2H, t, J = 8.0 Hz, 
ArC(5)H), 6.91 (2H, d, J = 7.5 Hz, ArC(4)H), 6.87 (2H, t, J = 1.5 Hz, ArC(2)H), 6.79 (2H, 
dd, J = 8.0, 1.5 Hz, ArC(6)H), 3.80 (6H, s, ArOCH3), 3.60 (4H, s, ArCH2NCH2Ar), 3.58 (2H, 
t, J = 5.0 Hz, NCH2CH2OH) and 2.67 (2H, t, J = 5.0 Hz, NCH2CH2OH). 
13
C NMR (100 
MHz; CDCl3): δC 159.7- (ArC(1)), 140.4- (ArC(3)), 129.4+ (ArC(5)H), 121.2+ (ArC(2)H), 
114.6+ (ArC(4)H), 112.4+ (ArC(6)H), 58.6- (NCH2CH2OH), 58.2- (ArCH2NCH2Ar), 55.1+ 
(ArOCH3) and 54.9- (NCH2CH2OH). MS m/z (+ESI) 302 (100 %, MH
+
) and 324 (13 %, 
MNa
+
). HRMS (+ESI) Found MH
+
 302.1748, C18H24NO3 requires 302.1756 and found 
MNa
+
 324.1554, C18H23NNaO3 requires 324.1576. IR νmax(liquid film): 3451 (OH), 2943 (C-
H), 1600 (C=C) and 1049 (C-O). Rf (50 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.6. 
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Synthesis of 2-iodo-N,N-bis(3-methoxybenzyl)ethanamine 39 
 
According to General Procedure 2, using alcohol 38 (602 mg, 2 mmol, 1 eq.), I2 (558 mg, 
2.2 mmol, 1.1 eq.), PPh3 (577 mg, 2.2 mmol, 1.1 eq.) and imidazole (150 mg, 2.2 mmol, 1.1 
eq.) in CH2Cl2 (8 mL) iodide 39 (550 mg, 67 % yield) was isolated as a clear brown oil. 
1
H 
NMR (400 MHz; CDCl3): δH 7.22 (2H, t, J = 8.0 Hz, ArC(5)H), 7.01 (2H, s, ArC(2)H), 6.95 
(2H, d, J = 7.5 Hz, ArC(6)H), 6.79 (2H, dd, J = 8.0 and 2.5 Hz, ArC(4)H), 3.82 (6H, s, 
ArOCH3), 3.60 (4H, s, ArCH2NCH2Ar), 3.19 (2H, t, J = 7.5 Hz, NCH2CH2I) and 2.82 (2H, t, 
J = 7.5 Hz, NCH2CH2I). 
13
C NMR (100 MHz; CDCl3): δC 159.7- (ArC(1)), 140.7 (ArC(3)), 
129.2+ (ArC(5)H), 121.0+ (ArC(2)H), 114.2 (ArC(4)H), 112.6+ (ArC(6)H), 58.0- 
(ArCH2NCH2Ar), 55.9- (NCH2CH2I), 55.2+ (ArOCH3) and 4.30- (NCH2CH2I). MS m/z 
(+ESI) 412 (MH
+
) and 284 (58 %, aziridinium
+
). HRMS (+ESI) Found aziridinium
+
 
284.1646, C18H22NO2 requires 284.1651. IR νmax(liquid film): 2939 (C-H), 1600 (C=C) and 
1050 (C-O). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.8. 
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Synthesis of 2-(dibenzylamino)ethanol 40 
 
According to General Procedure 1, using ethanolamine 37 (600 μL, 10 mmol, 1 eq.), 
nBu4NI (1.11 mg, 3 mmol, 0.3 eq.), benzyl chloride (2.5 mL, 22 mmol, 2.2 eq.) and K2CO3 
(4.15 g, 30 mmol, 3 eq.) in MeCN (30 mL) alcohol 40 (2.4 g, 99 % yield) was isolated as a 
white solid, m.p. 42-44 
o
C [lit.
161
 38 
o
C]. 
1
H NMR (400 MHz; CDCl3): δH 7.35-7.26 (10H, 
m, ArCH), 3.64 (4H, s, PhCH2NCH2Ph), 3.59 (2H, t, J = 5.5 Hz, NCH2CH2OH) and 2.68 
(2H, t, J = 5.5 Hz, NCH2CH2OH). 
13
C NMR (100 MHz; CDCl3): δC 138.7- (ArC(1)), 129.0+ 
(ArC(3)H), 128.4+ (ArC(2)H), 127.2+ (ArC(4)H), 58.5- (NCH2CH2OH), 58.2- 
(PhCH2NCH2Ph) and 54.8- (NCH2CH2OH). MS m/z (+ESI) 242 (100 %, MH
+
) and 264 (1 
%, MNa
+
). HRMS (+ESI) Found MH
+
 242.1546, C16H20NO requires 242.1545 and found 
MNa
+
 264.1368, C16H19NNaO requires 264.1364. IR νmax(liquid film): 3321 (OH) and 1600 
(C=C). Rf (20 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.3. Spectroscopic data are 
consistent with those previously reported by Wurm et al.
161
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Synthesis of N,N-dibenzyl-2-iodoethanamine 41 
 
According to General Procedure 2, using alcohol 40 (743 mg, 3.08 mmol, 1 eq.), I2 (858 
mg, 3.38 mmol, 1.1 eq.), PPh3 (887 mg, 3.38 mmol, 1.1 eq.) and imidazole (230 mg, 3.38 
mmol, 1.1 eq.) in CH2Cl2 (20 mL), iodide 41 (744 mg, 69 % yield) was isolated as a clear 
brown oil. 
1
H NMR (400 MHz; CDCl3): δH 7.31 (4H, t, J = 7.5 Hz, ArC(3)H), 7.27-7.23 
(4H, m, ArC(2)H), 7.19-7.15 (2H, m, ArC(4)H), 3.56 (4H, s, PhCH2NCH2Ph), 3.09 (2H, t, J 
= 7.5 Hz, NCH2CH2I) and 2.76 (2H, t, J = 7.5 Hz, NCH2CH2I). 
13
C NMR (100 MHz; 
CDCl3): δC 139.0- (ArC(1)), 128.8+ (ArC(3)H), 128.3+ (ArC(2)H), 127.1+ (ArC(4)H), 58.1- 
(PhCH2NCH2Ph), 56.1- (NCH2CH2I) and 4.0- (NCH2CH2I). MS m/z (+ESI) 224 (100 %, M
+
-
I) and 352 (11 %, MH
+
). HRMS (+ESI) Found MH
+
 352.0561, C16H19IN requires 352.0562. 
IR νmax(liquid film): 2925 (CH) and 1602 (C=C). Rf (30 % EtOAc in light petroleum (b.p. 
40-60 
o
C) 0.8.  
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Synthesis of Carbonic acid, bis(N,N-di(3-methoxybenzyl)aminoethyl) carbonate 43 
 
Iodide 39 (133 mg, 0.32 mmol, 1 eq.) was dissolved in CH2Cl2 (2 mL) and stirred under an 
atmosphere of CO2 (balloon) at room temperature for 2 hours. Ag2O (81 mg, 0.35 mmol, 1.1 
eq.) was added and the mixture was stirred under an atmosphere of CO2 at room temperature 
for 16 hours. The mixture was filtered through a pad of celite, the celite was washed with 
CH2Cl2 and the reaction mixture was concentrated under reduced pressure to afford 
symmetrical carbonate 43 (95 mg, 94 % yield) as a clear yellow oil. 
1
H NMR (400 MHz; 
CDCl3): δH 7.20 (4H, t, J = 8.0 Hz, ArC(5)H), 6.95 (4H, s, ArC(2)H), 6.93 (4H, d, J = 8.0 
Hz, ArC(4)H), 6.77 (4H, dd, J = 8.0 and 2.0 Hz, ArC(6)H), 4.19 (4H, t, J = 6.5 Hz, 
NCH2CH2O), 3.78 (12H, s, ArOCH3), 3.63 (8H, s, ArCH2NCH2Ar) and 2.76 (4H, t, J = 6.5 
Hz, NCH2CH2O). 
13
C NMR (100 MHz; CDCl3): δC 159.7- (ArC(3)) 155.1- (C=O), 140.9- 
(ArC(1)), 129.2+ (ArC(5)H, 121.0+ (ArC(4)H), 114.0+ (ArC(2)H), 112.5+ (ArC(6)H), 65.8- 
(NCH2CH2O), 58.6- (ArCH2NCH2N), 55.1+ (ArOCH3) and 51.6- (NCH2CH2O). MS m/z 
(+ESI) 651 (100 %, MNa
+
). HRMS (+ESI) Found MNa
+
 651.3028, C37H44N2NaO7 requires 
MNa 651.3004. IR νmax(liquid film): 3054 (CH), 1744 (C=O), 1601 (C=C) and 1264 (C-O). 
Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.4. 
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Synthesis of 2-(bis(3-methoxybenzyl)amino)ethyl methyl carbonate 44 
 
Iodide intermediate 39 (44 mg, 0.11 mmol, 1 eq.) was dissolved in CHCl3 (2 mL) and CO2 
(balloon) was bubbled through. MeOH (0.1 mL, 2.75 mmol, 25 eq.) was added, followed by 
Ag2O (27 mg, 0.12 mmol, 1.1 eq.). The reaction mixture was stirred under an atmosphere of 
CO2 at room temperature for 16 hours. The reaction was filtered through a cotton wool plug, 
the cotton wool was washed with CHCl3 (10 mL) and the solvent was removed under reduced 
pressure. Traces of silver were still present so the product was dissolved in CHCl3, the 
solution was filtered for a second time through a silica plug and the silica was washed with 
EtOAc (10 mL). The solvent was removed under reduced pressure to collect carbonate 44 (38 
mg, 99 % yield) as a pale yellow oil. 
1
H NMR (400 MHz; CDCl3): δC 7.14 (2H, t, J = 8.0 Hz, 
ArC(4)H), 6.89 (2H, s, ArC(2)H), 6.86 (2H, d, J = 7.5 Hz, ArC(5)H), 6.71 (2H, dd, J = 8.0 
and 2.5 Hz, ArC(6)H), 4.15 (2H, t, J = 6.0 Hz, NCH2CH2O), 3.73 (6H, s, ArOCH3), 3.68 
(3H, s, (CO)OCH3), 3.56 (4H, s, ArCH2NCH2Ar) and 2.70 (2H, t, J = 6.0 Hz, NCH2CH2O). 
13
C NMR (100 MHz; CDCl3): δC 159.7- (ArC(1)), 155.7- (C=O), 140.9- (ArC(3)), 129.2+ 
(ArC(4)H), 121.0+ (ArC(2)H), 114.0+ (ArC(5)H), 112.5+ (ArC(6)H), 65.9- (NCH2CH2O), 
58.6- (ArCH2NCH2Ar), 55.1+ (ArOCH3), 54.7+ ((CO)OCH3) and 51.7- (NCH2CH2O). MS 
m/z (+ESI) 360 (100 %, MH
+
). HRMS (+ESI) Found MH
+
 360.1805, C20H26NO5 requires 
MH 360.1805. IR νmax(liquid film): 2834 (CH), 1749 (C=O), 1600 (C=C) and 1047 (C-O). 
Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.6. 
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Synthesis of 2-methoxy-N,N-bis(3-methoxybenzyl)ethylamine 45 
 
Iodide intermediate 39 (80 mg, 0.19 mmol, 1.0 eq.) was placed under a N2 atmosphere for 10 
minutes and then dissolved in CHCl3 (3 mL). MeOH (0.2 mL, 4.75 mmol, 25 eq.) was added, 
followed by Ag2O (49 mg, 0.21 mmol, 1.1 eq.) and the reaction mixture was stirred under an 
atmosphere of N2 at room temperature for 16 hours. The reaction mixture was filtered 
through a cotton wool plug, the plug was washed with CHCl3 (10 mL) and the solvent was 
removed under reduced pressure. Traces of silver were still present so the product was 
dissolved in CHCl3, the solution was filtered for a second time through a silica plug and the 
silica was washed with EtOAc (10 mL). The solvent was removed under reduced pressure to 
collect ether 45 (60 mg, 98 % yield) as a pale yellow oil. 
1
H NMR (400 MHz; CDCl3): δH 
7.21 (2H, t, J = 8.0 Hz, ArC(5)H), 6.98 (2H, d, J = 2.5 Hz, ArC(2)H), 6.95 (2H, d, J = 8.0 
Hz, ArC(4)H), 6.78 (2H, dd, J = 8.0 and 2.5 Hz, ArC(6)H), 3.81 (6H, s, ArOCH3), 3.63 (4H, 
s, ArCH2NCH2Ar), 3.50 (2H, t, J = 6.0 Hz, NCH2CH2O), 3.29 (3H, s, OCH3) and 2.69 (2H, t, 
J = 6.0 Hz, NCH2CH2O). 
13
C NMR (100 MHz; CDCl3): δC 159.6- (ArC(1)), 141.5- 
(ArC(3)), 129.1+ (ArC(5)H), 121.0+ (ArC(2)H), 114.2+ (ArC(4)H), 112.3+ (ArC(6)H), 71.5- 
(NCH2CH2O), 58.8- (ArCH2NCH2Ar), 58.7+ (OCH3), 55.1+ (ArOCH3) and 52.8- 
(NCH2CH2O). MS m/z (+ESI) 316 (100 %, MH
+
) and 338 (1 %, MNa
+
). HRMS (+ESI) 
Found MH
+
 316.1891, C19H26NO3 requires MH 316.1907 and found MNa
+
 338.1718, 
C19H25NNaO3 requires MNa 338.1727. IR νmax(liquid film): 2833 (CH), 1600 (C=C) and 
1048 (C-O). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.7.  
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 Synthesis of 2-(dibenzylamino)ethyl methyl carbonate 46 
 
Method A 
Iodide intermediate 41 (160 mg, 0.46 mmol, 1 eq.) was dissolved in CHCl3 (4 mL) and CO2 
was bubbled through. MeOH (0.09 mL, 2.30 mmol, 5 eq.) was added, followed by Ag2CO3 
(141 mg, 0.51 mmol, 1.1 eq.). The reaction mixture was stirred under an atmosphere of CO2 
at room temperature for 3 hours. The reaction mixture was filtered through a pad of celite, 
the celite was washed with CHCl3 (10 mL) and the solvent was removed under reduced 
pressure to collect carbonate 46 (127 mg, 60 % yield) as a clear pale yellow oil. 
Method B 
Iodide intermediate 41 (196 mg, 0.56 mmol, 1 eq.) was dissolved in CHCl3 (5 mL) and CO2 
was bubbled through. MeOH (0.11 mL, 2.80 mmol, 5 eq.) was added, followed by Ag2O 
(144 mg, 0.62 mmol, 1.1 eq.) and the reaction mixture was stirred under an atmosphere of 
CO2 at room temperature for 3 hours. The reaction mixture was filtered through a pad of 
celite, the celite was washed with CHCl3 (10 mL) and the solvent was removed under 
reduced pressure to collect carbonate 46 (158 mg, 95 % yield) as a clear pale yellow oil.  
Method C 
Iodide intermediate 41 (50 mg, 0.14 mmol, 1 eq.) was dissolved in CHCl3 (2 mL) and CO2 
was bubbled through. MeOH (0.14 mL, 3.5 mmol, 25 eq.) was added, followed by Ag2O (37 
mg, 0.16 mmol, 1.1 eq.). The reaction mixture was stirred under an atmosphere of CO2 at 
room temperature for 16 hours. The reaction mixture was filtered through a cotton wool plug, 
the plug was washed with CHCl3 (10 mL) and the solvent was removed under reduced 
pressure. Traces of silver were still present so the product was dissolved in CHCl3, the 
solution was filtered for a second time through a silica plug and the silica was washed with 
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EtOAc (10 mL). The solvent was removed under reduced pressure to collect carbonate 46 (40 
mg, 95 % yield) as a colourless oil.  
1
H NMR (400 MHz; CDCl3): δH 7.36 (4H, d, J = 7.0 Hz, ArC(2)H), 7.30 (4H, t, J = 7.0 Hz, 
ArC(3)H), 7.23 (2H, t, J = 7.0 Hz, ArC(4)H), 4.20 (2H, t, J = 6.0 Hz, NCH2CH2O), 3.75 (3H, 
s, OCH3), 3.65 (4H, s, PhCH2NCH2Ph) and 2.76 (2H, t, J = 6.0 Hz, NCH2CH2O). 
13
C NMR 
(100 MHz; CDCl3): δC 155.7- (C=O), 139.2- (ArC(1)), 128.7+ (ArC(2)H), 128.2+ 
(ArC(3)H), 127.0+ (ArC(4)H), 66.0- (NCH2CH2O), 58.7- (PhCH2NCH2Ph), 54.7+ (OCH3) 
and 51.6- (NCH2CH2O). MS m/z (+ESI) 300 (100 %, MH
+
) and 322 (2 %, MNa
+
). HRMS 
(+ESI) Found MH
+
 300.1597, C18H22NO3 requires MH 300.1600 and found MNa
+
 322.1419, 
C18H21NNaO3 requires MNa 322.1419. IR νmax(liquid film): 2955 (CH), 1747 (C=O) and 
1602 (C=C). Rf (20 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.5. 
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Synthesis of N,N-dibenzyl-2-methoxyethylamine 47 
 
Iodide intermediate 41 (57 mg, 0.16 mmol, 1 eq.) was placed under a N2 atmosphere for 5 
minutes and then dissolved in CHCl3 (2 mL). MeOH (0.16 mL, 4 mmol, 25 eq.) was added, 
followed by Ag2O (41 mg, 0.18 mmol, 1.1 eq.). The reaction mixture was stirred under a N2 
atmosphere at room temperature for 35 minutes. The reaction mixture was filtered through a 
cotton wool plug, washed with CHCl3 (10 mL) and the solvent was removed under reduced 
pressure. Traces of silver were still present so the product was dissolved in CHCl3 and the 
solution was filtered for a second time through a silica plug, the silica was washed with 
EtOAc (10 mL) and concentrated under reduced pressure to collect ether 47 (37 mg, 91 % 
yield) as a colourless oil. 
1
H NMR (400 MHz; CDCl3): δH 7.38 (4H, d, J = 8.0 Hz, 
ArC(2)H), 7.30 (4H, t, J = 8.0 Hz, ArC(3)H), 7.25-7.21 (2H, m, ArC(4)H), 3.65 (4H, s, 
PhCH2NCH2Ph), 3.49 (2H, t, J = 6.5 Hz, NCH2CH2O), 3.28 (3H, s, OCH3) and 2.66 (2H, t, J 
= 6.5 Hz, NCH2CH2O). 
13
C NMR (100 MHz; CDCl3): δC 139.7- (ArC(1)), 128.8+ 
(ArC(2)H), 128.2+ (ArC(3)H), 126.8+ (ArC(2)H), 71.5- (NCH2CH2O), 58.9- 
(PhCH2NCH2Ph), 58.7+ (OCH3) and 52.7- (NCH2CH2O). MS m/z (+ESI) 256 (100 %, 
MH
+
). HRMS (+ESI) Found MH
+
 256.1691, C17H21NO requires MH 256.1701. IR 
νmax(liquid film): 2923 (CH) and 1601 (C=C). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.5. Spectroscopic data consistent with those reported by Henkel et al.
162
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Synthesis of bis(2-(dibenzylamino)ethyl) carbonate 48 
 
Following a procedure reported by Teranishi
68
 Ag2CO3 (938 mg, 3.40 mmol, 5 eq.) and 
MeOH (0.14 mL, 3.40 mmol, 5 eq.) were added to a stirred solution of iodide intermediate 41 
(237 mg, 0.68 mmol, 1 eq.) in CHCl3 (9 mL). The reaction flask was covered in aluminium 
foil and the reaction mixture was stirred at room temperature open to the atmosphere for 2.5 
hours. The reaction mixture was filtered through a pad of celite, washed with CHCl3 and the 
solvent was removed under reduced pressure to afford symmetrical carbonate 48 (197 mg, 57 
% yield) as a yellow oil. 
1
H NMR (400 MHz; CDCl3): δH 7.40-7.22 (20H, m, ArCH), 4.19 
(4H, t, J = 6.0 Hz, NCH2CH2O), 3.67 (8H, s, PhCH2NCH2Ph) and 2.78 (4H, t, J = 6.0 Hz, 
NCH2CH2O). 
13
C NMR (100 MHz; CDCl3): δC 155.1- (C=O), 139.2- (ArC(1)), 128.7+ 
(ArCH), 128.2+ (ArCH), 127.0+ (ArCH), 65.9- (NCH2CH2O), 58.7- (PhCH2NCH2Ph) and 
51.6- (NCH2CH2O). HRMS (+ESI) Found MH
+
 531.2704, C33H36N2NaO3 requires MH 
531.2624 (15 ppm). Rf (20 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.5. 
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Synthesis of N,N-dibenzyl-2-chloroethanamine 49 
 
Method A 
Iodide intermediate 41 (135 mg, 0.39 mmol, 1 eq.) was dissolved in CHCl3 (4 mL) and CO2 
was bubbled through. MeOH (0.39 mL, 9.75 mmol, 25 eq.) was added followed by AgCl (62 
mg, 0.43 mmol, 1.1 eq.) and the reaction mixture was stirred under a CO2 atmosphere at 
room temperature for 16 hours. The resulting cloudy pale yellow mixture was filtered 
through a pad of celite and the solvent was removed under reduced pressure to collect 
chloride product 49 (87 mg, 87 % yield) as a clear yellow oil.  
Method B 
Iodide intermediate 41 (82 mg, 0.23 mmol, 1 eq.) was dissolved in MeCN (2 mL) and CO2 
was bubbled through. MeOH (0.23 mL, 5.75 mmol, 25 eq.) was added followed by AgCl (36 
mg, 0.25 mmol, 1.1 eq.) and the reaction mixture was stirred under a CO2 atmosphere at 
room temperature for 16 hours. The reaction mixture was filtered through a pad of celite, 
washed with EtOAc and the solvent was removed under reduced pressure to collect chloride 
product 49 (60 mg, 99 % yield) as a clear yellow oil.  
1
H NMR (400 MHz; CDCl3): δH 7.37 (4H, d, J = 7.0 Hz, ArC(2)H), 7.31 (4H, t, J = 8.0 Hz, 
ArC(3)H), 7.24 (2H, t, J = 7.0 Hz, ArC(4)H), 3.65 (4H, s, PhCH2NCH2Ph), 3.48 (2H, t, J = 
7.0 Hz, NCH2CH2Cl) and 2.83 (2H, t, J = 7.0 Hz, NCH2CH2Cl). 
13
C NMR (100 MHz; 
CDCl3): δC 139.4- (ArC(1)), 129.0+ (ArC(4)H), 128.6+ (ArC(3)H), 127.4+ (ArC(2)H), 59.0- 
(PhCH2NCH2Ph), 55.6- (NCH2CH2Cl) and 42.1- (NCH2CH2Cl). MS m/z (+ESI) 260 (100 %, 
MH
+
 (
35
Cl)), 262 (31 %, MH
+
 (
37
Cl)) and 224 (12 %, aziridinium
+
). HRMS (+ESI) Found 
MH
+
 260.1185, C16H19
35
ClN requires MH 260.1206. IR νmax(liquid film): 3003 (CH) and 
1601 (C=C). Rf (20 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.6. Spectroscopic data are 
consistent with those reported by Bernier et al.
163
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Synthesis of hexyl methyl [
13
C]-carbonate 51 
 
 
To a solution of 1-iodohexane (212 mg, 1 mmol, 1 eq.) and Ag2O (278 mg, 1.2 mmol, 1.2 
eq.) in MeOH (2.02 mL) was bubbled CO2 generated from NaH
13
CO3 (425 mg, 5 mmol, 5 
eq.) and 3M HCl(aq.). The suspension was stirred at 40 
o
C for 4 hours. The reaction mixture 
was filtered through filter paper and cotton wool, washed with MeOH and the solvent was 
removed under reduced pressure to afford carbonate 51 (96 mg, 60 % yield) as a colourless 
oil. 
1
H NMR (400 MHz; CDCl3): δH 4.12 (2H, t, J = 7.0 Hz, CH2O), 3.76 (3H, s, OCH3), 
1.67 - 1.63 (2H, m, CH2), 1.30 - 1.27 (6H, m, CH2) and 0.89 - 0.86 (3H, m, CH3). 
13
C NMR 
(100 MHz; CDCl3): δC 155.8- (C=O), 68.2- (OCH2), 54.5+ (OCH3), 31.3- (CH2), 28.6- 
(CH2), 25.3- (CH2), 22.4- (CH2) and 13.9+ (CH3). HRMS (+ESI) Found MNa
+
 184.1008, 
12
C7
13
CH16NaO3 requires MNa 184.0997. 
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Synthesis of N-isopropylaniline 52 
 
Ag2O (510 mg, 2.2 mmol, 1.1 eq.) was added to a solution of 2-iodopropane (0.22 mL, 2.2 
mmol, 1.1 eq.) and aniline (0.91 mL, 10 mmol, 5 eq.) in CHCl3 (10 mL) and stirred at room 
temperature with an empty balloon on top. In a second sealed flask, 6M HCl(aq.) (1 mL) was 
added to NaHCO3 (168 mg, 2 mmol, 1 eq.) and, using a double headed needle, the CO2 
produced was pushed into the main reaction flask and bubbled through the reaction mixture. 
The reaction mixture was left to stir at room temperature for 2 hours under an atmosphere of 
CO2. Na2SO4 was added, the reaction mixture was filtered through a plug of celite and the 
celite was washed with CHCl3. The solvent was removed under reduced pressure and, after 
column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 
the compound 52 (124 mg, 46 % yield) was isolated as a yellow oil. 
1
H NMR (400 MHz; 
CDCl3): δH 7.17 (2H, t, J = 8.0 Hz, ArC(3)H), 6.68 (1H, d, J = 8.0 Hz, ArC(4)H), 6.59 (2H, 
d, J = 8.0 Hz, ArC(2)H), 3.61 (1H, sept, J = 6.0 Hz, CH) and 1.21 (6H, d, J = 6.0 Hz, CH3). 
13
C NMR (100 MHz; CDCl3): δC 147.3- (ArC(1)), 129.3+ (ArC(3)H), 117.1+ (ArC(4)H),  
113.3+ (ArC(2)H), 44.3+ (CH) and 23.0+ (CH3). Rf (40 % EtOAc in light petroleum (b.p. 
40-60 
o
C)) 0.6. Spectroscopic data are consistent with those reported by Williams et al.
164
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Synthesis of isopropyl N-benzylcarbamate 53 
 
Ag2O (510 mg, 2.2 mmol, 1.1 eq.) was added to a solution of 2-iodopropane (0.22 mL, 2.2 
mmol, 1.1 eq.) and benzylamine (1.09 mL, 10 mmol, 5 eq.) in CHCl3 (10 mL) and was 
stirred at room temperature with an empty balloon on top. In a second sealed flask, 6M 
HCl(aq.) (1 mL) was added to NaHCO3 (168 mg, 2 mmol, 1 eq.) and, using a double headed 
needle, the CO2 produced was pushed into the main reaction flask. The reaction mixture was 
left to stir at room temperature for 5 hours. Na2SO4 was added, the reaction mixture filtered 
through plug of celite and the celite was washed with CHCl3. The solvent was removed under 
reduced pressure and, after column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - 
EtOAc gradient column], carbonate 53 (50 mg, 14 % yield) was isolated as a yellow oil 
(Klopotek et al. report this to be a solid with m.p. 34-35 
o
C
165
). 
1
H NMR (400 MHz; CDCl3): 
δH 7.35-7.25 (5H, m, ArCH), 4.95 (1H, sept, J = 6.5 Hz, OCH), 4.93 (1H, m, NH), 4.36 (2H, 
d, J = 5.5 Hz, CH2) and 1.24 (6H, d, J = 6.5 Hz, CH3). 
13
C NMR (100 MHz; CDCl3): δC 
156.3- (C=O), 138.7- (ArC(1)), 128.6+ (ArCH), 127.5+ (ArCH), 127.4+ (ArCH), 68.2+ 
(OCH), 44.9- (CH2) and 22.1+ (CH3). MS m/z (+ESI) 194 (17 %, MH
+
), 216 (100 %, MNa
+
). 
HRMS (+ESI) Found MH
+
 194.1169, C11H16NO2 requires MH 194.1181 and found 
216.0982, C11H15NNaO2 requires MNa 216.1000. IR νmax(liquid film): 3447 (NH), 3055 
(CH), 1721 (C=O) and 1605 (C=C). Rf (60 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.7. 
Spectroscopic data are consistent with those reported by Hyde et al.
166
 
 - 152 -  
7.3.2.  Acylation - Schotten-Baumann Reactions 
 
Synthesis of 2-benzamidoacetic acid 56 
 
Following a procedure reported by Albrecht et al.,
78
 glycine.HCl (223 mg, 2 mmol, 1 eq.) 
dissolved in 2M NaOH(aq.) (2 mL) was added dropwise to benzoyl chloride (0.23 mL, 2 
mmol, 1 eq.) dissolved in Et2O (1 mL). The reaction mixture was left to stir at room 
temperature for 1 hour. 6M HCl(aq.) was added and the solid filtered and washed with CH2Cl2 
to collect 56 (165 mg, 46 % yield) as a white solid, m.p. 187-189 
o
C [lit.
167
 188 
o
C]. 
1
H 
NMR (400 MHz, CD3OD): δH 7.86-7.83 (2H, m, ArC(2)H), 7.55 (1H, tt, J = 7.5, 1.5 Hz, 
ArC(4)H), 7.48-7.44 (2H, m, ArC(3)H) and 4.11 (2H, s, CH2). 
13
C NMR (100 MHz, 
CD3OD): δC 172.0- ((CO)OH), 170.6- ((C=O)N), 135.1- (ArC(1)H), 133.0+ (ArC(4)H) 
129.6+ (ArC(3)H), 128.4+ (ArC(2)H) and 42.4- (CH2). MS m/z (ESI+) 202 (76 %, MNa
+
). 
HRMS (+ESI) Found MNa
+
 202.0498, C9H9NNaO3 requires MNa 202.0480. 
 
Synthesis of 3,4-methylenedioxybenzoyl chloride 57 
 
Piperonylic acid (332 mg, 2 mmol, 1 eq.) in SOCl2 (2 mL) with 1 drop of DMF were heated 
at 80 
o
C under an atmosphere of N2 for 4 hours. The reaction mixture was left to cool and the 
solvent was removed under reduced pressure to afford acid chloride 57 (369 mg, 100 % 
yield) as a white solid, m.p. 77-79 
o
C [lit.
168
 78-79 
o
C]. 
1
H NMR (400 MHz, CDCl3): δH 7.78 
(1H, dd, J = 8.5 and 2.0 Hz, ArC(6)H), 7.50 (1H, d, J = 2.0 Hz, ArC(2)H), 6.88 (1H, d, J = 
8.5 Hz, ArC(5)H) and 6.10 (2H, s, OCH2O). 
13
C NMR (100 MHz, CDCl3): δC 166.8- (C=O), 
153.9- (C), 148.4- (C), 128.9+ (ArC(6)H), 127.2- (C), 110.6+ (ArC(2)H), 108.3+ (ArC(5)H) 
and 102.6- (OCH2O).  
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Synthesis of 2-(benzo[d][1,3]dioxole-5-carboxamido)acetic acid 58 
 
Following a procedure reported by Albrecht et al.
78
 glycine.HCl (223 mg, 2 mmol, 1 eq.) 
dissolved in 2M NaOH(aq.) (2 mL) was added dropwise to acid chloride 57 (369 mg, 2 mmol, 
1 eq.) dissolved in Et2O (1 mL). The reaction mixture was left to stir at room temperature for 
1 hour. 6M HCl(aq.) was added and the solid was filtered and washed with CH2Cl2 to collect 
58 (119 mg, 27 % yield) as a white solid m.p. 174-177 
o
C [lit.
169
 178 
o
C].
 1
H NMR (400 
MHz, CD3OD): δH 7.45-7.42 (1H, m, ArC(6)H), 7.32 (1H, s, ArC(2)H), 6.89-6.86 (1H, m, 
ArC(5)H) 6.03-6.02 (2H, m, OCH2O) and 4.05-4.04 (2H, m, CH2). 
13
C NMR (100 MHz, 
CD3OD): δC 172.1- ((C=O)OH), 169.8- ((C=O)N), 152.3- (C), 149.5- (C), 129.0- (C), 123.6+ 
(ArC(6)H), 109.0+ (ArC(5)H), 108.5+ (ArC(2)H), 103.3- (OCH2O)  and 42.5- (CH2). 
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Synthesis of 2-(3,4,5-trimethoxybenzamido)acetic acid 61 
 
Glycine.HCl (1.12 g, 10 mmol, 1 eq.) dissolved in 2M NaOH(aq.) (10 mL) was added 
dropwise to 3,4,5-trimethoxybenzoyl chloride 59 (2.31 g, 10 mmol, 1 eq.) dissolved in 1,4-
dioxane (5 mL). The reaction mixture was left to stir at room temperature for 1 hour. 6M 
HCl(aq.) was added and the solid was filtered and washed with CH2Cl2 to collect 61 (1.70 g, 
63 % yield) as a white solid, m.p. 221-223 
o
C.
170
 
1
H NMR (400 MHz, (CD3)2SO): δH 8.79 
(1H, t, J = 5.5 Hz, NH), 7.20 (2H, s, ArC(2)H), 3.90 (2H, d, J = 6.0 Hz, CH2), 3.81 (6H, s, 
OCH3) and 3.69 (3H, s, OCH3). 
13
C NMR (100 MHz, (CD3)2SO): δC 171.3- ((C=O)OH), 
165.8- ((C=O)N), 152.6- (C),140.2- (C), 129.0- (C), 104.9+ (ArC(2)H), 60.1+ (OCH3), 56.0+ 
(OCH3) and 41.2- (CH2). MS m/z (ESI+) 292 (32 %, MNa
+
). HRMS (+ESI) Found MH
+
 
270.0969, C12H16NO6 requires MH 270.0978 and found MNa
+
 292.0783, C12H15NNaO6 
requires MNa 292.0797. 
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Synthesis of (S)-2-(3,4,5-trimethoxybenzamido)propanoic acid 62 
L-Alanine (356 mg, 4 mmol, 2 eq.) dissolved in 2M NaOH(aq.) (3 mL, 6 mmol, 3 eq.) was 
added dropwise to 3,4,5-trimethoxybenzoyl chloride 59 (461 mg, 2 mmol, 1 eq.) dissolved in 
1,4-dioxane (1 mL). The reaction mixture was left to stir at room temperature for 1 hour. 6M 
HCl(aq.) was added and the solid filtered to collect 468 mg of a white solid.  
 
Ratio by crude NMR:  85 % product 62 (73 % yield) 
    15 % 3,4,5-trimethoxybenzoic acid 60 (13 % yield) 
 
3,4,5-Trimethoxybenzoic acid 60 
1
H NMR (400 MHz, (CD3)2SO): δH 12.55 (1H, br. s. OH), 7.23 (2H, s, ArC(2)H), 3.82 (6H, 
s, OCH3) and 3.73 (3H, s, OCH3). 
13
C NMR (100 MHz, (CD3)2SO): δC 166.9- (C=O), 152.6- 
(C), 141.5- (C), 125.9- (C), 106.6+ (ArC(2)H), 66.3+ (OCH3) and 55.9+ (OCH3).  
 
Product 62
171
 
1
H NMR (400 MHz, (CD3)2SO): δH 12.55 (1H, br. s., OH), 8.57 (1H, d, J = 7.0 Hz, NH), 
7.23 (2H, s, ArC(2)H), 4.43 (1H, quint, J = 7.5 Hz, CH), 3.84 (6H, s, OCH3), 3.71 (3H, s, 
OCH3) and 1.40 (3H, d, J = 7.5 Hz, CH3). 
13
C NMR (100 MHz, (CD3)2SO): δC 174.2- 
((C=O)OH), 165.4- ((C=O)N), 152.5- (C),140.2- (C), 129.0- (C), 105.1+ (ArC(2)H), 60.1+ 
(OCH3), 56.0+ (OCH3), 48.2+ (CH) and 17.0+ (CH3). MS m/z (+ESI) 306 (100 %, MNa
+
). 
HRMS (+ESI) Found MNa
+ 
306.0936, C13H17NNaO6 requires MNa 306.0954.   
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Synthesis of (S)-4-methyl-2-(3,4,5-trimethoxybenzamido)pentanoic acid 63 
L-Leucine (262 mg, 2 mmol, 2 eq.) dissolved in 2M NaOH(aq.) (1.5 mL, 3 mmol, 3 eq.) was 
added dropwise to 3,4,5-trimethoxybenzoyl chloride 59 (231 mg, 1 mmol, 1 eq.) dissolved in 
1,4-dioxane (1 mL). The reaction mixture was left to stir at room temperature for 1 hour. 6M 
HCl(aq.) was added and the solid filtered to collect 287 mg of a yellow solid. 
 
Ratio by crude NMR:  66 % product 63 (66 % yield) 
    34 % 3,4,5-trimethoxybenzoic acid 60 (34 % yield) 
 
3,4,5-Trimethoxybenzoic acid 60 
1
H NMR (400 MHz, CDCl3): δH 10.62 (1H, br. s. OH), 7.31 (2H, s, ArC(2)H), 3.89 (3H, s, 
OCH3) and 3.83 (6H, s, OCH3). 
13
C NMR (100 MHz, CDCl3): δC 170.8- (C=O), 152.9- (C), 
142.9- (C), 124.1- (C), 107.4+ (ArC(2)H), 60.8+ (OCH3) and 56.2+ (OCH3).  
 
Product 63
172
 
1
H NMR (400 MHz, CDCl3): δH 10.62 (1H, br. s., OH), 7.03 (2H, s, ArC(2)H), 6.89 (1H, d, 
J = 8.0 Hz, NH), 4.84-4.79 (1H, m, (NH)CH), 3.87 (3H, s, OCH3), 3.84 (6H, s, OCH3), 1.80-
1.66 (3H, m, CH and CH2), 0.95 (3H, d, J = 6.0 Hz, CH3) and 0.95 (3H, d, J = 6.0 Hz, CH3). 
13
C NMR (100 MHz, CDCl3): δC 177.0- ((C=O)OH), 167.5- ((C=O)N), 152.9- (C), 141.4- 
(C), 128.7- (C), 104.8+ (ArC(2)H), 60.8+ (OCH3), 56.3+ (OCH3), 51.4+ ((NH)CH), 41.2- 
(CH2), 25.0+ (CH), 22.7+ (CH3) and 21.8+ (CH3). MS m/z (+ESI) 348 (44 %, MNa
+
). 
HRMS (+ESI) Found MNa
+ 
348.1398, C16H23NNaO6 requires MNa 348.1423 (7 ppm).   
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Synthesis of (S)-3-methyl-2-(3,4,5-trimethoxybenzamido)butanoic acid 64 
L-Valine (234 mg, 2 mmol, 2 eq.) dissolved in 2M NaOH(aq.) (1.5 mL, 3 mmol, 3 eq.) was 
added dropwise to 3,4,5-trimethoxybenzoyl chloride 59 (231 mg, 1 mmol, 1 eq.) dissolved in 
1,4-dioxane (1 mL). The reaction mixture was left to stir at room temperature for 1 hour. 6M 
HCl(aq.) was added and the solid filtered to collect 218 mg of a white solid. 
 
Ratio by crude NMR:  72 % product 64 (55 % yield) 
    28 % 3,4,5-trimethoxybenzoic acid 60 (22 % yield) 
 
3,4,5-Trimethoxybenzoic acid 60 
1
H NMR (400 MHz, CDCl3): δH 10.43 (1H, br. s. OH), 7.31 (2H, s, ArC(2)H), 3.89 (3H, s, 
OCH3) and 3.84 (6H, s, OCH3). 
13
C NMR (100 MHz, CDCl3): δC 170.6- (C=O), 152.9- (C), 
142.9- (C), 124.1- (C), 107.4+ (ArC(2)H), 60.8+ (OCH3) and 56.2+ (OCH3).  
 
Product 64
173
 
1
H NMR (400 MHz, CDCl3): δH 10.43 (1H, br. s., OH), 7.02 (2H, s, ArC(2)H), 6.77 (1H, d, 
J = 8.5 Hz, NH), 4.84-4.79 (1H, m, (NH)CH), 3.87 (3H, s, OCH3), 3.84 (6H, s, OCH3), 1.80-
1.66 (1H, m, CH), 1.07 (3H, d, J = 7.0 Hz, CH3) and 1.00 (3H, d, J = 7.0 Hz, CH3). 
13
C 
NMR (100 MHz, CDCl3): δC 175.4- ((C=O)OH), 167.7- ((C=O)N), 153.2- (C),141.4- (C), 
129.1- (C), 104.8+ (ArC(2)H), 60.8+ (OCH3), 56.3+ (OCH3), 57.7+ ((NH)CH), 31.2+ (CH), 
19.0+(CH3) and 17.9+ (CH3). MS m/z (+ESI) 312 (44 %, MH
+
) and 334 (100 %, MNa
+
). 
HRMS (+ESI) Found MNa
+
 334.1250, C15H21NNaO2 requires MNa 334.1266.  
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Synthesis of N-(3,4,5-trimethoxybenzoyl)-D-proline 65 
 (R)-Pyrrolidine-2-carboxylic acid (460 mg, 4 mmol, 2 eq.) dissolved in 2M NaOH(aq.) (3 mL, 
6 mmol, 3 eq.) was added dropwise to 3,4,5-trimethoxybenzoyl chloride 59 (461 mg, 2 
mmol, 1 eq.) dissolved in 1,4-dioxane (2 mL). The reaction mixture was left to stir at room 
temperature for 1 hour. 6M HCl(aq.) was added and the solid filtered to collect 554 mg of a 
white solid. 
 
Ratio by crude NMR:  67 % product 65 (67 % yield) 
    33 % 3,4,5-trimethoxybenzoic acid 60 (33 % yield) 
 
3,4,5-Trimethoxybenzoic acid 60 
1
H NMR (400 MHz, CDCl3): δH 10.40 (1H, br. s., OH), 7.31 (2H, s, ArC(2)H), 3.89 (3H, s, 
OCH3) and 3.84 (6H, s, OCH3). 
13
C NMR (100 MHz, CDCl3): δC 170.6- (C=O), 152.9- (C), 
142.9- (C), 124.1- (C), 107.4+ (ArC(2)H), 60.8+ (OCH3) and 56.2+ (OCH3).  
 
Product 65 
1
H NMR (400 MHz, CDCl3): δH 6.78 (2H, s, ArCH), 4.70 (1H, t, J = 7.0 Hz, NCH), 3.86 
(6H, s, OCH3), 3.85 (3H, s, OCH3), 3.61 (2H, t, J = 6.5 Hz, NCH2), 2.29-2.24 (2H, m, CH2) 
and 2.08-1.86 (2H, m, CH2).
 13
C NMR (100 MHz, CDCl3): δC 174.1- ((C=O)OH), 170.7- 
((C=O)N), 153.1- (C), 140.0- (C), 130.4- (C), 104.9+ (ArC(2)H), 60.8+ (OCH3), 59.8+ 
(NCH), 56.3+ (OCH3), 56.2+ (OCH3), 50.5- (NCH2), 28.5- (CH2) and 25.2- (CH2). MS m/z 
(+ESI) 310 (15 %, MH
+
) and 332 (99 %, MNa
+
). HRMS (+ESI) Found MH
+ 
310.1283, 
C15H20NO6 requires MH 310.1291. 
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Synthesis of N-(3,4,5-trimethoxybenzoyl)iminodiacetic acid 68 
 
Iminodiacetic acid (266 mg, 2 mmol, 2 eq.) in 2M NaOH(aq.) (3 mL) was added dropwise to 
3,4,5-trimethoxybenzoyl chloride 59 (231 mg, 1 mmol, 1 eq.) in 1,4-dioxane (1 mL). The 
reaction mixture was stirred for 1 hour at room temperature and acidified using 6M HCl(aq.). 
The reaction mixture was filtered and the white solid was washed with CH2Cl2 (10 mL) to 
collect 68 (245 mg, 75 % yield) as a white solid, m.p. 156-159 
o
C. 
1
H NMR (400 MHz, 
(CD3)2SO): δH 12.92 (2H, br.s. OH), 6.62 (2H, s, ArC(2)H), 4.10 (2H, s, CH2), 4.02 (2H, s, 
CH2), 3.76 (6H, s, OCH3) and 3.70 (3H, s, OCH3). 
13
C NMR (100 MHz, (CD3)2SO): δC 
171.2- (C=O), 170.7- (C=O), 170.1- (C=O), 152.8- (C), 138.8- (C), 130.3- (C), 104.1+ 
(ArC(2)H), 60.1+ (OCH3), 55.9+ (OCH3), 51.7- (CH2) and 48.0- (CH2). MS m/z (ESI+) 350 
(26 %, MNa
+
). HRMS (+ESI) Found MNa
+
 350.0890, C14H17NNaO8 requires MNa 
350.0852 (11 ppm). IR νmax(liquid film): 2940 (OH), 1715 (C=O), 1689 (C=O) and 1589 
(C=C). 
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Synthesis of methyl 2-chloro-2-(6,7,8-trimethoxy-2,4-dioxo-2H-benzo[e][1,3]thiazin-
3(4H)-yl)acetate 69 and methyl 3,4,5-trimethoxybenzoate 70 
 
Di-acid 68 (327 mg, 1 mmol, 1 eq.) in SOCl2 (1 mL) and a drop of DMF were heated at 80 
o
C under an atmosphere of N2 for 4 hours. The reaction mixture was allowed to cool, the 
reaction mixture was quenched with MeOH and the solvent was removed under reduced 
pressure. After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc 
gradient column], the cyclic product 69 (112 mg, 30 % yield) as a clear orange oil and ester 
70 (115 mg, 51 % yield) as a brown solid were isolated.  
Cyclic product 69: 
1
H NMR (400 MHz, CDCl3): δH 7.67 (1H, s, ArCH), 7.18 (1H, s, 
ClCH), 3.99 (3H, s, OCH3), 3.96 (3H, s, OCH3), 3.94 (3H, s, OCH3) and 3.84 (3H, s, 
(CO)OCH3). 
13
C NMR (100 MHz, CDCl3): δC 164.9- ((C=O)OCH3), 164.4- (S(C=O)N), 
161.3- (N(C=O)), 153.1- (C), 147.6- (C), 146.8- (C), 119.5- (C), 116.5- (C), 109.3+ (ArCH), 
61.3+ (OCH3), 61.2+ (OCH3), 60.7+ (ClCH), 56.4+ (OCH3) and 54.1+ (OCH3). MS m/z 
(+ESI) 398 (100 %, MNa
+
). HRMS (+ESI) Found MNa
+
 398.0048, C14H14ClNNaO7S 
requires MNa 398.0077 (7 ppm). Crystal Structure: 
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Ester 70: m.p. 79-83 
o
C [lit.
174
 81-83 
o
C]. 
1
H NMR (400 MHz, CDCl3): δH 7.28 (2H, s, 
ArCH) and 3.88 (12H, s, OCH3). Spectroscopic data are consistent with those reported by  
Keck et al.
175
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7.4. Chapter Three - A/B Analogues of Dihydroisoquinolinones 
 
7.4.1. Indanone Synthesis 
 
General Procedure 4, Intramolecular Indanone Synthesis 
The required acid (1 eq.) in TFAA (1 eq.) was heated at 100 
o
C for 2 hours in a sealed 
pressure tube. On cooling, the reaction mixture was transferred to a flask using CHCl3 and 
the solvent was removed under reduced pressure. After column chromatography, the desired 
indanone was isolated. 
 
General Procedure 5, Indanone Synthesis 
The required acid (1 eq.) in (TFAA/ TFA) was heated at 100 
o
C in a sealed pressure tube. 
CHCl3 or MeOH was added and the solvent was removed under reduced pressure. After 
column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column] 
the desired indanone was isolated.  
 
Synthesis of 6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-5-one 88 
 
Method A 
Following a procedure reported by Dallemagne et al.
90
 3-(1,3-benzodioxol-5-yl)propanoic 
acid 87 (194 mg, 1 mmol, 1 eq.) in TFAA: TFA (0.5 mL: 0.5 mL) was heated at 50 
o
C for 2.5 
hours. On cooling, the reaction mixture was adjusted to pH 12 using 2M NaOH(aq.) and the 
aqueous layer extracted with CHCl3 (3 x 20 mL). The combined organic layers were washed 
with brine (20 mL), dried on Na2SO4, filtered and the solvent was removed under reduced 
pressure. After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc 
gradient column], the desired indanone 88 (36 mg, 20 % yield) was isolated as a yellow solid. 
Method B 
 - 163 -  
3-(1,3-Benzodioxol-5-yl)propanoic acid 87 (194 mg, 1 mmol, 1 eq.) in TFAA: TFA (0.5 mL: 
0.5 mL) was heated at 50 
o
C for 3 hours. Methanol was added to quench the reaction mixture 
and the solvent was removed under reduced pressure. After column chromatography [silica, 
light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], the desired indanone 88 (141 mg, 
81 % yield) was isolated as a yellow solid. 
Method C  
Following General Procedure 5, using 3-(1,3-benzodioxol-5-yl)propanoic acid 87 on a 1 
mmol scale, in TFAA: TFA (0.5 mL: 1.0 mL) for 1 hour, using CHCl3 to transfer the reaction 
mixture, the indanone 88 (148 mg, 84 % yield) was isolated as a yellow solid. 
Method D 
3-(1,3-Benzodioxol-5-yl)propanoic acid 87 (388 mg, 2 mmol, 1 eq.) in TFAA: TFA (1.0 mL: 
2.0 mL) was heated at 100 
o
C in a sealed pressure tube for 2 hours. CHCl3 was added and the 
solvent was removed under reduced pressure. After column chromatography (x 2) [silica, 
CH2Cl2 - MeOH gradient column], the desired indanone 88 (255 mg, 72 % yield) was 
isolated as a yellow solid. 
Method E - Optimised Method 
Following General Procedure 4, using 3-(1,3-benzodioxol-5-yl)propanoic acid 87 on a 1 
mmol scale, after column chromatography [silica, CH2Cl2 - MeOH gradient column], the 
indanone 88 (141 mg, 80 % yield) was isolated as a yellow solid. 
m.p. 161-164 
o
C [lit.
176
 162-163 
o
C]. 
1
H NMR (400 MHz; CDCl3): δH 7.10 (1H, s, 
(C=O)CArCH), 6.83 (1H, s, CH2CArCH), 6.06 (2H, s, OCH2O), 3.02 (2H, t, J = 5.5 Hz, 
(CO)CH2CH2) and 2.64-2.62 (2H, m, (CO)CH2CH2). 
13
C NMR (100 MHz; CDCl3): δC 
204.9- (C=O), 154.2- (ArCOCH2), 152.6- (ArCCH2 or ArC(CO)), 148.2- (ArCOCH2), 131.7- 
(ArCCH2 or ArC(CO)), 105.7+ (CH2CArCH), 102.3+ ((C=O)CArCH), 102.2- (OCH2O), 
36.7- ((CO)CH2CH2) and 25.8- ((CO)CH2CH2). MS m/z (+ESI) 177 (82 %, MH
+
) and 199 
(100 %, MNa
+
). HRMS (+ESI) Found MH
+
 177.0543, C10H19O3 requires MH 177.0552 and 
found MNa
+
 199.0362, C10H8NaO3 requires MNa 199.0371. IR νmax(liquid film): 2987 (CH) 
and 1698 (C=O). Rf (50 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.5. Spectroscopic data 
are consistent with those reported by Odedra et al.
177
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Synthesis of 5, 6-dimethoxy-2,3-dihydro-1H-inden-1-one 90 
 
Method A 
Following General Procedure 5, using 3-(3,4-dimethoxyphenyl)propanoic acid 89 on a 2 
mmol scale, in TFAA: TFA (1.0 mL: 2.0 mL) for 16 hours, using CHCl3 to transfer the 
reaction mixture, indanone 90 (252 mg, 66 % yield) was isolated as a yellow solid. 
Method B – Optimised Method 
Following General Procedure 4, using 3-(3,4-dimethoxyphenyl)propanoic acid 89 on a 2 
mmol scale, after column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc 
gradient column], indanone 90 (285 mg, 74 % yield) was isolated as a yellow solid. 
m.p. 115-118 
o
C [lit.
176
 115-117 
o
C]. 
1
H NMR (400 MHz; CDCl3): δH 7.15 (1H, s, 
(C=O)CArCH), 6.87 (1H, s, CH2CArCH), 3.95 (3H, s, OCH3), 3.94 (3H, s, OCH3), 3.04 (2H, 
t, J = 5.5 Hz, (CO)CH2CH2) and 2.69-2.66 (2H, m, (CO)CH2CH2). 
13
C NMR (100 MHz; 
CDCl3): δC 202.7- (C=O), 155.7- (COCH3), 151.0- (CCH2 or C(CO)), 149.4- (COCH3), 
129.6- (CCH2 or C(CO)), 107.4+ (CH2CArCH), 104.2+ ((C=O)CArCH), 56.2+ (OCH3), 
56.0+ (OCH3), 36.4- ((CO)CH2CH2) and 25.6- ((CO)CH2CH2). MS m/z (+ESI) 193 (100 %, 
MH
+
). HRMS (+ESI) Found MH
+
 193.0851, C11H13O3 requires MH 193.0810 (21 ppm). IR 
νmax(liquid film): 2987 (CH), 1698 (C=O), 1606 (C=C) and 1030 (C-O). Rf (50 % EtOAc in 
light petroleum (b.p. 40-60 
o
C)) 0.3. Spectroscopic data are consistent with those reported by 
Fillion et al.
178
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Synthesis of 5,6,7-trimethoxy-2,3-dihydro-1H-inden-1-one 92 
 
Method A 
3-(3,4,5-Trimethoxyphenyl)propanoic acid 91 (240 mg, 1 mmol, 1 eq.) and TFAA (0.15 mL, 
1.1 mmol, 1.1 eq.) in TFA (0.5 mL) were heated at 100 
o
C for 2 hours in a sealed pressure 
tube. On cooling, CHCl3 was added and the solvent was removed under reduced pressure. 
H2O (10 mL) and EtOAc (10 mL) were added and the reaction mixture was stirred at room 
temperature for 24 hours. The layer was extracted with EtOAc (2 x 10 mL). The combined 
organic layers were washed with brine (10 mL), dried on Na2SO4 and filtered and the solvent 
was removed under reduced pressure. After column chromatography [silica, light petroleum 
(b.p. 40-60 
o
C) - EtOAc gradient column], the indanone 92 (171 mg, 77 % yield) was 
isolated as a yellow solid. 
Method B – Optimised Method 
Following General Procedure 4, using 3-(3,4,5-trimethoxyphenyl)propanoic acid 91 on a 2 
mmol scale, after column chromatography [silica, CH2Cl2 - MeOH gradient column], the 
indanone 92 (196 mg, 88 % yield) was isolated as a yellow solid.  
m.p. 111-114 
o
C [lit.
179
 111.5-113.5 
o
C]. 
1
H NMR (400 MHz; CDCl3): δH 6.65 (1H, s, 
ArCH), 4.00 (3H, s, OCH3), 3.90 (3H, s, OCH3), 3.81 (3H, s, OCH3), 2.98 (2H, t, J = 6.4 Hz, 
(CO)CH2CH2) and 2.64-2.61 (2H, m, (CO)CH2CH2). 
13
C NMR (100 MHz; CDCl3): δC 
203.5- (C=O), 159.8- (COCH3), 153.3- (C(CO)), 151.5- (COCH3), 140.5- (COCH3), 122.7- 
(CCH2), 103.7+ (ArCH), 61.8+ (OCH3), 61.3+ (OCH3), 56.2+ (OCH3), 37.1- ((CO)CH2CH2) 
and 25.62- ((CO)CH2CH2). MS m/z (+ESI) 223 (100 %, MH
+
) and 245 (41 %, MNa
+
). 
HRMS (+ESI) Found MH
+
 223.0954, C12H15O4 requires MH 223.0970 and found MNa
+
 
245.0779, C12H14NaO4 requires MNa 245.0790. IR νmax(liquid film): 2987 (CH), 1694 
(C=O), 1590 (C=C) and 1029 (C-O). Rf (50 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.3. 
Spectroscopic data are consistent with those reported by Cui et al.
180
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Synthesis of 2,3,4,9-tetrahydro-1H-carbazol-1-one 96 
 
Method A 
4-(Indol-3-yl)butanoic acid 95 (1.22 g, 6 mmol, 1 eq.) in TFAA (0.92 mL, 6.6 mmol, 1.1 eq.) 
was heated at 100 
o
C in a sealed pressure tube for 4 hours. On cooling, CHCl3 was added and 
the solvent was removed under reduced pressure. H2O (20 mL) and EtOAc (20 mL) were 
added, the reaction mixture was adjusted to pH 7 using 2M NaOH(aq.) and stirred at room 
temperature for 16 hours. The layers were separated and the aqueous layer extracted with 
EtOAc (2 x 20 mL). The combined organic layers were washed with brine (20 mL), dried on 
Na2SO4 and filtered and the solvent was removed under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column] followed 
by recrystallisation (EtOAc), compound 96 was isolated (592 mg, 53 % yield) as a yellow 
solid. 
Method B - Optimised Method 
Following General Procedure 4, using 4-(indol-3-yl)butanoic acid 95 on a 2 mmol scale, 
after column chromatography [silica, CH2Cl2 – MeOH gradient column], compound 96 (268 
mg, 72 % yield) was isolated as a pale yellow solid.  
m.p. 170-172 
o
C [lit.
181
 168-170 
o
C]. 
1
H NMR (400 MHz; CDCl3): δH 9.31 (1H, br. s, NH), 
7.66 (1H, d, J = 8.0 Hz, ArC(3)H), 7.45 (1H, dt, J = 8.0, 1.0 Hz, ArC(6)H), 7.37 (1H, t, J = 
8.0 Hz, ArC(5)H), 7.15 (1H, t, J = 7.5 Hz, ArC(4)H), 3.01 (2H, t, J = 6.0 Hz, 
(CO)CH2CH2CH2), 2.68 (2H, t, J = 6.0 Hz, (CO)CH2CH2CH2) and 2.27 (2H, quint, J = 6.0 
Hz, (CO)CH2CH2CH2). 
13
C NMR (100 MHz; CDCl3): δC 191.5- (C=O), 137.9- (C), 131.2- 
(C), 129.6- (C), 127.0+ (ArC(5)H), 125.8- (C), 121.3+ (ArC(3)H), 120.3+ (ArC(4)H), 112.6+ 
(ArC(6)H), 38.2- ((CO)CH2CH2CH2), 25.0- ((CO)CH2CH2CH2) and 21.4- 
((CO)CH2CH2CH2). MS m/z (+ESI) 186 (43 %, MH
+
) and 208 (100 %, MNa
+
). HRMS 
(+ESI) Found MH
+
 186.0909, C12H12NO requires MH 186.0919 and found MNa
+
 208.0726, 
C12H11NNaO requires MNa 208.0738. IR νmax(liquid film): 3450 (NH), 3054 (CH) and 1666 
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(C=O). Rf (50 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.5. Spectroscopic data are 
consistent with those reported by Li et al.
182
 
 
Synthesis of 1,2-dihydrocyclopenta[b]indol-3(4H)-one 98 
 
Following a procedure reported by Maertens et al.
92
 3-(indole-3-yl)propanoic acid 97 (378 
mg, 2 mmol, 1 eq.) was added to PPA (3.5 g, 35.7 mmol, 17.9 eq.) in toluene (20 mL) and 
the mixture was stirred at 110 
o
C for 4 hours. On cooling, ice water (80 mL) was added and 
the purple aqueous layer was extracted using CH2Cl2 (3 x 50 mL). The combined organic 
layers were washed with brine (30 mL), dried on Na2SO4, filtered and concentrated under 
reduced pressure to collect the desired compound 98 (278 mg, 81 % yield) as a beige solid, 
m.p. 255-258
o
C [lit.
183
 250-252 
o
C]. 
1
H NMR (400 MHz; CDCl3): δH 8.98 (1H, br. s. NH), 
7.75 (1H, dd, J = 8.0, 1.0 Hz, ArC(3)H), 7.52 (1H, dt, J = 8.5, 1.0 Hz, ArC(6)H), 7.44 (1H, 
ddd, J = 8.0, 7.0, 1.0 Hz, ArC(5)H), 7.23 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArC(4)H), 3.17-3.14 
(2H, m, (CO)CH2CH2) and 3.08-3.05 (2H, m, (CO)CH2CH2). 
13
C NMR (100 MHz; CDCl3): 
δC 194.5- (C=O), 127.4- (C), 147.2- (C), 143.8- (C), 127.4+ (ArC(5)H), 123.6- (C), 121.6+ 
(ArC(3)H), 120.8+ (ArC(4)H), 113.5+ (ArC(6)H), 41.0- ((CO)CH2CH2) and 20.1- 
((CO)CH2CH2). MS m/z (+ESI) 172 (82 %, MH
+
) and 194 (100 %, MNa
+
). HRMS (+ESI) 
Found MH
+
 172.0755, C11H10NO requires MH 172.0762 and found MNa
+
 194.0572, 
C11H9NNaO requires MNa 194.0581. IR νmax(liquid film): 3466 (NH), 3031 (CH) and 1682 
(C=O). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.6. Spectroscopic data are 
consistent with those reported by Cui et al.
180
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Synthesis of 3-(4-trifluoroacetyl)furan-2-yl)propanoic acid 100 
 
Following General Procedure 4, using 3-(furan-2-yl)propanoic acid 99 on a 2 mmol scale, 
using MeOH as the solvent to transfer the reaction mixture. After column chromatography 
[silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], compound 100 (72 mg, 14 
% yield) was isolated as a brown oil. 
1
H NMR (400 MHz; CDCl3): δH 7.43 (1H, d, J = 4.0 
Hz, OCHCH), 6.37 (1H, d, J = 4.0 Hz, OCHCH), 3.69 (3H, s, OCH3), 3.09 (2H, t, J = 7.5 
Hz, CH2) and 2.74 (2H, t, J = 7.5 Hz, CH2). 
13
C NMR (100 MHz; CDCl3): δC 172.1- (C=O), 
172.1- (C=O), 164.0- (C), 145.9- (C), 126.0+ (OCHCH), 117.8- (CF3), 110.1+ (OCHCH), 
51.9+ (OCH3), 31.4- (CH2) and 23.8 (CH2). 
19
F NMR (400MHz; CDCl3): δF -73.3 (CF3). 
MS m/z (+ESI) 251 (51 %, MH
+
) and 273 (100 %, MNa
+
). HRMS (+ESI) Found MNa
+
 
273.0343, C10H9F3NaO4 requires MNa 273.0351. IR νmax(liquid film): 3054 (CH), 1739 
(C=O), 1697 (C=O), 1509 (C=C) and 1265 (C-O). Rf (60 % EtOAc in light petroleum (b.p. 
40-60 
o
C) 0.8.  
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7.4.2. Schmidt Reactions 
 
General Procedure 6, Schmidt Reaction 
The required indanone (1 eq.) and NaN3 (2 eq.) in TFA (3 mL/ 1 mmol) were heated at 100 
o
C in a sealed pressure tube for 18 hours. The reaction mixture was cooled and sat. aq. 
NaHCO3 was added dropwise followed by EtOAc. The layers were separated and the 
aqueous layer was extracted with EtOAc (x 2). The combined organic layers were washed 
with brine, dried on Na2SO4, filtered and concentrated under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc - MeOH gradient column], 
the desired lactam was isolated.  
 
Synthesis of 7,8-dihydro-[1,3]dioxolo[4,5-g]isoquinolin-5(6H)-one 101 
 
Following General Procedure 6, using indanone 88 (176 mg, 1 mmol, 1 eq.) and NaN3 (130 
mg, 2 mmol, 2 eq.) in TFA (3 mL) desired lactam 101 (120 mg, 63 % yield) was isolated as a 
yellow solid, m.p. 184-187
 o
C [lit.
93
 185-187 
o
C]. 
1
H NMR (400 MHz; CDCl3): δH 7.49 (1H, 
s, (ArCHC(CO)), 6.70 (1H, br.s. NH), 6.64 (1H, s, ArCHCCH2), 5.98 (2H, s, OCH2O), 3.52 
(2H, br.s, NCH2CH2) and 2.89 (2H, t, J = 6.0 Hz, NCH2CH2). 
13
C NMR (100 MHz; CDCl3): 
δC 166.2- (CO), 150.8- (C), 146.8- (C), 134.6- (C), 122.8- (C), 107.9+ (ArCHC(CO)), 107.2+ 
(ArCHCCH2), 101.4-  (OCH2O), 40.2- (NCH2) and 28.4- (ArCH2). MS m/z (ESI+) 192 (100 
%, MH
+
) and 214 (50 %, MNa
+
). HRMS (+ESI) Found MH
+
 192.0648, C10H9NO3 requires 
MH 192.0661 (7 ppm). IR νmax(liquid film): 3419 (NH), 2987 (CH) and 1666 (C=O). Rf (100 
% EtOAc) 0.3. Spectroscopic data are consistent with those reported by Judd et al.
93
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Synthesis of 6,7-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one 114 
 
Method A - Optimised Method 
Following General Procedure 6, using indanone 90 (600 mg, 3.12 mmol, 1 eq.) and NaN3 
(406 mg, 6.24 mmol, 2 eq.) in TFA (9 mL) desired lactam 114 (387 mg, 60 % yield) was 
isolated as a yellow solid.  
Method B 
At 0 
o
C, NaN3 (107 mg, 1.64 mmol, 2 eq.) was added to indanone 90 (158 mg, 0.82 mmol, 1 
eq.) in H2SO4 (2 mL) and the reaction mixture was stirred at room temperature for 16 hours. 
The reaction mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 20 mL). 
The combined organic layers were washed with brine (20 mL), dried on Na2SO4, filtered and 
concentrated under reduced pressure to collect 142 mg of crude. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], the 
desired lactam 114 (111 mg, 65 % yield) was isolated as a yellow solid.  
m.p. 175-177 
o
C [lit.
93
 174-177 
o
C]. 
1
H NMR (400 MHz, CDCl3): δH 7.57 (1H, s, 
ArCHC(CO)), 6.67 (1H, s, ArCHCCH2), 6.45 (1H, br.s. NH), 3.93 (6H, s, OCH3), 3.55 (2H, 
td, J = 6.5, 2.5 Hz, NCH2CH2) and 2.93 (2H, t, J = 6.5 Hz, NHCH2CH2). 
13
C NMR (CDCl3, 
100 MHz): δC 166.4- (C=O), 150.8- (ArCO), 148.0- (ArCO), 132.6- (ArCCH2), 121.3- 
(ArC(CO)), 110.2+ (ArCHC(CO)), 109.6+ (ArCHCCH2), 56.1+ (OCH3), 56.0+ (OCH3), 
40.4- (NCH2CH2) and 28.4- (NCH2CH2).
 
MS 208 (75 %, MH
+
) and 230 (59 %, MNa
+
). 
HRMS m/z (+ESI) Found MNa
+
 230.0813, C11H13NNaO3 requires MNa 230.0793. Rf (100 
% EtOAc) 0.2. Spectroscopic data are consistent with those reported by Judd et al.
93 
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Synthesis of 6,7,8-trimethoxy-3,4-dihydroisoquinolin-1(2H)-one 115 
 
Following General Procedure 6, using indanone 92 (340 mg, 1.53 mmol, 1 eq.) and NaN3 
(199 mg, 3.06 mmol, 2 eq.) in TFA (2.5 mL) desired lactam 115 (113 mg, 31 % yield) was 
isolated as a beige solid. m.p. 131-134 
o
C [lit.
184
 138 
o
C]. 
1
H NMR (400 MHz, CDCl3): δH 
6.49 (1H, s, ArCH), 6.09 (1H, br. NH), 3.94 (3H, s, OCH3), 3.89 (3H, s, OCH3), 3.86 (3H, s, 
OCH3), 3.43 (2H, td, J = 6.5, 3.5 Hz, NCH2CH2) and 2.87 (2H, t, J = 6.5 Hz, NCH2CH2). 
13
C 
NMR (100 MHz; CDCl3): δC 164.4- (C=O), 155.9- (C), 155.3- (C), 142.0- (C), 136.7- (C), 
115.8- (C), 106.0+ (ArCH), 61.8+ (OCH3), 61.1+ (OCH3), 55.9+ (OCH3), 39.8- (NCH2CH2) 
and 30.1- (NCH2CH2). MS m/z (+ESI) 238 (100 %, MH
+
) and 260 (29 %, MNa
+
). HRMS 
(+ESI) Found MH
+
 238.1133, C12H16NO4 requires MH 238.1079 and found MNa
+
 260.0897, 
C12H15NNaO4 requires MNa 260.0899. IR νmax(liquid film): 3400 (NH), 2990 (CH) and 1668 
(C=O). Rf (100 % EtOAc) 0.1.  
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Synthesis of 2,3,4,5-tetrahydroazepino[3,4-b]indol-1(10H)-one 116 
 
Compound 96 (656 mg, 3.54 mmol, 1 eq.), NaN3 (460 mg, 7.08 mmol, 2 eq.) and TFA (10 
mL) were heated at 100 
o
C for 18 hours in a sealed pressure tube. On cooling, the reaction 
mixture was transferred to a flask using CHCl3 and the solvent was removed under reduced 
pressure. After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc 
gradient column], the desired lactam 116 (167 mg, 24 % yield) was isolated as a beige solid, 
m.p. 226-229 
o
C [lit.
93
 227-230 
o
C]. 
1
H NMR (400 MHz; CDCl3): δH 9.30 (1H, br. s. NH), 
7.59 (1H, d, J = 8.0 Hz, ArC(3)H or ArC(6)H), 7.40 (1H, d, J = 8.0 Hz, ArC(3)H or 
ArC(6)H), 7.32 (1H, td, J = 8.0, 1.0 Hz, ArC(4)H or ArC(5)H), 7.13 (1H, td, J = 8.0, 1.0 Hz, 
ArC(4)H or ArC(5)H), 7.02 (1H, br. s. NH), 3.51-3.48 (2H, m, CH2), 3.14 (2H, t, J = 6.0 Hz, 
CH2) and 2.22-2.17 (2H, m, CH2). 
13
C NMR (100 MHz; CDCl3): δC 165.9- (C=O), 136.0- 
(C), 128.0- (C), 125.8- (C), 125.5+ (ArC(4)H or ArC(5)H), 120.3+ (ArC(3)H or ArC(6)H), 
119.9+ (ArC(4)H or ArC(5)H), 119.9- (C), 111.8+ (ArC(3)H or ArC(6)H), 43.1- (CH2), 
26.5- (CH2) and 25.8- (CH2). MS m/z (+ESI) 201 (100 %, MH
+
) and 223 (50 %, MNa
+
). 
HRMS (+ESI) Found MNa
+
 223.0846, C12H12N2NaO requires MNa 223.0847. Rf (50 % 
EtOAc in light petroleum (b.p. 40-60 
o
C) 0.3. Spectroscopic data are consistent with Judd et 
al.
93
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7.4.3. Tetrazoles 
 
General Procedure 7, Schmidt and Tetrazole Reaction 
The required indanone (1 eq.) and NaN3 (4 eq.) in TFA (3 mL/ 1 mmol) were heated at 100 
o
C in a sealed pressure tube for 18 hours. The reaction mixture was cooled and sat. aq. 
NaHCO3 was added dropwise followed by EtOAc. The layers were separated and the 
aqueous layer was extracted with EtOAc (x 2). The combined organic layers were washed 
with brine, dried on Na2SO4, filtered and concentrated under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) – EtOAc - MeOH gradient column], 
the desired lactam was isolated. 
 
Synthesis of 6,7,8,9-tetrahydro-5H-tetrazolo[1,5-a]azepine 119 
 
Cyclohexanone 117 (0.21 mL, 2 mmol, 1 eq.), NaN3 (520 mg, 8 mmol, 4 eq.) and FeCl3 (973 
mg, 6 mmol, 3 eq.) in CH2Cl2 (10 mL) were heated at 40 
o
C for 16 hours. On cooling the 
solvent was removed under reduced pressure. 2M NaOH(aq.) (10 mL) and EtOAc (10 mL) 
were added, the layers separated and the aqueous layer washed with EtOAc (2 x 10 mL). The 
combined organic layers were washed with brine (10 mL), dried on Na2SO4, filtered and 
concentrated under reduced pressure to collect 307 mg of yellow oil. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], tetrazole 
119 (220 mg, 80 % yield) was isolated as a white solid, m.p. 58-61 
o
C [lit.
185
 60 
o
C]. 
1
H 
NMR (400 MHz; CDCl3): δH 4.42-4.39 (2H, m, NCH2), 3.01-2.98 (2H, m, CCH2), 1.92-1.86 
(2H, m, CH2), 1.82-1.76 (2H, m, CH2) and 1.70-1.65 (CH2).
 13
C NMR (100 MHz, CDCl3): 
δC 156.6- (C=N), 49.2- (NCH2), 29.7- (CH2), 27.0- (CH2), 24.5- (CH2) and 24.1 (CCH2). 
Spectroscopic data are consistent with those reported by Eshghi and Hassankhani.
101
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Synthesis of 8,9-dimethoxy-5,6-dihydrotetrazolo[5,1-a]isoquinoline 120 
 
Indanone 90 (156 mg, 0.81 mmol, 1 eq.) was dissolved in dichloroethane (5 mL). NaN3 (211 
mg, 3.24 mmol, 4 eq.) and FeCl3 (394 mg, 2.43 mmol, 3 eq.) were added and the reaction 
mixture was heated in a sealed pressure tube at 100 
o
C for 16 hours. On cooling, the reaction 
mixture was transferred to a flask using CHCl3 and the solvent was removed under reduced 
pressure. EtOAc (30 mL) and 2M NaOH(aq.) (30 mL) were added, the layers were separated 
and the aqueous layer was washed with EtOAc (2 x 20 mL). The combined organic layers 
were washed with brine (20 mL), dried on Na2SO4, filtered and concentrated under reduced 
pressure to collect 185 mg of yellow solid. After column chromatography [silica, MeOH - 
CH2Cl2 gradient column], the tetrazole 120 (82 mg, 44 % yield) was isolated as a yellow 
solid, m.p. 133-136 
o
C. 
1
H NMR (400 MHz, CDCl3): δH 7.61 (1H, s, ArCHC(CN)), 6.84 
(1H, s, ArCHCCH2), 4.63 (2H, t, J = 6.0 Hz, NCH2CH2), 3.97 (3H, s, OCH3), 3.95 (3H, s, 
OCH3) and 3.28 (2H, t, J = 6.0 Hz, NCH2CH2). 
13
C NMR (100 MHz, CDCl3): δC 151.9- 
(ArCOCH3), 151.1- (C=N), 149.0- (ArCOCH3), 127.0- (ArC), 113.6- (ArC), 110.9+ 
(ArCHCCH2), 108.2+ (ArCHC(CN)), 53.3+ (OCH3), 56.1+ (OCH3), 43.9- (NCH2CH2) and 
27.9- (NCH2CH2). MS m/z (+ESI) 233 (72 %, MH
+
) and 255 (100 %, MNa
+
). HRMS (+ESI) 
Found MH
+
 233.1022, C11H13N4O2 requires MH 233.1039 (7 ppm). IR νmax(liquid film): 
2990 (CH) and 1509 (C=N). Rf (100 % EtOAc) 0.6. HMBC See appendices 8.2.1. 
 - 175 -  
Synthesis of 6,7-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one 114 and 8,9-dimethoxy-
5,6-dihydrotetrazolo[5,1-a]isoquinoline 120 
 
Following General Procedure 7, using indanone 90 (154 mg, 0.80 mmol, 1 eq.) and NaN3 
(208 mg, 3.20 mmol, 4 eq.) in TFA (2 mL) lactam 114 (38 mg, 23 % yield) and tetrazole 120 
(23 mg, 12 % yield) were isolated as yellow solids.  
Lactam 114 Spectroscopic data are consistent with those previously reported for lactam 114 
(Page 170). 
Tetrazole 120 m.p. 133-136 
o
C. 
1
H NMR (400 MHz, CDCl3): 
1
H NMR (400 MHz, CDCl3): 
δH 7.61 (1H, s, ArCHC(CN)), 6.84 (1H, s, ArCHCCH2), 4.63 (2H, t, J = 6.0 Hz, NCH2CH2), 
3.97 (3H, s, OCH3), 3.95 (3H, s, OCH3) and 3.28 (2H, t, J = 6.0 Hz, NCH2CH2). 
13
C NMR 
(100 MHz, CDCl3): δC 151.9- (ArCOCH3), 151.1- (C=N), 149.0- (ArCOCH3), 127.0- (ArC), 
113.6- (ArC), 110.9+ (ArCHCCH2), 108.2+ (ArCHC(CN)), 53.3+ (OCH3), 56.1+ (OCH3), 
43.9- (NCH2CH2) and 27.9- (NCH2CH2). MS m/z (+ESI) 233 (72 %, MH
+
) and 255 (100 %, 
MNa
+
). HRMS (+ESI) Found MH
+
 233.1022, C11H13N4O2 requires MH 233.1039 (7 ppm). 
IR νmax(liquid film): 2990 (CH) and 1509 (C=N). Rf (100 % EtOAc) 0.6. HMBC See 
appendices 8.2.1. 
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Synthesis of 6,7-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one 101 and 5,6-dihydro-
[1,3]dioxolo[4,5-g]tetrazolo[5,1-a]isoquinoline 121 
 
Following General Procedure 7, using indanone 88 (141 mg, 0.80 mmol, 1 eq.) and NaN3 
(208 mg, 3.20 mmol, 4 eq.) in TFA (2 mL) lactam 101 (80 mg, 52 % yield) as a yellow solid 
and tetrazole 121 (11 mg, 6 % yield) as a beige solid, were isolated.  
Lactam 101 Spectroscopic data are consistent with those previously reported for lactam 101 
(Page 169). 
Tetrazole 121 m.p. 147-150 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 7.56 (1H, s, ArCHC(CN)), 
6.81 (1H, s, ArCHCCH2), 6.06 (2H, s, OCH2O), 4.59 (2H, t, J = 7.0 Hz, NCH2CH2) and 3.24 
(2H, t, J = 7.0 Hz, NCH2CH2). 
13
C NMR (100 MHz; CDCl3): δC 151.1- (C=N), 150.8- (C), 
147.7- (C), 128.8- (C), 114.8- (C) 108.6+ (ArCHCCH2), 105.9+ (ArCHC(CN)), 101.9- 
(OCH2O), 43.6- (NCH2CH2) and 28.3- (NCH2CH2). MS m/z (ESI+) 217 (100 %, MH
+
) and 
239 (73 %, MNa
+
). HRMS (+ESI) Found MNa
+
 239.0568, C10H8N4NaO2 requires MNa 
239.0545 (10 ppm). IR νmax(liquid film): 2985 (CH) and 1505 (C=N). Rf (100 % EtOAc) 
0.6. 
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Synthesis of 6,7,8-trimethoxy-3,4-dihydroisoquinolin-1(2H)-one 115 and 8,9,10-
trimethoxy-5,6-dihydrotetrazolo[5,1-a]isoquinoline 122 
 
Following General Procedure 7, using indanone 92 (154 mg, 0.80 mmol, 1 eq.) and NaN3 
(208 mg, 3.20 mmol, 4 eq.) in TFA (2 mL), lactam 115 (38 mg, 23% yield) and tetrazole 122 
(23 mg, 12 % yield) were isolated as beige solids.  
Lactam 115 Spectroscopic data are consistent with those previously reported for lactam 115 
(Page 171).  
Tetrazole 122 m.p. 115-117 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 6.67 (1H, s, ArCH), 4.59 
(2H, t, J = 7.0 Hz, NCH2CH2), 4.07 (3H, s, OCH3), 3.93 (3H, s, OCH3), 3.91 (3H, s, OCH3) 
and 3.22 (2H, t, J = 7.0 Hz, NCH2CH2). 
13
C NMR (100 MHz; CDCl3): δC 156.3- (C=N), 
152.5- (C), 149.2- (C), 142.4- (C), 130.6- (C), 109.0- (C), 107.5+ (ArCH), 61.6+ (OCH3), 
61.1+ (OCH3), 56.2+ (OCH3), 43.5- (NCH2CH2) and 28.9- (NCH2CH2). MS m/z (ESI+) 263 
(100 %, MH
+
) and 285 (30 %, MNa
+
). HRMS (+ESI) Found MNa
+
 285.0996, 
C12H14N4NaO3 requires MNa 285.0964 (11 ppm). IR νmax(liquid film): 2990 (CH) and 1503 
(C=N). Rf (100 % EtOAc) 0.7. 
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7.4.4. Oxidation Reactions 
 
Synthesis of 6,7-dimethoxyisoquinolin-1(2H)-one 123 
 
Method A - Optimised Method 
Following a procedure adapted from Dufour and Kirsch,
107
 Pd/C (10 % wt) (100 mg, 0.1 
mmol, 10 mol %) was added to lactam 114 (207 mg, 1 mmol, 1 eq.) in xylene (5 mL). The 
reaction vessel was degassed and placed in a microwave at 200 
o
C for 30 minutes, 300 W 
power. MeOH (10 mL) and silica were added and the reaction mixture was heated at reflux 
for 1 hour. The reaction mixture was concentrated under reduced pressure and dry loaded on 
a column. After column chromatography [silica, MeOH - CH2Cl2 gradient column], product 
123 (201 mg, 98 % yield) was isolated as a white solid.  
Method B 
Following a procedure reported by Mcnulty and Still,
109
 Pd/C (10 % wt) (10 mg) and lactam 
114 (20 mg, 10 mmol, 1 eq.) were ground together to a fine powder. The solid was 
transferred to a flask, flushed with N2 and the reaction mixture was heated to 200 
o
C for 1 
hour. On cooling the reaction mixture was flushed through a pad of celite using hot MeOH. 
The solvent was removed under reduced pressure to collect 123 (83 mg, 81 % yield) as a 
white solid. 
m.p. >220 
o
C [lit.
186
 227-230 
o
C]. 
1
H NMR (400 MHz, CDCl3): δH 11.35 (1H, br.s. NH), 
7.79 (1H, s, ArCH(C=O)), 7.09 (1H, d, J = 7.0 Hz, NHCHCH), 6.91 (1H, s, ArCH), 6.48 
(1H, d, J = 7.0 Hz, NCHCH) 4.02 (3H, s, OCH3) and 4.00 (3H, s, OCH3). 
13
C NMR (100 
MHz, CDCl3): δC 163.4- (C=O), 153.8- (C), 149.4- (C), 133.8- (C), 126.3+ (NCHCH), 120.1- 
(C), 107.2+ (ArCH(C=O)), 106.3+ (ArCH), 106.2+ (NCHCH), 56.2+ (OCH3) and 56.1+ 
(OCH3). MS m/z (+ESI) 206 (100 %, MH
+
) and 228 (86 %, MNa
+
). HRMS (+ESI) Found 
MH
+
 206.0817, C11H12NO3 requires MH 206.0817 and found MNa
+
 228.0626, C11H11NNaO3 
requires MNa 228.0637. IR νmax(liquid film): 3420 (NH), 2995 (CH) and 1655 (C=O). Rf 
(100 % EtOAc) 0.2. 
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Synthesis of 6,7,8-trimethoxyisoquinolin-1(2H)-one 124 
 
Following a procedure reported by Mcnulty and Still,
109
 Pd/C (10 % wt) (13 mg) and lactam 
115 (30 mg, 0.13 mmol, 1 eq.) were ground together to a fine powder. The solid was 
transferred to a flask, flushed with N2 and the reaction mixture was heated to 200 
o
C for 2 
hours. On cooling the reaction mixture was flushed through a pad of celite using hot MeOH. 
The solvent was removed under reduced pressure. After column chromatography [silica, light 
petroleum (b.p. 40-60 
o
C) - EtOAc - MeOH gradient column], 124 (7 mg, 23 % yield) was 
isolated as a white solid, m.p. 193-196 
o
C [lit.
187
 198 
o
C].
 1
H NMR (400 MHz, CDCl3): δH 
9.15 (1H, br.s. NH), 6.96 (1H, d, J = 7.0 Hz, NHCHCH), 6.69 (1H, s, ArCH), 6.32 (1H, d, J 
= 7.0 Hz, NHCHCH), 3.99 (3H, s, OCH3), 3.95 (3H, s, OCH3) and 3.93 (3H, s, OCH3). 
13
C 
NMR (100 MHz, CDCl3): δC 161.1- (C=O), 157.4- (C), 154.5- (C), 142.2- (C), 136.9- (C), 
127.2+ (NCHCH), 114.7- (C), 105.8+ (NCHCH), 103.0+ (ArCH), 62.1+ (OCH3), 61.5+ 
(OCH3) and 56.0+ (OCH3). MS m/z (+ESI) 236 (100 %, MH
+
) and 258 (62 %, MNa
+
). 
HRMS (+ESI) Found MNa
+
 258.0730, C12H13NNaO4 requires MNa 258.0742. IR νmax(liquid 
film): 3450 (NH), 2900 (CH), 1667 (C=O) and 1595 (C=C). Rf (100 % EtOAc) 0.2. 
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7.5. Chapter Four - A/B/C Analogues of Dihydroisoquinolinones 
 
7.5.1. Intermolecular Indanone Synthesis 
 
General Procedure 8, Indanone Synthesis - Route 1 
Cyclohexene-1-carboxylic acid and 1,3-benzodioxole in TFAA/ TFA were heated at 100 
o
C 
in a sealed pressure tube. On cooling, the reaction mixture was transferred to a flask using 
CHCl3 and the solvent was removed under reduced pressure. After column chromatography 
[silica, light petroleum (b.p. 40-60
o
C)-EtOAc gradient column], the desired indanone was 
isolated. 
 
General Procedure 9, Indanone Synthesis - Route 1 
Cyclohexene-1-carboxylic acid and 1,3-benzodioxole in TFAA/ TFA were heated at 100 
o
C 
for 4 hours in a sealed pressure tube. On cooling, the reaction mixture was transferred to a 
flask using CHCl3 and the solvent was removed under reduced pressure. Sat. aqueous 
NH4
+
Cl
-
 (30 mL) and EtOAc (30 mL) were added, the layers were separated and the aqueous 
layer was washed with EtOAc (2 x 30 mL). The combined organic layers were washed with 
brine (30 mL), dried on Na2SO4, filtered and concentrated under reduced pressure. After 
column chromatography [silica, CH2Cl2 - MeOH gradient column], the desired indanone was 
isolated. 
 
General Procedure 10, Indanone Synthesis - Route 2 
Piperonylic acid (1 eq.) and cyclohexene/ cyclopentene (1.0, 1.1 or 2.0 eq.) in (TFAA/ TFA) 
were heated in a sealed pressure tube at 100 
o
C. On cooling, CHCl3 was added and the 
solvent was removed under reduced pressure. EtOAc (5 mL) and H2O (5 mL) were added 
and the reaction mixture stirred at room temperature for 22 hours. The layers were separated 
and the aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic layers 
were washed with brine (20 mL), dried on Na2SO4, filtered and concentrated under reduced 
pressure. After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc 
gradient column], the desired indanone was isolated. 
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Synthesis of cyclohex-1-ene carbonyl chloride 133 
 
Following a procedure reported by Sibi et al.,
118
 a solution of cyclohexene-1-carboxylic acid 
(378 mg, 3 mmol, 1 eq.) in CH2Cl2 (4 mL) at 0 
o
C under a N2 atmosphere was added oxalyl 
choride (0.30 mL, 3.3 mmol, 1.1 eq.) followed by DMF (1 drop). After 10 minutes, the 
reaction mixture was warmed to room temperature and stirred for 3 hours. The solvent was 
removed under reduced pressure and the compound was used without purification in the next 
reaction.  
 
Synthesis of cyclohexenyl(4-methoxyphenyl)methanone 134 and (2-chloro-
cyclohexyl)(4-methoxyphenyl)methanone 135 
 
Following the procedure reported by Yin et al but at room temperature,
116
 to a rapidly stirred 
solution of acid chloride 133, (433 mg, 2.99 mmol, 1.1 eq.) and anisole (0.3 mL, 2.72 mmol, 
1 eq.) in anhydrous chlorobenzene (6 mL) was added anhydrous AlCl3 (1.09 g, 8.16 mmol, 3 
eq.) at room temperature. This was placed under a N2 atmosphere and stirred for 16 hours. 
12M HCl(aq.) (10 mL) was added, followed by ice (50 mL). The mixture was stirred until all 
the ice had melted and the resulting mixture was extracted with EtOAc (3 x 30 mL). The 
combined organic layers were washed with 2M HCl(aq.) (10 mL), H2O (10 mL), aq. NaHCO3 
(10 mL) and H2O (10 mL), dried on Na2SO4, filtered and the solvent was removed under 
reduced pressure to collect crude brown oil (1.16 g). After column chromatography [silica, 
light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], the compounds 134 (260 mg, 44 
% yield) and 135 (31 mg, 4.5 % yield) were isolated as yellow oils. 
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134 
1
H NMR (400 MHz; CDCl3): δH 7.68 (2H, d, J = 8.5 Hz, ArC(2)H), 6.91 (2H, d, J = 8.5 
Hz, ArC(3)H), 6.48 (1H, m, alkene CH), 3.84 (3H, s, OCH3), 2.41-2.38 (2H, m, CHCH2), 
2.26-2.22 (2H, m, CH2) and 1.74-1.65 (4H, m, CH2CH2). 
13
C NMR (100 MHz; CDCl3): δC 
197.1- (C=O), 162.4- (ArC(4)), 141.5+ (alkene CH), 138.6- ((CO)CCH), 131.5+ (ArC(2)H), 
130.9- (ArC(1)), 113.3+ (ArC(3)H), 55.4+ (OCH3), 25.9- (CH2), 24.3- (CHCH2), 22.1- (CH2) 
and 21.7- (CH2). MS m/z (+ESI) 217 (89 %, MH
+
) and 239 (100 %, MNa
+
). HRMS (+ESI) 
Found MH
+
 217.1231, C14H17O2 requires MH 217.1229 and found MNa
+
 239.1046, 
C14H16NaO2 requires MNa 239.1048. IR νmax(liquid film): 2859 (CH), 1638 (C=O), 1600 
(C=C) and 1029 (C-O). Rf (20 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.5. 
135 
1
H NMR (400 MHz; CDCl3): δH 7.77 (2H, d, J = 8.5 Hz, ArC(2)H), 6.87 (2H, d, J = 8.5 
Hz, ArC(3)H), 4.57-4.55 (1H, m, ClCH), 3.79 (3H, s, OCH3), 3.50-3.45 (1H, m, (CO)CH) 
and 2.12-1.18 (8H, m, CH2CH2CH2CH2). 
13
C NMR (100 MHz; CDCl3): δC 198.2- (C=O), 
163.3- (ArC(4)), 130.3+ (ArC(2)H), 129.1- (ArC(1)), 113.9+ (ArC(3)H), 60.5+ (ClCH), 
55.5+ (OCH3), 49.1+ ((CO)CH), 34.3- (CH2), 24.2- (CH2), 22.1- (CH2), 20.2- (CH2). MS m/z 
(+ESI) 253 (17 %, MH
+
), 275 (100 %, MNa
+
 (
35
Cl)) and 277 (30 %, MNa
+
 (
37
Cl)). HRMS 
(+ESI) Found MH
+
 253.0986, C14H18
35
ClO2 requires MH 253.0995 and found MNa
+
 
275.0805, C14H17
35
ClNaO2 requires MNa 275.0815. IR νmax(liquid film): 2937 (CH), 1374 
(C=O), 1599 (C=C) and 1023 (C-O). Rf (20 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.5. 
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Synthesis of (4bR,8aS)-6,7,8,8a-tetrahydro-4bH-fluoreno[2,3-d][1,3]dioxol-9(5H)one 136 
 
Route 1 
 
Method 1A 
Following General Procedure 8, cyclohexene-1-carboxylic acid (126 mg, 1 mmol, 1 eq.) 
and 1,3-benzodioxole (0.11 mL, 1 mmol, 1 eq.) in TFAA: TFA (0.5 mL: 1.0 mL) at 100 
o
C 
for 1 hour afforded indanone 136 (151 mg, 66 % yield) as a yellow solid. 
Method 1B 
Following General Procedure 8, cyclohexene-1-carboxylic acid (126 mg, 1 mmol, 1 eq.) 
and 1,3-benzodioxole (0.11 mL, 1 mmol, 1 eq.) in TFAA: TFA (0.5 mL: 1.0 mL) at 100 
o
C 
for 3.5 hours afforded indanone 136 (188 mg, 82 % yield) as a yellow solid. 
Method 1C 
Following General Procedure 8, cyclohexene-1-carboxylic acid (126 mg, 1 mmol, 1 eq.) 
and 1,3-benzodioxole (0.11 mL, 1 mmol, 1 eq.) in TFAA: TFA (0.5 mL: 1.0 mL) at 100 
o
C 
for 6 hours afforded indanone 136 (166 mg, 72 % yield) as a yellow  solid. 
Method 1D 
Following General Procedure 8, cyclohexene-1-carboxylic acid (126 mg, 1 mmol, 1 eq.) 
and 1,3-benzodioxole (0.13 mL, 1.1 mmol, 1.1 eq.) in TFAA: TFA (0.5 mL: 1.0 mL) at 100 
o
C for 17 hours afforded indanone 136 (129 mg, 56 % yield) as a yellow solid. 
Method 1E 
Following General Procedure 9, cyclohexene-1-carboxylic acid (252 mg, 2 mmol, 1 eq.) 
and 1,3-benzodioxole (0.46 mL, 4 mmol, 2 eq.) in TFAA: TFA (1.0 mL: 2.0 mL) at 100 
o
C 
for 4 hours afforded indanone 136 (270 mg, 59 % yield) as a yellow solid. 
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Method 1F 
Following General Procedure 9, cyclohexene-1-carboxylic acid (126 mg, 1 mmol, 1 eq.) 
and 1,3-benzodioxole (0.23 mL, 2 mmol, 2 eq.) in TFAA (0.49 mL, 3.5 mmol, 3.5 eq.) at 100 
o
C for 4 hours afforded indanone 136 (172 mg, 75 % yield) as a yellow solid. 
Method 1G 
Following a procedure reported by Luke et al,
120
 cyclohexene-1-carboxylic acid (126 mg, 1 
mmol, 1 eq.), 1,3-benzodioxole (0.23 mL, 2 mmol, 2 eq.) and TFAA (0.56 mL, 4 mmol, 4 
eq.) were added to a pressure tube. The reaction mixture was cooled to 0 
o
C and H3PO4 (0.06 
mL, 1 mmol, 1 eq.) was added. The tube was sealed and heated at 100 
o
C for 4 hours. On 
cooling to 0 
o
C, the reaction mixture was diluted with H2O (5 mL) and the pH was adjusted 
to ~ pH 9 by the careful addition of 10M NaOH(aq.). EtOAc (10 mL) was added and the 
reaction mixture was stirred for 10 minutes at room temperature, the layers were separated 
and the aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic layers 
were washed with brine (20 mL), dried on Na2SO4, filtered and concentrated under reduced 
pressure. After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc 
gradient column], the indanone 136 (130 mg, 57 % yield) was isolated as a yellow solid. 
Method 1H 
Cyclohexene-1-carboxylic acid (126 mg, 1 mmol, 1 eq.), 1,3-benzodioxole (0.23 mL, 2 
mmol, 2 eq.) and TFAA (0.56 mL, 4 mmol, 4 eq.) were added to a pressure tube. The 
reaction mixture was cooled to 0 
o
C and H2SO4 (0.05 mL, 1 mmol, 1 eq.) was added and the 
reaction mixture was heated at 100 
o
C for 4 hours in a sealed pressure tube. On cooling to 0 
o
C, the reaction mixture was diluted with H2O (5 mL) and the pH adjusted to ~ pH 9 by the 
careful addition of 10M NaOH(aq.). EtOAc (10 mL) was added and the reaction mixture was 
stirred for 10 minutes at room temperature, the layers were separated and the aqueous layer 
extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (20 
mL), dried on Na2SO4, filtered and concentrated under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], the 
indanone 136 was isolated (72 mg, 31 % yield) as a yellow solid. 
Method 1I - Optimised Method 
Following General Procedure 8, cyclohexene-1-carboxylic acid (505 mg, 4 mmol, 1 eq.) 
and 1,3-benzodioxole (0.92 mL, 8 mmol, 2 eq.) in TFAA (1.95 mL, 14 mmol, 3.5 eq.) were 
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heated at 100 
o
C for 4 hours. Using MeOH to transfer the reaction mixture, indanone 136 
(774 mg, 84 % yield) was isolated as a yellow solid. 
 
Route 2 
 
Method 2A 
Following General Procedure 10, piperonylic acid on a 1 mmol scale and cyclohexene (1 
eq.) in TFAA (3.5 eq.) at 100 
o
C for 4 hours, afforded indanone 136 (81 mg, 35 % yield) as a 
yellow solid. 
Method 2B 
Following General Procedure 10, piperonylic acid on a 1 mmol scale and cyclohexene (1.1 
eq.) in TFAA (3.5 eq.) at 100 
o
C for 6 hours, afforded indanone 136 (32 mg, 14 % yield) as a 
yellow solid. 
Method 2C - Optimised Method 
Following General Procedure 10, piperonylic acid on a 1 mmol scale and cyclohexene (1.1 
eq.) in TFAA (3.5 eq.) at 100 
o
C for 16 hours, afforded indanone 136 (118 mg, 51 % yield) 
as a yellow solid. 
Method 2D 
Following General Procedure 10, piperonylic acid on a 2 mmol scale and cyclohexene (2 
eq.) in TFAA (3.5 eq.) at 100 
o
C for 17 hours, afforded indanone 136 (215 mg, 47 % yield) 
as a yellow solid. 
Method 2E 
Following General Procedure 10, piperonylic acid on a 2 mmol scale and cyclohexene (1.1 
eq.) in TFAA (2 eq.) and TFA (1 mL) at 100 
o
C for 17 hours, afforded indanone 136 (47 mg, 
10 % yield) as a yellow solid. 
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Method 2F 
Following General Procedure 10, piperonylic acid on a 2 mmol scale and cyclohexene (1.1 
eq.) in TFAA (1.1 eq.) and TFA (1 mL) at 100 
o
C for 16 hours, afforded indanone 136 (81 
mg, 18 % yield) as a yellow solid. 
136 m.p. 113-115 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 7.11 (1H, s, ArCHC(C=O)), 6.83 
(1H, s, ArCHCCH), 6.06 (2H, m, OCH2O), 3.26 (1H, ddd, J = 16.0, 9.0, 7.0 Hz, 
(CO)CHCH), 2.74 (1H, dt, J = 12.0, 7.0 Hz, (CO)CHCH), 2.09-1.98 (2H, m, CH2), 1.79-1.70 
(1H, m, CH2), 1.57-1.33 (3H, m, CH2CH2) and 1.30-1.16 (2H, m, CH2). 
13
C NMR (100 
MHz; CDCl3): δC 206.1- (C=O), 156.0- (ArC), 153.8- (ArC), 148.0- (ArC), 130.1- (ArC), 
104.6+ (ArCHCCH), 102.8+ (ArCHC(C=O)), 102.0- (OCH2O), 48.5+ ((CO)CHCH), 38.5+ 
((CO)CHCH), 30.7- (CH2), 23.2- (CH2), 22.1- (CH2) and 21.9- (CH2). MS (+ESI) 231 (100 
%, MH
+
) and 253 (85 %, MNa
+
). HRMS m/z (+ESI) Found MH
+
 231.1004, C14H15O3 
requires MH
+
 231.1021 (7 ppm). IR νmax(liquid film): 3054 (CH), 1693 (C=O) and 1031 (C-
O). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.8.  
Crystal Structure (See appendices 8.3.1. for crystal data) 
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Synthesis of 8a-trifluoroacetyl-6,7,8,8a-tetrahydro-4bH-fluoreno[2,3-d][1,3] dioxol-
9(5H)-one 137 
 
Cyclohexene-1-carboxylic acid (505 mg, 4 mmol, 1 eq.) and 1,3-benzodioxole (0.92 mL, 8 
mmol, 2 eq.) in TFAA (1.95 mL, 14 mmol, 3.5 eq.) were heated at 100 
o
C for 4 hours in a 
sealed pressure tube. On cooling, the reaction mixture was transferred to a flask using 
chloroform and the solvent was removed under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], the 
indanone 137 (887 mg, 68 % yield) was isolated as a yellow solid. 
1
H NMR (400MHz; 
CDCl3): δH 6.89 (1H, s, ArCHC(C=O)), 6.58 (1H, s, ArCHCCH), 5.95 (2H, s, OCH2O), 3.05 
(1H, m, CH), 2.64-2.59 (1H, m, CH-cyclohexane), 2.51-2.47 (1H, m, CH-cyclohexane), 2.17 
(1H, dt, J = 13.0 and 5.0 Hz, CH-cyclohexane), 1.99-1.94 (1H, m, CH-cyclohexane), 1.90-
1.72 (1H, m, CH-cyclohexane), 1.52-1.47 (1H, m, CH-cyclohexane), 1.30-1.91 (1H, m, CH-
cyclohexane) and 0.98 (1H, dq, J = 13.0 and 3.5 Hz, CH-cyclohexane). 
13
C NMR (100 MHz; 
CDCl3): δC 146.8- (C=O), 146.3- (C=O), 139.0- (C), 138.0- (C), 135.1- (C), 131.0- (C), 
121.6- (C), 116.0- (C), 104.7- (ArCHC(C=O)), 101.1- (OCH2O), 98.6+ (ArCHCCH), 46.4+ 
(CH), 32.1- (CH2), 26.6- (CH2), 25.0- (CH2) and 24.7- (CH2). 
19
F NMR (400MHz; CDCl3): -
74.35 (CF3). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.9. 
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Synthesis of 6,7,8-trimethoxy-2,3,4,4a-tetrahydro-1H-fluoren-9(9aH)-one 138 
 
Route 1 
 
Method 1A 
Cyclohexene-1-carboxylic acid (126 mg, 1 mmol, 1 eq.) and 1,2,3-trimethoxybenzene (336 
mg, 2 mmol, 2 eq.) in TFAA (0.49 mL, 3.5 mmol, 3.5 eq.) were heated at 100 
o
C for 4 hours 
in a sealed pressure tube. On cooling, the reaction mixture was transferred to a flask using 
CHCl3 and the solvent was removed under reduced pressure. An initial column [silica, 
CH2Cl2 - MeOH gradient column], followed by a second column [silica, light petroleum (b.p. 
40-60 
o
C) - EtOAc gradient column], afforded indanone 138 (77 mg, 28 % yield) as a white 
solid. 
Method 1B - Optimised Method 
Cyclohexene-1-carboxylic acid (126 mg, 1 mmol, 1 eq.) and 1,2,3-trimethoxybenzene (336 
mg, 2 mmol, 2 eq.) in TFAA (0.49 mL, 3.5 mmol, 3.5 eq.) were heated at 100 
o
C for 4 hours 
in a sealed pressure tube. On cooling, the reaction mixture was transferred to a flask using 
CHCl3 and the solvent was removed under reduced pressure. H2O (5 mL) and EtOAc (5 mL) 
were added and the reaction mixture was stirred at 20 
o
C for 22 hours. The layers were 
separated and the aqueous layer was washed with EtOAc (2 x 10 mL). The combined organic 
layers were washed with brine (10 mL), dried on Na2SO4, filtered and concentrated under 
reduced pressure. After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - 
EtOAc gradient column], indanone 138 (156 mg, 57 % yield) was isolated as a white solid. 
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Route 2 
 
Method 2A 
2,3,4-Trimethoxybenzoic acid (849 mg, 4 mmol, 1 eq.) and cyclohexene (0.45 mL, 4.4 
mmol, 1.1 eq.) in TFAA (1.95 mL, 14 mmol, 3.5 eq.) were heated in a pressure tube at 100 
o
C for 16 hours. On cooling, the reaction mixture was transferred to a flask using CHCl3 and 
the solvent was removed under reduced pressure. H2O (20 mL) and EtOAc (20 mL) were 
added and the reaction mixture stirred at room temperature for 24 hours. The layers were 
separated and the aqueous layer was extracted with EtOAc (2 x 20 mL). The combined 
organic layers were washed with sat. aq. NaHCO3 (20 mL), brine (20 mL), dried on MgSO4, 
filtered and concentrated under reduced pressure. After column chromatography [silica, light 
petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], the indanone 138 (142 mg, 13 % yield) 
was isolated as a light beige solid. 
Method 2B 
2,3,4-Trimethoxybenzoic acid (424 mg, 2 mmol, 1 eq.) and cyclohexene (0.22 mL, 2.2 
mmol, 1.1 eq.) in TFAA (0.97 mL, 7 mmol, 3.5 eq.) were heated in a pressure tube at 100 
o
C 
for 18 hours. On cooling, the reaction mixture was transferred to a flask using CHCl3 and the 
solvent was removed under reduced pressure. Saturated aq. NaHCO3 (20 mL) and THF (2 
mL) were added and the reaction mixture stirred at room temperature for 22 hours. H2O (20 
mL) and EtOAc (20 mL) were added, the layers were separated and the aqueous layer was 
extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (20 
mL), dried on MgSO4, filtered and concentrated under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], the 
indanone 138 was isolated (89 mg, 16 % yield) as a light beige solid. 
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Method  2C 
2,3,4-Trimethoxybenzoic acid (424 mg, 2 mmol, 1 eq.) and cyclohexene (0.22 mL, 2.2 
mmol, 1.1 eq.) in TFAA (0.97 mL, 7 mmol, 3.5 eq.) were heated in a pressure tube at 100 
o
C 
for 6 hours. On cooling, the reaction mixture was tranferred to a flask using CHCl3 and the 
solvent was removed under reduced pressure. Aqueous NaHCO3 (20 mL) and THF (2 mL) 
were added and the reaction mixture stirred at room temperature for 16 hours. H2O (20 mL) 
and EtOAc (20 mL) were added, the layers were separated and the aqueous layer was 
extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (20 
mL), dried on MgSO4, filtered and concentrated under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60
o
C) EtOAc gradient column], the 
indanone 138 was isolated (50 mg, 9 % yield) as a light beige solid. 
Method 2D 
2,3,4-Trimethoxybenzoic acid (212 mg, 1 mmol, 1 eq.) and cyclohexene (0.11 mL, 1.1 
mmol, 1.1 eq.) in TFAA (0.97 mL, 7 mmol, 3.5 eq.) were heated in a pressure tube at 100 
o
C 
for 24 hours. On cooling, the reaction mixture was transferred to a flask using CHCl3 and the 
solvent was removed under reduced pressure. Sat. aq. NaHCO3 (10 mL) and THF (2 mL) 
were added and the reaction mixture stirred at room temperature for 16 hours. H2O (10 mL) 
and EtOAc (10 mL) were added, the layers were separated and the aqueous layer was 
extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (20 
mL), dried on MgSO4, filtered and concentrated under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], the 
indanone 138 was isolated (20 mg, 7 % yield) as a light beige solid.  
Method 2E - Optimised Method  
2,3,4-Trimethoxybenzoic acid (212 mg, 1 mmol, 1 eq.) and cyclohexene (0.20 mL, 2 mmol, 
2 eq.) in TFAA (0.15 mL, 1.1 mmol, 1.1 eq.) and TFA (0.5 mL) were heated in a pressure 
tube at 100 
o
C for 16 hours. On cooling, the reaction mixture was tranferred to a flask using 
CHCl3 and the solvent was removed under reduced pressure. Sat. aq. NaHCO3 (10 mL) and 
THF (1 mL) were added and the reaction mixture stirred at room temperature for 6 hours. 
H2O (10 mL) and EtOAc (20 mL) were added, the layers were separated and the aqueous 
layer was extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with 
brine (20 mL), dried on Na2SO4, filtered and concentrated under reduced pressure. After 
 - 191 -  
column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 
the indanone 138 was isolated (104 mg, 38 % yield) as a light beige solid. 
138 m.p. 89-91 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 6.64 (1H, s, ArCH), 4.04 (3H, s, 
OCH3), 3.93 (3H, s, OCH3), 3.84 (3H, s, OCH3), 3.23 (1H, dt, J = 9.0, 6.5 Hz, COCHCH), 
2.70 (1H, td, J = 7.0, 5.0 Hz, COCHCH), 2.09-2.02 (2H, m, CH2) and 1.74-1.16 (6H, m, 
CH2). 
13
C NMR (100 MHz; CDCl3): δC 203.9- (C=O), 159.3- (C), 156.3- (C), 151.7- (C), 
140.5- (C), 120.9- (C), 102.3+ (ArCH), 61.9+ (CH), 61.3+ (CH), 56.2+ (OCH3), 48.9+ 
(OCH3), 38.5+ (OCH3), 31.2- (CH2), 23.2- (CH2), 22.5- (CH2), 22.2- (CH2). MS m/z (+ESI) 
277 (53 %, MH
+
) and 299 (18 %, MNa
+
). HRMS (+ESI) Found MH
+
 277.1427, C16H21O4 
requires MH 277.1440 and found MNa
+
 299.1248, C16H20NaO4 requires MNa 299.1259. IR 
νmax(liquid film): 3054 (CH) and 1702 (C=O). Rf (40 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.4. 
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Synthesis of (4aR,9aS)-5,6,7-trimethoxy-2,3,4,4a-tetrahydro-1H-fluoren-9(9aH)-one 
138a 
 
3,4,5-Trimethoxybenzoic acid (424 mg, 2 mmol, 1 eq.) and cyclohexene (0.41 mL, 4 mmol, 
2 eq.) in TFAA (0.31 mL, 2.2 mmol, 1.1 eq.) and TFA (1 mL) were heated in a pressure tube 
at 100 
o
C for 16 hours. On cooling, the reaction mixture was transferred to a flask using 
CHCl3 and the solvent was removed under reduced pressure. Sat. aq. NaHCO3 (10 mL) and 
THF (1 mL) were added and the reaction mixture stirred at room temperature for 6 hours. 
H2O (10 mL) and EtOAc (20 mL) were added, the layers were separated and the aqueous 
layer was extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with 
brine (20 mL), dried on Na2SO4, filtered and concentrated under reduced pressure. After 
column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 
the indanone 138a was isolated (50 mg, 9 % yield) as a white solid, m.p. 72-75 
o
C. 
1
H NMR 
(400 MHz; CDCl3): δH 7.03 (1H, s, ArCH), 3.96 (3H, s, OCH3), 3.93 (3H, s, OCH3), 3.88 
(3H, s, OCH3), 3.43 (1H, dt, J = 13.0, 7.0 Hz, COCHCH), 2.67 (1H, td, J = 7.0, 4.0 Hz, 
COCHCH), 2.28-2.21 (2H, m, CH2), 1.70-1.65 (1H, m, CH2), 1.62-1.53 (2H, m, CH2) and 
1.37-0.93 (2H, m, CH2). 
13
C NMR (100 MHz; CDCl3): δC 206.6- (C=O), 153.9- (C), 150.0- 
(C), 147.5- (C), 144.9- (C), 131.0- (C), 101.1+ (ArCH), 60.9+ (OCH3), 60.9+ (OCH3), 56.1+ 
(OCH3), 48.4+ (COCHCH), 36.3+ (COCHCH), 31.1- (CH2), 22.8- (CH2), 22.8- (CH2) and 
22.1- (CH2). MS m/z (+ESI) 277 (100 %, MH
+
) and 299 (27 %, MNa
+
). HRMS (+ESI) 
Found MNa
+
 299.1256, C16H20NaO4 requires MNa 299.1259. IR νmax(liquid film): 2939 
(CH), 1705 (C=O) and 1601 (C=C). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.8. 
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Synthesis of (3R,4S,5R)-3,4,5-triacetoxycyclohex-1-enecarboxylic acid 140 
 
Following a procedure reported by Streicher et al.,
123
 shikimic acid 139 (174 mg, 1 mmol, 1 
eq.) dissolved in pyridine (2 mL) and acetic anhydride (1 mL) was stirred at room 
temperature for 5 hours. The solvent was removed under reduced pressure and the residue 
was dissolved in EtOAc (10 mL), washed with 1M HCl(aq.) (2 x 10 mL), brine (10 mL), dried 
on Na2SO4, filtered and concentrated under reduced pressure. After column chromatography 
[silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], compound 140 (298 mg, 
99 % yield) was isolated as a colourless oil (Srinavas et al.
188
 report this compound as white 
crystals). 
1
H NMR (400 MHz; CDCl3): δH 6.82 (1H, t, J = 2.0 Hz, alkene CH), 5.76-5.74 
(1H, m, OCH), 5.31-5.25 (2H, m, OCH), 2.91-2.85 (1H, m, CHaHb), 2.45-2.40 (1H, m, 
CHaHb), 2.08 (3H, s, CH3), 2.07 (3H, s, CH3) and 2.05 (3H, s, CH3). 
13
C NMR (100 MHz; 
CDCl3): δC 170.3- ((C=O)OH), 170.0- and 169.9- (3 x (C=O)), 135.1+ (alkene CH), 130.5- 
(alkeneC), 67.4+ (OCH), 66.7+ (OCH), 66.0+ (OCH), 28.0- (CH2), 21.0+ and 20.7+ (3 x 
CH3). IR νmax(liquid film): 1728 (C=O) and 1655 (C=O). MS m/z (+ESI) 323 (100 %, 
MNa
+
). HRMS (+ESI) Found MNa
+
 323.0784, C13H16NaO8 requires MNa 323.0743 (13 
ppm). Rf (100 % EtOAc) 0.5. Spectroscopic data are consistent with those reported by 
Streicher et al.
123
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Synthesis of Diels-Alder product 143 
 
N-Phenylmaleimide (520 mg, 3 mmol, 1 eq.) and 3-furoic acid (672 mg, 6 mmol, 2 eq.) were 
dissolved in MeCN (20 mL) and heated at 80 
o
C for 2 days. The reaction mixture was cooled 
and the solvent was removed under reduced pressure. Et2O was added and the white solid 
was filtered and dried to collect acid 143 (560 mg, 65 % yield) as a white solid, m.p. >220 
o
C. 
1
H NMR (400 MHz; (CD3)2SO): δH 7.58-7.47 (3H, m, ArCH), 7.33 (1H, d, J = 1.5 Hz, 
alkene CH), 7.29-7.23 (2H, m, ArCH), 5.47 (1H, s, (CO)H), 5.40 (1H, s, (CO)H), 3.33 (1H, 
d, J = 6.5 Hz, (C=O)CH) and 3.23 (1H, d, J = 6.5 Hz, (C=O)CH). 
13
C NMR (100 MHz; 
(CD3)2SO): δC 175.1- (C=O)N), 175.0- (C=O)N), 163.3- ((C=O)OH), 145.1+ (alkene CH), 
142.7- (C), 132.0- (C), 129.0+ (ArCH), 128.5+ (ArCH), 126.8+ (ArCH), 82.3+ (C-O), 80.4+ 
(C-O), 47.4+ ((C=O)CH) and 47.3+ ((C=O)CH). MS m/z (ESI+) 308 (19 %, MNa
+
). HRMS 
(+ESI) Found MNa
+
 308.0562, C15H11NNaO5 requires MNa 308.0535 (9 ppm). IR 
νmax(liquid film): 2990 (CH), 1783 (C=O), 1718 (C=O) and 1599 (C=C). 
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Synthesis of Diels-Alder product 144 
 
N-Ethylmaleimide (375 mg, 3 mmol, 1 eq.) and 3-furoic acid (672 mg, 6 mmol, 2 eq.) were 
dissolved in MeCN (20 mL) and heated at 80 
o
C for 2 days. The reaction mixture was cooled 
and the solvent was removed under reduced pressure. Et2O was added and the white solid 
was filtered and dried to collect acid 144 (465 mg, 65 % yield) as a white solid, m.p. >220 
o
C. 
1
H NMR (400 MHz; (CD3)2SO): δH 7.20 (1H, d, J = 2.0 Hz, alkene CH), 5.27 (1H, d, J = 
1.5 Hz, (CO)H), 5.19 (1H, s, (CO)H), 3.38 (2H, q, J = 7.0 Hz, CH2), 3.07 (1H, d, J = 7.0 Hz, 
CH(C=O)), 2.98 (1H, d, J = 7.0 Hz, CH(C=O)) and 1.00 (3H, t, J = 7.0 Hz, CH3). 
13
C NMR 
(100 MHz; (CD3)2SO): δC 175.6- (C=O)N), 175.6- (C=O)N), 163.3- ((C=O)OH), 145.0+ 
(alkene CH), 142.5- (C), 81.4+ CHO), 79.9+ (CHO), 47.1+ (CH(C=O)), 47.0+ (CH(C=O)) 
33.1- (CH2) and 12.7+ (CH3). MS m/z (ESI+) 260 (63 %, MNa
+
). HRMS (+ESI) Found 
MNa
+
 260.0546, C11H11NNaO5 requires MNa 260.0535. IR νmax(liquid film): 1783 (C=N), 
1705 (C=O) and 1604 (C=C).  
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Synthesis of indanone 145 
 
Following General Procedure 10, piperonylic acid on a 2 mmol scale and cyclopentene (2 
eq.) in TFAA (3.5 eq.) at 100 
o
C for 16 hours, afforded the indanone 145 (178 mg, 41 % 
yield) as a yellow solid, m.p. 80-83 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 7.01 (1H, s, 
ArCHC(C=O)), 6.82 (1H, s, ArCHCCH), 6.05-6.04 (2H, m, OCH2O), 3.64-3.60 (1H, m, 
(CO)CHCH), 3.04 (1H, ddd, J = 10.0, 7.0, 2.0 Hz, (CO)CHCH), 2.04-1.74 (4H, m, CH2CH2), 
1.60-1.56 (1H, m, CH2) and 1.19-1.13 (1H, m, CH2). 
13
C NMR (100 MHz; CDCl3): δC 
207.8- (C=O), 156.2- (C), 154.5- (C), 148.3- (C), 132.1- (C) 104.9+ (ArCHCCH), 102.1+ 
(ArCHC(C=O)), 101.6- (OCH2O), 52.9+ ((CO)CHCH), 43.7+ ((CO)CHCH), 32.8- (CH2), 
30.6- (CH2) and 24.4- (CH2). MS m/z (+ESI) 217 (100 %, MH
+
) and 239 (70 %, MNa
+
). 
HRMS (+ESI) Found MNa
+
 239.0702, C13H13NNaO2 requires MNa 239.0684 (8 ppm). IR 
νmax(liquid film): 2958 (CH), 1693 (C=O) and 1609 (C=C). Rf (30 % EtOAc in light 
petroleum (b.p. 40-60 
o
C)) 0.7. 
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Synthesis of Diels-Alder product 146 
 
N-Phenylmaleimide (693 mg, 4 mmol, 1 eq.) and furan (0.58 mL, 8 mmol, 2 eq.) in THF (6 
mL) were stirred at room temperature for 48 hours. The reaction mixture was concentrated 
under reduced pressure to collect 884 mg of yellow solid. After column chromatography 
[silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], compound 146 (694 mg, 
72 % yield) was collected as a white solid, m.p. 150-152 
o
C [lit.
189
 164-165 
o
C]. 
1
H NMR 
(400 MHz, CDCl3): δH 7.48-7.43 (2H, m, ArCH), 7.38 (1H, tt, J = 8.0, 1.0 Hz, ArC(4)H), 
7.28-7.26 (2H, m, ArCH), 6.55 (2H, t, J = 1.0 Hz, alkene CH), 5.38 (2H, t, J = 1.0 Hz, 
(CO)H) and 2.99 (2H, s, CH(C=O)). 
13
C NMR (CDCl3, 100 MHz): δC 175.3- (C=O)), 
136.7+ (alkene CH), 131.8- (ArC(1)), 129.1- (ArCH), 128.8+ (ArCH), 126.6+ (ArCH), 81.5+ 
(CO)H), 47.6+ (CH(C=O). MS m/z (+ESI) 264 (91 %, MNa
+
). HRMS (+ESI) Found MNa
+
 
264.0623, C14H11NNaO3 requires MNa 264.0637. IR νmax(liquid film): 2988 (CH), 1714 
(C=O) and 1598 (C=C). Rf (40 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.4. 
Spectroscopic data are consistent with those reported by Riande et al.
189
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7.5.2. Schmidt Reaction and Beckmann Rearrangement 
Synthesis of (4aR,9aS)-6,7-dihydroxy-2,3,4,4a-tetrahydro-1H-fluoren-9(9aH)-one 147 
 
NaN3 (338 mg, 5.20 mmol, 4 eq.) was added to 136 (300 mg, 1.30 mmol, 1 eq.) in toluene: 
H2SO4 (2.5 mL: 2.5 mL). The reaction mixture was heated at 100 
o
C for 4 hours; on cooling, 
sat. aq. NaHCO3 (15 mL) and EtOAc (15 mL) were added and the mixture was stirred at 
room temperature for 10 minutes. The aqueous layer was extracted with EtOAc (4 x 15 mL); 
the combined organic layers were washed with brine (15 mL), dried on Na2SO4, filtered and 
concentrated under reduced pressure. The aqueous layer was extracted with CHCl3 (4 x 15 
mL), the combined organic layers were washed with brine (15 mL), dried on Na2SO4, filtered 
and concentrated under reduced pressure. Both the crude products were combined and, after 
column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 
indanone 147 (151 mg, 53 % yield) was isolated as a white solid, m.p. 199-202 
o
C. 
1
H NMR 
(400 MHz; CDCl3): δH 7.21 (1H, s, ArCHC(C=O)), 6.86 (1H, s, ArCHCCH), 3.20 (1H, dt, J 
= 15.0, 7.0 Hz, (CO)CHCH), 2.65 (1H, dt, J = 13.0, 7.0 Hz, (CO)CHCH) and 2.09-1.16 (8H, 
m, (CH2)4). MS m/z (+ESI) 219 (100 %, MH
+
) and 241 (71 %, MNa
+
). HRMS (+ESI) Found 
MNa
+
 241.0843, C13H14NaO3 requires MNa 241.0841. IR νmax(liquid film): 3600 (OH) and 
1701 (C=O). Rf (40 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.3. 
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Synthesis of 1,2,3,4,4a,5-hexahydro-[1,3]dioxolo[4,5-j]phenanthridin-6(11bH)-one 148 
 
Method A  
Following the procedure reported by Irie et al.,
98
 indanone 136 (248 mg, 1.08 mmol, 1 eq.) 
was dissolved in trichloroacetic acid (3 mL) and the reaction mixture was heated to 60 
o
C. 
NaN3 (280 mg, 4.32 mmol, 4 eq.) was added slowly portionwise over 6 hours (1.08 mmol 
every 2 hours). The reaction mixture was left to stir for a further two days and the reaction 
mixture was neutralised with 1M NaOH(aq.). The aqueous layer was extracted with CHCl3 (3 
x 30 mL) and the combined organic layers were washed with brine, dried on Na2SO4 and 
filtered and the solvent was removed under reduced pressure to afford a crude orange oil. 
After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient 
column], the lactam 148 (50 mg, 19 % yield) was isolated as a yellow solid. 
Method B 
Following the procedure reported by Jesudason et al.,
96
 NaN3 (249 mg, 3.84 mmol, 4 eq.) 
was added to indanone 136 (220 mg, 0.96 mmol, 1 eq.) in toluene: H2SO4 (0.5 mL: 0.5 mL) 
and the reaction mixture was stirred at room temperature for 4 days. Sat. aq. NaHCO3 (20 
mL) and EtOAc (20 mL) were added and the reaction mixture stirred at room temperature for 
1 hour. The aqueous layer was extracted with EtOAc (2 x 20 mL), the combined organic 
layers were washed with brine (20 mL), dried on Na2SO4 and filtered and the solvent was 
removed under reduced pressure to afford a crude brown solid. The aqueous layer was re-
extracted with CHCl3 (3 x 20 mL) and the combined organic layers were washed with brine 
(20 mL), dried on Na2SO4 and filtered and the solvent was removed under reduced pressure 
to afford a second portion of crude brown solid. After column chromatography [silica, light 
petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], the lactam 148 (50 mg, 21 % yield) was 
isolated as a yellow solid.  
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Method C - Optimised Method 
Following General Procedure 7, using indanone 136 (95 mg, 0.41 mmol, 1 eq.) and NaN3 
(107 mg, 1.64 mmol, 4 eq.) in TFA (1 mL), the lactam 148 (40 mg, 40% yield) was isolated 
as a yellow solid. 
m.p. 259-261 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 7.44 (1H, s, ArCHC(C=O)), 6.57 (1H, s, 
ArCHCCH), 5.93 (2H, m, OCH2O), 5.54 (1H, br.s. NH), 3.81 (1H, m, NCHCH), 2.61 (1H, 
m, NCHCH) and 1.74-1.25 (8H, m, (CH2)4). 
13
C NMR (100 MHz; CDCl3): δC 166.3- (C=O), 
151.0- (ArC-O), 146.8- (ArC-O), 137.1- (ArC), 121.5- (ArC), 108.0+ (ArCHC(C=O)), 
106.7+ (ArCHCCH), 101.5- (OCH2O), 50.1+ (NCHCH), 40.3+ (NCHCH), 30.1- (CH2), 
29.7- (CH2), 29.2- (CH2) and 19.8- (CH2). MS m/z (ESI+) 246 (39 %, MH
+
) and 268 (8.4 %, 
MNa
+
). HRMS (+ESI) Found MH
+
 246.1118, C14H15NO3 requires MH 246.1130 and found 
MNa
+
 268.0939, C14H14NNaO3 requires MNa 268.0949. IR νmax(liquid film): 3402 (NH), 
2987 (CH) and 1664 (C=O). Rf (100 % EtOAc) 0.5.  
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Synthesis of 6,7,8,8a-tetrahydro-4bH-fluoreno[2,3-d][1,3]dioxol-9(5H)-one oxime 150 
 
NH2OH.HCl (129 mg, 1.85 mmol, 2.5 eq.) was added to a solution of indanone 136 (171 mg, 
0.74 mmol, 1 eq.) dissolved in MeOH-pyridine (2 mL: 2 mL) and the reaction mixture was 
heated at 90 
o
C for 18 hours. The reaction mixture was cooled and concentrated under 
reduced pressure to collect oxime 150 (159 mg, 88 % yield) as a white solid, m.p. 195-197 
o
C. 
1
H NMR (400 MHz; (CD3)2SO): δH 10.80 (1H, br, OH), 7.74 (1H, s, ArCHC(C=N)), 
7.01 (1H, s, ArCHCCH), 6.10 (2H, d, J = 2.5 Hz, OCH2O), 3.12 (1H, q, J = 7.0 Hz, 
(C=N)CHCH), 2.98 (1H, q, J = 6.5 Hz, (C=N)CHCH) and 1.93-1.64 (8H, m, (CH2)4). 
13
C 
NMR (100 MHz; (CD3)2SO): δC 157.7- (C=N), 149.1- (C), 147.1- (C), 145.9- (C), 126.2- 
(C), 108.3+ (ArCHC(C=N)), 104.5+ (ArCHCCH), 101.1- (OCH2O), 42.2- (C=N)CHCH), 
40.3- (C=N)CHCH), 29.5- (CH2), 25.7- (CH2), 22.0- (CH2) and 21.9 (CH2). MS m/z (+ESI) 
246 (100 %, MH
+
) and 268 (13 %, MNa
+
). HRMS (+ESI) Found MNa
+
 268.0935, 
C14H15NNaO3 requires MNa 268.0950. IR νmax(liquid film): 3600 (OH), 2933 (CH) and 1470 
(C=N). 
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7.5.3. Heck Reaction 
Synthesis of 6-(3,4,5-trimethoxyphenyl)cyclohex-1-ene carboxylic acid 157 
 
Method A 
Following a procedure reported by Davidson et al.
133
 but using K2CO3 as a base and 
(PPh3)2PdCl2 as the Pd source, 3,4,5-trimethoxy-5-bromobenzene 156 (494 mg, 2 mmol, 2 
eq.), cyclohexene-1-carboxylic acid (126 mg, 1 mmol, 1 eq.) and K2CO3 (415 mg, 3 mmol, 3 
eq.) in H2O (8 mL) were degassed and placed under an Ar atmosphere. (PPh3)2PdCl2 (70 mg, 
0.1 mmol, 10 mol %) was then added, the reaction mixture was degassed for a second time 
and placed under an Ar atmosphere. The reaction mixture was stirred at 100 
o
C for 24 hours; 
on cooling, the reaction mixture was filtered through a pad of celite and the celite was 
washed with sat. aq. NaHCO3. The aqueous layer was washed with Et2O (3 x 20 mL), which 
was discarded and the aqueous layer was acidified using 6M HCl(aq.). This was then extracted 
with EtOAc (3 x 20 mL), the combined organic layers were washed with brine (20 mL), 
dried on NaSO4 and filtered and the solvent was removed under reduced pressure to collect 
197 mg of crude brown oil. After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 157 (127 mg, 43 % yield) was isolated as a white solid. 
Method B - Optimised Method 
Following a procedure reported by Davidson et al.
133
 but using K2CO3 as a base and 
(PPh3)2PdCl2 as the Pd source, 3,4,5-trimethoxy-5-bromobenzene 156 (494 mg, 2 mmol, 2 
eq.), cyclohexene-1-carboxylic acid (126 mg, 1 mmol, 1 eq.) and K2CO3 (415 mg, 3 mmol, 3 
eq.) in H2O (8 mL) were degassed and placed under an Ar atmosphere. (PPh3)2PdCl2 (70 mg, 
0.1 mmol, 10 mol %) was then added, the reaction mixture was degassed for a second time 
and placed under an Ar atmosphere. The reaction mixture was stirred at 100 
o
C for 24 hours, 
on cooling the reaction mixture was acidified using 6M HCl(aq.) and the water was removed 
under reduced pressure. After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) 
- EtOAc gradient column] 157 (229 mg, 78 % yield) was isolated as a white solid, m.p. 103-
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105 
o
C. 
1
H NMR (400MHz, CDCl3): δH 7.36 (1H, t, J = 3.5 Hz, CH-alkene), 6.31 (2H, s, 
ArC(2)H), 3.84 (1H, m, ArC(1)CH), 3.81 (6H, s, OCH3), 3.80 (3H, s, OCH3), 2.34-2.26 (2H, 
m, CH2), 1.86-1.75 (2H, m, CH2) and 1.53-1.49 (2H, m, CH2). 
13
C NMR (100 MHz, CDCl3): 
δC 172.2- (C=O), 152.9- (ArC(3)), 144.5+ (CH-alkene), 140.4- (ArC(4)), 136.1- (ArC(1)), 
131.1- (C(C=O)), 104.7+ (ArC(2)H), 60.7+ (OCH3), 56.0+ (OCH3), 39.1+ (ArC(1)CH), 
31.2- (CH2), 25.0- (CH2) and 16.7- (CH2). MS m/z (+ESI) 293 (100 %, MH
+
) and 315 (25 %, 
MNa
+
). HRMS (+ESI) Found MNa
+
 315.1213, C16H20NaO5 requires MNa 315.1208. 
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Synthesis of 6-(3,4-dimethoxyphenyl)cyclohexene-1-carboxylic acid 160 
 
4-Bromoveratrole 159 (0.29 mL, 2 mmol, 1 eq.), cyclohexene-1-carboxylic acid (126 mg, 1 
mmol, 1 eq.) and K2CO3 (415 mg, 3 mmol, 3 eq.) in H2O (8 mL) were degassed and placed 
under an Ar atmosphere. (PPh3)2PdCl2 (70 mg, 0.1 mmol, 10 mol %) was then added, the 
reaction mixture was degassed for a second time and placed under an Ar atmosphere. The 
reaction mixture was stirred at 100 
o
C for 24 hours, on cooling the reaction mixture was 
acidified using 6M HCl(aq.) and the water removed under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 160 (165 
mg, 63 % yield) was isolated as a white solid, m.p. 108-111 
o
C. 
1
H NMR (400MHz, CDCl3): 
δH 7.33 (1H, t, J = 4.0 Hz, CH-alkene), 6.74 (1H, d, J = 8.0 Hz, ArC(5)H), 6.67 (1H, d, J = 
2.0 Hz, ArC(2)H), 6.61 (1H, dd, J = 8.0, 2.0 Hz, ArC(6)H), 3.84-3.82 (1H, m, ArC(1)CH), 
3.84 (3H, s, OCH3), 3.82 (3H, s, OCH3), 2.38-2.18 (2H, m, CH2), 1.90-1.72 (2H, m, CH2) 
and 1.53-1.46 (2H, m, CH2). 
13
C NMR (100 MHz, CDCl3): δC 172.0- (C=O), 148.8- 
(ArC(3)), 147.3- (ArC(4)), 143.9+ (CH-alkene), 137.3- (ArC(1)), 131.3- (C(C=O)), 119.5+ 
(ArC(6)H), 111.3+ (ArC(2)H), 110.8+ (ArC(5)H), 55.8+ (OCH3), 55.8+ (OCH3), 38.5+ 
(ArC(1)CH), 31.2- (CH2), 26.0- (CH2) and 16.6- (CH2). MS m/z (+ESI) 263 (18 %, MH
+
). 
HRMS (+ESI) Found MH
+ 
263.1279, C15H19O4 requires MH 263.1283. IR νmax(liquid film): 
2950 (OH), 1687 (C=O) and 1515 (C=C). 
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Synthesis of 6-(benzo[d][1,3]dioxol-5-yl)cyclohexene-1-carboxylic acid 162 
 
5-Bromo-1,3-benzodioxole 161 (0.24 mL, 2 mmol, 1 eq.), cyclohexene-1-carboxylic acid 
(126 mg, 1 mmol, 1 eq.) and K2CO3 (415 mg, 3 mmol, 3 eq.) in H2O (8 mL) were degassed 
and placed under an Ar atmosphere. (PPh3)2PdCl2 (70 mg, 0.1 mmol, 10 mol%) was then 
added, the reaction mixture was degassed for a second time and placed under an Ar 
atmosphere. The reaction mixture was stirred at 100 
o
C for 24 hours; on cooling, the reaction 
mixture was acidified using 6M HCl(aq.) and the water was removed under reduced pressure. 
After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient 
column], 162 (99 mg, 40 % yield) was isolated as a white solid, m.p. 163-166 
o
C. 
1
H NMR 
(400MHz, CDCl3): δH 7.33 (1H, t, J = 3.5 Hz, CH-alkene), 6.70 (1H, d, J = 8.0 Hz, 
ArC(5)H), 6.62 (1H, d, J = 2.0 Hz, (ArC(2)H), 6.56 (1H, dd, J = 8.0, 2.0 Hz, ArC(6)H), 5.90 
(2H, s, OCH2O), 3.82 (1H, br.s. ArC(1)CH), 2.37-2.17 (2H, m, CH2) and 1.90-1.46 (4H, m, 
CH2CH2). 
13
C NMR (100 MHz, CDCl3): δC 171.8- (C=O), 147.4- (ArC(3)), 145.8- (ArC(4)), 
144.1+ (CH-alkene), 138.6- (ArC(1)), 131.3- (C(C=O)), 120.6+ (ArC(6)H), 108.3+ 
(ArC(2)H), 107.9+ (ArC(5)H), 100.7- (OCH2O), 38.6+ (ArC(1)CH), 31.2- (CH2), 26.0- 
(CH2) and 16.4- (CH2). MS m/z (+ESI) 247 (20 %, MH
+
) and 269 (100 %, MNa
+
). HRMS 
(+ESI) Found MNa
+
 269.0791, C14H14NaO4 requires MNa 269.0790. 
 - 206 -  
Synthesis of benzyl-(3R,4S,5R)-3,4,5-tri(benzyloxy)cyclohexene-1-carboxylate 163 
 
Following a procedure reported by Evers et al.,
143
 shikimic acid 139 (174 mg, 1 mmol, 1 eq.) 
was dissolved in DMF (3 mL) and cooled to 0 
o
C. NaH (60% in mineral oil) (180 mg, 4.5 
mmol, 4.5 eq.) was added and the mixture was stirred for 30 minutes. Benzyl bromide (0.48 
mL, 4.05 mmol, 4.05 eq.) was added and the reaction mixture stirred at room temperature for 
16 hours. The solvent was removed under reduced pressure, the residue was dissolved in H2O 
(10 mL), extracted with Et2O (10 mL), acidified with 5 % aqueous citric acid and extracted 
with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (10 mL), 
dried on Na2SO4, filtered and concentrated under reduced pressure. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 
compound 163 (78 mg, 15 % yield) was isolated as a colourless oil. 
1
H NMR (400 MHz; 
CDCl3): δH 7.38-7.22 (20H, m, ArCH), 6.97 (1H, s, alkene CH), 5.18 (2H, m, PhCH2), 4.75-
4.66 (2H, m PhCH2), 4.66 (2H, s, PhCH2), 4.60-4.49 (2H, m, PhCH2), 4.35 (1H, s, OCH), 
3.98-3.95 (1H, m, OCH), 3.85-3.82 (1H, m, OCH), 2.77-2.71 (1H, m, CHaHb) and 2.51-2.45 
(1H, m, CHaHb). 
13
C NMR (100 MHz; CDCl3): δC 166.3- (C=O), 138.4- (C), 138.2- (C), 
136.7- (C), 135.9- (C), 130.9- (C), 129.1+ (CH), 128.8+ (CH), 128.5+ (CH), 128.4+ (CH), 
128.3+ (CH), 128.2+ (CH), 128.1+ (CH), 128.0+ (CH), 127.8+ (CH), 127.7+ (CH), 127.7+ 
(CH), 127.7+ (CH), 127.5+ (CH), 74.7+ (OCH), 73.6+ (OCH), 73.2+ (OCH), 72.9- (CH2), 
71.7- (CH2), 71.6- (CH2), 66.4- (CH2) and 60.4- (CH2). IR νmax(liquid film): 2999 (CH) and 
1713 (C=O). MS m/z (+ESI) 557 (12 %, MNa
+
). HRMS (+ESI) Found 557.2284, 
C35H34NaO5 requires MNa 557.2304. Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 
0.8. 
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Synthesis of (3R,4S,5R)-3,4,5-tri(benzyloxy)cyclohex-1-ene carboxylic acid 164 
 
Ester 163 (217 mg, 0.42 mmol, 1 eq.) in EtOH (1.5 mL) was added to 1M NaOH(aq.) (0.5 mL, 
0.50 mmol, 1.2 eq.). The mixture was stirred at room temperature for 1 hour, upon which 
another aliquot of 1M NaOH(aq.) (0.5 mL, 0.5 mmol, 1.2 eq.) was added. Stirring was 
continued for 16 hours, the reaction mixture was diluted with H2O (10 mL) and washed with 
PE (3 x 10 mL) which was then discarded. The aqueous layer was acidified with HCl(aq.) and 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (10 
mL), dried on Na2SO4, filtered and concentrated under reduced pressure to afford 164 (172 
mg, 95 % yield) as a colouress oil. 
1
H NMR (400 MHz; CDCl3): δH 7.38-7.22 (15H, m, 
ArCH), 7.06 (1H, s, alkene CH), 4.75-4.65 (4H, m, PhCH2), 4.58 (1H, d, J = 10.0 Hz, 
PhCHaHb), 4.50 (1H, d, J = 10.0 Hz, PhCHaHb), 4.37 (1H, s, OCH), 3.98-3.95 (1H, m, 
OCH), 3.86-3.84 (1H, m, OCH), 2.72-2.68 (1H, m, CHaHb) and 2.47-2.43 (1H, m, CHaHb). 
13
C NMR (100 MHz; CDCl3): δC 171.4- (C=O), 138.9- (CH), 138.4- (C), 138.1- (C), 128.4- 
(C), 128.4- (CH), 128.3+ (CH), 127.8+ (CH), 127.8+ (CH), 127.7+ (CH), 127.7+ (CH), 
127.7+ (CH), 127.5+ (CH), 127.3+ (CH), 74.8+ (OCH), 73.6+ (OCH), 73.2+ (OCH), 73.0- 
(CH2), 71.7- (CH2), 71.5- (CH2) and 27.3- (CH2). IR νmax(liquid film): 2990 (CH) and 1694 
(C=O). MS m/z (+ESI) 467 (81 %, MNa
+
). HRMS (+ESI) Found MNa
+
 467.1865, 
C28H28NaO5 requires MNa 467.1834 (6.6 ppm). 
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Synthesis of ethyl 6-hydroxycyclohex-1-ene carboxylate 166 and (2E,7E)-diethyl nona-
2,7-dienedioate 167 
 
Following a procedure reported by Iwabuchi et al.
145
 but with triethyl phosphonoacetate, 
6.4M K2CO3(aq.)(1.95 mL, 12.5 mmol, 1 eq.) was added to 25 % aqueous glutaraldehyde (2 
mL, 5 mmol, 1 eq.) in triethyl phosphonoacetate (0.99 mL, 5 mmol, 1 eq.). The reaction 
mixture was left to stir at room temperature for 20 hours. The reaction mixture was diluted 
with H2O (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were 
washed with brine (10 mL), dried on Na2SO4 and filtered and the solvent was removed under 
reduced pressure to collect 1.26 g of colourless oil. After column chromatography [silica, 
light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], compounds 166 (335 mg, 39 % 
yield) and 167 (62 mg, 5 % yield) were isolated as colourless oils. 
Ester 166 
1
H NMR (400 MHz; CDCl3): δH 7.05 (1H, t, J = 4.0 Hz, alkene CH), 4.51-4.49 
(1H, m, CHOH), 4.19 (2H, q, J = 7.0 Hz, OCH2CH3), 3.14 (1H, br.s. OH), 2.27-2.06 (2H, m, 
CH2), 1.83-1.54 (4H, m, CH2CH2) and 1.27 (3H, t, J = 7.0 Hz, OCH2CH3). 
13
C NMR (100 
MHz; CDCl3): δC 167.3- (C=O), 142.7+ (alkene CH), 122.2- (C), 63.4+ (CHOH), 60.5- 
(OCH2CH3), 29.8- (CH2), 26.0- (CH2), 17.5- (CH2) and 14.1+ (OCH2CH3). HRMS (+ESI) 
Found MH
+
 171.1029, C9H15O3 requires MH 171.1021. IR νmax(liquid film): 3600 (OH), 
2949 (CH) and 1701 (C=O). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.4. 
Spectroscopic data are consistent with those reported by Alexakis et al.
190
 
Diester 167 
1
H NMR (400 MHz; CDCl3): δH 6.90 (2H, dt, J = 15.5, 7.0 Hz, CO2CHCHCH2), 
5.80 (2H, dt, J = 15.5, 1.5 Hz, CO2CHCHCH2), 4.15 (4H, q, J = 7.0 Hz, CH3CH2CO2), 2.20 
(4H, qd, J = 7.5, 1.5 Hz, CO2CHCHCH2), 1.61 (2H, quint. J = 7.5 Hz, CH2) and 1.26 (6H, t, 
J = 7.0 Hz, CH3CH2CO2). 
13
C NMR (100 MHz; CDCl3): δC 166.4- (C=O), 147.9+ 
(CO2CHCHCH2), 121.9+ (CO2CHCHCH2), 60.1- (CH3CH2CO2), 31.3- (CO2CHCHCH2), 
26.3- (CH2) and 14.2+ (CH3CH2CO2). MS m/z (+ESI) 241 (12 %, MH
+
) and 263 (100 %, 
MNa
+
). HRMS (+ESI) Found MH
+
 241.1448, C13H21O4 requires MH 241.1440. IR 
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νmax(liquid film): 2975 (CH) and 1718 (C=O). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C)) 0.8.  
 
Synthesis of 6-hydroxycyclohex-1-ene carboxylic acid 168 
 
Following a procedure reported by Bultman et al.,
146
 ester 166 (267 mg, 1.57 mmol, 1 eq.) in 
EtOH (2 mL) was added to 1M NaOH(aq.) (1.88 mL, 1.88 mmol, 1.2 eq.). The mixture was 
stirred at room temperature for 1 hour, upon which another aliquot of 1M NaOH(aq.) (1.88 
mL, 1.88 mmol, 1.2 eq.) was added. Stirring was continued for 16 hours and the reaction 
mixture was diluted with H2O (20 mL) and washed with PE (3 x 10 mL) which were then 
discarded. The aqueous layer was acidified with HCl(aq.) and was extracted with EtOAc (3 x 
20 mL). The combined organic layers were washed with brine (10 mL), dried on Na2SO4, 
filtered and concentrated under reduced pressure to afford 168 (128 mg, 58 % yield) as a 
colourless oil. 
1
H NMR (400 MHz; CDCl3): δH 7.25 (1H, t, J = 4.0 Hz, alkene CH), 4.55 
(1H, t, J = 4.0 Hz, CHOH), 2.35-2.14 (2H, m, CH2) and 1.90-1.77 (4H, m, CH2CH2). 
13
C 
NMR (100 MHz; CDCl3): δC 171.7- (C=O), 146.0+ (alkene CH), 131.5- (C), 63.2+ (CHOH), 
29.8- (CH2), 26.3- (CH2) and 17.2- (CH2). MS m/z (+ESI) 165 (100 %, MNa
+
). HRMS 
(+ESI) Found MNa
+
 165.0533, C7H10NaO3 requires MNa 165.0522 (6.6 ppm). IR νmax(liquid 
film): 3600 (OH), 2951 (OH) and 1696 (C=O). 
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7.5.4. Modified Curtius Rearrangement 
Synthesis of 8-hydroxy-6,7-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one 126 
 
Following a procedure reported by Judd et al.,
93
 diphenylphosphoryl azide (0.65 mL, 3 
mmol, 1 eq.) was added dropwise to a stirred solution of 3-(3,4,5-
trimethoxyphenyl)propanoic acid (721 mg, 3 mmol, 1 eq.) and Et3N (0.42 mL, 3 mmol, 1 
eq.), in anydrous toluene (10 mL) at room temperature under N2. The reaction mixture was 
then heated with stirring at 90
o
C for 90 minutes. Most of the solvent was removed under 
reduced pressure to afford a mobile oil and the flask was cooled to 0
o
C under N2. BF3.Et2O (2 
mL) was added dropwise to the rapidly stirred reaction mixture. The reaction mixture was 
warmed to room temperature and left to stir for 16 hours. The reaction mixture was quenched 
with aq. 1M NaOH (to pH 10) and EtOAc (10 mL) added. The rapidly stirred mixture was 
heated to 50
o
C for 1 hour, dissolving all the crude material. The mixture was cooled to room 
temperature, the layers separated and the aqueous layer was further extracted with EtOAc (2 
x 10 mL). The combined organic layers were washed with brine (10 mL), dried on NaSO4 
and filtered and the solvent was removed to give 1g of the crude product. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 126 (511 
mg, 76 % yield) was isolated as a white solid, m.p. 179-182 
o
C, [lit.
93
 181-183 
o
C]. 
1
H NMR 
(400 MHz, CDCl3): δH 12.38 (1H, s, OH), 6.39 (1H, br. NH), 6.26 (1H, s, ArCH), 3.89 (3H, 
s, OCH3), 3.87 (3H, s, OCH3), 3.53 (2H, dt, J = 2.5 and 6.5 Hz, NHCH2CH2) and 2.91 (2H, t, 
J = 6.5 Hz, NHCH2CH2). 
13
C NMR (100MHz, CDCl3): δC 170.5- (C=O), 156.8- (C), 155.8- 
(C), 135.1- (C), 134.9- (C), 105.7- (C), 101.7+ (ArCH), 60.65+ (OCH3), 55.9+ (OCH3), 40.2- 
(NHCH2CH2) and 28.0- (NHCH2CH2). Spectroscopic data are consistent with those reported 
by Judd et. al.
93
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Synthesis of 7-hydroxy-8,9-dimethoxy-1,2,3,4-tetrahydrophenanthridin-6(5H)-one 170 
and its boron complex 171 
 
Following a procedure reported by Judd et al.,
93
 diphenylphosphoryl azide (0.09 mL, 0.40 
mmol, 1 eq.) was added dropwise to a stirred solution of 157 (118 mg, 0.40 mmol, 1 eq.) and 
Et3N (0.06 mL, 0.40 mmol, 1 eq.), in anydrous toluene (2 mL) at room temperature under N2. 
The reaction mixture was then heated with stirring at 90 
o
C for 90 minutes. Most of the 
solvent was removed under reduced pressure to afford a mobile oil and the flask was cooled 
to 0 
o
C under N2. BF3.Et2O (1 mL) was added dropwise to the rapidly stirred reaction 
mixture. The reaction mixture was warmed to room temperature and left to stir for 16 hours. 
The reaction mixture was quenched with aq. 1M NaOH (to pH 10) and EtOAc (10 mL) was 
added. The rapidly stirred mixture was heated to 50 
o
C for 1 hour, dissolving all the crude 
material. The mixture was cooled to room temperature, the layers were separated and the 
aqueous fraction was further extracted with EtOAc (2 x 10 mL). The combined organic 
layers were washed with brine (10 mL), dried on NaSO4 and filtered and the solvent was 
removed to give 248 mg of the crude product. After column chromatography [silica, light 
petroleum (b.p. 40-60 
o
C) EtOAc gradient column], 170 (23 mg, 21 % yield) and 171 (50 mg, 
39 % yield) were isolated as white solids. 
Lactam Product 170 m.p. >220 
o
C. 
1
H NMR (400 MHz, CDCl3): δH 12.96 (1H, br.s. NH), 
10.63 (1H, br.s. OH), 6.43 (1H, s, ArCH), 3.96 (3H, s, OCH3), 3.93 (3H, s, OCH3), 2.64-2.57 
(4H, m, allylic-CH2) and 1.87-1.85 (4H, m, (CH2)2). 
13
C NMR (100MHz, CDCl3): δC 165.6- 
(C=O), 158.2- (C), 154.5- (C), 135.9- (C),  134.4- (C), 133.8- (C), 111.2- (C), 106.0- (C), 
93.8+.(ArCH), 60.6+ (OCH3), 55.8+ (OCH3), 27.0- (CH2), 23.3- (CH2), 22.4- (CH2) and 
21.8- (CH2). MS m/z (+ESI) 276 (100 %, MH
+
) and 298 (38 %, MNa
+
). HRMS (+ESI) 
Found MNa
+
 298.1051, C15H17NNaO4 requires MNa 298.1055. IR νmax(liquid film): 3400 
(OH, NH), 2990 (CH) and 1649 (C=O). Rf (100 % EtOAc) 0.5.  
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Boron complex
93
 171 
1
H NMR (400 MHz, CDCl3): δH 13.47 (1H, br.s. NH), 6.65 (1H, s, 
ArCH), 3.89 (3H, s, OCH3), 3.67 (3H, s, OCH3), 2.63 (2H, br.s. allylic-CH2), 2.62 (2H, br.s. 
allylic-CH2) and 1.72 (4H, br.s. (CH2)2).  
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Synthesis of 7-hydroxy-8,9-dimethoxy-1,2,3,4-tetrahydrophenanthridin-6(5H)-one 170 
 
Following a procedure reported by Judd et al.,
93
 diphenylphosphoryl azide (0.17 mL, 0.81 
mmol, 1 eq.) was added dropwise to a stirred solution of 157 (238 mg, 0.81 mmol, 1 eq.) and 
Et3N (0.11 mL, 0.81 mmol, 1 eqin anhydrous toluene (4 mL) at room temperature under N2. 
The reaction mixture was then heated with stirring at 90 
o
C for 90 minutes. Most of the 
solvent was removed under reduced pressure to afford a mobile oil and the flask was cooled 
to 0 
o
C under N2. BF3.Et2O (2 mL) was added dropwise to the rapidly stirred reaction 
mixture. The reaction mixture was warmed to room temperature and left to stir for 16 hours. 
The reaction mixture was quenched with aq. 1M NaOH (to pH 10) and EtOAc (10 mL) was 
added. The rapidly stirred mixture was heated to 60 
o
C for 4 hours, dissolving all the crude 
material. The mixture was cooled to room temperature, the layers were separated and the 
aqueous fraction was further extracted with EtOAc (2 x 10 mL). The combined organic 
layers were washed with brine (10 mL), dried on NaSO4 and filtered and the solvent was 
removed to give 248 mg of the crude product. After column chromatography [silica, light 
petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 170 (146 mg, 65 % yield) was isolated 
as a white solid. Data consistent to that previously reported for lactam 170 (page 211). 
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7.6. Indanocine chapter  
 
General Procedure 11, Methylation Reaction 
Following the procedure reported by Judd et al.,
93
 MeI (2.4 eq.) was added to a rapidly 
stirred mixture of KOH (2.9 eq.) and the desired indole (1 eq.) in acetone (10 mL/  1 mmol). 
After 18 hours at room temperature, the acetone was removed under reduced pressure. H2O 
was added to the residue followed by acidification to pH 1 with 6M HCl(aq.). The aqueous 
layer was extracted with CH2Cl2 and the combined organic layers were washed with brine, 
dried on Na2SO4, filtered and concentrated under reduced pressure to afford the desired 
methylated product.  
 
Synthesis of 4-methyl-1,2-dihydrocyclopenta[b]indol-3(4H)-one 174 
 
Following General Procedure 11,
93
 using cyclic ketone 98 on a 6.37 mmol scale, 
methylated compound 174 (1.12 g, 95 % yield) was isolated as a beige solid, m.p. 138-142 
o
C [lit.
191
 135.1-136.1 
o
C]. 
1
H NMR (400 MHz; CDCl3): δH 7.69 (1H, dt, J = 8.0, 1.0 Hz, 
ArCH), 7.41 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.36 (1H, dt, J = 8.5, 1.0 Hz, ArCH), 
7.17 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 3.91 (3H, s, NCH3), 3.07-3.05 (2H, m, 
(CO)CH2CH2) and 2.99-2.97 (2H, m, (CO)CH2CH2). 
13
C NMR (100 MHz; CDCl3): δC 
194.8- (C=O), 145.0- (C), 144.8- (C), 138.9- (C), 126.8+ (ArCH), 123.1- (C), 121.7+ 
(ArCH), 120.2+ (ArCH), 110.9+ (ArCH), 41.5- ((CO)CH2CH2), 30.0+ (NCH3) and 19.6- 
((CO)CH2CH2). MS m/z (+ESI) 186 (100 %, MH
+
). HRMS (+ESI) Found MH
+
 186.0914, 
C12H12NO requires MH 186.0919 and found MNa
+
 208.0736, C12H11NNaO requires MNa 
208.0738. IR νmax(liquid film): 3033 (CH), 1681 (C=O). Rf (30 % EtOAc in light petroleum 
(b.p. 40-60 
o
C) 0.4. Spectroscopic data are consistent with those reported by Maertens et al.
92
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Synthesis of 9-methyl-2,3,4,9-tetrahydro-1H-carbazol-1-one 175 
 
Following General Procedure 11,
93
 using cyclic ketone 96 on a 1.95 mmol scale, 
methylated compound 175 (358 mg, 92 % yield) was isolated as a beige solid, m.p. 96-99 
o
C 
[lit.
192
 100-101 
o
C]. 
1
H NMR (400 MHz; CDCl3): δH 7.69 (1H, dt, J = 8.0, 1.0 Hz, ArCH), 
7.44 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.38 (1H, dt, J = 8.5, 1.0 Hz, ArCH), 7.18 (1H, 
ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 4.11 (3H, s, NCH3), 3.06 (2H, t, J = 6.0 Hz, 
(CO)CH2CH2CH2), 2.69 (2H, t, J = 6.0 Hz, (CO)CH2CH2CH2) and 2.26 (2H, quint, J = 6.0 
Hz, (CO)CH2CH2CH2). 
13
C NMR (100 MHz; CDCl3): δC 192.3- (C=O), 139.7- (C), 130.5- 
(C), 129.2- (C), 126.7+ (ArCH), 124.8- (C), 121.3+ (ArCH), 120.0+ (ArCH), 110.3+ 
(ArCH), 40.0- ((CO)CH2CH2CH2), 31.5+ (NCH3), 24.8- ((CO)CH2CH2CH2) and 21.9- 
((CO)CH2CH2CH2). MS m/z (+ESI) 200 (100 %, MH
+
) and 222 (29 %, MNa
+
). HRMS 
(+ESI) Found MH
+
 200.1068, C13H14NO requires MH 200.1075 and found MNa
+
 222.0886, 
C13H13NNaO requires MNa 222.0894. IR νmax(liquid film): 3031 (CH) and 1662 (C=O). Rf 
(30 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.8. Spectroscopic data are consistent with 
those reported by Maertens et al.
92
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Synthesis of (E)-2-(3,5-dimethylbenzylidene)-1,2-dihydrocyclopenta[b]indol-3(4H)-one 
176 
 
A mixture of ketone 98 (171 mg, 1 mmol, 1 eq.) and 3,5-dimethylbenzaldehyde (0.15 mL, 
1.1 mmol, 1.1 eq.) were treated with 4 % (w/v) ethanolic KOH (10 mL) and stirred at room 
temperature for 16 hours.
159
 The mixture was cooled in an ice-bath and the solid was filtered 
and washed with EtOH: H2O (10 mL: 10 mL). H2O (20 mL) was added to the filtrate which 
was then neutralised using AcOH, followed by a second filtration. The solid was again 
washed with EtOH: H2O (10 mL: 10 mL) to collect 176 (206 mg, 71 % yield) as a yellow 
solid, m.p. 288-292 
o
C. 
1
H NMR (400 MHz; (CD3)2SO): δH 11.90 (1H, br.s, NH), 7.80 (1H, 
d, J = 8.0 Hz, ArCH), 7.45 (1H, d, J = 8.5 Hz, ArCH), 7.37-7.33 (3H, m, ArCH and Ar’CH), 
7.29 (1H, br.s, alkene CH), 7.14 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.05 (1H, s, Ar’CH), 
4.04 (2H, s, CH2) and 2.33 (6H, s, Ar’CH3). 
13
C NMR (100 MHz; (CD3)2SO): δC 181.8- 
(CO), 143.5- (C), 140.5- (C), 139.9- (C), 139.6- (C), 138.0- (C), 134.9- (C), 130.8+ (alkene 
CH), 130.8+ (Ar’CH), 128.1+ (ArCH or Ar’CH), 126.8+ (Ar’CH or ArCH), 122.7- (C), 
121.7+ (ArCH), 120.3+ (ArCH), 113.6+ (ArCH), 26.3- (CH2) and 20.9+ (Ar’CH3). MS m/z 
(+ESI) 288 (100 %, MH
+
) and 310 (14 %, MNa
+
). HRMS (+ESI) Found MH
+
 288.1369, 
C20H18NO requires MH 288.1388 and found MNa
+
 310.1190, C20H17NNaO requires MNa 
310.1208. IR νmax(liquid film): 3464 (NH), 3028 (CH), 1678 (C=O) and 1627 (C=C). Rf (30 
% EtOAc in light petroleum (b.p. 40-60 
o
C) 0.5. Analysis (Found: H, 5.92; N, 4.86. 
C20H17NO requires H, 5.96; N, 4.87 %). 
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Synthesis of (E)-2-(4-hydroxy-3,5-dimethylbenzylidene)-1,2-dihydrocyclopenta[b] indol-
3(4H)-one 177 
 
Ketone 98 (128 mg, 0.75 mmol, 1 eq.) and 3,5-dimethyl-4-hydroxybenzaldehyde (123 mg, 
0.82 mmol, 1.1 eq.) were dissolved in 2-methoxyethanol (1 mL), followed by the addition of 
>99 % aqueous KOH solution (0.5 mL). The reaction mixture was heated at 120 
o
C for 20 
hours. The mixture was cooled in an ice bath and the solid was filtered and washed with 
EtOH: H2O (10 mL: 10 mL). H2O (15 mL) was added to the filtrate which was then 
neutralised using AcOH, followed by a second filtration. The solid was again washed with 
EtOH: H2O (10mL: 10mL) to collect 177 (139 mg, 61 % yield) as a yellow solid, m.p. > 330 
o
C. 
1
H NMR (400 MHz; (CD3)2SO): δH 11.80 (1H, br.s, NH), 8.78 (1H, br.s, OH), 7.79 (1H, 
d, J = 8.0 Hz, ArCH), 7.44 (1H, d, J = 8.5 Hz, ArCH), 7.35-7.32 (3H, m, Ar’CH and ArCH), 
7.22 (1H, br.s, alkene CH), 7.13 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 3.97 (2H, s, CH2) and 
2.22 (6H, s, Ar’CH3). 
13
C NMR (100 MHz; (CD3)2SO): δC 182.1- (CO), 155.0- (C), 143.3- 
(C), 140.8- (C), 138.8- (C), 136.7- (C), 131.2+ (alkene CH), 131.0+ (Ar’CH), 126.5+ 
(ArCH), 126.1- (C), 124.7- (C), 121.5+ (ArCH), 120.2+ (ArCH), 113.6+ (ArCH), 26.3- 
(CH2) and 16.6+ (Ar’CH3). MS m/z (+ESI) 304 (100 %, MH
+
) and 326 (11 %, MNa
+
). 
HRMS (+ESI) Found MH
+
 304.1334, C20H18NO2 requires MH 304.1338 and found MNa
+
 
326.1170, C20H17NNaO2 requires MNa 326.1157. IR νmax(liquid film): 3605 (OH), 3463 
(NH), 3036 (CH), 1677 (C=O) and 1601 (C=C). Rf (30 % EtOAc in light petroleum (b.p. 40-
60 
o
C) 0.2.  
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Synthesis of (E)-2-(3,5-dimethoxybenzylidene)-1,2-dihydrocyclopenta[b]indol-3(4H)-one 
178 
 
A mixture of ketone 98 (171 mg, 1 mmol, 1eq.) and 3,5-dimethoxybenzaldehyde (183 mg, 
1.1 mmol, 1.1 eq.) were treated with 4 % (w/v) ethanolic KOH (10 mL) and stirred at room 
temperature for 16 hours.
159
 The mixture was cooled in an ice-bath and the solid was filtered 
and washed with EtOH: H2O (10 mL: 10 mL). H2O (15 mL) was added to the filtrate which 
was then neutralised using AcOH, followed by a second filtration. The solid was again 
washed with EtOH: H2O (10 mL: 10 mL) to collect 178 (232 mg, 72 % yield) as a yellow 
solid, m.p. >220 
o
C. 
1
H NMR (400 MHz; (CD3)2SO): δH 11.86 (1H, br.s, NH), 7.80 (1H, d, J 
= 8.0 Hz, ArCH), 7.45 (1H, d, J = 8.5 Hz, ArCH), 7.36 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 
7.30 (1H, m, alkene CH), 7.14 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 6.90 (2H, d, J = 2.0 Hz, 
Ar’CH), 6.57 (1H, t, J = 2.0 Hz, Ar’CH), 4.03 (2H, d, J = 1.5 Hz, CH2) and 3.81 (6H, s, 
Ar’OCH3). 
13
C NMR (100 MHz; (CD3)2SO): δC 181.7- (CO), 160.7- (C), 143.5- (C), 140.7- 
(C), 140.4- (C), 139.8- (C), 136.8- (C), 130.6+ (alkene CH), 126.9+ (ArCH), 122.6- (C), 
121.8+ (ArCH), 120.3+ (ArCH), 113.6+ (ArCH), 108.3+ (Ar’CH), 101.3+ (Ar’CH), 55.4+ 
(Ar’OCH3) and 26.2- (CH2). MS m/z (+ESI) 320 (100 %, MH
+
) and 342 (9 %, MNa
+
). 
HRMS (+ESI) Found MH
+
 320.1281, C20H18NO3 requires MH 320.1287. IR νmax(liquid 
film): 3464 (NH), 3026 (CH), 1674 (C=O) and 1624 (C=C). Rf (30 % EtOAc in light 
petroleum (b.p. 40-60 
o
C) 0.3. 
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Synthesis of (E)-2-(3,5-dimethoxybenzylidene)-1,2-dihydrocyclopenta[b]indol-3(4H)-one 
179 
 
Ketone 98 (171 mg, 1 mmol, 1 eq.) and 3,5-dimethoxy-4-hydroxybenzaldehyde (200 mg, 1.1 
mmol, 1.1 eq.) were dissolved in 2-methoxyethanol (1 mL), followed by the addition of >99 
% aqueous KOH solution (0.5 mL). The reaction mixture was heated at 120 
o
C for 20 hours. 
The mixture was cooled in an ice-bath and the solid was filtered and washed with EtOH: H2O 
(10 mL: 10 mL). H2O (15 mL) was added to the filtrate which was then neutralised using 
AcOH, followed by a second filtration. The solid was again washed with EtOH: H2O (10 mL: 
10 mL) to collect 179 (182 mg, 54 % yield) as a yellow solid, m.p. 237-239 
o
C. 
1
H NMR 
(400 MHz; (CD3)2SO): δH 11.86 (1H, br.s. NH), 8.94 (1H, s, OH), 7.80 (1H, d, J = 8.0 Hz, 
ArCH), 7.55 (1H, d, J = 8.5 Hz, ArCH), 7.40 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.29 
(1H, br.s, alkene CH), 7.17 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.02 (2H, s, Ar’CH), 4.03 
(2H, s, CH2) and 3.85 (6H, s, Ar’OCH3). 
13
C NMR (100 MHz; (CD3)2SO): δC 182.0- (C=O), 
148.1- (C), 143.3- (C), 140.7- (C), 139.0- (C), 137.7- (C), 137.3- (C), 131.6+ (alkene CH), 
126.6+ (ArCH), 125.4- (C), 122.7- (C), 121.6+ (ArCH), 120.2+ (ArCH), 113.6+ (ArCH), 
108.5+ (Ar’CH), 56.2+ (Ar’OCH3) and 26.1- (CH2). MS m/z (+ESI) 350 (100 %, MH
+
) and 
372 (12 %, MNa
+
). HRMS (+ESI) Found MH
+
 350.1376, C21H20NO4 requires MH 350.1392 
and found MNa
+
 372.1189, C21H19NNaO4 requires MNa 372.1212. IR νmax(liquid film): 3529 
(OH), 3011 (CH), 1673 (C=O) and 1624 (C=C). Rf (70 % EtOAc in light petroleum (b.p. 40-
60 
o
C) 0.6. 
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Synthesis of (E)-2-(3,5-dimethylbenzylidene)-4-methyl-1,2-dihydrocyclopenta[b] indol-
3(4H)-one 180 
 
A mixture of ketone 174 (185 mg, 1 mmol, 1 eq.) and 3,5-dimethylbenzaldehyde (0.15 mL, 
1.1 mmol, 1.1 eq.) were treated with 4 % (w/v) ethanolic KOH (10 mL) and stirred at room 
temperature for 16 hours.
159
 The mixture was cooled in an ice-bath and the solid was filtered 
and washed with EtOH: H2O (10 mL: 10 mL). H2O (20 mL) was added to the filtrate which 
was then neutralised using AcOH, followed by a second filtration. The solid was again 
washed with EtOH: H2O (10 mL: 10 mL) to collect 180 (135 mg, 45 % yield) as a yellow 
solid, m.p. 174-177 
o
C. 
1
H NMR (400 MHz; (CD3)2SO): δH 7.76 (1H, dt, J = 8.0, 1.0 Hz, 
ArCH), 7.47 (1H, t, J = 1.5 Hz, alkene CH), 7.42 (1H, ddd, J = 8.5, 6.5, 1.0 Hz, ArCH), 7.38 
(1H, dt, J = 8.5, 1.0 Hz, ArCH), 7.28 (2H, s, Ar’CH), 7.20 (1H, ddd, J = 8.0, 6.5, 1.0 Hz, 
ArCH), 7.02 (1H, s, Ar’CH), 4.00 (3H, s, NCH3), 3.95 (2H, d, J = 1.5 Hz, CH2) and 2.39 
(6H, s, Ar’CH3). 
13
C NMR (100 MHz; (CD3)2SO): δC 183.4- (C=O), 144.6- (C), 140.9- (C), 
139.8- (C), 138.6- (C), 138.3- (C), 135.5- (C), 132.0+ (alkene CH), 131.0+ (Ar’CH), 128.3+ 
(Ar’CH), 126.8+ (ArCH), 123.0- (C), 121.9+ (ArCH), 120.5+ (ArCH), 111.0+ (ArCH), 
30.3+ (NCH3), 26.5- (CH2) and 21.4+ (Ar’CH3). MS m/z (+ESI) 302 (100 %, MH
+
). HRMS 
(+ESI) Found MH
+
 302.1535, C21H20NO requires MH 302.1545 and found MNa
+
 324.1353, 
C21H19NNaO requires MNa 324.1364. IR νmax(liquid film): 3029 (CH), 1678 (C=O) and 
1628 (C=C). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.8. Analysis (Found: H, 
6.47; N, 4.29. C21H19NO requires H, 6.35; N, 4.65 %). 
 
 
 - 221 -  
Synthesis of (E)-2-(4-hydroxy-3,5-dimethylbenzylidene)-4-methyl-1,2-dihydrocyclo- 
penta[b]indol-3(4H)-one 181 
 
Ketone 174 (226 mg, 1.22 mmol, 1 eq.) and 3,5-dimethyl-4-hydroxybenzaldehyde (201 mg, 
1.34 mmol, 1.1 eq.) were dissolved in 2-methoxyethanol (1.2 mL), followed by the addition 
of >99 % aqueous KOH solution (0.6 mL). The reaction mixture was heated at 120 
o
C for 20 
hours. The mixture was cooled, H2O (10 mL) was added and the mixture was neutralised 
using AcOH. The product was extracted using CHCl3 (3 x 20 mL), the combined organic 
layers were washed with brine (20 mL), dried on Na2SO4, filtered and concentrated under 
reduced pressure. After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - 
EtOAc gradient column], product 181 (13 mg, 3 % yield) was isolated as yellow crystals, 
m.p. 221-224 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 7.77 (1H, dt, J = 8.0, 1.0 Hz, ArCH), 
7.42-7.40 (3H, m, alkene CH, ArCH, ArCH), 7.34 (2H, s, Ar’CH), 7.20 (1H, ddd, J = 8.0, 
6.5, 1.0 Hz, ArCH), 4.86 (1H, s, OH), 4.02 (3H, s, NCH3), 3.95 (2H, d, J = 1.5 Hz, CH2) and 
2.32 (6H, s, Ar’CH3). MS m/z (+ESI) 318 (100 %, MH
+
) and 340 (34 %. MNa
+
). HRMS 
Found MH
+
 318.1499, C21H20NO2 requires MH 318.1494. IR νmax(liquid film): 3387 (OH), 
3022 (CH), 1671 (C=O) and 1600 (C=C). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C) 
0.5. 
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Synthesis of (E)-2-(3,5-dimethoxybenzylidene)-4-methyl-1,2-dihydrocyclopenta[b] 
indol-3(4H)-one 182 
 
A mixture of ketone 174 (185 mg, 1 mmol, 1 eq.) and 3,5-dimethoxybenzaldehyde (183 mg, 
1.1 mmol, 1.1 eq.) were treated with 4 % (w/v) ethanolic KOH (10 mL) and stirred at room 
temperature for 17 hours.
159
 The mixture was cooled in an ice-bath and the solid was filtered 
and washed with EtOH: H2O (10 mL: 10 mL). H2O (15 mL) was added to the filtrate which 
was then neutralised using AcOH, followed by a second filtration. The solid was again 
washed with EtOH: H2O (10 mL: 10 mL) to collect 301 mg of crude product. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], product 
182 (40 mg, 12 % yield) was isolated as a yellow solid, m.p. 178-180 
o
C. 
1
H NMR (400 
MHz; CDCl3): δH 7.73 (1H, dt, J = 8.0, 1.0 Hz, ArCH), 7.44-7.37 (3H, m, ArCH and alkene 
CH), 7.20 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 6.81 (2H, d, J = 2.0 Hz, Ar’CH), 6.51 (1H, 
t, J = 2.0 Hz, Ar’CH), 4.01 (3H, s, NCH3), 3.97 (2H, d, J = 1.5 Hz, CH2) and 3.86 (6H, s, 
Ar’OCH3). 
13
C NMR (100 MHz; CDCl3): δC 183.1- (C=O), 161.0- (C), 144.7- (C), 140.8- 
(C), 140.7- (C), 138.7- (C), 137.3- (C), 131.6+ (alkene CH), 127.0+ (ArCH), 122.9- (C), 
121.9+ (ArCH), 120.6+ (ArCH), 111.0+ (ArCH), 108.5+ (Ar’CH), 101.2+ (Ar’CH), 55.5+ 
(Ar’OCH3), 30.3 (NCH3) and 26.4- (CH2). MS m/z (+ESI) 334 (100 %, MH
+
) and 356 (8 %, 
MNa
+
). HRMS (+ESI) Found MH
+
 334.1445, C21H20NO3 requires MH 334.1443 and found 
MNa
+
 356.1270, C21H19NNaO3 requires MNa 356.1263. IR νmax(liquid film): 3014 (CH), 
1677 (C=O) and 1592 (C=C). Rf (40 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.4 
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Synthesis of (E)-2-(4-hydroxy-3,5-dimethoxybenzylidene)-4-methyl-1,2-dihydro-
cyclopenta[b] indol-3(4H)-one 183 
 
Ketone 174 (185 mg, 1 mmol, 1 eq.) and 3,5-dimethoxy-4-hydroxybenzaldehyde (200 mg, 
1.1 mmol, 1.1 eq.) were dissolved in 2-methoxyethanol (1 mL), followed by the addition of 
>99 % aqueous KOH solution (0.5 mL). The reaction mixture was heated at 120 
o
C for 20 
hours. The mixture was cooled in an ice-bath and the solid filtered and washed with EtOH: 
H2O (10 mL: 10 mL). H2O (15 mL) was added to the filtrate which was then neutralised 
using AcOH, followed by a second filtration. The solid was again washed with EtOH: H2O 
(10 mL: 10 mL) to collect 183 (171 mg, 49 % yield) as a yellow solid, m.p. 191-194 
o
C. 
1
H 
NMR (400 MHz; (CD3)2SO): δH 8.97 (1H, br.s. OH), 7.80 (1H, d, J = 8.0 Hz, ArCH), 7.55 
(1H, d, J = 8.0 Hz, ArCH), 7.40 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.29 (1H, br.s, alkene 
CH), 7.17 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.02 (2H, s, Ar’CH), 4.00 (2H, s, CH2), 3.91 
(3H, s, NCH3) and 3.85 (6H, s, Ar’OCH3). 
13
C NMR (100 MHz; (CD3)2SO): δC 182.3- 
(C=O), 148.1- (C), 144.1- (C), 140.2- (C), 137.8- (C), 137.8- (C), 137.3- (C), 131.7+ (alkene 
CH), 126.6+ (ArCH), 125.2- (C), 122.3- (C), 121.8+ (ArCH), 120.3+ (ArCH), 111.5+ 
(ArCH), 108.5+ (Ar’CH), 56.2+ (Ar’OCH3), 30.0 (NCH3) and 25.8- (CH2). MS m/z (+ESI) 
336 (100 %, MH
+
) and 358 (12 %, MNa
+
). HRMS (+ESI) Found MH
+
 336.1228, C20H18NO4 
requires MH 336.1236 and found MNa
+
 358.1050, C20H17NNaO4 requires MNa 358.1055. IR 
νmax(liquid film): 3690 (OH), 3464 (NH), 1677 (C=O) and 1627 (C=C). 
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Synthesis of (3,5-dimethoxyphenyl)methanol 184 
 
Ketone 98 (255 mg, 1.49 mmol, 1 eq.) and LiOH.H2O (188 mg, 4.48 mmol, 3 eq.) in EtOH 
(2 mL) were stirred for 10 minutes, followed by the addition of 3,5-dimethoxybenzaldehyde 
(494 mg, 2.97 mmol, 2 eq.). The reaction mixture was stirred at 30 
o
C for 26 hours and the 
solvent was removed under reduced pressure. After column chromatography [silica, light 
petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], product 184 (84 mg, 17 % yield) was 
isolated as a pale yellow solid, m.p. 45-48 
o
C [lit.
193
 46-48 
o
C]. 
1
H NMR (CDCl3, 400 MHz): 
δH 6.56 (2H, d, J = 2.5 Hz, ArCH), 6.42 (1H, t, J = 2.5 Hz, ArCH), 4.67 (2H, s, CH2), 3.83 
(6H, s, OCH3) and 1.80 (1H, m, OH). 
13
C NMR (100 MHz; CDCl3): δC 161.1- (C), 143.4- 
(C), 104.6+ (ArCH), 99.7+ (ArCH), 65.4- (CH2) and 55.4+ (OCH3). Spectroscopic data are 
consistent with those reported by Lesch et al.
194
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Synthesis of (E)-2-(4-methoxybenzylidene)-1,2-dihydrocyclopenta[b]indol-3(4h)-one 185 
 
A mixture of ketone 98 (171 mg, 1 mmol, 1 eq.) and 4-methoxybenzaldehyde (0.12 mL, 1 
mmol, 1 eq.) were treated with 4 % (w/v) ethanolic KOH (10 mL) and stirred at room 
temperature for 17 hours.
159
 The mixture was cooled in an ice-bath and the solid was filtered 
and washed with EtOH: H2O (10 mL: 10 mL). H2O (20 mL) was added to the filtrate which 
was then neutralised using AcOH, followed by a second filtration. The solid was again 
washed with EtOH: H2O (10 mL: 10 mL) to collect 185 (181 mg, 62 % yield) as a yellow 
solid, m.p. 278-281 
o
C [lit.
195
 262 
o
C]. 
1
H NMR (400 MHz; (CD3)2SO): δH 11.84 (1H, br.s, 
NH), 7.76 (1H, d, J = 8.0 Hz, ArCH), 7.70 (2H, d, J = 8.5 Hz, Ar’CH), 7.45 (1H, d, J = 8.5 
Hz, ArCH), 7.34 (1H, t, J = 7.0 Hz, ArCH), 7.33 (1H, br.s, alkene CH), 7.14 (1H, t, J = 7.5 
Hz, ArCH), 7.03 (2H, d, J = 8.5 Hz, Ar’CH), 3.99 (2H, s, CH2) and 3.81 (3H, s, Ar’OCH3). 
13
C NMR (100 MHz; (CD3)2SO): δC 182.0- (C=O), 160.2- (C), 143.4- (C), 140.7- (C), 139.1- 
(C), 137.8- (C), 132.1+ (Ar’CH), 130.4+ (alkene CH), 127.6- (C), 126.6+ (ArCH), 122.7- 
(C), 121.5+ (ArCH), 120.2+ (ArCH), 114.5+ (Ar’CH), 113.6+ (ArCH), 55.3+ (Ar’OCH3) 
and 26.3- (CH2). MS m/z (+ESI) 290 (100 %, MH
+
) and 312 (6 %, MNa
+
). HRMS (+ESI) 
Found MH
+
 290.1184, C19H16NO2 requires MH 290.1181 and found MNa
+
 312.1000, 
C19H15NNaO2 requires MNa 312.1000. IR νmax(liquid film): 3464 (NH), 3024 (CH), 1673 
(C=O) and 1602 (C=C). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.3. Analysis 
(Found: H, 4.90; N, 4.60. C19H15NO2 requires H, 5.23; N, 4.84 %). 
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Synthesis of (E)-2-(3,5-dimethyl benzylidene)-2,3,4,9-tetrahydro-1H-carbazol-1-one 186 
 
Following a procedure reported by Chakraborti et al.
156
 ketone 96 (203 mg, 1.1 mmol, 1 eq.) 
and LiOH.H2O (51 mg, 1.21 mmol, 1.1 eq.) in EtOH (3 mL) were stirred for 10 minutes, 
followed by the addition of 3,5-dimethylbenzaldehyde (0.15 mL, 1.1 mmol, 1.1 eq.). The 
reaction mixture was stirred at 30 
o
C for 21 hours. The solvent was removed under reduced 
pressure and the yellow residue was diluted with H2O (10 mL) and EtOAc (10 mL). The 
mixture was neutralised with 6M HCl(aq.) followed by extraction with EtOAc (2 x 10 mL). 
The combined organic layers were washed with brine (10 mL), dried on Na2SO4, filtered and 
concentrated under reduced pressure. After column chromatography [silica, light petroleum 
(b.p. 40-60 
o
C) - EtOAc gradient column], product 186 (95 mg, 32 % yield) was isolated as a 
pale yellow solid, m.p. 209-211 
o
C (recrystallised from EtOAc). 
1
H NMR (400 MHz; 
CDCl3): δH 9.21 (1H, br.s, NH), 7.80 (1H, br.s, alkene CH), 7.70 (1H, dd, J = 8.0, 1.0 Hz, 
ArCH), 7.48 (1H, dt, J = 8.5, 1.0 Hz, ArCH), 7.41 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 
7.20 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.11 (2H, s, Ar’CH), 7.04 (1H, s, Ar’CH), 3.30 
(2H, td, J = 6.5, 1.5 Hz, CH2CH2C=CH), 3.11 (2H, t, J = 6.5 Hz, CH2CH2C=CH), 2.41 (6H, 
s, Ar’CH3). 
13
C NMR (100 MHz; CDCl3): δC 181.1- (C=O), 138.6- (C), 138.0- (C), 136.1- 
(C), 136.0- (C), 135.7+ (alkene CH), 132.4- (C), 130.1+ (Ar’CH), 128.3- (C), 127.6+ 
(Ar’CH), 127.2+ (ArCH), 126.0- (C), 121.4+ (ArCH), 120.5+ (ArCH), 112.5+ (ArCH), 27.7- 
(CH2CH2C=CH), 21.4+ (Ar’CH3) 20.9- (CH2CH2C=CH). MS m/z (+ESI) 302 (100 %, MH
+
) 
and 324 (32 %, MNa
+
). HRMS (+ESI)  Found MH
+
, 302.1546, C21H20NO requires MH 
302.1545 and found MNa
+
 324.1363, C21H19NNaO requires MNa 324.1364. IR νmax(liquid 
film): 3460 (NH), 3046 (CH), 1651 (C=O) and 1601 (C=C). Rf (30 % EtOAc in light 
petroleum (b.p. 40-60 
o
C) 0.8.  
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Synthesis of (E)-2-(4-hydroxy-3,5-dimethylbenzylidene)-2,3,4,9-tetrahydro-1H-
carbazol-1-one 187 
 
All glassware was dried under N2 using a heatgun. Ketone 96 (192 mg, 1.04 mmol, 1 eq.) and 
3,5-dimethyl-4-hydroxybenzaldehyde (156 mg, 1.04 mmol, 1 eq.) were added to the flask 
followed by anhydrous dioxane (2 mL). BF3·Et2O (0.4 mL, 3.12 mmol, 3 eq.) was added 
slowly and the reaction mixture was heated at 60 
o
C for 6 hours.
160
 On cooling, H2O (60 mL), 
2M NaOH(aq.) (20 mL) and EtOAc (60 mL) were added to the reaction mixture. The layers 
were separated and the aqueous layer was extracted with EtOAc (2 x 60 mL). The combined 
organic layers were washed with brine (60 mL), dried on Na2SO4, filtered and concentrated 
under reduced pressure to collect 343 mg of crude product. After column chromatography 
[silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], product 187 (70 mg, 21 % 
yield) was isolated as a yellow solid, m.p. 186-188 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 8.80 
(1H, br.s, NH), 7.73 (1H, br.s, alkene CH), 7.70 (1H, dd, J = 8.0, 1.0 Hz, ArCH), 7.46 (1H, 
dt, J = 8.5, 1.0 Hz, ArCH), 7.41 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.20 (1H, ddd, J = 
8.0, 7.0, 1.0 Hz, ArCH), 7.17 (2H, s, Ar’CH), 4.84 (1H, br.s, OH), 3.32 (2H, td, J = 6.5, 1.5 
Hz, CH2CH2C=CH), 3.11 (2H, t, J = 6.5 Hz, CH2CH2C=CH) and 2.35 (6H, s, Ar’CH3). 
13
C 
NMR (100 MHz; CDCl3): δC 181.1- (C=O), 152.8- (C), 138.4- (C), 135.8+ (alkene CH), 
134.1- (C), 132.5- (C), 130.7+ (Ar’CH), 128.2- (C), 127.9- (C), 127.0+ (ArCH), 126.0- (C), 
123.2- (C), 121.3+ (ArCH), 120.4+ (ArCH), 112.5+ (ArCH), 27.7- (CH2CH2C=CH), 20.8- 
(CH2CH2C=CH) and 16.0+ (Ar’CH3). MS m/z (+ESI) 318 (100 %, MH
+
) and 340 (19 %, 
MNa
+
). HRMS (+ESI) Found MH
+
 318.1486, C21H20NO2 requires MH 318.1494 and found 
MNa
+
 340.1302, C21H19NNaO2 requires MNa, 340.1313. IR νmax(liquid film): 3605 (OH), 
3460 (NH), 3042 (CH), 1648 (C=O) and 1599 (C=C). Rf (30 % EtOAc in light petroleum 
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(b.p. 40-60 
o
C) 0.5. NOESY NMR Interaction observed between 7.17 (2H, s, Ar’CH) and 
3.32 (2H, td, J = 6.5, 1.5 Hz, CH2CH2C=CH) to confirm E configuration.  
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Synthesis of (E)-2-(3,5-dimethoxybenzylidene)-2,3,4,9-tetrahydro-1H-carbazol-1-one 
188 
 
Method A 
A mixture of ketone 96 (260 mg, 1.40 mmol, 1 eq.) and 3,5-dimethoxybenzaldehyde (256 
mg, 1.54 mmol, 1.1 eq.) were treated with 4 % (w/v) ethanolic KOH (10 mL) and stirred at 
room temperature for 16 hours.
159
 The mixture was cooled in an ice-bath and the solid was 
filtered and washed with EtOH: H2O (10 mL: 10 mL). H2O (20 mL) was added to the filtrate 
which was then neutralised using AcOH, followed by a second filtration. The solid was again 
washed with EtOH: H2O (10 mL: 10 mL) to collect 188 (158 mg, 34 % yield) as a yellow 
solid.  
Method B - optimised method 
Following a procedure reported by Chakraborti et al.
156
 ketone 96 (235 mg, 1.27 mmol, 1 
eq.) and LiOH.H2O (133 mg, 3.18 mmol, 2.5 eq.) in EtOH (2 mL) were stirred for 10 
minutes, followed by the addition of 3,5-dimethoxybenzaldehyde (318 mg, 1.91 mmol, 1.5 
eq.). The reaction mixture was stirred at 30 
o
C for 6 hours. The solvent was removed under 
reduced pressure and the yellow residue was diluted with water (20 mL) and EtOAc (20 mL). 
The mixture was neutralised with 6M HCl(aq.) followed by extraction with EtOAc (2 x 10 
mL). The combined organic layers were washed with brine (20 mL), dried on Na2SO4, 
filtered and concentrated under reduced pressure to collect 456 mg of crude product. After 
column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], 
product 188 (197 mg, 52 % yield) was isolated as a yellow solid.  
m.p. 168-170 
o
C.
 1
H NMR (400 MHz; CDCl3): δH 8.96 (1H, br.s, NH), 7.76 (1H, br.s, alkene 
CH), 7.70 (1H, dd, J = 8.0, 1.0 Hz, ArCH), 7.48 (1H, dt, J = 8.5, 1.0 Hz, ArCH), 7.42 (1H, 
ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.20 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 6.63 (2H, dd, J 
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= 2.5, 0.5 Hz, Ar’CH), 6.51 (1H, t, J = 2.5 Hz, Ar’CH), 3.87 (6H, s, Ar’OCH3), 3.30 (2H, td, 
J = 6.5, 2.0 Hz, CH2CH2C=CH) and 3.11 (2H, t, J = 6.5 Hz, CH2CH2C=CH). 
13
C NMR (100 
MHz; CDCl3): δC 181.7- (C=O), 160.8- (C), 140.0- (C), 138.1- (C), 138.0- (C), 135.4- (C), 
135.3+ (alkene CH), 132.3- (C), 127.3+ (ArCH), 128.0- (C), 127.3+ (ArCH), 121.5+ 
(ArCH), 120.6+ (ArCH), 112.5+ (ArCH), 107.8+ (Ar’CH), 100.4+ (Ar’CH), 55.4 (OCH3), 
27.7- (CH2CH2C=CH) and 20.9- (CH2CH2C=CH). MS m/z (+ESI) 334 (100 %, MH
+
) and 
356 (9 %, MNa
+
). HRMS (+ESI) Found MH
+
 334.1433, C21H20NO3 requires MH 334.1443 
and found MNa
+
 356.1249, C21H19NNaO3 requires MNa 356.1263. IR νmax(liquid film): 3460 
(NH), 3026 (CH), 1652 (C=O) and 1597 (C=C). Rf (70 % EtOAc in light petroleum (b.p. 40-
60 
o
C) 0.9. Analysis (Found: H, 5.74; N, 4.20. C21H19NO3 requires H, 5.74; N, 4.20 %). 
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Synthesis of (E)-2-(4-hydroxy-3,5-dimethoxybenzylidene)-2,3,4,9-tetrahydro-1H-
carbazol-1-one 189 
 
All glassware was dried under N2 using a heatgun. Ketone 96 (309 mg, 1.67 mmol, 2.5 eq.) 
and syringaldehyde (122 mg, 0.67 mmol, 1 eq.) were added to the flask followed by 
anhydrous dioxane (4 mL). BF3·Et2O (0.25 mL, 2.01 mmol, 3 eq.) was added slowly and the 
reaction mixture was heated at 70 
o
C for 21 hours.
160
 On cooling, H2O (30 mL), 2M 
NaOH(aq.) (10 mL) and EtOAc (30 mL) were added to the reaction mixture. The layers were 
separated and the aqueous layer was extracted with EtOAc (2 x 30 mL). The combined 
organic layers were washed with brine (30 mL), dried on Na2SO4, filtered and concentrated 
under reduced pressure to collect 465 mg of crude product. After column chromatography 
[silica, light petroleum (b.p. 40-60 
o
C) EtOAc gradient column], product 189 (78 mg, 33 % 
yield) was isolated as a yellow solid, m.p. 155-157 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 9.09 
(1H, br.s, NH), 7.78 (1H, br.s, alkene CH), 7.70 (1H, dd, J = 8.0, 1.0 Hz, ArCH), 7.47 (1H, 
dt, J = 8.5, 1.0 Hz, ArCH), 7.42 (1H, ddd, J = 8.0, 7.0, 1.0 Hz, ArCH), 7.20 (1H, ddd, J = 
8.0, 7.0, 1.0 Hz, ArCH), 6.76 (2H, s, Ar’CH), 5.72 (1H, s, OH), 3.97 (6H, s, Ar’OCH3), 3.35 
(2H, td, J = 6.5, 1.5 Hz, CH2CH2C=CH) and 3.13 (2H, t, J = 6.5 Hz, CH2CH2C=CH). 
13
C 
NMR (100 MHz; CDCl3): δC 180.7- (CO), 147.0- (C), 138.5- (C), 135.9+ (alkene CH), 
135.6- (C), 134.7- (C), 132.4- (C), 128.0- (C), 127.4- (C), 127.2+ (ArCH), 126.0- (C), 121.4+ 
(ArCH), 120.5+ (ArCH), 112.5+ (ArCH), 107.2+ (Ar’CH), 56.5+ (Ar’OCH3), 27.7- 
(CH2CH2C=CH) and 20.8- (CH2CH2C=CH). MS m/z (+ESI) 350 (100 %, MH
+
). HRMS 
(+ESI) Found MH
+
 350.1394, C21H19NO4 requires MH, 350.1400. IR νmax(liquid film): 3534 
(OH), 3460 (NH), 3033 (CH), 1649 (C=O) and 1612 (C=C). Rf (70 % EtOAc in light 
petroleum (b.p. 40-60 
o
C) 0.7. 
 - 232 -  
Synthesis of (E)-2-(3,5-dimethylbenzylidene)-9-methyl-2,3,4,9-tetrahydro-1H-carbazol-
1-one 190 
 
Following a procedure reported by Chakraborti et al.
156
 ketone 175 (172 mg, 0.86 mmol, 2 
eq.) and LiOH.H2O (54 mg, 1.29 mmol, 3 eq.) in EtOH (2 mL) were stirred for 10 minutes, 
followed by the addition of 3,5-dimethylbenzaldehyde (58 mg, 0.43 mmol, 1 eq.). The 
reaction mixture was stirred at 30 
o
C for 20 hours and the solvent was removed under 
reduced pressure. After column chromatography [silica, light petroleum (b.p. 40-60 
o
C) - 
EtOAc gradient column], product 190 (75 mg, 55 % yield) was isolated as a yellow solid, 
m.p. 96-98 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 7.77 (1H, br.s, alkene CH), 7.69 (1H, dt, J = 
8.0, 1.0 Hz, ArCH), 7.45 (1H, td, J = 8.5, 1.0 Hz, ArCH), 7.41 (1H, dt, J = 8.5, 1.0 Hz, 
ArCH), 7.19 (1H, ddd, J = 8.0, 6.5, 1.0 Hz, ArCH), 7.09 (2H, s, Ar’CH), 7.03 (1H, s, 
Ar’CH), 4.20 (3H, s, NCH3), 3.24 (2H, td, J = 6.0, 1.0 Hz, CH2CH2C=C), 3.09 (2H, t, J = 6.0 
Hz, CH2CH2C=C) and 2.40 (6H, s, Ar’CH3). 
13
C NMR (CDCl3, 100 MHz): δC 181.9- (C=O), 
140.4- (C), 137.9- (C), 137.2- (C), 136.3- (C), 135.4+ (alkene CH), 131.6- (C), 129.9+ 
(Ar’CH), 128.3- (C), 127.5+ (Ar’CH), 126.8+ (ArCH), 124.7- (C), 121.3+ (ArCH), 120.1+ 
(ArCH), 110.3+ (ArCH), 31.7+ (NCH3), 27.7- (CH2CH2C=C), 21.4+ (Ar’CH3) and 21.1- 
(CH2CH2C=C). MS m/z (+ESI) 316 (100 %, MH
+
) and 338 (15 %, MNa
+
). HRMS (+ESI) 
Found MH
+
 316.1701, C22H22NO requires MH 316.1701 and found MNa
+
 338.1517, 
C22H21NNaO requires MNa 338.1521. IR νmax(liquid film): 3027 (CH), 1651 (C=O) and 
1613 (C=C). Rf (30 % EtOAc in light petroleum (b.p. 40-60 
o
C) 0.9.  
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Synthesis of (E)-2-(4-hydroxy-3,5-dimethylbenzylidene)-9-methyl-2,3,4,9-tetrahydro-
1H-carbazol-1-one 191 
 
All glassware was dried under N2 using a heatgun. Ketone 175 (106 mg, 0.53 mmol, 2 eq.) 
and 3,5-dimethyl-4-hydroxybenzaldehyde (41 mg, 0.27 mmol, 1 eq.) were added to the flask 
followed by anhydrous dioxane (2 mL). BF3·Et2O (0.1 mL, 0.8 mmol, 2.3 eq.) was added 
slowly and the reaction mixture was heated at 60 
o
C for 14 hours.
160
 On cooling, H2O (40 
mL), 2M NaOH(aq.) (20 mL) and EtOAc (40 mL) were added to the reaction mixture. The 
layers were separated and the aqueous layer was extracted with EtOAc (2 x 40 mL). The 
combined organic layers were washed with brine (40 mL), dried on Na2SO4, filtered and 
concentrated under reduced pressure to collect 139 mg of crude product. After column 
chromatography [silica, light petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], product 
191 (10 mg, 11 % yield) was isolated as a yellow solid, m.p. 203-205 
o
C. 
1
H NMR (CDCl3, 
400 MHz): δH  7.72 (1H, br.s, alkene CH), 7.69 (1H, dt, J = 8.0, 1.0 Hz, ArCH), 7.47-7.43 
(1H, m, ArCH), 7.41 (1H, dt, J = 8.0, 1.0 Hz, ArCH), 7.19 (1H, ddd, J = 8.0, 6.5, 1.0 Hz, 
ArCH), 7.15 (2H, s, Ar’CH), 4.81 (1H, br.s, OH), 4.19 (3H, s, NCH3), 3.26 (2H, td, J = 6.5, 
1.0 Hz, CH2CH2C=CH), 3.09 (2H, t, J = 6.5 Hz, CH2CH2C=CH) and 2.33 (6H, s, Ar’CH3). 
13
C NMR (100 MHz; CDCl3): δC 181.9- (CO), 152.6- (C), 140.4- (C), 135.5- (C), 135.4+ 
(alkene CH), 131.6- (C), 130.5+ (Ar’CH), 128.5- (C), 127.9- (C), 126.7+ (ArCH), 124.7- (C), 
123.0- (C), 121.3+ (ArCH), 120.1+ (ArCH), 110.3+ (ArCH), 31.6+ (NCH3), 27.6- 
(CH2CH2C=CH), 21.0- (CH2CH2C=CH) and 15.9+ (Ar’CH3). MS m/z (+ESI) 332 (100 %, 
MH
+
) and 354 (28 %, MNa
+
). HRMS (+ESI) Found MH
+
 332.1634, C22H22NO2 requires MH 
332.1651 and found MNa
+
 354.1453, C22H21NNaO2 requires MNa 354.1470. IR νmax(liquid 
film): 3608 (OH), 3038 (CH), 1648 (C=O) and 1601 (C=C). Rf (30 % EtOAc in light 
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petroleum (b.p. 40-60 
o
C) 0.8. NOESY NMR Interaction observed between 7.15 (2H, s, 
Ar’CH) and 3.26 (2H, td, J = 6.5, 1.0 Hz, CH2CH2C=CH) to confirm E configuration.  
 
Synthesis of (E)-2-(3,5-dimethoxybenzylidene)-9-methyl-2,3,4,9-tetrahydro-1H-
carbazol-1-one 192 
 
Method A - Optimised method 
A mixture of ketone 175 (229 mg, 1.15 mmol, 1 eq.) and 3,5-dimethoxybenzaldehyde (211 
mg, 1.27 mmol, 1.1 eq.) were treated with 4 % (w/v) ethanolic KOH (11.5 mL) and stirred at 
room temperature for 16 hours.
159
 The mixture was cooled in an ice-bath and the solid was 
filtered and washed with EtOH: H2O (10 mL: 10 mL). H2O (20 mL) was added to the filtrate 
which was then neutralised using AcOH, followed by a second filtration. The solid was again 
washed with EtOH: H2O (10 mL: 10 mL) to collect 192 (97 mg, 28 % yield) as a yellow 
solid.  
Method B 
Ketone 175 (139 mg, 0.70 mmol, 2 eq.) and LiOH.H2O (44 mg, 1.05 mmol, 3 eq.) in EtOH 
(2 mL) were stirred for 10 minutes, followed by the addition of 3,5-dimethoxybenzaldehyde 
(58 mg, 0.35 mmol, 1 eq.). The reaction mixture was stirred at 30 
o
C for 19 hours and the 
solvent was removed under reduced pressure. After column chromatography [silica, light 
petroleum (b.p. 40-60 
o
C) - EtOAc gradient column], product 192 (31 mg, 25 % yield) was 
isolated as yellow crystals. 
m.p. 134-135 
o
C. 
1
H NMR (400 MHz; CDCl3): δH 7.74 (1H, br.s, alkene CH), 7.69 (1H, dt, J 
= 8.0, 1.0 Hz, ArCH), 7.46 (1H, ddd, J = 8.5, 6.5, 1.0 Hz, ArCH), 7.41 (1H, dt, J = 8.5, 1.0 
Hz, ArCH), 7.19 (1H, ddd, J = 8.0, 6.5, 1.0 Hz, ArCH), 6.61 (2H, dd, J = 2.5, 0.5 Hz, 
Ar’CH), 6.50 (1H, t, J = 2.5 Hz, Ar’CH), 4.19 (3H, s, NCH3), 3.86 (6H, s, Ar’OCH3), 3.24 
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(2H, td, J = 6.5, 1.0 Hz, CH2CH2C=CH), 3.09 (2H, t, J = 6.5 Hz, CH2CH2C=CH). 
13
C NMR 
(100 MHz; CDCl3): δC 181.7- (C=O), 160.7- (C), 140.5- (C), 138.3- (C), 138.0- (C), 134.9+ 
(alkene CH), 131.5- (C), 128.6- (C), 126.9+ (ArCH), 124.6- (C), 121.4+ (ArCH), 120.2+ 
(ArCH), 110.4+ (ArCH), 107.7+ (Ar’CH), 100.2+ (Ar’CH), 55.4+ (Ar’OCH3), 31.7+ 
(NCH3), 27.7- (CH2CH2C=CH) and 21.1 (CH2CH2C=CH). MS m/z (+ESI) 348 (100 %, 
MH
+
) and 370 (18 %, MNa
+
) HRMS (+ESI) Found MH
+
 348.1606, C22H22NO3 requires MH 
348.1600 and found MNa
+
 370.1423, C22H21NNaO3 requires MNa 370.1419. IR νmax(liquid 
film): 3026 (CH), 1652 (C=O) and 1594 (C=C). Rf (30 % EtOAc in light petroleum (b.p. 40-
60 
o
C) 0.8. Analysis (Found: H, 6.06; N, 3.93. C22H21NO3 requires H, 6.09; N, 4.03 %). 
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8. Appendices 
 
8.1. Chapter Two 
 
8.1.1. CO2 Labelling experiments 
 
NMR 
Simultaneous equations: x is the proportion of the integral corresponding to the 
12
C 
compound and y is the proportion of the integral corresponding to the 
13
C compound. 
 
Owing to different relaxation times, the integral of the C=O peak differs to the integrals of 
the remaining peaks. From the background 
13
C NMR spectra, we can determine the 
difference in the integrals, which is incorporated in the equation as the “integration factor”. 
 
In addition, the C=O signal for the 
13
C compound x will be 100 % abundant, so in order to 
make a direct comparison with the C=O signal for the 
12
C compound y, we must use a 
conversion factor which take into account the natural abundance of 
13
C which is 1.11 %. For 
all other C signals, x + y will simply equal the integral of that peak. 
 
Measured ratio 0:100 NaH
12
CO3:NaH
13
CO3 
 
Comparison of C=O peak at 155.8 ppm integral 23.9895 with 68.2 ppm integral 1.0000 
Integration factor = 3.6904 
 
1) x + y = 1.0000 
2) x + (100y/1.11) = 23.9895 × 3.6904 
 
Rearranging Eq. 1 to y = 1.0000 – x and substituting into Eq. 2 gives: 
 
3) x + (100(1 – x)/1.11) = 88.5309, becomes 
4) 90.0901 – 89.0901x = 88.5309, becomes 
5) 89.0901x = 1.5592, 
6) x = 0.0175 
 
From Eq. 1, x + y = 1.0000; x = 0.0175 and y = 0.9825, 
12
C = 1.75% and 
13
C = 98.25% 
 
 
Comparison of C=O peak at 155.8 ppm integral 23.9895 with 54.5 ppm integral 0.7221 
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Integration factor = 2.6110 
 
1) x + y = 0.7221 
2) x + (100y/1.11) = 23.9895 × 2.6110 
 
Rearranging Eq. 1 to y = 0.7221 – x and substituting into Eq. 2 gives: 
 
3) x + (100(0.7221 – x)/1.11) = 62.6366, becomes 
4) 66.0541 – 89.0901x = 62.6366, becomes 
5) 89.0901x = 2.4175, 
6) x = 0.0271 
 
From Eq. 1, x + y = 0.7221, x = 0.0271 and y = 0.6950, 
12
C = 3.8% and 
13
C = 96.2% 
 
 
Comparison of C=O peak at 155.8 ppm integral 23.9895 with 31.3 ppm integral 0.9621 
Integration factor = 3.5564 
 
1) x + y = 0.9621 
2) x + (100y/1.11) = 23.9895 × 3.5564 
 
Rearranging Eq. 1 to y = 0.9621 – x and substituting into Eq. 2 gives: 
 
3) x + (100(0.9621 – x)/1.11) = 85.3163, becomes 
4) 86.6757 – 89.0901x = 66.2632, becomes 
5) 89.0901x = 1.3594, 
6) x = 0.0153 
 
From Eq. 1, x + y = 0.9621; x = 0.0153 and y = 0.9468, 
12
C = 1.6% and 
13
C = 98.4% 
Comparison of C=O peak at 155.8 ppm integral 23.9895 with 28.6 ppm integral 0.9770 
Integration factor = 3.5026 
 
1) x + y = 0.9770 
2) x + (100y/1.11) = 23.9895 × 3.5026 
 
Rearranging Eq. 1 to y = 0.9770 – x and substituting into Eq. 2 gives: 
 
3) x + (100(0.9770 – x)/1.11) = 84.0256, becomes 
4) 88.0180 – 89.0901x = 84.0256, becomes 
5) 89.0901x = 3.9924, 
6) x = 0.0448 
 
From Eq. 1, x + y = 0.9770; x = 0.0448 and y = 0.9322, 
12
C = 4.6% and 
13
C = 95.4% 
 
 
Comparison of C=O peak at 155.8 ppm integral 23.9895 with 25.3 ppm integral 0.9535 
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Integration factor = 3.4658 
 
1) x + y = 0.9535 
2) x + (100y/1.11) = 23.9895 × 3.4658 
 
Rearranging Eq. 1 to y = 0.9535 – x and substituting into Eq. 2 gives: 
 
3) x + (100(0.9535 – x)/1.11) = 83.1428, becomes 
4) 85.9009 – 89.0901x = 83.1428, becomes 
5) 89.0901x = 2.7581, 
6) x = 0.0310 
 
From Eq. 1, x + y = 0.9535; x = 0.0310 and y = 0.9225, 
12
C = 3.2% and 
13
C = 96.8% 
 
 
Comparison of C=O peak at 155.8 ppm integral 23.9895 with 22.4 ppm integral 0.9107 
Integration factor = 3.3807 
 
1) x + y = 0.9107 
2) x + (100y/1.11) = 23.9895 × 3.3807 
 
Rearranging Eq. 1 to y = 0.9107 – x and substituting into Eq. 2 gives: 
 
3) x + (100(0.9107 – x)/1.11) = 81.1013, becomes 
4) 82.0450 – 89.0901x = 81.1013, becomes 
5) 89.0901x = 0.9437, 
6) x = 0.0106 
 
From Eq. 1, x + y = 0.9107; x = 0.0106 and y = 0.9001, 
12
C = 1.2% and 
13
C = 98.8% 
 
 
Comparison of C=O peak at 155.8 ppm integral 23.9895 with 13.9 ppm integral 0.9068 
Integration factor = 3.4515 
 
1) x + y = 0.9068 
2) x + (100y/1.11) = 23.9895 × 3.4515 
 
Rearranging Eq. 1 to y = 0.9068 – x and substituting into Eq. 2 gives: 
 
3) x + (100(0.9068 – x)/1.11) = 82.7998, becomes 
4) 81.6937 – 89.0901x = 82.7998, becomes 
5) 89.0901x = –1.1061, 
6) x = –0.0124 
 
From Eq. 1, x + y = 0.9068; x = –0.0124 and y = 0.9192, 12C = –1.4% and 13C = 101.4% 
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Average of the 7 peaks 
 
1.75 + 3.8 + 1.6 + 4.6 + 3.2 + 1.2 –1.4 = 12C = 2.1% and 13C = 97.9% 
   7 
 
Determination of ratios by High Resolution Mass spectrometry 
 
 
 
m/z of 100 % 
12
C compound x shows the MNa
+
 ion at 183.1035 (39 090, 91.26 %) and 
184.1067 (3 746, 8.74 %), due to natural abundance of 
13
C present in this compound. Using 
this background reading, the ratios of the mixtures are calculated below. 
 
The proportion of the peak at 184.1 due to the natural abundance of 
13
C is (3 746/39 090) of 
the peak at 183.09.  
 
x is the proportion of the integral corresponding to the 
12
C compound and y is the proportion 
of the integral corresponding to the 
13
C compound. 
 
Measured ratio 0:100 NaH
12
CO3:NaH
13
CO3 
 
MNa
+ 
183.0973, integration 24 203 (is solely due to compound x) 
MNa
+ 
184.1008, integration 800 762 (is due to the natural abundance of 
13
C in compound x 
plus compound y), therefore 
 
1) x = 24 203 
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2) (3 746/39 090)x + y = 800 762 
 
Substituting Eq. 1 into Eq. 2 gives: 
 
3) (3 746/39 090) × 24 203 + y = 800 762, becomes 
4) y = 798 442.623 
 
From Eq. 1 x = 24 203 and Eq. 4 y = 798 442.623, 
12
C = 2.9% and 
13
C = 97.1% 
 
8.1.2. Crystal Structure Data - Compound 69 
 
 
 
 
Table 1. Crystal data and structure refinement for compound 69                                 
 Identification code h10farm1 
 Empirical formula C14 H14 Cl N O7 S 
 Formula weight 375.77 
 Temperature 150(2) K 
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 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/a 
 Unit cell dimensions a = 7.2820(1)Å  = 90o 
       b = 18.8380(4)Å  = 102.451(1)o 
       c = 11.8360(3)Å  = 90o 
 Volume 1585.46(6) Å
3
 
 Z 4 
 Density (calculated) 1.574 Mg/m
3
 
 Absorption coefficient 0.410 mm
-1
 
 F(000) 776 
 Crystal size 0.30 x 0.15 x 0.15 mm 
 Theta range for data collection 2.07 to 27.48
o
 
 Index ranges -9<=h<=9; -23<=k<=24; -15<=l<=15 
 Reflections collected 17860 
 Independent reflections 3624 [R(int) = 0.0402] 
 Reflections observed (>2) 2843 
 Data Completeness 0.997 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.938 and 0.894 
 Refinement method Full-matrix least-squares on F
2
 
 Data / restraints / parameters 3624 / 0 / 222 
 Goodness-of-fit on F
2
 1.050 
 Final R indices [I>2(I)] R1 = 0.0361   wR2 = 0.0837 
 R indices (all data) R1 = 0.0550  wR2 = 0.0933 
 Largest diff. peak and hole 0.301 and -0.362 eÅ
-3
 
  
Table 2. Atomic coordinates ( x 10
4
) and equivalent isotropic displacement parameters (Å
2
 x 10
3
) for 
compound 69.U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.                                                                   
  Atom   x   y   z  U(eq) 
                                  
Cl(1) 3558(1) 1580(1) 5842(1) 43(1) 
S(1) 3991(1) 929(1) 9922(1) 24(1) 
O(1) 3892(2) 3842(1) 11704(1) 24(1) 
O(2) 3433(2) 2686(1) 13007(1) 25(1) 
O(3) 3467(2) 1342(1) 12107(1) 25(1) 
O(4) 5331(2) 2818(1) 8029(1) 30(1) 
O(5) 4092(2) 470(1) 7900(1) 35(1) 
O(6) 7994(2) 770(1) 7852(1) 35(1) 
O(7) 6896(2) 758(1) 5932(1) 45(1) 
N(1) 5002(2) 1623(1) 8120(1) 22(1) 
C(1) 4086(2) 3192(1) 11243(2) 20(1) 
C(2) 3840(2) 2608(1) 11938(1) 20(1) 
C(3) 3864(2) 1926(1) 11507(2) 20(1) 
C(4) 4169(2) 1813(1) 10391(2) 19(1) 
C(5) 4504(2) 2388(1) 9730(2) 19(1) 
C(6) 4444(2) 3080(1) 10156(2) 20(1) 
C(7) 4959(2) 2315(1) 8584(2) 21(1) 
C(8) 4340(3) 992(1) 8509(2) 24(1) 
 - 242 -  
C(9) 5559(3) 1583(1) 7020(2) 25(1) 
C(10) 6933(3) 973(1) 7005(2) 27(1) 
C(11) 8353(4) 251(2) 5829(2) 61(1) 
C(12) 4225(3) 4450(1) 11046(2) 27(1) 
C(13) 4759(3) 3083(1) 13850(2) 33(1) 
C(14) 4986(3) 1122(1) 13040(2) 29(1) 
                                     
Table 3.  Bond lengths [Å] and angles [
o
] for compound 69. 
Cl(1)-C(9) 1.7864(19) S(1)-C(8) 1.7487(19) 
S(1)-C(4) 1.7509(17) O(1)-C(1) 1.361(2) 
O(1)-C(12) 1.434(2) O(2)-C(2) 1.368(2) 
O(2)-C(13) 1.441(2) O(3)-C(3) 1.375(2) 
O(3)-C(14) 1.445(2) O(4)-C(7) 1.215(2) 
O(5)-C(8) 1.208(2) O(6)-C(10) 1.189(2) 
O(7)-C(10) 1.328(2) O(7)-C(11) 1.452(3) 
N(1)-C(8) 1.399(2) N(1)-C(7) 1.416(2) 
N(1)-C(9) 1.447(2) C(1)-C(6) 1.383(2) 
C(1)-C(2) 1.408(2) C(2)-C(3) 1.384(3) 
C(3)-C(4) 1.401(2) C(4)-C(5) 1.389(2) 
C(5)-C(6) 1.402(2) C(5)-C(7) 1.471(2) 
C(6)-H(6) 0.9500 C(9)-C(10) 1.526(3) 
C(9)-H(9) 1.0000 C(11)-H(11A) 0.9800 
C(11)-H(11B) 0.9800 C(11)-H(11C) 0.9800 
C(12)-H(12A) 0.9800 C(12)-H(12B) 0.9800 
C(12)-H(12C) 0.9800 C(13)-H(13A) 0.9800 
C(13)-H(13B) 0.9800 C(13)-H(13C) 0.9800 
C(14)-H(14A) 0.9800 C(14)-H(14B) 0.9800 
C(14)-H(14C) 0.9800   
     
C(8)-S(1)-C(4) 102.93(9) C(1)-O(1)-C(12) 117.18(14) 
C(2)-O(2)-C(13) 116.68(14) C(3)-O(3)-C(14) 114.35(13) 
C(10)-O(7)-C(11) 114.58(18) C(8)-N(1)-C(7) 128.10(15) 
C(8)-N(1)-C(9) 115.72(15) C(7)-N(1)-C(9) 115.56(14) 
O(1)-C(1)-C(6) 124.50(16) O(1)-C(1)-C(2) 115.58(15) 
C(6)-C(1)-C(2) 119.88(16) O(2)-C(2)-C(3) 117.57(15) 
O(2)-C(2)-C(1) 122.50(16) C(3)-C(2)-C(1) 119.74(15) 
O(3)-C(3)-C(2) 122.11(15) O(3)-C(3)-C(4) 117.34(16) 
C(2)-C(3)-C(4) 120.39(16) C(5)-C(4)-C(3) 119.68(16) 
C(5)-C(4)-S(1) 124.96(13) C(3)-C(4)-S(1) 115.30(13) 
C(4)-C(5)-C(6) 120.01(16) C(4)-C(5)-C(7) 123.26(16) 
C(6)-C(5)-C(7) 116.72(15) C(1)-C(6)-C(5) 120.16(16) 
C(1)-C(6)-H(6) 119.9 C(5)-C(6)-H(6) 119.9 
O(4)-C(7)-N(1) 118.76(16) O(4)-C(7)-C(5) 123.07(16) 
N(1)-C(7)-C(5) 118.16(15) O(5)-C(8)-N(1) 120.90(17) 
O(5)-C(8)-S(1) 118.80(15) N(1)-C(8)-S(1) 120.19(13) 
N(1)-C(9)-C(10) 111.25(15) N(1)-C(9)-Cl(1) 111.30(13) 
C(10)-C(9)-Cl(1) 114.51(13) N(1)-C(9)-H(9) 106.4 
C(10)-C(9)-H(9) 106.4 Cl(1)-C(9)-H(9) 106.4 
O(6)-C(10)-O(7) 125.73(18) O(6)-C(10)-C(9) 122.70(17) 
 - 243 -  
O(7)-C(10)-C(9) 111.27(16) O(7)-C(11)-H(11A) 109.5 
O(7)-C(11)-H(11B) 109.5 H(11A)-C(11)-H(11B) 109.5 
O(7)-C(11)-H(11C) 109.5 H(11A)-C(11)-H(11C) 109.5 
H(11B)-C(11)-H(11C) 109.5 O(1)-C(12)-H(12A) 109.5 
O(1)-C(12)-H(12B) 109.5 H(12A)-C(12)-H(12B) 109.5 
O(1)-C(12)-H(12C) 109.5 H(12A)-C(12)-H(12C) 109.5 
H(12B)-C(12)-H(12C) 109.5 O(2)-C(13)-H(13A) 109.5 
O(2)-C(13)-H(13B) 109.5 H(13A)-C(13)-H(13B) 109.5 
O(2)-C(13)-H(13C) 109.5 H(13A)-C(13)-H(13C) 109.5 
H(13B)-C(13)-H(13C) 109.5 O(3)-C(14)-H(14A) 109.5 
O(3)-C(14)-H(14B) 109.5 H(14A)-C(14)-H(14B) 109.5 
O(3)-C(14)-H(14C) 109.5 H(14A)-C(14)-H(14C) 109.5 
H(14B)-C(14)-H(14C) 109.5   
  
Table 4.  Anisotropic displacement parameters (Å
2
 x 10
3
) for compound 69. The anisotropic 
displacement factor exponent takes the form: -2 gpi
2
 [ h
2
 a*
2
 U11 + ... + 2 h k a* b* U                                                                           
  Atom  U11  U22  U33  U23  U13  U12 
                                                
Cl(1) 40(1) 62(1) 23(1) -4(1) -1(1) 14(1) 
S(1) 29(1) 20(1) 25(1) -2(1) 9(1) -3(1) 
O(1) 28(1) 20(1) 27(1) -3(1) 10(1) 1(1) 
O(2) 25(1) 30(1) 20(1) -4(1) 8(1) -4(1) 
O(3) 24(1) 25(1) 25(1) 4(1) 6(1) -4(1) 
O(4) 44(1) 24(1) 27(1) 4(1) 16(1) 4(1) 
O(5) 43(1) 30(1) 35(1) -11(1) 15(1) -9(1) 
O(6) 33(1) 33(1) 37(1) -1(1) 5(1) 8(1) 
O(7) 53(1) 54(1) 33(1) -8(1) 19(1) 19(1) 
N(1) 23(1) 24(1) 19(1) -1(1) 7(1) 2(1) 
C(1) 15(1) 21(1) 24(1) -4(1) 3(1) 1(1) 
C(2) 15(1) 27(1) 19(1) -2(1) 4(1) 0(1) 
C(3) 15(1) 24(1) 21(1) 1(1) 4(1) -2(1) 
C(4) 14(1) 21(1) 22(1) -2(1) 3(1) 0(1) 
C(5) 15(1) 22(1) 20(1) 0(1) 4(1) 1(1) 
C(6) 17(1) 20(1) 23(1) 0(1) 5(1) 2(1) 
C(7) 20(1) 23(1) 22(1) 0(1) 4(1) 3(1) 
C(8) 23(1) 25(1) 26(1) -4(1) 7(1) -3(1) 
C(9) 27(1) 28(1) 19(1) -1(1) 7(1) 4(1) 
C(10) 28(1) 26(1) 29(1) -4(1) 12(1) 0(1) 
C(11) 65(2) 64(2) 64(2) -14(1) 34(1) 26(1) 
C(12) 28(1) 19(1) 34(1) 0(1) 9(1) 1(1) 
C(13) 31(1) 45(1) 21(1) -10(1) 3(1) -3(1) 
C(14) 32(1) 30(1) 24(1) 7(1) 7(1) 1(1) 
  
Table 5.  Hydrogen coordinates ( x 10
4
) and isotropic displacement parameters (Å
2
 x 10
3
) for 
compound 69.                                    
  Atom   x   y   z  U(eq) 
                                  
H(6) 4649 3474 9696 24 
H(9) 6264 2030 6947 29 
 - 244 -  
H(11A) 9586 482 6036 92 
H(11B) 8142 78 5031 92 
H(11C) 8315 -150 6352 92 
H(12A) 5525 4440 10944 40 
H(12B) 4017 4883 11458 40 
H(12C) 3360 4441 10287 40 
H(13A) 6033 3005 13727 49 
H(13B) 4693 2926 14629 49 
H(13C) 4455 3590 13766 49 
H(14A) 6124 1045 12739 43 
H(14B) 4641 679 13377 43 
H(14C) 5225 1492 13635 43 
  
Table 6.  Dihedral angles [
o
] for compound 69.                             
  Atom1  -  Atom2  -  Atom3  -  Atom4  Dihedral 
                                                  
C(12) - O(1) - C(1) - C(6) -4.9(2) 
C(12) - O(1) - C(1) - C(2) 176.97(15) 
C(13) - O(2) - C(2) - C(3) 126.48(17) 
C(13) - O(2) - C(2) - C(1) -58.5(2) 
O(1) - C(1) - C(2) - O(2) 0.0(2) 
C(6) - C(1) - C(2) - O(2) -178.16(14) 
O(1) - C(1) - C(2) - C(3) 174.96(14) 
C(6) - C(1) - C(2) - C(3) -3.2(2) 
C(14) - O(3) - C(3) - C(2) -77.5(2) 
C(14) - O(3) - C(3) - C(4) 106.94(17) 
O(2) - C(2) - C(3) - O(3) 1.1(2) 
C(1) - C(2) - C(3) - O(3) -174.11(15) 
O(2) - C(2) - C(3) - C(4) 176.46(14) 
C(1) - C(2) - C(3) - C(4) 1.3(2) 
O(3) - C(3) - C(4) - C(5) 177.52(14) 
C(2) - C(3) - C(4) - C(5) 1.9(2) 
O(3) - C(3) - C(4) - S(1) 0.10(19) 
C(2) - C(3) - C(4) - S(1) -175.52(13) 
C(8) - S(1) - C(4) - C(5) 0.19(17) 
C(8) - S(1) - C(4) - C(3) 177.46(13) 
C(3) - C(4) - C(5) - C(6) -3.2(2) 
S(1) - C(4) - C(5) - C(6) 174.00(13) 
C(3) - C(4) - C(5) - C(7) 175.92(15) 
S(1) - C(4) - C(5) - C(7) -6.9(2) 
O(1) - C(1) - C(6) - C(5) -176.04(15) 
C(2) - C(1) - C(6) - C(5) 2.0(2) 
C(4) - C(5) - C(6) - C(1) 1.2(2) 
C(7) - C(5) - C(6) - C(1) -177.92(14) 
C(8) - N(1) - C(7) - O(4) -168.67(17) 
C(9) - N(1) - C(7) - O(4) 1.9(2) 
C(8) - N(1) - C(7) - C(5) 12.7(3) 
C(9) - N(1) - C(7) - C(5) -176.71(14) 
C(4) - C(5) - C(7) - O(4) -176.70(17) 
 - 245 -  
C(6) - C(5) - C(7) - O(4) 2.4(2) 
C(4) - C(5) - C(7) - N(1) 1.9(2) 
C(6) - C(5) - C(7) - N(1) -179.03(15) 
C(7) - N(1) - C(8) - O(5) 163.85(17) 
C(9) - N(1) - C(8) - O(5) -6.7(3) 
C(7) - N(1) - C(8) - S(1) -20.0(2) 
C(9) - N(1) - C(8) - S(1) 169.41(13) 
C(4) - S(1) - C(8) - O(5) -171.89(15) 
C(4) - S(1) - C(8) - N(1) 11.89(16) 
C(8) - N(1) - C(9) - C(10) -51.7(2) 
C(7) - N(1) - C(9) - C(10) 136.52(16) 
C(8) - N(1) - C(9) - Cl(1) 77.30(17) 
C(7) - N(1) - C(9) - Cl(1) -94.48(16) 
C(11) - O(7) - C(10) - O(6) -2.4(3) 
C(11) - O(7) - C(10) - C(9) 171.47(19) 
N(1) - C(9) - C(10) - O(6) -29.8(3) 
Cl(1) - C(9) - C(10) - O(6) -157.10(16) 
N(1) - C(9) - C(10) - O(7) 156.09(16) 
Cl(1) - C(9) - C(10) - O(7) 28.8(2) 
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8.2. Chapter Three 
 
8.2.1. HMBC of Tetrazole 120 
 
 
 
Imine carbon at 151.14 ppm can be seen from not only the proton at 4.63 ppm but also from 
the proton at 7.61 ppm. This would only occur if the tetrazole was as the regioisomer shown. 
There is an overlap of the interaction between imine carbon 151.14 ppm and the proton at 
7.61 ppm in the HMBC but it can clearly be seen (see Expansion C). 
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8.2.2. IC50 Values of A/B Lactams and Tetrazoles in HT29 and MDA231 Cancer 
Cell Lines 
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8.3. Chapter Four 
 
8.3.1. Crystal Structure Data - Indanone 136 
 
 
 
Table 1. Crystal data and structure refinement for compound 136.                                                        
 Identification code p09farm1 
 Empirical formula C14 H14 O3 
 Formula weight 230.25 
 Temperature 150(2) K 
 Wavelength 1.54184 Å 
 Crystal system Monoclinic 
 Space group P21/n 
 Unit cell dimensions a = 10.1099(3)Å  = 90o 
       b = 5.0318(2)Å  = 91.870(3)o 
       c = 21.5241(6)Å  = 90o 
 Volume 1094.37(6) Å
3
 
 Z 4 
 Density (calculated) 1.397 Mg/m
3
 
 Absorption coefficient 0.797 mm
-1
 
 F(000) 488 
 Crystal size 0.18 x 0.15 x 0.08 mm 
 - 255 -  
 Theta range for data collection 7.69 to 62.30 
o
. 
 Index ranges -11<=h<=11; -5<=k<=5; -24<=l<=24 
 Reflections collected 34832 
 Independent reflections 1726 [R(int) = 0.0286] 
 Reflections observed (>2) 1579 
 Data Completeness 0.997 
 Max. and min. transmission 1.0000, 0.4681 
 Refinement method Full-matrix least-squares on F
2
 
 Data / restraints / parameters 1726 / 0 / 155 
 Goodness-of-fit on F
2
 1.079 
 Final R indices [I>2(I)] R1 = 0.0292   wR2 = 0.0734 
 R indices (all data) R1 = 0.0320  wR2 = 0.0754 
 Largest diff. peak and hole 0.185 and -0.137 eÅ
-3
 
    
 Table 2. Atomic coordinates ( x 10
4
) and equivalent isotropic displacement parameters (Å
2
 x 10
3
) for 
compound 136.U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.                                                                                                  
  Atom   x   y   z  U(eq) 
                                  
O(1) 6861(1) 4915(2) 1454(1) 33(1) 
O(2) 7812(1) 1947(2) 2159(1) 31(1) 
O(3) 13128(1) 4300(2) 2010(1) 27(1) 
C(1) 6604(1) 2643(3) 1838(1) 35(1) 
C(2) 8205(1) 5255(3) 1480(1) 25(1) 
C(3) 8922(1) 7063(3) 1153(1) 27(1) 
C(4) 10290(1) 7028(3) 1278(1) 23(1) 
C(5) 11342(1) 8592(3) 955(1) 25(1) 
C(6) 11591(1) 7374(3) 313(1) 31(1) 
C(7) 12926(1) 8168(3) 62(1) 37(1) 
C(8) 14035(1) 7258(3) 509(1) 35(1) 
C(9) 13917(1) 8598(3) 1137(1) 29(1) 
C(10) 12554(1) 8292(3) 1409(1) 24(1) 
C(11) 12295(1) 5702(3) 1747(1) 22(1) 
C(12) 10853(1) 5265(3) 1708(1) 22(1) 
C(13) 10109(1) 3398(3) 2036(1) 24(1) 
C(14) 8779(1) 3474(3) 1904(1) 24(1) 
     
 Table 3.  Bond lengths [Å] and angles [
o
] for compound 136. 
O(1)-C(2) 1.3694(15) O(1)-C(1) 1.4390(18) 
O(2)-C(14) 1.3724(16) O(2)-C(1) 1.4275(16) 
O(3)-C(11) 1.2236(15) C(2)-C(3) 1.3719(19) 
C(2)-C(14) 1.3917(19) C(3)-C(4) 1.3997(17) 
C(4)-C(12) 1.3915(18) C(4)-C(5) 1.5111(18) 
C(5)-C(6) 1.5399(18) C(5)-C(10) 1.5494(17) 
C(6)-C(7) 1.5236(19) C(7)-C(8) 1.523(2) 
C(8)-C(9) 1.519(2) C(9)-C(10) 1.5218(17) 
C(10)-C(11) 1.5196(18) C(11)-C(12) 1.4732(17) 
C(12)-C(13) 1.4072(18) C(13)-C(14) 1.3658(18) 
                                                 
C(2)-O(1)-C(1) 105.89(10) C(14)-O(2)-C(1) 106.17(10) 
 - 256 -  
O(2)-C(1)-O(1) 107.75(10) O(1)-C(2)-C(3) 127.05(12) 
O(1)-C(2)-C(14) 109.76(11) C(3)-C(2)-C(14) 123.19(12) 
C(2)-C(3)-C(4) 115.34(12) C(12)-C(4)-C(3) 121.11(12) 
C(12)-C(4)-C(5) 111.04(11) C(3)-C(4)-C(5) 127.65(11) 
C(4)-C(5)-C(6) 110.10(11) C(4)-C(5)-C(10) 102.33(10) 
C(6)-C(5)-C(10) 112.24(11) C(7)-C(6)-C(5) 112.70(11) 
C(6)-C(7)-C(8) 109.86(11) C(9)-C(8)-C(7) 110.57(12) 
C(8)-C(9)-C(10) 113.30(11) C(11)-C(10)-C(9) 116.31(11) 
C(11)-C(10)-C(5) 103.89(10) C(9)-C(10)-C(5) 117.07(10) 
O(3)-C(11)-C(12) 127.20(12) O(3)-C(11)-C(10) 126.09(11) 
C(12)-C(11)-C(10) 106.69(10) C(4)-C(12)-C(13) 123.04(11) 
C(4)-C(12)-C(11) 108.97(11) C(13)-C(12)-C(11) 127.99(11) 
C(14)-C(13)-C(12) 114.56(12) C(13)-C(14)-O(2) 127.60(12) 
C(13)-C(14)-C(2) 122.76(12) O(2)-C(14)-C(2) 109.62(11) 
                                                         
 Table 4.  Anisotropic displacement parameters (Å
2
 x 10
3
) for compound 136. The anisotropic 
displacement factor exponent takes the form: -2 gpi
2
 [ h
2
 a*
2
 U11 + ... + 2 h k a* b* U                                                                               
  Atom  U11  U22  U33  U23  U13  U12 
                                                
O(1) 19(1) 47(1) 33(1) 5(1) -2(1) -2(1) 
O(2) 23(1) 35(1) 34(1) 5(1) 3(1) -5(1) 
O(3) 23(1) 28(1) 29(1) 0(1) -5(1) 1(1) 
C(1) 24(1) 42(1) 40(1) 2(1) -2(1) -7(1) 
C(2) 20(1) 33(1) 24(1) -5(1) -2(1) 0(1) 
C(3) 25(1) 31(1) 24(1) 2(1) -3(1) 3(1) 
C(4) 24(1) 24(1) 22(1) -3(1) -1(1) 1(1) 
C(5) 24(1) 24(1) 26(1) 2(1) -1(1) 0(1) 
C(6) 31(1) 38(1) 24(1) 2(1) -2(1) -6(1) 
C(7) 37(1) 48(1) 26(1) 2(1) 4(1) -6(1) 
C(8) 29(1) 39(1) 36(1) 2(1) 9(1) -2(1) 
C(9) 23(1) 29(1) 34(1) 4(1) -2(1) -4(1) 
C(10) 24(1) 23(1) 25(1) -3(1) -2(1) -2(1) 
C(11) 23(1) 24(1) 19(1) -5(1) -2(1) 0(1) 
C(12) 23(1) 23(1) 20(1) -3(1) -1(1) 0(1) 
C(13) 25(1) 24(1) 21(1) -1(1) -1(1) 1(1) 
C(14) 23(1) 25(1) 22(1) -3(1) 3(1) -3(1) 
    
 Table 5.  Hydrogen coordinates ( x 10
4
) and isotropic displacement parameters (Å
2
 x 10
3
) for 
compound 136.                                   
  Atom   x   y   z  U(eq) 
H(1A) 5916 3077 2139 42 
H(1B) 6284 1138 1577 42 
H(3) 8519 8256 862 32 
H(5) 11079 10501 913 30 
H(6A) 11548 5413 344 37 
H(6B) 10880 7953 16 37 
H(7A) 12964 10122 12 44 
H(7B) 13038 7344 -351 44 
H(8A) 13990 5306 561 41 
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H(8B) 14901 7701 334 41 
H(9A) 14115 10514 1093 35 
H(9B) 14587 7831 1431 35 
H(10) 12477 9738 1725 28 
H(13) 10500 2183 2326 28 
 
8.3.2. 1H NMR and HRMS of Indanone 141 
 
HRMS (+ESI) Found MH
+
 405.1180, C20H21O9 requires MH 405.1186 and found MNa
+
 
427.0995, C20H20NaO9 requires MNa 427.1005. 
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The presence of two 1H peaks in the 
1
H NMR at 3.09 and 2.54 ppm again reinforces 
indanone 141 had been synthesised. 
 
 
8.3.3. NOESY spectrum of Indanone 145 
 
Proton at 3.64-3.60 ppm (1H, m, (CO)CHCH) can be seen from proton at 3.04 ppm (1H, ddd, 
J = 10.0, 7.0, 2.0 Hz, (CO)CHCH), which reinforces that the indanone 145 has the cis 
configuration.  
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8.3.4. NOESY spectrum of Lactam 148 
 
 
Proton at 3.81 ppm (1H, d, J = 4.0 Hz, NCHCH) can be seen from proton at 2.61 ppm (1H, 
br.s. NCHCH), which reinforces that the lactam 148 has the cis configuration.   
 
Proton at  5.54 (1H, br.s. NH) can be seen from proton at 3.81 ppm (1H, d, J = 4.0 Hz, 
NCHCH) but not proton at 2.61 ppm (1H, br.s. NCHCH), which indicates that the correct 
regioisomer is shown. 
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8.3.5. IC50 Values of A/B/C Indanones and Lactams in the HT29 Cancer Cell 
Line 
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8.4. Chapter Five 
 
8.4.1. IC50 Values of Indanocine Analogues in HT29 and MDA231 Cancer Cell 
Lines 
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HT29 Human Colon Carcinoma
Test Compound 191
3 Day Exposure MTS
GT04:20:02 Concentration (uM)
1 10
O
D
4
9
0
n
m
0.1
0.2
0.3
0.4
0.5
0.6
IC50 = 5.6 μM 
1% DMSO only 
Points are means +- s.d. 
n=4 
* 500μM, 
200μM and 
100μM were 
deleted due 
to insolubility 
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8.4.2. NCI 60 Cell Line Screen - One-Dose Data 
177 
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8.4.3. NCI 60 Cell Line Screen - Five-Dose Data 
177 
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191 
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8.4.4. Repeat of Five-Dose Data 
177 
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187 
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191 
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8.4.5. COMPARE Data of Compound 177 
GI50 
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TGI 
 
LC50 
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